

FORM PTO-100 (Modified)

U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE

ATTORNEY'S SCKET NUMBER

**TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371**

REDC-2110 USA

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

**09/623548**

INTERNATIONAL APPLICATION NO.

**PCT/US00/13576**

INTERNATIONAL FILING DATE

**17 May 2000 (17.05.00)**

PRIORITY DATE CLAIMED

**17.05.99 (17.05.99)**

TITLE OF INVENTION

**PROTECTION OF ENDOGENOUS THERAPEUTIC PEPTIDES FROM PEPTIDASE ACTIVITY THROUGH  
CONJUGATION TO BLOOD COMPONENTS**

APPLICANT(S) FOR DO/EO/US

**BRIDON, Dominique P.; EZRIN, Alan M.; MILNER, Peter G.; HOLMES, Darren L.; and THIBAudeau, Karen**

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☐ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
  - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☐ has been transmitted by the International Bureau.
  - c. ☒ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. 371 (c)(2)).
7. ☐ A copy of the International Search Report (PCT/ISA/210).
8. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
  - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☐ have been transmitted by the International Bureau.
  - c. ☒ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☐ have not been made and will not be made.
9. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).
10. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)). **(signed)**
11. ☐ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).

**Items 13 to 20 below concern document(s) or information included:**

13. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☒ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☐ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☒ Certificate of Mailing by Express Mail
20. ☒ Other items or information:

- a. Copy of Request, description, claims, and abstract of International Application No. PCT/US00/13576 as originally filed 17 May 2000 (17.05.00).
- b. Copy of Response to Communication in Cases For Which No Other Form Is Applicable with substitute pages 184-186 of the claims filed 06 July 2000 (06.07.00).
- c. Copy of Response to Invitation to Furnish Nucleotide and/or Amino Acid Sequence Listing with revised paper copy of Sequence Listing (pages 1-544) and revised copy of Sequence Listing in computer readable form filed with ISA/EP on 22 August 2000 (22.08.00).
- d. Copy of Form PCT/IB/301 - Notification of Receipt of Record Copy.
- e. Copy of Form PCT/IB/304 - Notification Concerning Submission or Transmittal of Priority Documents.
- f. Verified Statement (Declaration) Claiming Small Entity Status - Small Business Concern (signed).

**533 Rec'd PCT/PTO 05 SEP 2000**

U.S. APPLICATION NO. (IF KNOWN) <b>37 CFR</b> <div style="font-size: 1.5em; font-weight: bold; margin-top: 5px;">09/623548</div>	INTERNATIONAL APPLICATION NO. <b>PCT/US00/13576</b>	ATTORNEY'S DOCKET NUMBER <b>REDC-2110 USA</b>
---	--	--

21. The following fees are submitted:

**BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :**

<input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO .....	<b>\$970.00</b>
<input checked="" type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO .....	<b>\$840.00</b>
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO .....	<b>\$690.00</b>
<input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) .....	<b>\$670.00</b>
<input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) .....	<b>\$96.00</b>

**ENTER APPROPRIATE BASIC FEE AMOUNT =**

	<b>\$840.00</b>
--	-----------------

Surcharge of **\$130.00** for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492 (e)). ☐ 20 ☐ 30

	<b>\$0.00</b>
--	---------------

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	
Total claims	25 - 20 =	5	x \$18.00	<b>\$90.00</b>
Independent claims	4 - 3 =	1	x \$78.00	<b>\$78.00</b>
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>				<b>\$0.00</b>
<b>TOTAL OF ABOVE CALCULATIONS =</b>				<b>\$1,008.00</b>
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) (check if applicable). <input checked="" type="checkbox"/>				<b>\$504.00</b>
<b>SUBTOTAL =</b>				<b>\$504.00</b>
Processing fee of <b>\$130.00</b> for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492 (f)). <input type="checkbox"/> 20 <input type="checkbox"/> 30				<b>\$0.00</b>
<b>TOTAL NATIONAL FEE =</b>				<b>\$504.00</b>
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). <input checked="" type="checkbox"/>				<b>\$40.00</b>
<b>TOTAL FEES ENCLOSED =</b>				<b>\$544.00</b>
				Amount to be refunded \$
				charged \$

☒ A check in the amount of **\$544.00** to cover the above fees is enclosed.

☐ Please charge my Deposit Account No. \_\_\_\_\_ in the amount of \_\_\_\_\_ to cover the above fees.  
A duplicate copy of this sheet is enclosed.

☒ The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. **12-1420** A duplicate copy of this sheet is enclosed.

**NOTE:** Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

**SEND ALL CORRESPONDENCE TO:**

**Michael R. Ward, Esq.**  
**LIMBACH & LIMBACH L.L.P.**  
 2001 Ferry Building  
 San Francisco, California 94111-4207  
 United States of America  
 Telephone: (415) 433-4150  
 Facsimile: (415) 433-8716

Michael R Ward

SIGNATURE

---

**MICHAEL R. WARD**

NAME

---

**38,651**

REGISTRATION NUMBER

---

**05 September 2000 (05.09.00)**

DATE

Page 2 of 2

09/623548

533 Rec'd PCT/PTO 05 SEP 2000

PATENT COOPERATION TREATY

EUROPEAN PATENT OFFICE  
INTERNATIONAL SEARCHING AUTHORITY

Docket No.: REDC-2110 PCT

International Application No.: PCT/US00/13576

International Filing Date: 17 May 2000 (17.05.00)

Title: PROTECTION OF ENDOGENOUS THERAPEUTIC PEPTIDES  
FROM PEPTIDASE ACTIVITY THROUGH CONJUGATION  
TO BLOOD COMPONENTS

Applicant(s): CONJUCHEM, INC. et al.

RESPONSE TO INVITATION TO FURNISH  
NUCLEOTIDE AND/OR AMINO ACID SEQUENCE LISTING

European Patent Office  
International Searching Authority  
P.B. 5818  
Patentlaan 2  
NL-2280 HV Rijswijk  
NETHERLANDS

Attention: Zorka Bota-Madsen  
Authorized Officer

Sir:

In response to the Invitation to Furnish Nucleotide and/or Amino Acid Sequence Listing Complying with WIPO Standard ST25 mailed August 7, 2000, applicants hereby submit the following documents for filing in connection with the above-identified International Application:

(1) Revised paper copy of Sequence Listing, including numeric identifier <211> and <400> for SEQ ID NO. 81, 108, 409, and 414.

(2) Computer readable copy of Sequence Listing, including numeric identifiers <211> and <400> for SEQ ID NO. 81, 108, 409, and 414.

Applicants assert that the revised Sequence Listing submitted herewith complies with WIPO Standard ST. 23 in a machine readable form provided, under Section 208, in

Annex C of the *Administrative Instructions*.

The Sequence Listing has been modified to include numeric identifiers <211> and <400> for SEQ ID NO. 81, 108, 409, and 414. Specifically, the code "000" has been used to indicate that these sequences are not explicitly present in the application. This change in the Sequence Listing is a correction within the meaning of Rule 26.4 PCT and is not a rectification within the meaning of Rule 91.1 PCT.

Applicants assert that the paper copy and the computer readable format copy submitted herewith are identical. In addition, since the revised Sequence Listing is merely an inclusion of numeric identifiers <211> and <400> from information in the International Application as filed, the revised Sequence Listing does not go beyond the disclosure in the International Application as filed.

Respectfully submitted,

LIMBACH & LIMBACH L.L.P.

Date: August 22, 2000 By: Michael R. Ward

Michael R. Ward

2001 Ferry Building  
San Francisco, CA 94111-4262  
(415) 433-4150  
Attorneys for Applicants

REDC-2110 PCT



09/623548  
533 Rec'd PCT/PTO 05 SEP 2000

PATENT COOPERATION TREATY

UNITED STATES RECEIVING OFFICE

In re Int'l Application of	)	Authorized Officer:
CONJUCHEM, INC. ET AL.	)	Yolanda Harrod
International Application	)	
PCT/US00/13576	)	RESPONSE TO
International Filing Date:	)	COMMUNICATION IN CASES
17 May 2000 (17.05.00)	)	FOR WHICH NO OTHER FORM
	)	<u>IS APPLICABLE</u>
For: PROTECTION OF ENDOGENOUS	)	
THERAPEUTIC PEPTIDES	)	EL247151065US
FROM PEPTIDASE ACTIVITY	)	
THROUGH CONJUGATION TO	)	2001 Ferry Building
BLOOD COMPONENTS	)	San Francisco, CA
	)	94111-4207
	)	(415) 433-4150

Assistant Commissioner for Patents  
Box PCT  
Washington, D.C. 20231

Attention: RO/US

CERTIFICATION UNDER 37 CFR §1.10

I hereby certify that the documents referred to as enclosed herein are being deposited with the United States Postal Service on this date **July 6, 2000**, in an envelope bearing "Express Mail Post Office To Addressee" Mailing Label Number **EL247151065US** addressed to: Assistant Commissioner for Patents, Box PCT, Washington, D.C. 20231-0001, Attention: RO/US.

Elizabeth A. Reicker  
Name

Elizabeth A. Reicker  
Signature

Dear Sir:

Applicants hereby respond to the Communication In Cases For Which No Other Form Is Applicable mailed June 20, 2000, by providing the PCT Receiving Office with substitute pages 184-186 of the claims for filing in the above-identified International Application.

In the International Application as originally filed, Claim 9 was omitted due to an oversight in connection with numbering of the claims. In addition, original Claim 18

was incorrectly dependent upon itself, and original Claim 19 was incorrectly dependent upon itself.

The claims have been renumbered in chronological order, and the claim references have been corrected and changed accordingly. Original claims 1-8 remain unchanged. Previous claims 10-15 have been replaced with renumbered claims 9-14, respectively. Previous claim 16 has been renumbered as claim 15. Previous claims 17-26 have been renumbered as new claims 16-25. New claims 16-25 each depend from claim 15. As such, each of the claims 1-25 find support in the International Application as filed. No new matter has been added.

Dated: July 6, 2000

Respectfully submitted,

LIMBACH & LIMBACH L.L.P.

By Michael R. Ward

Michael R. Ward  
Reg. No. 38,651  
2001 Ferry Building  
San Francisco, CA 94111  
(415) 433-4150  
Attorneys for Applicants

MRW/EAR  
REDC-2110PCT

amino acid located between the amino terminal amino acid and the carboxy terminal amino acid, such that said modified peptide is capable of forming a covalent bond in vivo with a reactive functionality on a blood component;

5 (b) forming a covalent bond between said reactive group and a reactive functionality on a blood component to form a peptide-blood component conjugate, thereby protecting said peptide from peptidase activity; and

(c) analyzing the stability of said peptide-blood component  
10 conjugate to assess the protection of said peptide from peptidase activity.

8. A method according to claim 7, further comprising the step of administering said modified peptide in vivo before step (b), such that the  
15 peptide-blood component conjugate is formed in vivo.

9. A method according to claim 7, wherein step (b) occurs ex vivo.

10. A method according to claim 7 wherein step (c) is performed in  
20 vivo.

11. A method according to claim 7, wherein said reactive group is a maleimido group.

25 12. A method according to claim 7, wherein said reactive group is attached to said peptide via a linking group.

13. A method according to claim 7, wherein said blood component is albumin.

30 14. A method according to claim 7, wherein one or more of said amino acids is synthetic.

5

(a)

10

15

20

16

25

18

30

20. A method according to claim 15, wherein step (d) is performed ex vivo.

21. A method according to claim 15, wherein said peptide has a  
5 carboxy terminus, an amino terminus, a carboxy terminal amino acid and an amino terminal amino acid, and wherein step (b) further comprises:

(a) if said less therapeutically active portion is located at the carboxy terminus of said peptide, then modifying said peptide at the carboxy terminal amino acid of said peptide;

10 (b) if said less active portion is located at the amino terminus of said peptide, then modifying said peptide at the amino terminal amino acid of said peptide; and

(c) if said less active portion is located at neither the amino terminus nor the carboxy terminus of said peptide, then modifying said  
15 peptide at an amino acid located between the carboxy terminus and the amino terminus.

22. A method according to claim 15, wherein said reactive group is a maleimido group.

20

23. A method according to claim 15, wherein said reactive entity is attached to said peptide via a linking group.

24. A method according to claim 15, wherein said blood component is  
25 albumin.

25. A method according to claim 15, wherein one or more of said amino acids is synthetic.

30

Applicant or Patentee: DOMINIQUE P. BRIDON ET AL.

Attorney's

Appln. or Patent No.:

Docket No.: REDC-2110 USAFiled or Issued: HEREWITHFor: PROTECTION OF ENDOGENOUS THERAPEUTIC PEPTIDES FROM PEPTIDASE ACTIVITY THROUGH CONJUGATION TO BLOOD COMPONENTS**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS (37 CFR 1.9(f) and 1.27(c)) - SMALL BUSINESS CONCERN**

I hereby declare that I am

☐ the owner of the small business concern identified below:☒ an official of the small business concern empowered to act on behalf of the concern identified below:NAME OF CONCERN CONJUCHEM, INC.ADDRESS OF CONCERN 225 President Kennedy Avenue West, Third Floor, Suite 3950, Montreal, Quebec H2X 3Y8, Canada

I hereby declare that the above identified small business concern qualifies as a small business concern as defined in 37 CFR 1.21.3-18, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees under section 41(a) and (b) of Title 35, United States Code, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention, entitled PROTECTION OF ENDOGENOUS THERAPEUTIC PEPTIDES FROM PEPTIDASE ACTIVITY THROUGH CONJUGATION TO BLOOD COMPONENTS by inventor(s) DOMINIQUE P. BRIDON ET AL., described in

☒ the specification filed herewith with title as listed above.☐ application no. \_\_\_\_\_, filed \_\_\_\_\_.☐ patent no. \_\_\_\_\_, issued \_\_\_\_\_.

If the rights held by the above identified small business concern are not exclusive, each individual, concern or organization having rights to the invention is listed below\* and no rights to the invention are held by any person, other than the inventor, who could not qualify as an independent inventor under 37 CFR 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

\*NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27).

NAME \_\_\_\_\_

ADDRESS \_\_\_\_\_  
☐ Individual ☐ Small Business Concern ☐ Nonprofit Organization

NAME \_\_\_\_\_

ADDRESS \_\_\_\_\_  
☐ Individual ☐ Small Business Concern ☐ Nonprofit Organization

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time or paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING Dominique P. BridonTITLE OF PERSON OTHER THAN OWNER Vice President of ResearchADDRESS OF PERSON SIGNING 225 President Kennedy Avenue West, Third Floor, Suite 3950, Montreal, Quebec H2X 3Y8, CanadaSIGNATURE: DATE: August 30, 2000

- 1 - 533 Rec'd PCT/PTO 0 5 SEP 2000

**PROTECTION OF ENDOGENOUS THERAPEUTIC PEPTIDES**  
**FROM PEPTIDASE ACTIVITY THROUGH CONJUGATION**  
**TO BLOOD COMPONENTS**

5

**FIELD OF THE INVENTION**

This invention relates to modified therapeutic peptides. In particular, this invention relates to protection of endogenous therapeutic peptides from peptidase activity through a modification that enables the peptide to selectively conjugate to blood components, thus protecting the peptide from peptidase activity and increasing the duration of action of the therapeutic peptide for the treatment of various disorders.

**BACKGROUND OF THE INVENTION**

Many endogenous peptides have been described as key components of biological processes. Some of these peptides have been identified as key therapeutic agents for the management of various disorders. In general, endogenous peptides are more desirable as therapeutic agents than synthetic peptides with non-native sequences, because they do not produce an immune response due to their endogenous character. In addition, endogenous peptides are highly specific for their target receptors and are easy to synthesize and manufacture. However, a major difficulty with the delivery of such therapeutic peptides is their short plasma half-life, mainly due to rapid serum clearance and proteolytic degradation via the action of peptidases.

Peptidases break a peptide bond in peptides by inserting a water molecule across the bond. Generally, most peptides are broken down by peptidases in the body in a manner of a few minutes or less. In addition, some peptidases are specific for certain types of peptides, making their degradation even more rapid. Thus, if a peptide is used as a therapeutic agent, its activity is generally reduced as the peptide quickly degrades in the body due to the action of peptidases.

One way to overcome this disadvantage is to administer large dosages of the therapeutic peptide of interest to the patient so that even if some of the peptide is degraded, enough remains to be therapeutically effective. However, this method is quite uncomfortable for the patient.

- 5 Since most therapeutic peptides cannot be administered orally, the therapeutic peptide would have to be either constantly infused, frequently administered by intravenous injections, or administered frequently by the inconvenient route of subcutaneous injections. The need for frequent administration also results in many potential peptide
- 10 therapeutics having an unacceptably high projected cost per treatment course. The presence of large amounts of degraded peptide may also generate undesired side effects.

- Discomfort in administration and high costs are two reasons why most therapeutic peptides with attractive bioactivity profiles are not
- 15 developed as drug candidates. Instead, these therapeutic peptides are used as templates for the development of peptidomimetic compounds to substitute for the therapeutic peptide. Biotechnology and large pharmaceutical firms frequently undertake lengthy and expensive optimization programs to attempt to develop non-peptide, organic
- 20 compounds which mimic the activity seen with therapeutic peptides without incurring an unacceptable side effect profile. For example, cyclic peptides, peptidomimetics and small molecules coming from expensive SAR (Structure Activity Relationship) and molecular modeling studies have led to the development of an incredible amount of peptide mimics.
- 25 However, these peptide mimics in no way reflect the exact original biological nature of the therapeutic peptide, and thus are inferior to the endogenous therapeutic peptide as therapeutic agents.

- An alternative to creating peptide mimics is to block the action of peptidases to prevent degradation of the therapeutic peptide or to modify
- 30 the therapeutic peptides in such a way that their degradation is slowed down while still maintaining biological activity. Such methods include conjugation with polymeric materials such as dextrans, polyvinyl



pyrrolidones, glycopeptides, polyethylene glycol and polyamino acids, conjugation with adroitin sulfates, as well as conjugation with polysaccharides, low molecular weight compounds such as aminolethacin, fatty acids, vitamin B<sub>12</sub>, and glycosides. These

5 conjugates, however, are still often susceptible to protease activity. In addition, the therapeutic activity of these peptides is often reduced by the addition of the polymeric material. Finally, there is the risk of the conjugates generating an immune response when the material is injected *in vivo*. Several methods include *ex vivo* conjugation with  
10 carrier proteins, resulting in the production of randomized conjugates. Since conjugates are difficult to manufacture, and their interest is limited by commercial availability of the carriers, as well as by their poor pharmaco economics.

There is thus a need for novel methods to modify therapeutic  
15 peptides to protect them from peptidase activity and to provide longer duration of action *in vivo*, while maintaining low toxicity yet retaining the therapeutic advantages of the modified peptides.

### SUMMARY OF THE INVENTION

This invention is directed to overcoming the problem of peptide  
20 degradation in the body by modifying the therapeutic peptide of interest and attaching it to protein carriers, such that the action of peptidases is prevented, or slowed down. More specifically, this invention relates to novel chemically reactive derivatives of therapeutic peptides that can react with available functionalities on blood proteins to form covalent  
25 linkages, specifically a therapeutic peptide-maleimide derivative. The invention also relates to novel chemically reactive derivatives or analogs of such therapeutic peptides. The invention additionally pertains to the therapeutic uses of such compounds.

The present invention is directed to modifying and attaching  
30 therapeutic peptides to protein carriers, preferentially albumin, through *in vivo* or *ex vivo* technology to prevent or reduce the action of peptidases

by virtue of a synthetic modification on the first residue to be cleaved. Therapeutic peptides are usually active at the N-terminus portion, at the C-terminus portion, or in an interior portion of the peptide chain. Using the technology of this invention, a site other than the active portion of a

5 therapeutic peptide is modified with certain reactive groups. These reactive groups are capable of forming covalent bonds with functionalities present on blood components. The reactive group is placed at a site such that when the therapeutic peptide is bonded to the blood component, the peptide retains a substantial proportion of the

10 parent compound's activity.

The modification of the therapeutic peptide through the chemical modification used in the invention is done in such a way that all or most of the peptide specificity is conserved despite attachment to a blood component. This therapeutic peptide-blood component complex is now

15 capable of traveling to various body regions without and being degraded by peptidases, with the peptide still retaining its therapeutic activity. The invention is applicable to all known therapeutic peptides and is easily tested under physiological conditions by the direct comparison of the pharmacokinetic parameters for the free and the modified therapeutic

20 peptide.

The present invention is directed to a modified therapeutic peptide capable of forming a peptidase stabilized therapeutic peptide composed of between 3 and 50 amino acids. The peptide has a carboxy terminal amino acid, an amino terminal amino acid, a therapeutically

25 active region of amino acids and a less therapeutically active region of amino acids. The peptide comprises a reactive group which reacts with amino groups, hydroxyl groups, or thiol groups on blood components to form a stable covalent bond and thereby forms the peptidase stabilized therapeutic peptide. In the peptide of the invention the reactive group is

30 selected from the group consisting of succinimidyl and maleimido groups and the reactive group is attached to an amino acid positioned in the less therapeutically active region of amino acids.

In one embodiment, the therapeutically active region of the peptide includes the carboxy terminal amino acid and the reactive group is attached to said amino terminal amino acid.

5 In another embodiment, the therapeutically active region of the peptide includes the amino terminal amino acid and the reactive group is attached to the carboxy terminal amino acid.

10 In another embodiment, the therapeutically active region of the peptide includes the carboxy terminal amino acid and the reactive group is attached to an amino acid positioned between the amino terminal amino acid and the carboxy terminal amino acid.

15 In yet another embodiment, the therapeutically active region includes the amino terminal amino acid and the reactive group is attached to an amino acid positioned between the amino terminal amino acid and the carboxy terminal amino acid.

20 The present invention is also directed to a method of synthesizing the modified therapeutic peptide. The method comprises the following steps. In the first step, if the therapeutic peptide does not contain a cysteine, then the peptide is synthesized from the carboxy terminal amino acid and the reactive group is added to the carboxy terminal amino acid. Alternatively, a terminal lysine is added to the carboxy terminal amino acid and the reactive group is added to the terminal lysine. In the second step, if the therapeutic peptide contains only one cysteine, then the cysteine is reacted with a protective group prior to addition of the reactive group to an amino acid in the less therapeutically  
25 active region of the peptide. In the third step, if the therapeutic peptide contains two cysteines as a disulfide bridge, then the two cysteines are oxidized and the reactive group is added to the amino terminal amino acid, or to the carboxy terminal amino acid, or to an amino acid positioned between the carboxy terminal amino acid and the amino  
30 terminal amino acid of the therapeutic peptide. In the fourth step, if the therapeutic peptide contains more than two cysteines as disulfide bridges, the cysteines are sequentially oxidized in the disulfide bridges

and the peptide is purified prior to the addition of the reactive groups to the carboxy terminal amino acid.

The present invention is also directed to a method for protecting a therapeutic peptide from peptidase activity in vivo, the peptide being composed of between 3 and 50 amino acids and having a carboxy terminus and an amino terminus and a carboxy terminal amino acid amino acid and an amino terminal amino acid. The method comprises the following steps:

- (a) modifying the peptide by attaching a reactive group to the carboxy terminal amino acid, to the amino terminal amino acid, or to an amino acid located between the amino terminal amino acid and the carboxy terminal amino acid, such that the modified peptide is capable of forming a covalent bond in vivo with a reactive functionality on a blood component;
- (b) forming a covalent bond between the reactive group and a reactive functionality on a blood component to form a peptide-blood component conjugate, thereby protecting the peptide from peptidase activity; and
- (c) analyzing the stability of the peptide-blood component conjugate to assess the protection of the peptide from peptidase activity. These steps may be performed either *in vivo* or *ex vivo*.

The present invention is also directed to a method for protecting a therapeutic peptide from peptidase activity in vivo, the peptide being composed of between 3 and 50 amino acids and having a therapeutically active region of amino acids and a less therapeutically active region of amino acids. The method comprises the following steps:

- (a) determining the therapeutically active region of amino acids;
- (b) modifying the peptide at an amino acid included in the less therapeutically active region of amino acids by attaching a reactive group to the amino acid to form a modified peptide, such that the

modified peptide has therapeutic activity and is capable of forming a covalent bond *in vivo* with a reactive functionality on a blood component;

- (c) forming a covalent bond between the reactive entity and a reactive functionality on a blood component to form a peptide-blood component conjugate, thereby protecting the peptide from peptidase activity; and
  - (d) analyzing the stability of the peptide-blood component conjugate to assess the protection of the peptide from peptidase activity.
- These steps may be performed either *in vivo* or *ex vivo*.

The peptides useful in the compositions and methods of the present invention include, but are not limited to, the peptides presented in SEQ ID NO:1 to SEQ ID NO:1617.

## DETAILED DESCRIPTION OF THE INVENTION

### DEFINITIONS

To ensure a complete understanding of the invention, the following definitions are provided:

**Reactive Groups**: Reactive groups are entities capable of forming a covalent bond. Such reactive groups are coupled or bonded to a therapeutic peptide of interest. Reactive groups will generally be stable in an aqueous environment and will usually be carboxy, phosphoryl, or convenient acyl group, either as an ester or a mixed anhydride, or an imidate, thereby capable of forming a covalent bond with functionalities such as an amino group, a hydroxy or a thiol at the target site on mobile blood components. For the most part, the esters will involve phenolic compounds, or be thiol esters, alkyl esters, phosphate esters, or the like. Reactive groups include succinidyl and maleimido groups.

**Functionalities:** Functionalities are groups on blood components, including mobile and fixed proteins, to which reactive groups on modified therapeutic peptides react to form covalent bonds.

- 5 Functionalities usually include hydroxyl groups for bonding to ester reactive groups, thiol groups for bonding to maleimides, imidates and thioester groups; amino groups for bonding to activated carboxyl, phosphoryl or any other acyl groups on reactive groups.

- 10 **Blood Components:** Blood components may be either fixed or mobile. Fixed blood components are non-mobile blood components and include tissues, membrane receptors, interstitial proteins, fibrin proteins, collagens, platelets, endothelial cells, epithelial cells and their associated membrane and membraneous receptors, somatic body cells, skeletal
- 15 and smooth muscle cells, neuronal components, osteocytes and osteoclasts and all body tissues especially those associated with the circulatory and lymphatic systems. Mobile blood components are blood components that do not have a fixed situs for any extended period of time, generally not exceeding 5, more usually one minute. These blood
- 20 components are not membrane-associated and are present in the blood for extended periods of time and are present in a minimum concentration of at least 0.1 µg/ml. Mobile blood components include serum albumin, transferrin, ferritin and immunoglobulins such as IgM and IgG. The half-life of mobile blood components is at least about 12 hours.

- 25 **Protective Groups:** Protective groups are chemical moieties utilized to protect peptide derivatives from reacting with themselves. Various protective groups are disclosed herein and in U.S. 5,493,007 which is hereby incorporated by reference. Such protective groups
- 30 include acetyl, fluorenylmethyloxycarbonyl (Fmoc), t-butyloxycarbonyl (Boc), benzyloxycarbonyl (Cbz), and the like. The specific protected amino acids are depicted in Table 1.

**Linking Groups**: Linking groups are chemical moieties that link or connect reactive groups to therapeutic peptides. Linking groups may comprise one or more alkyl groups, alkoxy group, alkenyl group, alkynyl group or amino group substituted by alkyl groups, cycloalkyl group, polycyclic group, aryl groups, polyaryl groups, substituted aryl groups, heterocyclic groups, and substituted heterocyclic groups. Linking groups may also comprise poly ethoxy aminoacids such as AEA ((2-amino ethoxy acetic acid) or a preferred linking group AEEA ([2-(2-amino)ethoxy])ethoxy acetic acid). A preferred linking group is aminoethoxyethoxyacetic acid (AEEA).

**Sensitive Functional Groups** – A sensitive functional group is a group of atoms that represents a potential reaction site on a therapeutic peptide. If present, a sensitive functional group may be chosen as the attachment point for the linker-reactive group modification. Sensitive functional groups include but are not limited to carboxyl, amino, thiol, and hydroxyl groups.

**Modified Therapeutic Peptides** – A modified therapeutic peptide peptide is a therapeutic peptide that has been modified by attaching a reactive group, and is capable of forming a peptidase stabilized peptide through conjugation to blood components. The reactive group may be attached to the therapeutic peptide either via a linking group, or optionally without using a linking group. It is also contemplated that one or more additional amino acids may be added to the therapeutic peptide to facilitate the attachment of the reactive group. Modified peptides may be administered *in vivo* such that conjugation with blood components occurs *in vivo*, or they may be first conjugated to blood components *in vitro* and the resulting peptidase stabilized peptide (as defined below) administered *in vivo*. The terms “modified therapeutic peptide” and “modified peptide” may be used interchangeably in this application.

**Peptidase Stabilized Therapeutic Peptides** – A peptidase stabilized therapeutic peptide is a modified peptide that has been conjugated to a blood component via a covalent bond formed between the reactive group of the modified peptide and the functionalities of the blood component, with or without a linking group. Peptidase stabilized peptides are more stable in the presence of peptidases *in vivo* than a non-stabilized peptide. A peptidase stabilized therapeutic peptide generally has an increased half life of at least 10-50% as compared to a non-stabilized peptide of identical sequence. Peptidase stability is determined by comparing the half life of the unmodified therapeutic peptide in serum or blood to the half life of a modified counterpart therapeutic peptide in serum or blood. Half life is determined by sampling the serum or blood after administration of the modified and non-modified peptides and determining the activity of the peptide. In addition to determining the activity, the length of the therapeutic peptide may also be measured.

**Therapeutic Peptides** – As used in this invention, therapeutic peptides are amino acid chains of between 2-50 amino acids with therapeutic activity, as defined below. Each therapeutic peptide has an amino terminus (also referred to as N-terminus or amino terminal amino acid), a carboxyl terminus (also referred to as C-terminus terminal carboxyl terminal amino acid) and internal amino acids located between the amino terminus and the carboxyl terminus. The amino terminus is defined by the only amino acid in the therapeutic peptide chain with a free  $\alpha$ -amino group. The carboxyl terminus is defined by the only amino acid in the therapeutic peptide chain with a free  $\alpha$ -carboxyl group.

Therapeutic peptides used in the present invention contain a therapeutically active region generally located at the amino terminus, at the carboxyl terminus, or at an internal amino acid. The therapeutically active region may be identified using blind or structure activity



relationship (SAR) driven substitution, as defined in more detail in this application. SAR is an analysis which defines the relationship between the structure of a molecule and its pharmacological activity for a series of compounds. Alternatively, where the therapeutically active region has previously been defined and is available in the literature, it may be obtained by referring to references such as scientific journals. Knowledge of the location of the therapeutically active region of the peptide is important for modifying the therapeutic peptide, as defined in more detail below.

- 5
- 10       Therapeutic peptides used in this invention also contain a less therapeutically active region generally located at the amino terminus, at or near the carboxyl terminus, or at or near an internal amino acid. The less therapeutically active region is a region of amino acids that does not coincide with the therapeutically active region of the therapeutic peptide.
- 15       The less therapeutically active region is generally located away from the therapeutically active region, such that modification at the less therapeutically active region does not substantially affect the therapeutic activity of the therapeutic peptide. For example, if the therapeutically active region is located at the amino terminus, the therapeutic peptide will be modified at either the carboxyl terminus or at an internal amino acid. Alternatively, if the therapeutically active region is located at the carboxyl terminus, the therapeutic peptide will be modified at either the amino terminus or at an internal amino acid. Finally, if the therapeutically active region is located at an internal region, the therapeutic peptide will be modified at either the amino terminus or the carboxyl terminus.
- 20
- 25

"Therapeutic activity" is any activity directed toward healing or curing a biological disorder in a patient. Examples of said therapeutic peptides include pituitary hormones such as vasopressin, oxytocin, melanocyte stimulating hormones, adrenocorticotrophic hormones, growth hormones; hypothalamic hormones such as growth hormone releasing factor, corticotropin releasing factor, prolactin releasing

30

- peptides, gonadotropin releasing hormone and its associated peptides, luteinizing hormone release hormones, thyrotropin releasing hormone, orexin, and somatostatin; thyroid hormones such as calcitonins, calcitonin precursors, and calcitonin gene related peptides; parathyroid
- 5 hormones and their related proteins; pancreatic hormones such as insulin and insulin-like peptides, glucagon, somatostatin, pancreatic polypeptides, amylin, peptide YY, and neuropeptide Y; digestive hormones such as gastrin, gastrin releasing peptides, gastrin inhibitory peptides, cholecystokinin, secretin, motilin, and vasoactive intestinal
- 10 peptide; natriuretic peptides such as atrial natriuretic peptides, brain natriuretic peptides, and C-type natriuretic peptides; neurokinins such as neurokinin A, neurokinin B, and substance P; renin related peptides such as renin substrates and inhibitors and angiotensins; endothelins, including big endothelin, endothelin A receptor antagonists, and
- 15 sarafotoxin peptides; and other peptides such as adrenomedullin peptides, allatostatin peptides, amyloid beta protein fragments, antibiotic and antimicrobial peptides, apoptosis related peptides, bag cell peptides, bombesin, bone Gla protein peptides, CART peptides, chemotactic peptides, cortistatin peptides, fibronectin fragments and fibrin related
- 20 peptides, FMRF and analog peptides, galanin and related peptides, growth factors and related peptides, Gtherapeutic peptide-binding protein fragments, guanylin and uroguanylin, inhibin peptides, interleukin and interleukin receptor proteins, laminin fragments, leptin fragment peptides, leucokinins, mast cell degranulating peptides, pituitary
- 25 adenylate cyclase activating polypeptides, pancreastatin, peptide T, polypeptides, virus related peptides, signal transduction reagents, toxins, and miscellaneous peptides such as adjuvant peptide analogs, alpha mating factor, antiarrhythmic peptide, antifreeze polypeptide, anorexigenic peptide, bovine pineal antireproductive peptide, bursin, C3
- 30 peptide P16, tumor necrosis factor, cadherin peptide, chromogranin A fragment, contraceptive tetrapeptide, conantokin G, conantokin T, crustacean cardioactive peptide, C-telopeptide, cytochrome b588

peptide, decorsin, delicious peptide, delta-sleep-inducing peptide, diazepam-binding inhibitor fragment, nitric oxide synthase blocking peptide, OVA peptide, platelet calpain inhibitor (P1), plasminogen activator inhibitor 1, rigin, schizophrenia related peptide, serum thymic factor, sodium potassium Atherapeutic peptidease inhibiro-1, speract, sperm activating peptide, systemin, thrombin receptor agonist, thymic humoral gamma2 factor, thymopentin, thymosin alpha 1, thymus factor, tuftsin, adipokinetic hormone, uremic pentapeptide and other therapeutic peptides.

10 Taking into account these definitions, the focus of this invention is to modify therapeutic peptides to protect them from peptidase activity *in vivo* and thereby extend the effective therapeutic life of the therapeutic peptide in question as compared to administration of the peptide per se to a patient.

15

#### **1. Therapeutic Peptides Used in the Present Invention**

Peptide fragments chosen from the determined amino acid sequence of a therapeutic peptide as provided in the attached SEQUENCE LISTING constitute the starting point in the development comprising the present invention. The peptides range from 2 to 50 amino acids in length. The interchangeable terms "peptide fragment" and "peptide moiety" are meant to include both synthetic and naturally occurring amino acid sequences derivable from a naturally occurring amino acid sequence.

25 In one embodiment, peptide and peptide fragments are synthesized by conventional means, either by bench-top methods or by automated peptide synthesis machines as discussed in detail below. However, it is also possible to obtain fragments of the peptides by fragmenting the naturally occurring amino acid sequence, using, for example, a proteolytic enzyme. Further, it is possible to obtain the desired fragments of the therapeutic peptide through the use of recombinant DNA technology, as disclosed by Maniatis, T., et al.,

30

Molecular Biology: A Laboratory Manual, Cold Spring Harbor, New York (1982), which is hereby incorporated by reference. The use of other new modifications to existing methodologies is also contemplated.

The present invention includes peptides which are derivable from the naturally occurring sequence of the therapeutic peptide. A peptide is said to be "derivable from a naturally occurring amino acid sequence" if it can be obtained by fragmenting a naturally occurring sequence, or if it can be synthesized based upon a knowledge of the sequence of the naturally occurring amino acid sequence or of the genetic material (DNA or RNA) which encodes this sequence. Included within the scope of the present invention are those molecules which are said to be "derivatives" of a peptide. Such a "derivative" has the following characteristics: (1) it shares substantial homology with the therapeutic peptide or a similarly sized fragment of the peptide and (2) it is capable of functioning with the same therapeutic activity as the peptide.

A derivative of a peptide is said to share "substantial homology" with the peptide if the amino acid sequences of the derivative is at least 80%, and more preferably at least 90%, and most preferably at least 95%, the same as that of either the peptide or a fragment of the peptide having the same number of amino acid residues as the derivative.

The derivatives of the present invention include fragments which, in addition to containing a sequence that is substantially homologous to that of a naturally occurring therapeutic peptide may contain one or more additional amino acids at their amino and/or their carboxy termini as discussed in detail below. Thus, the invention pertains to polypeptide fragments of the therapeutic peptide that may contain one or more amino acids that may not be present in a naturally occurring therapeutic peptide sequence provided that such fragments have a therapeutic activity which exceeds that of the therapeutic peptide.

Similarly, the invention includes polypeptide fragments which, although containing a sequence that is substantially homologous to that of a naturally occurring therapeutic peptide, may lack one or more

additional amino acids at their amino and/or their carboxy termini that are naturally found on the therapeutic peptide. Thus, the invention pertains to polypeptide fragments of the therapeutic peptide that may lack one or more amino acids that are normally present in the naturally occurring peptide sequence provided that such polypeptides have a therapeutic activity which exceeds that of the therapeutic peptide.

The invention also encompasses the obvious or trivial variants of the above-described fragments which have inconsequential amino acid substitutions (and thus have amino acid sequences which differ from that of the natural sequence) provided that such variants have an activity which is substantially identical to that of the above-described derivatives. Examples of obvious or trivial substitutions include the substitution of one basic residue for another (i.e. Arg for Lys), the substitution of one hydrophobic residue for another (i.e. Leu for Ile), or the substitution of one aromatic residue for another (i.e. Phe for Tyr), etc.

As is known in the art, the amino acid residues may be in their protected or unprotected form, using appropriate amino or carboxyl protecting groups as discussed in detail below. The variable length peptides may be in the form of the free amines (on the N-terminus), or acid-addition salts thereof. Common acid addition salts are hydrohalic acid salts, i.e., HBr, HI, or, more preferably, HCl. Useful cations are alkali or alkaline earth metallic cations (i.e., Na, K, Li, Ca, Ba, etc.) or amine cations (i.e., tetraalkylammonium, trialkylammonium, where alkyl can be C<sub>1</sub>C<sub>12</sub>).

Any peptide having a therapeutic activity may be used in this invention. The following list of peptides provides examples of peptides that may be used in this invention, but is not exhaustive and in no way limits the number or type of peptides that may be used in this invention. These therapeutic peptides and fragments produced from these peptides may be modified according to the present invention, and used therapeutically in the body.

**A. Pituitary Hormones (SEQ ID NOS: 1-72)**

**Adrenocorticotrophic Hormones (ACTH, aka corticotropin)**

(SEQ ID NOS: 1-22) - The endocrine functions of the adrenal cortex are regulated by an anterior pituitary hormone, ACTH. ACTH, a 39-amino acid peptide is generated in the corticotrophic cells of the anterior pituitary under the control of corticotropin releasing factor. ACTH is derived by post-translational modification from a 241-amino acid precursor known as pro-opiomelanocortin (POMC).

The biological role of ACTH is to maintain the bulk and the viability of the adrenal cortex and to stimulate the production of adrenal cortex steroids, principally cortisol and corticosterone. The mechanism of action of ACTH involves binding to the ACTH receptor followed by activation of adenylate cyclase, elevation of cyclic AMP (cAMP), and increased protein kinase A (PKA) activity of adrenal cortex tissue. The main effect of these events is to increase the activity of a side chain-cleaving enzyme, which converts cholesterol to pregnenolone. Because of the distribution of enzymes in the various adrenal cortex subdivisions, the principal physiological effect of ACTH is production of the glucocorticosteroids.

Aside from its function controlling adrenal cortical activity, ACTH appears to have diverse biological roles including modulation of endocrine and exocrine glands, temperature regulation and influences on nerve regeneration and development. In addition, ACTH and its fragments affect motivation, learning, and behavior. The use of ACTH as a therapeutic agent may thus help the control of these functions. ACTH release from the anterior pituitary is mediated by corticotropin releasing factor (CRF).

**Growth Hormone Peptides (SEQ ID NOS: 23-24, 45)** – Human

placental lactogen (hPL), growth hormones, and prolactin (PrI) comprise the growth hormone family. All have about 200 amino acids, 2 disulfide bonds, and no glycosylation. Although each has special receptors and

unique characteristics to their activity, they all possess growth-promoting and lactogenic activity. Mature GH (22,000 daltons) is synthesized in acidophilic pituitary somatotropes as a single polypeptide chain.

Because of alternate RNA splicing, a small amount of a somewhat smaller molecular form is also secreted.

There are a number of genetic deficiencies associated with GH. GH-deficient dwarfs lack the ability to synthesize or secrete GH, and these short-statured individuals respond well to GH therapy. Pygmies lack the IGF-1 response to GH but not its metabolic effects; thus in pygmies the deficiency is post-receptor in nature. Finally, Laron dwarfs have normal or excess plasma GH, but lack liver GH receptors and have low levels of circulating IGF-1. The defect in these individuals is clearly related to an inability to respond to GH by the production of IGF-1. The production of excessive amounts of GH before epiphyseal closure of the long bones leads to gigantism, and when GH becomes excessive after epiphyseal closure, acral bone growth leads to the characteristic features of acromegaly. Using GH as a therapeutic agent would aid in treating these disorders, and potentially stimulate growth in other cases of short stature with low or normal GH levels.

**Melanocyte Stimulating Hormones (MSH) (SEQ ID NOS: 25-39)** - Melanocyte stimulating hormone (MSH) is generated in the intermediary pituitary under the control of dopamine. MSH may have important physiological roles in the control of vertebrate pigment cell melanogenesis, neural functioning related to learning and behavior, and fetal development. See Sawyer, T.K. et al., Proc. Nat. Acad. Sci USA, 79, 1751 (1982).

**Oxytocin (SEQ ID NOS: 40-44)** - Oxytocin is involved in the enhancement of lactation, contraction of the uterus, and relaxation of the pelvis prior to childbirth. Oxytocin secretion in nursing women is stimulated by direct neural feedback obtained by stimulation of the nipple during suckling. Its physiological effects include the contraction of mammary gland myoepithelial cells, which induces the ejection of milk

- from mammary glands, and the stimulation of uterine smooth muscle contraction leading to childbirth. Oxytocin causes myoepithelial cells surrounding secretory acini of mammary glands to contract, pushing milk through ducts. In addition, it stimulates the release of prolactin, and
- 5 prolactin is trophic on the breast and stimulates acinar formation of milk. A conjugated oxytocin could thus be used to aid lactation and help relax the pelvis prior to birth. It could also be used to prevent post partum uterine hemorrhage.

- Vasopressin (ADH) (SEQ ID NOS: 46-72)**– Vasopressin is also
- 10 known as antidiuretic hormone (ADH), because it is the main regulator of body fluid osmolarity, causing antidiuresis and increase in blood pressure. Vasopressin binds plasma membrane receptors and acts through G-proteins to activate the cyclic AMP/protein kinase A (cAMP/PKA) regulatory system. The secretion of vasopressin is
- 15 regulated in the hypothalamus by osmoreceptors, which sense water concentration and stimulate increased vasopressin secretion when plasma osmolarity increases. The secreted vasopressin increases the reabsorption rate of water in kidney tubule cells, causing the excretion of urine that is concentrated in  $\text{Na}^+$  and thus yielding a net drop in
- 20 osmolarity of body fluids. Vasopressin deficiency leads to watery urine and polydipsia, a condition known as diabetes insipidus. Using conjugated vasopressin or vasopressin fragments would thus prevent these disorders and allow the regular maintenance of the body's osmolarity.

25

## **B. Hypothalamic Hormones (Releasing factors)**

- Corticotropin Releasing Factor (CRF) & related peptides (SEQ ID NOS: 73-102)** – Corticotrophin-releasing factor (CRF), a 41 amino acid peptide, plays a significant role in coordinating the overall
- 30 response to stress through actions both in the brain and the periphery. In the brain, CRF is produced and secreted primarily from parvocellular neurons of the paraventricular hypothalamic nucleus. From there, the



CRF-containing neurons project to the portal capillary zone of the median eminence and act to stimulate the secretion of adrenocorticotrophic hormone (ACTH), beta-endorphin, and other proopiomelanocortin (POMC)-derived peptides from the pituitary gland.

- 5 The subsequent ACTH-induced release of adrenal glucocorticoids represents the final stage in the hypothalamic-pituitary-adrenal axis (HPA), which mediates the endocrine response to stress. Besides its neuroendocrine role, CRF also functions as a neurotransmitter and neuromodulator to elicit a wide spectrum of autonomic, behavioral and
- 10 immune effects to physiological, pharmacological, and pathological stimuli.

- Clinical studies indicated that CRF hypersecretion is associated with various diseases, such as major depression, anxiety-related illness, eating disorder, as well as inflammatory disorder. Low levels of CRF
- 15 have been found in Alzheimer's disease, dementias, obesity, and many endocrine diseases. Therefore, the use of CRF as a therapeutic agent to counter the effects associated with high levels or low levels of CRF will provide a basis for the treatment of diseases that are associated with abnormal CRF levels. Several peptide antagonists and nonpeptide
- 20 antagonists have been discovered and widely studied, including a-helical CRF(9-41), Astressin, D-PheCRF(12-41) (peptide antagonist) and CP-154526 (nonpeptide antagonist). These CRF antagonists may provide a novel agent for treatment of depression, anxiety and other CRF related illnesses. Conjugated CRF peptides could thus be used to maintain
- 25 adrenal health and viability during long term steroid use or as anti-inflammatory agents.

- Gonadotropin Releasing Hormone Associated peptides (GAP) (SEQ ID NOS: 103-110)** - GAP is contained in the precursor molecule to gonadotropin-releasing hormone (GnRH). GAP has
- 30 prolactin inhibiting properties. Gn-RH is a hormone secreted by the hypothalamus that stimulate the release of gonadotrophic hormones follicle stimulating hormone (FSH) and luteinizing hormone (LH). Low

levels of circulating sex hormone reduce feedback inhibition on GnRH synthesis, leading to elevated levels of FSH and LH. The latter peptide hormones bind to gonadal tissue, resulting in sex hormone production via cyclic AMP (cAMP) and protein kinase A (PKA) mediated pathways.

- 5 A conjugated GnRM could be used to aid fertility, or as a contraceptive in either males or females. This agent would have use in animals as well as humans.

**Growth Hormone Releasing Factor (GRF) (SEQ ID NOS: 111-134)**- GRF is a hypothalamic peptide that plays a critical role in

- 10 controlling the synthesis and secretion of growth hormone in the anterior pituitary. Some structurally unrelated short peptides have also been reported to elicit growth hormone secretion by a different mechanism.

Under the influence of GRF, growth hormone is released into the systemic circulation, causing the target tissue to secrete IGF-1. Growth

15 hormone also has other more direct metabolic effects; it is both hyperglycemic and lipolytic. The principal source of systemic IGF-1 is the liver, although most other tissues secrete and contribute to systemic IGF-1. Liver IGF-1 is considered to be the principal regulator of tissue growth. In particular, the IGF-1 secreted by the liver is believed to

- 20 synchronize growth throughout the body, resulting in a homeostatic balance of tissue size and mass. IGF-1 secreted by peripheral tissues is generally considered to be autocrine or paracrine in its biological action. The use of a conjugated GRF as a therapeutic agent to increase GH release, would then help treat disorders involving growth functions
- 25 regulated by GRF.

**Luteinizing Hormone Release Hormones (LH-RH) (SEQ ID NOS: 135-161)** – Luteinizing hormone releasing hormone is the key mediator in the neuroregulation of the secretion of gonadotropins, luteinizing hormone (LH) and follicle stimulating hormone (FSH). LH-RH

30 can modify sexual behavior by regulating plasma gonadotropin and sex steroid levels. See Vale, W.W. et al., Peptides, Structure and Biological Function, Proceedings of the Sixth American Peptide Symposium,

Gross, E. and Meienhofer, M., eds., 781 (1979). A conjugated LH-RH agent could be used to stimulate ovulation in humans or animals as an aid to fertility.

**Orexins (SEQ ID NOS: 162-164)** – Orexins are a family of  
5 neuropeptides from the hypothalamus that have been recently  
discovered and characterized. Orexins stimulate appetite and food  
consumption. Their genes are expressed bilaterally and symmetrically in  
the lateral hypothalamus, which was earlier determined to be the  
"feeding center" of the hypothalamus. In contrast, the so-called satiety  
10 center is expressed in the ventromedial hypothalamus and is dominated  
by the leptin-regulated neuropeptide network.

**Prolactin Releasing Peptides (SEQ ID NOS: 65-170)** – Prolactin  
is produced by acidophilic pituitary lactotropes. Prolactin releasing  
peptides act on lactotrope to release prolactin. PRL initiates and  
15 maintains lactation in mammals, but normally only in mammary tissue  
that has been primed with estrogenic sex hormones. A conjugated PRP  
could be used to increase lactation in humans or animals.

**Somatostatin (SEQ ID NOS: 171-201)** – Also known as Growth  
Hormone Release Inhibiting Factors (GIF), somatostatin is a 14 amino  
20 acid peptide is secreted by both the hypothalamus and by d cells of the  
pancreas (its pancreatic version is discussed below). Somatostatin has  
been reported to modulate physiological functions at various sites  
including pituitary, pancreas, gut and brain. It inhibits the release of  
growth hormone, insulin, and glucagon. It has many biological roles,  
25 including: inhibition of basal and stimulated hormone secretion from  
endocrine and exocrine cells, an effect on locomotor activity and  
cognitive function, and possible therapeutic value in small cell lung  
cancer. See Reubi, J. C. et al, Endocrinology, 110, 1049 (1982). A  
conjugated somatostatin could be used to treat gigantism in children or  
30 acromegaly in the adult.

### **Thyrotropin Releasing Hormone (THR) and Analogs (SEQ ID**

**NOS: 202-214)** – THR stimulates the production of thyroid stimulating hormone (TSH, also known as thyrotropin) and prolactin secretion. In adults, TSH is responsible for up-regulating general protein synthesis and inducing a state of positive nitrogen balance. In the embryo, it is necessary for normal development. Hypothyroidism in the embryo is responsible for cretinism, which is characterized by multiple congenital defects and mental retardation. A conjugated THR could then be used as a therapeutic agent in the treatment of these disorders. It could also be used to treat pituitary causes of thyroid insufficiency or in the diagnosis of human tumors of the thyroid.

### **C. Thyroid Hormones**

#### **Calcitonins (CT) & Calcitonins Precursor Peptides (SEQ ID**

**NOS: 215-224)** - Calcitonin (CT) is a 32-amino acid peptide secreted by C cells of the thyroid gland. Calcitonin is employed therapeutically to relieve the symptoms of osteoporosis, although details of its mechanism of action remain unclear. However, it has been observed that CT induces the synthesis of parathyroid hormone (PTH) in isolated cells, which leads *in vivo* to increased plasma  $\text{Ca}^{2+}$  levels. In addition, CT has been shown to reduce the synthesis of osteopontin (Opn), a protein made by osteoclasts and responsible for attaching osteoclasts to bone. Thus, using conjugated CT as a therapeutic peptide would elevate plasma  $\text{Ca}^{2+}$  via PTH induction and reduce bone reabsorption by decreasing osteoclast binding to bone.

#### **Calcitonins Gene Related Peptide (CGRP) (SEQ ID NOS: 225-**

**253)**– CGRP is a 37 amino acid peptide that results from alternative splicing of calcitonin gene transcripts. It exists in at least two forms: alpha-CGRP (or CGRP-I) and beta-CGRP (or CGRP-II). CGRP has considerable homology with amylin and adrenomedullin, and is widely distributed both centrally and peripherally in organs including the skin,

the heart, the pancreas, the lungs, and the kidneys. CGRP has many biological roles, affecting the nervous and cardiovascular systems, inflammation and metabolism.

5 **D. Parathyroid Hormones and Related Proteins**

**Parathyroid Hormones (PTH) (SEQ ID NOS: 254-293) -**

Parathyroid hormone (PTH) is synthesized and secreted by chief cells of the parathyroid in response to systemic  $\text{Ca}^{2+}$  levels. It plays a major role in the modulation of serum calcium concentration and thereby affect the  
10 physiology of mineral and bone metabolism. The  $\text{Ca}^{2+}$  receptor of the parathyroid gland responds to  $\text{Ca}^{2+}$  by increasing intracellular levels of PKC,  $\text{Ca}^{2+}$  and  $\text{IP}_3$ ; this stage is followed, after a period of protein synthesis, by PTH secretion. The synthesis and secretion of PTH in chief cells is constitutive, but  $\text{Ca}^{2+}$  regulates the level of PTH in chief  
15 cells (and thus its secretion) by increasing the rate of PTH proteolysis when plasma  $\text{Ca}^{2+}$  levels rise and by decreasing the proteolysis of PTH when  $\text{Ca}^{2+}$  levels fall. The role of PTH is to regulate  $\text{Ca}^{2+}$  concentration in extracellular fluids. The feedback loop that regulates PTH secretion therefore involves the parathyroids,  $\text{Ca}^{2+}$ , and the target tissues  
20 described below.

PTH acts by binding to cAMP-coupled plasma membrane receptors, initiating a cascade of reactions that culminates in the biological response. The body's response to PTH is complex but is aimed in all tissues at increasing  $\text{Ca}^{2+}$  levels in extracellular fluids. PTH  
25 induces the dissolution of bone by stimulating osteoclast activity, which leads to elevated plasma  $\text{Ca}^{2+}$  and phosphate. In the kidney, PTH reduces renal  $\text{Ca}^{2+}$  clearance by stimulating its reabsorption; at the same time, PTH reduces the reabsorption of phosphate and thereby increases its clearance. Finally, PTH acts on the liver, kidney, and  
30 intestine to stimulate the production of the steroid hormone 1,25-dihydroxycholecalciferol (calcitriol), which is responsible for  $\text{Ca}^{2+}$  absorption in the intestine. A conjugated PTH could be used to regulate

calcium homeostasis in patients with parathyroid hormone deficiency states. Inhibitor analogues could be used to block PTH action in renal failure or other patients with excessive PTH levels.

**Parathyroid Hormone Related Proteins (PTHrP) (SEQ ID NOS:**

- 5   **294-309)** - Parathyroid hormone-related protein (PTHrP) has received attention as a physiological regulator attenuating chondrocytic differentiation and preventing apoptotic cell death. PTHrP was initially identified as a tumor-derived, secretory protein with structural similarity to parathyroid hormone (PTH), the major regulator of calcium
- 10   homeostasis. PTH and PTHrP bind to a common G protein-coupled cell surface receptor (PTH/PTHrP or PTH-1 receptor) that recognizes the N-terminal (1-34) region of these peptides. Hence, when tumor-derived PTHrP enters the circulation, it activates receptors in classic PTH target organs such as bone and kidney and elicits PTH-like bioactivity. By
- 15   promoting bone resorption and inhibiting calcium excretion, circulating PTHrP gives rise to the common paraneoplastic syndrome of malignancy-associated humoral hypercalcemia.

- Although initially discovered in tumors, PTHrP was subsequently shown to be expressed in a remarkable variety of normal tissues
- 20   including the fetal and adult skeleton, where acting in concert with its amino terminal PTH-1 receptor, it serves to regulate cellular growth and differentiation. The anabolic effects of intermittent PTH administration on bone and its therapeutic potential in osteoporosis have been extensively explored. With the recognition that PTHrP is the
- 25   endogenous ligand for the PTH/PTHrP receptor in osteoblasts, its use as an anabolic agent has also been investigated. Modified PTHrP peptides could be used for similar indications as PTH.

- E.    Pancreatic Hormones** - The principal role of the pancreatic
- 30   hormones is the regulation of whole-body energy metabolism, principally

by regulating the concentration and activity of numerous enzymes involved in catabolism and anabolism of the major cell energy supplies.

- Amylin (SEQ ID NOS: 310-335)**- Pancreatic beta-cell hormone amylin is a 37-amino-acid peptide related to CGRP and calcitonin. It is co-secreted with insulin from pancreatic beta-cells. Amylin is deficient with type 1 diabetes mellitus. Amylin appears to work with insulin to regulate plasma glucose concentrations in the bloodstream, suppressing the posttherapeutic peptiderandial secretion of glucagon and restraining the rate of gastric emptying. People with diabetes have a deficiency in the secretion of amylin that parallels the deficiency in insulin secretion, resulting in an excessive inflow of glucose into the bloodstream during the posttherapeutic peptiderandial period.

- While insulin replacement therapy is a cornerstone of diabetes treatment, replacement of the function of both amylin and insulin may allow a more complete restoration of the normal physiology of glucose control. Type 2 diabetes is characterized by islet amyloid deposits, which are primarily composed of the amyloidogenic human form of islet amyloid polypeptide. A conjugated amylin could be used in the management of diabetes to limit post prandial hyperglycemia.

- Glucagon (SEQ ID NOS: 336-376)** - Glucagon is a 29-amino acid hormone synthesized by the a cells of the islets of Langerhans as a very much larger proglucagon molecule. Like insulin, glucagon lacks a plasma carrier protein, and like insulin its circulating half life is also about 5 minutes. As a consequence of the latter trait, the principal effect of glucagon is on the liver, which is the first tissue perfused by blood containing pancreatic secretions. Glucagon binds to plasma membrane receptors and is coupled through G-proteins to adenylate cyclase. The resultant increases in cAMP and PKA reverse all of the effects described above that insulin has on liver. The increases also lead to a marked elevation of circulating glucose, with the glucose being derived from liver gluconeogenesis and liver glycogenolysis. A conjugated glucagon

construct could be used to manage brittle diabetes with recurrent hypoglycemia or to prevent or treat iatrogenic hypoglycemia.

**Insulin and Insulin-Like peptides (SEQ ID NOS: 377-382) –**

The earliest of these hormones recognized was insulin, a disulfide bonded dipeptide of 21 and 30 amino acids produced by the pancreas, whose major function is to counter the concerted action of a number of hyperglycemia-generating hormones and to maintain low blood glucose levels. Insulin is a member of a family of structurally and functionally similar molecules that include IGF-1, IGF-2, and relaxin. The tertiary structure of all 4 molecules is similar, and all have growth-promoting activities, but the dominant role of insulin is metabolic while the dominant roles of the IGFs and relaxin are in the regulation of cell growth and differentiation.

Insulin is synthesized as a prehormone in the b cells of the islets of Langerhans. Its signal peptide is removed in the cisternae of the endoplasmic reticulum and it is packaged into secretory vesicles in the Golgi, folded to its native structure, and locked in this conformation by the formation of 2 disulfide bonds. Specific protease activity cleaves the center third of the molecule, which dissociates as C peptide, leaving the amino terminal B peptide disulfide bonded to the carboxy terminal A peptide.

Insulin generates its intracellular effects by binding to a plasma membrane receptor, which is the same in all cells. The receptor is a disulfide-bonded glycoprotein. One function of insulin (aside from its role in signal transduction) is to increase glucose transport in extrahepatic tissue is by increasing the number of glucose transport molecules in the plasma membrane. Glucose transporters are in a continuous state of turnover. Increases in the plasma membrane content of transporters stem from an increase in the rate of recruitment of new transporters into the plasma membrane, deriving from a special pool of preformed transporters localized in the cytoplasm.



In addition to its role in regulating glucose metabolism (and its therapeutic use in treating diabetes), insulin stimulates lipogenesis, diminishes lipolysis, and increases amino acid transport into cells.

- Insulin also modulates transcription, altering the cell content of numerous mRNAs. It stimulates growth, DNA synthesis, and cell replication, effects that it holds in common with the IGFs and relaxin. A conjugated insulin could thus be used to manage diabetes.

**NeuroPeptide Y (SEQ ID NOS: 383-389) – Neuropeptide Y**

- (NPY), a peptide with 36 amino acid residues, is one of the most abundant neuropeptides in both the peripheral and the central nervous systems. It belongs to the pancreatic polypeptide family of peptides. Like its relatives, peptide YY (PYY) and pancreatic polypeptide (PP), NPY is bent into hairpin configuration that is important in bringing the free ends of the molecule together for binding to the receptors.
- NPY exerts a wide range of effects in the central nervous system (CNS) and the periphery. Its CNS actions include major effects on feeding and energy expenditure, and alterations in heart rate, blood pressure, arousal and mood. In the periphery, NPY causes vasoconstriction and hypertension; it is also found in the gastrointestinal and urogenital tract, implicating its functions by action upon gastrointestinal and renal targets. In recent studies, hypothalamic NPY has been found to play a fundamental role in developing the features of obesity, it is a major transducer in the pathways signalling body fat to the hypothalamus, and in regulating body fat content. Leptin, an obese gene product, has been found to decrease NPY gene expression in obese (ob/ob) mice. Insulin and corticosteroids are also involved in the regulation of hypothalamic NPY synthesis, with insulin decreasing and corticosteroids increasing NPY expression. A conjugated NPY could be used to treat obesity and MODM (Type II DM) in obese patients.

**Pancreatic Polypeptides (PP) (SEQ ID NOS: 390-396) -**

Pancreatic polypeptide (PP) is a 36-amino acid hormone produced by F cells within the pancreatic islets and the exocrine pancreas. It is a

member of the PP fold family of regulatory peptides, and increases glycogenolysis and regulates gastrointestinal activity. A conjugated pancreatic polypeptide could thus be used to alter absorption and metabolism of foods.

- 5           **Peptide YY (SEQ ID NOS: 397-400)** - PYY is a thirty six amino acid long peptide, first isolated from porcine intestinal tissue and mainly localized in intestinal endocrine cells. It has many biological activities, including a range of activities within the digestive system and potent inhibition of intestinal electrolyte and fluid secretion.

- 10           **Somatostatin (SEQ ID NOS: 171-201)** – The somatostatin secreted by d cells of the pancreas is a 14-amino acid peptide identical to somatostatin secreted by the hypothalamus. In neural tissue somatostatin inhibits GH secretion and thus has systemic effects. In the pancreas, somatostatin acts a paracrine inhibitor of other pancreatic
- 15           hormones and thus also has systemic effects. It has been speculated that somatostatin secretion responds principally to blood glucose levels, increasing as blood glucose levels rise and thus leading to down-regulation of glucagon secretion. A conjugated somatostatin could then be used to aid in the management of diabetes.

20

#### **F. Digestive Hormones**

- Cholecystokinin (CCK) & related peptides (SEQ ID NOS: 401-416)** – CCK is a polypeptide of 33 amino acids originally isolated from pig small intestine that stimulates gallbladder contraction and bile flow
- 25           and increases secretion of digestive enzymes from pancreas. It exists in multiple forms, including CCK-4 and CCK-8, with the octapeptide representing the dominant molecular species showing the greatest activity. It belongs to the CCK/gastrin peptide family and is distributed centrally in the nervous system and peripherally in the gastrointestinal
- 30           system. It has many biological roles, including stimulation of pancreatic secretion, gall bladder contraction and intestinal mobility in the GI tract

as well as the possible mediation of satiety and painful stimuli. A conjugated CCK could be used in diagnostic studies of the gall bladder or in chronic cholecystitis.

**Gastrin Releasing Peptide (GRP) (SEQ ID NOS: 417-429) -**

- 5 GRP is a 27-amino acid peptide originally isolated from porcine non-antral gastric tissue, and is the homolog of the frog skin peptide named bombesin growth. It is widely distributed both centrally and peripherally in tissues including brain, lung and gastrointestinal tract. It regulates a variety of cell physiological processes including secretion, smooth
- 10 muscle contraction, neurotransmission and cell growth. A conjugated GRP could be used in the treatment of adynamic ileus or constipation in the elderly.

**Gastrin & related peptides (SEQ ID NOS: 417-429) –** Gastrin is

- a polypeptide of 17 amino acids produced by stomach antrum, which
- 15 stimulates acid and pepsin secretion. Gastrin also stimulates pancreatic secretions. Multiple active products are generated from the gastrin precursor, and there are multiple control points in gastrin biosynthesis. Biosynthetic precursors and intermediates (progastrin and Gly-gastrins) are putative growth factors; their products, the amidated gastrins,
- 20 regulate epithelial cell proliferation, the differentiation of acid-producing parietal cells and histamine-secreting enterochromaffin-like (ECL) cells, and the expression of genes associated with histamine synthesis and storage in ECL cells, as well as acutely stimulating acid secretion. Gastrin also stimulates the production of members of the epidermal
- 25 growth factor (EGF) family, which in turn inhibit parietal cell function but stimulate the growth of surface epithelial cells. Plasma gastrin concentrations are elevated in subjects with *Helicobacter pylori*, who are known to have increased risk of duodenal ulcer disease and gastric cancer. The use of gastrin or gastrin antagonists as a therapeutic agent
- 30 may therefore contribute to treating major upper gastrointestinal tract disease.

**Gastrin Inhibitory peptides (SEQ ID NOS: 417-429)** – Gastrin inhibitory peptide is a polypeptide of 43 amino acids that inhibits secretion of gastrin. A conjugated GIP could be used to treat severe peptic ulcer disease.

5       **Motilin (SEQ ID NOS: 430-433)** – Motilin is a polypeptide of 22 amino acids that controls gastrointestinal muscles. Motilin-producing cells are distributed in the duodenum, upper jejunum, and colorectal adenocarcinomas and in midgut carcinoids. Motilin stimulates gut motility.

10       **Secretin (SEQ ID NOS: 434-441)** – Secretin is a polypeptide of 27 amino acids secreted from duodenum at pH values below 4.5, stimulates pancreatic acinar cells to release bicarbonate and H<sub>2</sub>O. Secretin is a neurotransmitter (a chemical messenger) in the neuropeptide group. It is one of the hormones that controls digestion  
15       (gastrin and cholecystokinin are the others). It is a polypeptide composed of 27 amino acids and is secreted by cells in the digestive system when the stomach empties. Secretin stimulates the pancreas to emit digestive fluids that are rich in bicarbonate which neutralizes the acidity of the intestines, the stomach to produce pepsin (an enzyme that  
20       aids digestion of protein), and the liver to produce bile.

      Secretin may be useful in treating autism. In one study, children with autistic spectrum disorders underwent upper gastrointestinal endoscopy and intravenous administration of secretin to stimulate pancreaticobiliary secretion. All three had an increased  
25       pancreaticobiliary secretory response when compared with nonautistic patients (7.5 to 10 mL/min versus 1 to 2 mL/min). Within 5 weeks of the secretin infusion, a significant amelioration of the children's gastrointestinal symptoms was observed, as was a dramatic improvement in their behavior, manifested by improved eye contact,  
30       alertness, and expansion of expressive language. These clinical observations suggest an association between gastrointestinal and brain function in patients with autistic behavior.

**Vasoactive Intestinal Peptide (VIP) and related peptides**

**(SEQ ID NOS: 442-464)** –VIP is a polypeptide of 28 residues produced by hypothalamus and GI tract. It relaxes the GI, inhibits acid and pepsin secretion, acts as a neurotransmitter in peripheral autonomic nervous system, and increases secretion of H<sub>2</sub>O and electrolytes from pancreas and gut. It was originally discovered in lung and intestine and is also found in tissues including brain, liver, pancreas, smooth muscle and lymphocytes. It is structurally related to a family of peptides which include PACAP, PHI, secretin and glucagon. It has a diverse range of biological actions including vasodilation, electrolyte secretion, modulation of immune function and neurotransmission. A conjugated VIP may be useful in the treatment of achlorhydria, ischemic colitis and irritable bowel syndrome (IBS).

- 15 **G. Natriuretic Peptides** - There are three members in the natriuretic peptide hormone family, atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP, brain natriuretic peptide), and C-type natriuretic peptide (CNP), that are involved in the regulation of blood pressure and fluid homeostasis.

20 **Atrial-Natriuretic Peptides (ANP) (SEQ ID NOS: 465-507)–**

- ANP is a 28-amino acid peptide hormone containing a disulfide bond. It exerts natriuretic, diuretic, and vasorelaxant effects and play an important role in the body's blood volume and blood pressure homeostasis. See Smith, F.G. et al., J. Dev. Physiol. 12, 55 (1989). The mechanisms controlling ANP release have been the subject of intense research, and are now fairly well understood. The major determinant of ANP secretion is myocyte stretch. Although much less is known about the factors regulating BNP release from the heart, myocyte stretch has also been reported to stimulate BNP release from both atria and ventricles. However, whether wall stretch acts directly or via factors such as endothelin-1, nitric oxide, or angiotensin II liberated in response to distension has not been established. Recent studies show that by

stimulating endothelin type A receptors endothelin plays an important physiological role as a mediator of acute-volume load-induced ANP secretion from atrial myocytes in conscious animals. In fact, endogenous paracrine/autocrine factors liberated in response to atrial wall stretch rather than direct stretch appears to be responsible for activation of ANP secretion in response to volume load, as evidenced by almost complete blockade of ANP secretion during combined inhibition of endothelin type A/B and angiotensin II receptors. Furthermore, under certain experimental conditions angiotensin II and nitric oxide may also exert a significant modulatory effect on stretch-activated ANP secretion. The molecular mechanisms by which endothelin-1, angiotensin II, and nitric oxide synergistically regulate stretch-activated ANP release are yet unclear. Abstract Volume 75 Issue 11/12 (1997) pp 876-885, Journal of Molecular Medicine. A conjugated would be useful in the management of malignant hypertension or severe hypertension and renal failure.

**Brain Natriuretic Peptides (BNP) (SEQ ID NOS: 507-516) -**

Brain natriuretic peptide (BNP), a member of the natriuretic peptide family, is produced and released from cardiac ventricles. BNP regulates the body fluid volume, blood pressure, and vascular tones through the A-type guanylate cyclase-coupled receptor. The BNP plays a role in electrolyte-fluid homeostasis such as atrial natriuretic peptides (ANP). A conjugated BNP could be useful in the management of heart failure.

**C-Type Natriuretic Peptides (CNP) (SEQ ID NOS: 517-524) - C-**

type natriuretic peptide (CNP), the third member of the natriuretic peptide family, is produced in vascular endothelial cells (ECs) and acts as an endothelium-derived relaxing peptide. Although atrial and brain natriuretic peptides are well known to be involved in the regulation of cardiovascular and endocrine functions as circulating hormones, the roles of the C-type natriuretic peptide (CNP) remain unknown.

CNP is found principally in the central nervous system and vascular endothelial cells while ANP and BNP are cardiac hormones.

ANP is synthesized mainly in the atria of the normal adult heart, while BNP is produced by both the atria and ventricles.

- H. **Tachykinins (SEQ ID NOS: 525-627)** – A family of peptides, including neurokinin A and substance P, that share a common C terminal sequence (F-X-GLM-NH<sub>2</sub>) which is required for full biological activity including Neurokinin A, B, and Substance P.

**Neurokinin A** – Neurokinin A is a decapeptide, previously known as substance K. It is a member of the tachykinin family of neuropeptides which includes substance P and neurokinin B. It exhibits a variety of activities related to smooth muscle contraction, pain transmission, bronchoconstriction, vasodilation and modulation of the immune system.

- Neuromedin**- Neuromedins, smooth-muscle-stimulating peptides, are commonly divided into four groups: bombesin-like, kassinin-like, neurotensin-like and neuromedins U. These neuropeptides and their receptors are localized to all components of the HPA hypophyseal pituitary axis, the only exemption seems to be neurokinin B, which is not detected in the adenohypophysis. Neuromedins exert a manifold effect on HPA axis, and their action on the adrenal suggests their involvement in the regulation of growth, structure and function of the adrenal cortex. Neuromedins may exert both direct and indirect effects on the adrenal cortex. Direct effect is proven by the stimulation of mineralo- and glucocorticoid therapeutic peptides by isolated or cultured adrenocortical cells and by mobilisation of intracellular [Ca<sup>2+</sup>]. Indirect effects, on the other hand, may be mediated by ACTH, arginine-vasopressin, angiotensin II, catecholamines or by other regulatory substances of medullary origin.

- Substance P and Related Peptides** – Substance P is an eleven amino acid peptide, first isolated from brain and intestine. It has been proposed as a neuromodulator involved in pain transmission in the spinal cord. It also affects contraction of smooth muscle, reduction of

blood pressure, stimulation of secretory tissue, and release of histamine from mast cells.

### **I. Renin Related Peptides**

- 5        **Angiotensins (SEQ ID NOS: 628-677)**– Angiotensin is a 10 amino acid peptide derived from enzymatic cleavage of  $\alpha$ 2-globin by the kidney enzyme renin. The C-terminal 2 amino acids are then released to yield angiotensin I, which is responsible for essential hypertension through stimulated synthesis and release of aldosterone from adrenal
- 10      cells. It is a multifunctional hormone regulating blood pressure, plasma volume, neuronal function thirst, and water intake.

Angiotensin II is an octapeptide derived from angiotensin I by angiotensin converting enzyme, and is widely distributed both centrally and peripherally in organs such as the heart, the kidneys, and the liver.

- 15      Angiotensin IV is the terminal hexapeptide fragment of angiotensin II formed metabolically by proteolytic cleavage from either angiotensin I or angiotensin II. It plays a role in vascular control, cardiac growth, renal blood flow and memory function.

- Angiotensin II is the key peptide hormone that regulates vascular
- 20      smooth muscle tone, blood pressure, free water intake and sodium retention. It controls vascular homeostasis compensating for loss of intravascular volume by stimulating increased vasospastic tone, increase sodium retention and increased free water intake.

### **Renin substrates and Inhibitors (SEQ ID NOS: 678-684) -**

- 25      Renin is a very specific aspartic protease, which is synthesized and released by differentiated smooth muscle cells in the vasculature of the kidney called granular epithelial cells. Renin is specific for its substrate, angiotensinogen, which it cleaves specifically at the Leu<sup>10</sup>-Val<sup>11</sup> bond to form the decapeptide, angiotensin I (AI). The renin-angiotensin system
- 30      is involved in the control of fluid and mineral balance throughout the vertebrates. Renin can be found in mammals, birds, reptiles, amphibians, bony fishes, cartilaginous fishes, and agnathans. Specific



renin inhibitors can also be designed, with therapeutic applications for treatment of for example hypertension and congestive heart failure (Blundell et al., 1987).

5     **J.     Endothelins and Related Peptides (SEQ ID NOS: 685-744) -**

The endothelin peptide family consists of the 21 amino acid isoforms endothelin-1, endothelin-2, endothelin-3, sarafotoxin (a snake venom) and scorpion toxin.

- 10     **Endothelins (ET) and Big Endothelins** – Endothelins are found on endothelial cells in a wide variety of organ systems. Examples of pathologies and physiological processes associated with changes in endothelin levels and synthetics include: atherosclerosis and hypertension, coronary vasospasm, acute renal failure, changes in intracellular  $\text{Ca}^{2+}$  levels, and effects on the renin-angiotensin system.
- 15     Endothelins are released in response to variations in angiotensin II, vasopressin, and cytokines (e.g.  $\text{TGF-}\beta$ ,  $\text{TNF-}\alpha$ ,  $\text{IL-}\beta$ ) levels as well as other physiological events including increase blood flow.

- The endothelin family of peptides consists of highly potent endogenous vasoconstrictor agents first isolated from endothelial cell supernatant. They regulate blood flow to organs by exporting a vasoconstrictive effect on arteries. Endothelins are derived from big-endothelin, which is cleaved by a unique membrane-bound metalloprotease, endothelin-converting enzyme, into the 21-amino-acid bioactive forms (ET-1, ET-2 and ET-3).
- 20

- 25     Of the 3 isoforms (ET-1, ET-2, ET-3), endothelin-1 is the major isoform and plays an important role for regulation of vascular function. Endogenous endothelin peptides and their receptors are differentially distributed throughout the many smooth muscle tissues including blood vessels, uterus, bladder and intestine. Through this widespread distribution and localization, they exert biological functions in regulating vascular tone and causing mitogenesis. ETs and their receptor subtypes are also present in various endocrine organs. It appears to act as
- 30

modulator of secretion of prolactin, gonadotropins GH and TSH. Endothelin may also be the disease marker or an etiologic factor in ischemic heart disease, atherosclerosis, congestive heart failure, renal failure, systemic hypertension, pulmonary hypertension, cerebral vasospasm.

Exogenously administered endothelin-1 has been demonstrated to increase peripheral resistance and blood pressure in a dose-dependent manner. However, during the first minutes of intravenous administration endothelins also decrease peripheral resistance and blood pressure, presumably due to the release of vasodilatory compounds such as nitric oxide, prostacyclin, and atrial natriuretic peptide.

**ET(A) Receptor Antagonists** – Endothelin receptors exist as two types: A (ET-A) and B (ET-B1 and ET-B2). ET-A receptors are responsible for while ET-B1 and ET-B2 mediate vasorelaxation and vasoconstriction respectively.

**Sarafotoxin peptides** – As already described, endothelin (ET) peptides are potent growth factors binding to G protein-coupled receptors. Sarafotoxins (S6) isolated from *Atractaspis engaddensis* are highly homologous to endothelins. Sarafotoxin peptides have marked vasoconstrictive activity and are responsible for the ischemic limb loss that follows snake or scorpion bites. They could be used therapeutically as a peptidase stabilized peptide as a vasopressive agent in shock and sepsis.

**K. Opioid Peptides (SEQ ID NOS: 745-927)** - Opioids are a large class of drugs, used clinically as painkillers, that include both plant-derived and synthetic alkaloids and peptides found endogenously in the mammalian brain. While the plant-derived alkaloids have been known and used for thousands of years, the endogenous opioid peptides were discovered only in the mid-1970s.

Opioids include casomorphin peptides, demorphins, endorphins, enkephalins, deltorphins, dynorphins, and analogs and derivatives of these.

- Casomorphin Peptides** – Casomorphin peptides are novel opioid peptides derived from casein( $\beta$ -casomorphins). Beta casomorphins are the more extensive studied opioid peptides arising from food proteins (beta-caseins). They were originally isolated from bovine beta-casein, the same sequences occur in ovine and buffalo beta-caseins.
- Demorphins** – Demorphin is a seven amino acid peptide, originally isolated from *Phylomedusa sauvagei* frog skin. It is a ligand which binds with high affinity to the  $\mu$  opioid receptor, and has many biological roles including analgesia, endocrine modulation, immunomodulation, increased  $K^+$  conductance and inhibition of action potentials.
- Dynorphin/New-Endorphin Precursor Related Peptides** – Dynorphins are a class of endogenous opioids that exist in multiple forms in the central nervous system. Dynorphins are derived from the precursor prodynorphin (proenkephalin B). Dynorphin, also known as Dynorphin A1-17, is a well known opioid which has the sequence Tyr-Gly-Gly-Phe-Leu<sup>5</sup>-Arg-Arg-Ile-Arg-Pro<sup>10</sup>-Lys-Leu-Lys-Trp-Asp<sup>15</sup>-Asn-Gln. SEQ ID NO:1. A number of derivatives and analogs of dynorphin are known including Dyn A1-13, SEQ ID NO: 2 Dyn A2-13, SEQ ID NO:3, Dyn A1-12, Dyn A2-12 and Dyn A2-17 as well as amide analogs such as those mentioned in U.S. Patent 4,462,941 of Lee et al., N-terminus truncated dynorphin analogs such as those described in International Patent Application WO 96/06626 of Lee et al. and des-Tyr or des-Tyr-Gly analogs such as those disclosed in International Patent Application WO 93/25217 also of Lee et al. The dynorphins are highly potent opioids, and demonstrate selective affinity for the kappa receptor. See Goldstein, A., Peptides, Structure and Function, Proceedings of the 8th

American Peptides Symposium, Hruby, V.J. and Rich, D.H., eds., 409 (1983).

**Endorphins** – The endorphins are derived from the precursor protein -lipotropin. They have been found to elicit several biological reactions such as analgesia, behavioral changes and growth hormone release. See Akil, H. et al., Ann. Rev. Neurosci., 7, 223 (1984).

**Enkepalins & related peptides** – Enkephalins and endorphins are neurohormones that inhibit transmission of pain impulses. The activity of neurons in both the central and peripheral nervous systems is affected by a large number of neurohormones that act on cells quite distant from their site of release. Neurohormones can modify the ability of nerve cells to respond to synaptic neurotransmitters. Several small peptides with profound effects on the nervous system have been discovered recently, for example enkephalins (e.g. Met-enkephalin and Leu-enkephalin) and endorphins (e.g.  $\beta$  endorphin). These three contain a common tetrapeptide sequence (Tyr-Gly-Gly-Phe) that is essential to their functions. Enkephalins and endorphins function as natural pain killers or opiates and decrease the pain responses in the central nervous system. See also Akil, H. etl al., Ann. Rev. Neurosci., 7, 223 (1984).

**L. Thymic peptides (SEQ ID NOS: 928-934)** – The thymus is thought to be responsible for the development and regulation of T cell immunity in both infants and adults. The thymus seems to exert its regulatory functions through the secretion of various noncellular, hormonelike products via its epithelial cells, called thymic peptides.

Thymic peptides are reported to have many effects on T cells. Several studies have reported that thymic peptides can assist development of immature, precursor cells into fully competent T cells. Thymic peptides seem to regulate the expression of various cytokine and monokine receptors on T cells and induce secretion of IL-2, interferon alpha, and interferon gamma (disease-fighting substances)

when the immune system is challenged. There are reports that the use of thymic hormones in children with immuno-deficiencies caused by chemotherapy has resulted in an increase in circulating T cells, normalization of T cell subsets, and restoration of delayed hypersensitivity reactions.

**Thymopoietin** - Thymopoietin is the largest of the known thymic hormones and consists of 49 amino acids.

**Thymulin** - Previously known as thymic serum factor, thymulin is the smallest of the chemically characterized thymic hormones and consists of 9 amino acids. Thymulin is the hormone responsible for stimulating the production of immune-system T cells

**Thymopentin** - Thymopentin is a small, synthesized thymic peptide drug, also known as therapeutic peptide-5 or Timunox. In the U.S. it is being developed as an AIDS therapy by the Immunobiology Research Institute. Thymopentin has been studied more extensively than most other thymic peptide drugs. At least one study has claimed a significant rise in T cells and slight clinical improvement in those patients who received thymopentin three times a week, compared to untreated control participants. Compared to the 14 untreated control participants, those taking the drug showed greater "immunologic stability" and some clinical improvement.

**Thymosin** - Thymosin is a mixture of 15 or more proteins. One of these proteins is thymosin alpha-1 which consists of 28 amino acids. Thymosin has therapeutic use for the treatment of primary immunodeficiencies and as a booster for influenza vaccine in renal dialysis patients. It is also being tested in ongoing clinical trials for activity against chronic hepatitis B and C, HIV infection, and certain forms of cancer.

**Thymic Humoral Factor (THF)** - THF is a thymic peptide currently being examined as an anti- HIV treatment. In preclinical

studies in rats with CMV-related immunosuppression, THF restored immune competence through modulation of T cells. In addition, it may have therapeutic use in the treatment of herpes, causing (at least in one study) the viral infection's rapid regression and increase of T-cell

5 populations.

#### L. Other Peptides

##### **Adrenomedullin Peptides (AM) (SEQ ID NOS: 935-945) -**

Adrenomedullin is a potent vasodilator peptide that exerts major effects on cardiovascular functions. Its systemic administration causes a rapid and profound fall in blood pressure and an increase in pulmonary blood flow. Its other actions are bronchodilatation, being an inhibitor of drinking behavior and an inhibitor of angiotensin-induced aldosterone secretion. See The Journal of Biological Chemistry, Vol. 270, No. 43, pp 25344-25347, 1995 and in the references cited therein

##### **Allatostatin Peptides (SEQ ID NOS: 946-949) -**

Allatostatins are 6-18 amino acid peptides synthesized by insects to control production of juvenile hormones, which in turn regulate functions including metamorphosis and egg production. While neuropeptides of the allatostatin family inhibit *in vitro* production of juvenile hormone, which modulates aspects of development and reproduction in the cockroach, *Diploptera punctata*, they are susceptible to inactivation by peptidases in the hemolymph, gut, and bound to internal tissues.

##### **Amyloid Beta-Protein Fragments (A $\beta$ fragments) (SEQ ID**

**NOS: 950-1010)** – These are the principle component of the amyloid plaques that accumulate intracellularly and extracellularly in the neuritic plaques in the brain in Alzheimer's Disease. A $\beta$  is a 4.5 kD protein, about 40-42 amino acids long, that is derived from the C-terminus of amyloid precursor protein (APP). APP is a membrane-spanning glycoprotein that, in the normal processing pathway, is cleaved inside the A $\beta$  protein to produce  $\alpha$ -sAPP, a secreted form of APP. Formation of  $\alpha$ -sAPP precludes formation of A $\beta$ . It has been proposed that A $\beta$

- accumulates by virtue of abnormal processing of APP, so that compounds that inhibit the activity of enzymes responsible for A $\beta$  production are being sought. See, e.g., Wagner et al. Biotech. Report (1994/1995), pp. 106-107; and Selkoe (1993) TINS 16:403-409. Under
- 5 certain conditions A $\beta$  peptides first aggregate and then are deposited as a folded  $\beta$ -sheet structure that is characteristic of amyloid fibrils.  $\beta$ -amyloid (1-42) forms aggregates at a significantly greater rate and to a greater extent than  $\beta$ -amyloid (1-40).

**Antimicrobial peptides (SEQ ID NOS: 1011-1047) -**

- 10 Antimicrobial peptides are a key component of the innate immune systems of most multicellular organisms, being active against one or more microorganisms such as bacteria, fungi, protozoa, yeast, and mycobacteria. Examples of such peptides include defensin, cecropin, buforin, and magainin. Despite broad divergences in sequence and
- 15 taxonomy, most antimicrobial peptides share a common mechanism of action, i.e., membrane permeabilization of the pathogen. They are classified in two broad groups: linear and cyclic. In the linear antimicrobial peptides, there are two subgroups: linear peptides tending to adopt  $\alpha$ -helical amphipathic conformation and linear peptides of
- 20 unusual composition, rich in amino acids such as Pro, Arg, or Trp. The cyclic group encompasses all cysteine-containing peptides, and can be further divided into two subgroups corresponding to single or multiple disulfide structures.

- Most antimicrobial peptides provoke an increase in plasma
- 25 membrane permeability. There is also evidence of other mechanisms, such as inhibition of specific membrane proteins, synthesis of stress proteins, arrest of DNA synthesis, breakage of single-strand DNA by defensins, interaction with DNA (without arrest of synthesis) by buforins, or production of hydrogen peroxide. Antimicrobial peptides can also act
- 30 by triggering self-destructive mechanisms such as apoptosis in eukaryotic cells or autolysis in bacterial targets. Antimicrobial peptides are also known to act as inhibitors of enzymes produced by pathogenic

organisms, either by serving as pseudo-substrates or by tight binding to the active site that disturbs the access of the substrate.

Increased levels of antimicrobial peptides have been reported for several animal and human infections for example for  $\alpha$ -defensins in

- 5 *Mycobacterium*, *Pasteurella*, or *Cryptosporidium* infections and for a variety of peptides in blisters and wound fluid. Inflammatory situations or stimuli are also associated with induction of antibiotic peptides.

Depleted levels of antimicrobial peptides are associated to several pathologies. Thus, patients of specific granule-deficiency

- 10 syndrome, completely lacking in  $\alpha$ -defensins, suffer from frequent and severe bacterial infections. Low levels of histatins from saliva in HIV patients has been correlated with a higher incidence of oral candidiasis and fungal infections. Perhaps the most compelling illustration of the implication of antimicrobial peptides in human pathology comes from
- 15 cystic fibrosis, a genetic disease associated with recurrent bacterial infections of the airways. The defective chloride channel causing the disease increases the salinity of the alveolar fluid, and thus impairs the bactericidal activity of  $\beta$ -defensins, which are salt sensitive. Andreu D, (Ed.) (1998) "Antimicrobial peptides" Biopolymers (Peptide Science) vol
- 20 47, N° 6, pp413-491. A. Andreu, L. Rivas (1998) *Animal Antimicrobial Peptides: An Overview*, Biopolymers (Pep. Sci.) 47: pp415-433.

#### **Antioxidant Peptides (SEQ ID NOS: 1048-1050)** - Antioxidants

are agents that prevents oxidative damage to tissue. Mammalian cells

- 25 are continuously exposed to activated oxygen species such as superoxide, hydrogen peroxide, hydroxyl radical, and singlet oxygen. These reactive oxygen intermediates are generated *in vivo* by cells in response to aerobic metabolism, catabolism of drugs and other xenobiotics, ultraviolet and x-ray radiation, and the respiratory burst of
- 30 phagocytic cells (such as white blood cells) to kill invading bacteria such as those introduced through wounds. Hydrogen peroxide, for example,



is produced during respiration of most living organisms especially by stressed and injured cells.

One example of antioxidant peptides is natural killer-enhancing factor B (NKEF-B), which belongs to a highly conserved family of recently discovered antioxidants. Natural killer-enhancing factor (NKEF) was identified and cloned on the basis of its ability to increase NK cytotoxicity. Two genes, NKEF-A and -B, encode NKEF proteins and sequence analysis presented suggests that each belongs to a highly conserved family of antioxidants. The role of NKEF-B as an antioxidant has been demonstrated by its protection of transfected cells to oxidative damage by hydrogen peroxide. NKEF-B has antioxidant activities toward prooxidants such as alkyl hydroperoxide and MeHg. Together with its antioxidant activity, the induction of NKEF-B by HP indicates that NKEF-B is an important oxidative stress protein providing protection against a variety of xenobiotic toxic agents.

#### **Apoptosis Related Peptides (SEQ ID NOS: 1051-1075) -**

Animal cells can self-destruct via an intrinsic program of cell death (Steller, 1995). Apoptosis is a form of programmed cell death that is characterized by specific morphologic and biochemical properties (Wyllie *et al.*, 1980). Morphologically, apoptosis is characterized by a series of structural changes in dying cells: blebbing (i.e. blistering) of the plasma membrane, condensation of the cytoplasm and nucleus, and cellular fragmentation into membrane apoptotic bodies (Steller, 1995; Wyllie *et al.*, 1980).

Biochemically, apoptosis is characterized by the degradation of chromatin, initially into large fragments of 50-300 kilobases and subsequently into smaller fragments that are monomers and multimers of 200 bases (Oberhammer *et al.*, 1993; Wyllie, 1980). Other biochemical indicators of apoptosis are induced or increased levels of the protein clusterin (Pearse *et al.*, 1992), also known as TRPM-2 or SGP-2, and activation of the enzyme typell transglutaminase, which

crosslinks proteins to the envelope of apoptotic bodies (Fesus *et al.*, 1991). Apoptosis is a complex phenomenon of related morphological and biochemical processes that can vary with tissue and cell type (Zakeri *et al.*, 1995).

5       The execution of apoptosis minimizes the leakage of cellular constituents from dying cells (apoptosis causes the cell to involute). For example, proteases could damage adjacent cells or stimulate an inflammatory response. This cardinal feature of apoptosis distinguishes it from necrosis, which usually results from trauma that causes injured  
10      cells to swell and lyse, releasing the cytoplasmic material that stimulates an inflammatory response (Steller, 1995; Wyllie *et al.*, 1980)

**Bag Cell Peptides (BCP) (SEQ ID NOS: 1076-1080)** – The neuropeptidergic bag cells of the marine mollusc *Aplysia californica* are involved in the egg-laying behavior of the animal. These neurosecretory  
15      cells synthesize an egg-laying hormone (ELH) precursor protein, yielding multiple bioactive peptides, including ELH, several bag cell peptides (BCP) and acidic peptide (AP). The bag cells of the marine mollusc *Aplysia californica* are well-characterized neuroendocrine cells that initiate egg laying. During sexual maturation, these cells (bag cell  
20      neurons), develop the capability of storing hormones that are released during periods of nervous system stimulation. The hormones are important to the process of egg laying, and so must not be released before the animal is sexually mature. Alpha-bag cell peptide belong to a small family of structurally related peptides that can elicit bag-cell activity  
25      in vitro.

**Bombesin (SEQ ID NOS: 1081-1090)** – Bombesin is a bioactive tetradecapeptide neuropeptide that belongs to a family of peptides sharing a common C terminal sequence, Trp-Ala-X-Gly-His-Met-NH<sub>2</sub>, and the N terminal region. It has a modulatory role found in nerves of  
30      the brain and gut that prevents gastric injury by release of endogenous gastrin. The mammalian homologue of bombesin is gastrin-releasing peptide (GRP).

**Bone Gla Protein Peptides (SEQ ID NOS: 1091-1097) -**

Osteocalcin (bone Gla-protein, or BGP) is produced and secreted by osteoblasts in the process of bone formation. As with collagen, this protein is a component of bone matrix. Serum osteocalcin rises when bone formation rates increase. Levels are high during puberty when bone growth is most rapid. Often levels are also high in diseases having high bone turnover, such as hyperparathyroidism and hyperthyroidism. In postmenopausal osteoporosis, osteocalcin levels are sometimes increased, reflecting the increased turnover of bone secondary to rapid bone resorption. In senile osteoporosis, occurring in more elderly subjects, osteocalcin levels are more likely to be low, reflecting reduced rates of both bone turnover and bone formation. A treatment regimen that increases bone formation also raises the serum osteocalcin levels.

**CART Peptides (SEQ ID NOS: 1098-1100) -** Cocaine and

amphetamine regulated transcript peptide (CART), is a recently discovered hypothalamic peptide with a potent appetite suppressing activity. In the rat the CART gene encodes a peptide of either 129 or 116 amino acid residues whereas only the short form exists in humans. The predicted signal sequence is 27 amino acid residues resulting in a prohormone of 102 or 89 residues. The C-terminal end of CART, consisting of 48 amino acid residues and 3 disulphide bonds, is thought to constitute a biologically active part of the molecule.

In the central nervous system CART is highly expressed in many hypothalamic nuclei, some of which are involved in regulating feeding behavior. The CART mRNA is regulated by leptin, and the expressed CART is a potent inhibitor of feeding that even overrides the feeding response induced by neuropeptide Y. The putative CART receptor is therefore a potential therapeutic target for an anti-obesity drug. See CART, a new anorectic peptide Thim L; Kristensen P; Larsen PJ; Wulff BS, Int J Biochem Cell Biol, 30(12):1281-4 1998 Dec.

**Cell Adhesion Peptides (SEQ ID NO: 1101)** - Cellular adhesion

peptides are directly involved in the cellular response to external stimuli. For example, during an inflammatory response, leukocytes must leave the plasma compartment and migrate to the point of antigenic insult. The

- 5 mechanism of this migratory event is a complex interplay between soluble mediators and membrane-bound cellular adhesion molecules. Soluble cellular chemotactic factors, which are produced in the damaged tissue by a variety of resident cells, set up a chemical concentration gradient out to the plasma compartment. Interaction of these factors with
- 10 their receptors on leukocytes leads to a directional migration of the leukocytes toward increasing concentrations of the chemotactic factor. Simultaneously, various adhesion peptides are upregulated on the leukocyte which mediate the initial rolling on the endothelial tissue, binding to a specific ligand on the activated endothelial tissue, and finally
- 15 migration between endothelial cells into the tissue. The steps in this cascade of events are mediated by the interaction of specific cell surface proteins, termed "cell adhesion molecules such as. E-selectin (ELAM-1, endothelial leukocyte adhesion molecule-1), ICAM-1 (intercellular adhesion molecule-1), and VCAM-1 (vascular cell adhesion molecule-1).

20 **Chemotactic Peptides (SEQ ID NOS: 1102-1113)** -

Chemotactic peptides are peptides that stimulate the migration of white cells, leukocytes and macrophages into tissues at the site of infection or injury or alternatively the prevent the migration of these same cells away from these sites.

25 **Complement Inhibitors (SEQ ID NOS: 1114-1120)** - Inhibition

of complement attack on xenotransplants may be accomplished by the use of complement inhibitors. The rejection of transplanted organs may involve both an extremely rapid hyperacute rejection (HAR) phase and a slower cellular rejection phase. HAR of xenotransplants is initiated by

30 preformed "natural" antibodies that bind to donor organ endothelium and activate complement attack by the recipient immune system. Activation of complement leads to the generation of fluid phase (C3a, C5a) and

membrane bound (C3b and C5b-9, i.e., C5b, C6, C7, C8, and C9) proteins with chemotactic, procoagulant, proinflammatory, adhesive, and cytolytic properties. Complement inhibitors inhibit this process.

**Cortistatin Peptides (SEQ ID NOS: 1121-1124)** – Cortistatin,

- 5 whose mRNA accumulates during sleep deprivation, apparently acts by antagonizing the effects of acetylcholine on cortical excitability, thereby causing synchronization brain slow waves. Cortistatin-14 (CST-14) shares 11 of its 14 residues with somatostatin-14 (SRIF-14), yet its effects on sleep physiology, locomotor behavior and hippocampal
- 10 function are quite different from those of somatostatin.

**Fibronectin Fragments & Fibrin Related Peptides (SEQ ID NOS: 1125-1174)** – Fibronectin is a large glycoprotein that is composed of blocks of three types of repeating, homologous peptide sequences.

- Several of the homologous blocks form functional domains that are
- 15 organized in a linear array on two nearly identical subunit arms. Each arm can be divided into functional domains, which are often referred to by one of the substances which bind in that region, for example the heparin-binding fragment, the fibrin binding fragment, and the cell-binding fragment. In several cell types, the Arg-Gly-Asp (RGD)
- 20 sequence in the cell-binding domain of fibronectin interacts with a cell-surface glycoprotein designated  $\alpha 5 \beta 1$ . Fibronectin also binds to extracellular and basement-membrane components, to the envelope glycoprotein of viruses, to a variety of bacteria including staphylococci and streptococci, and to parasites such as *Trypanosoma cruzi* and
- 25 *Leishmania* species.

- Fibronectin has several adhesive functions, for example cell-to-cell adhesion, cell-to-basement-membrane attachment, and clot stabilization. In addition, fibronectin promotes embryogenesis, nerve regeneration, fibroblast migration, macrophage function, and pathogen
- 30 (virus, fungus, bacteria, and protozoa) binding to mammalian cells and extracellular matrix. Thus, fibronectin is involved in the pathogenesis of

infections from the initiation of the infection through the final stages of wound healing. See Proctor, R.A., Rev. Infect. Dis., 9, 317 (1987).

**FMRF and Analog peptides (SEQ ID NOS: 1175-1187) –**

- 5 FMRF are neuropeptides encoded in the FMRFamide gene and have a common C-terminal FMRFamide but different N-terminal extensions. FMRFamide-related peptides (FaRPs) are present throughout the animal kingdom and affect both neural and gastrointestinal functions. Organisms have several genes encoding numerous FaRPs with a common C-terminal structure but different N-terminal amino acid
- 10 extensions.

**Galanin & related peptides (SEQ ID NOS: 1188-1208)-**

- is a 29-30 amino acid peptide originally isolated from pig small intestine. It is found in two biologically active forms: GAL (1-19), and GAL (1-30), a non-amidated form. It has many biological roles including: the inhibition
- 15 of the release of biogenic amines in the hypothalamus, the pre- and post-synaptic inhibition of cholinergic function, the maintenance of gastrointestinal homeostasis, and the regulation of insulin and glucagon secretion.

**Growth Factors & related peptides (SEQ ID NOS: 1209-1240)**

- 20 – Growth factors are a family of proteins that regulate cell division. Some growth factors are cell type specific, stimulating division of only those cells with appropriate receptors. Other growth factors are more general in their effects. There are also extracellular factors that antagonize the effects of growth factors, slowing or preventing division
- 25 (for example transforming growth factor beta and tumor necrosis factor). These extracellular signals act through cell surface receptors very similar to those for hormones, and by similar mechanisms: the production of intracellular second messengers, protein phosphorylation, and ultimately, alteration of gene expression.

- 30 **Gtherapeutic peptide-Binding protein fragments (SEQ ID NOS: 1241-1246)** – Members of a family of Gtherapeutic peptide-binding regulatory proteins (G-proteins) transduce signals from

membrane-bound receptors to intracellular effectors. The family includes  $G_s$  and  $G_i$ , which are responsible for stimulation and inhibition, respectively, of adenylate cyclase. Transducin (T), localized in the disc membranes of retinal rod outer segments, couples activation of rhodopsin by light to increased cyclin GMP phosphodiesterase activity.  $G_o$ , found originally in bovine brain, is a fourth member of the family.

Purified G proteins have similar physical properties. They are heterodimers composed of  $\alpha$ ,  $\beta$ , and  $\gamma$  subunits. The  $\alpha$  subunits bind and hydrolyze Gtherapeutic peptide. See S. M. Mumby et al., PNAS 83, 265 (1986) and Lehninger p. 764.

**Guanylin and Uroguanylin (SEQ ID NOS: 1247-1249) -**

Guanylin and uroguanylin are peptides isolated from intestinal mucosa, and urine, which regulate cyclic GMP production in enterocytes bind to and activate guanylate cyclase C and control salt and water transport in many epithelia in vertebrates, mimicking the action of several heat-stable bacteria enterotoxins. In the kidney, both of them have well-documented natriuretic and kaliuretic effects.

Chloride secretion in the intestine is regulated by these hormones via activation of guanylate cyclase C (GC-C). Both peptides are expressed in a variety of tissues and organs, including the kidney. In the isolated perfused kidney and in vivo these hormones induce natriuresis and diuresis, however, localisation and cellular mechanisms of their action in the kidney are still unknown.

**Inhibin Peptides (SEQ ID NOS: 1250-1255) -** Inhibin is

composed of two subunits ( $\alpha$  is 134 amino acids;  $\beta$  is 115 and 116 amino acids). Its role is inhibition of FSH secretion. The two inhibin isoforms, inhibin A and inhibin B, are produced by the gonads in the course of gamete maturation and have different patterns of secretion during the menstrual cycle. Inhibins are also produced by the placenta and fetal membranes and may be involved in physiological adaptation of pregnancy. Clinically, inhibins may serve as sensitive tumor markers in postmenopausal women, or as useful tools for evaluating ovarian

reserve in infertile women; they may also be used in the diagnosis of materno-fetal disorders and to prevent maturation of the ovum or to inhibit ovulation.

**Interleukin (IL) and Interleukin Receptor Proteins (SEQ ID**

- 5 **NOS: 1256-1263)** – Interleukins are growth factors targeted to cells of hematopoietic origin. A variety of biological activities associated with immune and inflammatory responses have been ascribed to interleukins. These responses include fever, cartilage breakdown, bone resorption, thymocyte proliferation, activation of T and B lymphocytes, induction of
- 10 acute-phase protein synthesis from hepatocytes, fibroblast proliferation, and differentiation and proliferation of bone marrow cells.

**Laminin Fragments (SEQ ID NOS: 1264-1284)** - Laminin, the major noncollagenous glycoprotein of basement membranes, has been shown to promote the adhesion, spreading, and migration of a variety of

15 tumor cell types in vitro. In particular, the major current studies in the laboratory utilize intact laminin, purified proteolytic fragments of laminin, and synthetic peptides of laminin to identify functionally active sites on this large protein. Components of such basement membranes are important modulators of growth, development, and differentiation for

20 various cell types. A conjugated laminin could be used to prevent inflammation or fibrosis in tissues.

- This category also includes the peptide kringle-5 (or K-5). As used herein, the term "kringle 5" refers to the region of mammalian plasminogen having three disulfide bonds which contribute to the
- 25 specific three-dimensional conformation defined by the fifth kringle region of the mammalian plasminogen molecule. One such disulfide bond links the cysteine residues located at amino acid positions 462 and 541, a second links the cysteine residues located at amino acid positions 483 and 524 and a third links the cysteine residues located at amino acid
- 30 positions 512 and 536. The term "kringle 5 peptide peptides" refers to peptides with anti-angiogenic activity of between 4 and 104 amino acids



(inclusive) with a substantial sequence homology to the corresponding peptide fragment of mammalian plasminogen.

**Leptin Fragment Peptides (SEQ ID NOS: 1285-1288)** – Leptin, the protein product of the obesity gene, is secreted by fat cells. Leptin is involved in the regulation of bodyweight and metabolism in man and might also be involved in the pathophysiology of the insulin resistance syndrome, which is associated with the development of cardiovascular diseases

**Leucokinins (SEQ ID NOS: 1289-98)** - Leucokinins are a group of widespread insect hormones that stimulate gut motility and tubule fluid secretion rates. In tubules, their major action is to raise chloride permeability by binding to a receptor on the basolateral membrane.

**Pituitary Adenylate Cyclase Activating Polypeptide (PACAP) (SEQ ID NOS: 1299-1311)** – It is a thirty-eight amino acid peptide first isolated from ovine hypothalamus, which also occurs in a 27 amino acid form called PACAP-27. PACAP has been localized in the hypothalamus, elsewhere in the brain, respiratory tract and gastrointestinal system. It has many biological actions, including neurotransmitter and hormonal functions, involvement in regulation of energy metabolism, and neuronal cytoprotective activity.

**Pancreastatin (SEQ ID NOS: 1312-1324)** – Pancreastatin is a 49 amino acid peptide first isolated, purified and characterized from porcine pancreas. Its biological activity in different tissues can be assigned to the C-terminal part of the molecule. Pancreastatin has a prohormonal precursor, chromogranin A, which is a glycoprotein present in neuroendocrine cells, including the endocrine pancreas

**Polypeptides (SEQ ID NOS: 1325-1326)** – these are repetitive chains. Two examples are provided: (pro-Hyp-Gly)<sub>10</sub>\*20H<sub>2</sub>O and Poly-L-Lysine Hydrochloride.

**Signal Transduction Reagents (SEQ ID NOS: 1327-1367)** – Signal transduction is the process by which an extracellular signal (for example chemical, mechanical, or electrical) is amplified and converted

to a cellular response. Many reagents are involved in this process, for example achatin-1, glycogen synthase, autacamtide 2, calcineurin autoinhibitory peptide, calmodulin dependent protein kinase II, calmodulin dependent protein kinase substrate, calmodulin dependent

- 5 protein kinase substrate analog, CKS-17, Cys-Kemptide, autacamtide 2, malantide, melittin, phosphate acceptor peptide, protein kinase C fragments, P34cd2 kinase fragment, P60c-src substrate II, protein kinase A fragments, tyrosine protein kinase substrate, syntide 2, S6 kinase substrate peptide 32, tyrosine specific protein kinase inhibitor, 10 and their derivatives and fragments.

- Thrombin Inhibitors (SEQ ID NOS: 1368-1377)** - Thrombin is a key regulatory enzyme in the coagulation cascade; it serves a pluralistic role as both a positive and negative feedback regulator. In addition to its direct effect on hemostasis, thrombin exerts direct effects on diverse cell 15 types that support and amplify pathogenesis of arterial thrombus disease. The enzyme is the strongest activator of platelets causing them to aggregate and release substances (eg. ADP TXA.sub.2 NE) that further propagate the thrombotic cycle. Platelets in a fibrin mesh comprise the principal framework of a white thrombus. Thrombin also 20 exerts direct effects on endothelial cells causing release of vasoconstrictor substances and translocation of adhesion molecules that become sites for attachment of immune cells. In addition, the enzyme causes mitogenesis of smooth muscle cells and proliferation of fibroblasts. From this analysis, it is apparent that inhibition of thrombin 25 activity by thrombin inhibitors constitutes a viable therapeutic approach towards the attenuation of proliferative events associated with thrombosis.

- Toxins (SEQ ID NOS: 1378-1415)** - A toxin can be conjugated using the present invention to target cancer cells, receptors, viruses, or 30 blood cells. Once the toxin binds to the target cells the toxin is allowed to internalize and cause cell toxicity and eventually cell death. Toxins have been widely used as cancer therapeutics.

One example of a class of toxins is the mast cell degranulating peptide, a cationic 22-amino acid residue peptide with two disulfide bridges isolated from bee venom, causes mast cell degranulation and histamine release at low concentrations and has anti-inflammatory activity at higher concentrations. It is a powerful anti-inflammatory, more than 100 times more effective than hydrocortisone in reducing inflammation. Because of these unique immunologic properties, MCD peptide may serve as a useful tool for studying secretory mechanisms of inflammatory cells such as mast cells, basophils, and leukocytes, leading to the design of compounds with therapeutic potential. An example of a mast cell degranulating peptide is mastoparans, originating from wasp venom. It degranulates mast cells in the concentration of 0.5 µg/ml and releases histamine from the cells in the same concentration. See IY. Hirai et al., Chem. Pharm. Bull. 27, 1942 (1979).

Other examples of such toxins include omega-agatoxin TK, agelenin, apamin, calcicudine, calciseptine, charbdotoxin, chlorotoxin, conotoxins, endotoxin inhibitors, geographutoxins, iberiotoxin, kaliotoxin, mast cell degranulating peptides, margatoxin, neurotoxin NSTX-3, PLTX-II, scyllatoxin, stichodactyla toxin, and derivatives and fragments thereof.

**Trypsin Inhibitors (SEQ ID NOS: 1416-1418)** - Trypsin inhibitors functions as an inhibitors of trypsin, as well as other serine proteases. Useful for treatment of lung inflammation, pancreatitis, myocardial infarction, cerebrovascular ischemia

**Virus Related Peptides (SEQ ID NOS: 1419-1529)** – Virus related peptides are proteins related to viruses, for example virus receptors, virus inhibitors, and envelope proteins. Examples include but are not limited to peptide inhibitors of human immunodeficiency virus (HIV), respiratory syncytial virus (RSV), human parainfluenza virus (HPV), measles virus (MeV), and simian immunodeficiency virus (SIV),

fluorogenic Human CMV Protease Substrate, HCV Core Protein, HCV NS4A Protein, Hepatitis B Virus Receptor Binding Fragment, Hepatitis B Virus Pre-S Region, Herpes Virus Inhibitor 2, HIV Envelope Protein Fragment, HIV gag fragment, HIV substrate, HIV-1 Inhibitory Peptide, peptide T, T21, V3 decapeptide, Virus Replication Inhibitor Peptide, and their fragments and derivatives.

These peptides can be administered therapeutically. For example, peptide T is a chain of 8 amino acids from the V2 region of HIV-1 gp120. These amino acids look like a portion of HIV's outer envelope. It is under investigation as a treatment for HIV-related neurological and constitutional symptoms, as peptide T may be able to alleviate symptoms like fevers, night sweats, weight loss, and fatigue. It has also been shown to resolve psoriatic lesions.

**Miscellaneous peptides (SEQ ID NOS: 1529-1617)** – Including

adjuvant peptide analogs, alpha mating factor, antiarrhythmic peptide, anorexigenic peptide, alpha-1 antitrypsin, bovine pineal antireproductive peptide, bursin, C3 peptide P16, cadherin peptide, chromogranin A fragment, contraceptive tetrapeptide, conantokin G, conantokin T, crustacean cardioactive peptide, C-telopeptide, cytochrome b588 peptide, decorsin, delicious peptide, delta-sleep-inducing peptide, diazepam-binding inhibitor fragment, nitric oxide synthase blocking peptide, OVA peptide, platelet calpain inhibitor (P1), plasminogen activator inhibitor 1, rigin, schizophrenia related peptide, sodium potassium Atherapeutic peptidease inhibitor-1, speract, sperm activating peptide, systemin, thrombin receptor agonist (three peptides), tuftsin, adipokinetic hormone, uremic pentapeptide, Antifreeze Polypeptide, tumor necrosis factor, leech [Des Asp10]Decorsin, L-Ornithyltaurine Hydrochloride, p-Aminophenylacetyl Tuftsin, Ac-Glu-Glu-Val-Val-Ala-Cys-pNA, Ac-Ser-Asp-Lys-Pro, Ac-rfwink-NH2, Cys-Gly-Tyr-Gly-Pro-Lys-Lys-Lys-Arg-Lys-Val-Gly-Gly, DAla-Leu, D-D-D-D-D, D-D-D-D-D-D, N-P-N-A-N-P-N-A, V-A-I-T-V-L-V-K, V-G-V-R-V-R, V-I-H-S, V-P-D-P-R, Val-Thr-Cys-Gly, R-S-R, Sea Urchin Sperm Activating Peptide, SHU-


- 9119 MC3-R & MC4-R Antagonist, glaspimod (immunostimulant, useful against bacterial infections, fungal infections, immune deficiency immune disorder, leukopenia), HP-228 (melanocortin, useful against chemotherapy induced emesis, toxicity, pain, diabetes mellitus,
- 5 inflammation, rheumatoid arthritis, obesity), alpha 2-plasmin inhibitor (plasmin inhibitor), APC tumor suppressor (tumor suppressor, useful against neoplasm), early pregnancy factor (immunosuppressor), endozepine diazepam binding inhibitor (receptor peptide), gamma interferon (useful against leukemia), glandular kallikrein-1
- 10 (immunostimulant), placental ribonuclease inhibitor, sarcolectin binding protein, surfactant protein D, wilms' tumor suppressor, wilm's tumor suppressor, GABAB 1b receptor peptide, prion related peptide (iPrP13), choline binding protein fragment (bacterial related peptide), telomerase inhibitor, cardiostatin peptide, endostatin derived peptide (angiogenesis
- 15 inhibitor), prion inhibiting peptide, N-methyl D-aspartate receptor antagonist, C-peptide analog (useful against diabetic complications).

## **2. Modified Therapeutic Peptides**

- This invention relates to modified therapeutic peptides and their derivatives. The modified therapeutic peptides of the invention include
- 20 reactive groups which can react with available reactive functionalities on blood components to form covalent bonds. The invention also relates to such modifications, such combinations with blood components and methods for their use. These methods include extending the effective
- 25 therapeutic *in vivo* half life of the modified therapeutic peptides.

- To form covalent bonds with functionalities on a protein, one may use as a reactive group a wide variety of active carboxyl groups, particularly esters, where the hydroxyl moiety is physiologically acceptable at the levels required to modify the therapeutic peptide.
- 30 While a number of different hydroxyl groups may be employed in these linking agents, the most convenient would be N-hydroxysuccinimide (NHS), and N-hydroxy-sulfosuccinimide (sulfo-NHS).


Primary amines are the principal targets for NHS esters as diagramed in schematic 1A below. Accessible  $\alpha$ -amine groups present on the N-termini of proteins react with NHS esters. However,  $\alpha$ -amino groups on a protein may not be desirable or available for the NHS coupling. While five amino acids have nitrogen in their side chains, only the  $\epsilon$ -amine of lysine reacts significantly with NHS esters. An amide bond is formed when the NHS ester conjugation reaction reacts with primary amines releasing N-hydroxysuccinimide as demonstrated in schematic 1A below.



Schematic 1A

In the preferred embodiments of this invention, the functionality on the protein will be a thiol group and the reactive group will be a maleimido-containing group such as gamma-maleimide-butyralamide (GMBA) or MPA. The maleimido group is most selective for sulfhydryl groups on peptides when the pH of the reaction mixture is kept between 6.5 and 7.4 as shown in schematic 1B below. At pH 7.0, the rate of reaction of maleimido groups with sulfhydryls is 1000-fold faster than with amines. A stable thioether linkage between the maleimido group and the sulfhydryl is formed which cannot be cleaved under physiological conditions.

Schematic 1B



The therapeutic peptides and peptide derivatives of the invention may be modified for specific labeling and non-specific labeling of blood components.

### A. Specific Labeling

Preferably, the therapeutic peptides of this invention are designed to specifically react with thiol groups on mobile blood proteins. Such reaction is preferably established by covalent bonding of a therapeutic peptide modified with a maleimide link (e.g. prepared from GMBS, MPA or other maleimides) to a thiol group on a mobile blood protein such as serum albumin or IgG.

Under certain circumstances, specific labeling with maleimides offers several advantages over non-specific labeling of mobile proteins with groups such as NHS and sulfo-NHS. Thiol groups are less abundant *in vivo* than amino groups. Therefore, the maleimide derivatives of this invention will covalently bond to fewer proteins. For example, in albumin (the most abundant blood protein) there is only a single thiol group. Thus, therapeutic peptide-maleimide-albumin conjugates will tend to comprise approximately a 1:1 molar ratio of therapeutic peptide to albumin. In addition to albumin, IgG molecules (class II) also have free thiols. Since IgG molecules and serum albumin make up the majority of the soluble protein in blood they also make up

the majority of the free thiol groups in blood that are available to covalently bond to maleimide-modified therapeutic peptides.

Further, even among free thiol-containing blood proteins, specific labeling with maleimides leads to the preferential formation of therapeutic peptide-maleimide-albumin conjugates, due to the unique characteristics of albumin itself. The single free thiol group of albumin, highly conserved among species, is located at amino acid residue 34 (Cys<sup>34</sup>). It has been demonstrated recently that the Cys<sup>34</sup> of albumin has increased reactivity relative to free thiols on other free thiol-containing proteins. This is due in part to the very low pK value of 5.5 for the Cys<sup>34</sup> of albumin. This is much lower than typical pK values for cysteines residues in general, which are typically about 8. Due to this low pK, under normal physiological conditions Cys<sup>34</sup> of albumin is predominantly in the ionized form, which dramatically increases its reactivity. In addition to the low pK value of Cys<sup>34</sup>, another factor which enhances the reactivity of Cys<sup>34</sup> is its location, which is in a crevice close to the surface of one loop of region V of albumin. This location makes Cys<sup>34</sup> very available to ligands of all kinds, and is an important factor in Cys<sup>34</sup>'s biological role as free radical trap and free thiol scavenger. These properties make Cys<sup>34</sup> highly reactive with therapeutic peptide-maleimides, and the reaction rate acceleration can be as much as 1000-fold relative to rates of reaction of therapeutic peptide-maleimides with other free-thiol containing proteins.

Another advantage of therapeutic peptide-maleimide-albumin conjugates is the reproducibility associated with the 1:1 loading of peptide to albumin specifically at Cys<sup>34</sup>. Other techniques, such as glutaraldehyde, DCC, EDC and other chemical activations of, for example, free amines lack this selectivity. For example, albumin contains 52 lysine residues, 25-30 of which are located on the surface of albumin and accessible for conjugation. Activating these lysine residues, or alternatively modifying peptides to couple through these lysine residues, results in a heterogenous population of conjugates.



Even if 1:1 molar ratios of peptide to albumin are employed, the yield will consist of multiple conjugation products, some containing 0, 1, 2 or more peptides per albumin, and each having peptides randomly coupled at any one of the 25-30 available lysine sites. Given the numerous

- 5 combinations possible, characterization of the exact composition and nature of each batch becomes difficult, and batch-to-batch reproducibility is all but impossible, making such conjugates less desirable as a therapeutic. Additionally, while it would seem that conjugation through lysine residues of albumin would at least have the advantage of
- 10 delivering more therapeutic agent per albumin molecule, studies have shown that a 1:1 ratio of therapeutic agent to albumin is preferred. In an article by Stehle, et al., "The Loading Rate Determines Tumor Targeting Properties of Methotrexate-Albumin Conjugates in Rats," Anti-Cancer Drugs, Vol. 8, pp. 677-685 (1997), incorporated herein in its entirety, the
- 15 authors report that a 1:1 ratio of the anti-cancer methotrexate to albumin conjugated via glutaraldehyde gave the most promising results. These conjugates were taken up by tumor cells, whereas conjugates bearing 5:1 to 20:1 methotrexate molecules had altered HPLC profiles and were quickly taken up by the liver *in vivo*. It is postulated that at these higher
- 20 ratios, conformational changes to albumin diminish its effectiveness as a therapeutic carrier.

- Through controlled administration of maleimide-therapeutic peptides *in vivo*, one can control the specific labeling of albumin and IgG *in vivo*. In typical administrations, 80-90% of the administered
- 25 maleimide-therapeutic peptides will label albumin and less than 5% will label IgG. Trace labeling of free thiols such as glutathione will also occur. Such specific labeling is preferred for *in vivo* use as it permits an accurate calculation of the estimated half-life of the administered agent.

- In addition to providing controlled specific *in vivo* labeling,
- 30 maleimide-therapeutic peptides can provide specific labeling of serum albumin and IgG *ex vivo*. Such *ex vivo* labeling involves the addition of maleimide-therapeutic peptides to blood, serum or saline solution

containing serum albumin and/or IgG. Once modified *ex vivo* with maleimide-therapeutic peptides, the blood, serum or saline solution can be readministered to the blood for *in vivo* treatment.

In contrast to NHS-peptides, maleimide-therapeutic peptides are generally quite stable in the presence of aqueous solutions and in the presence of free amines. Since maleimide-therapeutic peptides will only react with free thiols, protective groups are generally not necessary to prevent the maleimide-therapeutic peptides from reacting with itself. In addition, the increased stability of the peptide permits the use of further purification steps such as HPLC to prepare highly purified products suitable for *in vivo* use. Lastly, the increased chemical stability provides a product with a longer shelf life.

#### **B. Non-Specific Labeling**

The therapeutic peptides of the invention may also be modified for non-specific labeling of blood components. Bonds to amino groups will generally be employed, particularly with the formation of amide bonds for non-specific labeling. To form such bonds, one may use as a chemically reactive group coupled to the therapeutic peptide a wide variety of active carboxyl groups, particularly esters, where the hydroxyl moiety is physiologically acceptable at the levels required. While a number of different hydroxyl groups may be employed in these linking agents, the most convenient would be N-hydroxysuccinimide (NHS) and N-hydroxy-sulfosuccinimide (sulfo-NHS).

Other linking agents which may be utilized are described in U.S. Patent 5,612,034, which is hereby incorporated herein.

The various sites with which the chemically reactive groups of the non-specific therapeutic peptides may react *in vivo* include cells, particularly red blood cells (erythrocytes) and platelets, and proteins, such as immunoglobulins, including IgG and IgM, serum albumin, ferritin, steroid binding proteins, transferrin, thyroxin binding protein,  $\alpha$ -2-macroglobulin, and the like. Those receptors with which the derivatized

therapeutic peptides react, which are not long-lived, will generally be eliminated from the human host within about three days. The proteins indicated above (including the proteins of the cells) will remain in the bloodstream at least three days, and may remain five days or more

5 (usually not exceeding 60 days, more usually not exceeding 30 days) particularly as to the half life, based on the concentration in the blood.

For the most part, reaction will be with mobile components in the blood, particularly blood proteins and cells, more particularly blood proteins and erythrocytes. By "mobile" is intended that the component

10 does not have a fixed situs for any extended period of time, generally not exceeding 5 minutes, more usually one minute, although some of the blood components may be relatively stationary for extended periods of time. Initially, there will be a relatively heterogeneous population of labeled proteins and cells. However, for the most part, the population

15 within a few days after administration will vary substantially from the initial population, depending upon the half-life of the labeled proteins in the blood stream. Therefore, usually within about three days or more, IgG will become the predominant labeled protein in the blood stream.

Usually, by day 5 post-administration, IgG, serum albumin and

20 erythrocytes will be at least about 60 mole %, usually at least about 75 mole %, of the conjugated components in blood, with IgG, IgM (to a substantially lesser extent) and serum albumin being at least about 50 mole %, usually at least about 75 mole %, more usually at least about 80 mole %, of the non-cellular conjugated components.

25 The desired conjugates of non-specific therapeutic peptides to blood components may be prepared *in vivo* by administration of the therapeutic peptides directly to the patient, which may be a human or other mammal. The administration may be done in the form of a bolus or introduced slowly over time by infusion using metered flow or the like.

30 If desired, the subject conjugates may also be prepared *ex vivo* by combining blood with modified therapeutic peptides of the present invention, allowing covalent bonding of the modified therapeutic peptides

to reactive functionalities on blood components and then returning or administering the conjugated blood to the host. Moreover, the above may also be accomplished by first purifying an individual blood component or limited number of components, such as red blood cells, immunoglobulins, serum albumin, or the like, and combining the component or components *ex vivo* with the chemically reactive therapeutic peptides. The labeled blood or blood component may then be returned to the host to provide *in vivo* the subject therapeutically effective conjugates. The blood also may be treated to prevent coagulation during handling *ex vivo*.

### 3. Synthesis of Therapeutic Peptides Used in the Present Invention

Peptide fragments may be synthesized by standard methods of solid phase peptide chemistry known to those of ordinary skill in the art. For example, peptide fragments may be synthesized by solid phase chemistry techniques following the procedures described by Steward and Young (Steward, J. M. and Young, J. D., Solid Phase Peptide Synthesis, 2nd Ed., Pierce Chemical Company, Rockford, Ill., (1984) using an Applied Biosystem synthesizer. Similarly, multiple fragments may be synthesized then linked together to form larger fragments. These synthetic peptide fragments can also be made with amino acid substitutions at specific locations.

For solid phase peptide synthesis, a summary of the many techniques may be found in J. M. Stewart and J. D. Young, Solid Phase Peptide Synthesis, W. H. Freeman Co. (San Francisco), 1963 and J. Meienhofer, Hormonal Proteins and Peptides, vol. 2, p. 46, Academic Press (New York), 1973. For classical solution synthesis see G.

Schroder and K. Lupke, The Peptides, Vol. 1, Academic Press (New York). In general, these methods comprise the sequential addition of one or more amino acids or suitably protected amino acids to a growing peptide chain. Normally, either the amino or carboxyl group of the first

amino acid is protected by a suitable protecting group. The protected or derivatized amino acid is then either attached to an inert solid support or utilized in solution by adding the next amino acid in the sequence having the complimentary (amino or carboxyl) group suitably protected and  
5 under conditions suitable for forming the amide linkage. The protecting group is then removed from this newly added amino acid residue and the next amino acid (suitably protected) is added, and so forth.

After all the desired amino acids have been linked in the proper sequence, any remaining protecting groups (and any solid support) are  
10 removed sequentially or concurrently to afford the final polypeptide. By simple modification of this general procedure, it is possible to add more than one amino acid at a time to a growing chain, for example, by coupling (under conditions which do not racemize chiral centers) a protected tripeptide with a properly protected dipeptide to form, after  
15 deprotection, a pentapeptide.

A particularly preferred method of preparing compounds of the present invention involves solid phase peptide synthesis wherein the amino acid  $\alpha$ -N-terminal is protected by an acid or base sensitive group. Such protecting groups should have the properties of being stable to the  
20 conditions of peptide linkage formation while being readily removable without destruction of the growing peptide chain or racemization of any of the chiral centers contained therein. Suitable protecting groups are 9-fluorenylmethyloxycarbonyl (Fmoc), t-butyloxycarbonyl (Boc), benzyloxycarbonyl (Cbz), biphenylisopropyloxycarbonyl, t-  
25 amylloxycarbonyl, isobutyloxycarbonyl,  $\alpha$ ,  $\alpha$ -dimethyl-3,5-dimethoxybenzyloxycarbonyl, o-nitrophenylsulfonyl, 2-cyano-t-butyloxycarbonyl, and the like. The 9-fluorenyl-methyloxycarbonyl (Fmoc) protecting group is particularly preferred for the synthesis of  
30 therapeutic peptide fragments. Other preferred side chain protecting groups are, for side chain amino groups like lysine and arginine, 2,2,5,7,8-pentamethylchroman-6-sulfonyl (pmc), nitro, p-toluenesulfonyl, 4-methoxybenzene-sulfonyl, Cbz, Boc, and adamantyloxycarbonyl; for

- tyrosine, benzyl, o-bromobenzyloxycarbonyl, 2,6-dichlorobenzyl, isopropyl, t-butyl (t-Bu), cyclohexyl, cyclophenyl and acetyl (Ac); for serine, t-butyl, benzyl and tetrahydropyranyl; for histidine, trityl, benzyl, Cbz, p-toluenesulfonyl and 2,4-dinitrophenyl; for tryptophan, formyl; for aspartic acid and glutamic acid, benzyl and t-butyl and for cysteine, triphenylmethyl (trityl).

- In the solid phase peptide synthesis method, the  $\alpha$ -C-terminal amino acid is attached to a suitable solid support or resin. Suitable solid supports useful for the above synthesis are those materials which are inert to the reagents and reaction conditions of the stepwise condensation-deprotection reactions, as well as being insoluble in the media used. The preferred solid support for synthesis of  $\alpha$ -C-terminal carboxy peptides is 4-hydroxymethylphenoxymethyl-copoly(styrene-1% divinylbenzene). The preferred solid support for  $\alpha$ -C-terminal amide peptides is the 4-(2',4'-dimethoxyphenyl-Fmoc-aminomethyl)phenoxyacetamidoethyl resin available from Applied Biosystems (Foster City, Calif.). The  $\alpha$ -C-terminal amino acid is coupled to the resin by means of N,N'-dicyclohexylcarbodiimide (DCC), N,N'-diisopropylcarbodiimide (DIC) or O-benzotriazol-1-yl-N,N,N',N'-tetramethyluronium-hexafluorophosphate (HBTU), with or without 4-dimethylaminopyridine (DMAP), 1-hydroxybenzotriazole (HOBT), benzotriazol-1-yloxy-tris(dimethylamino)phosphonium-hexafluorophosphate (BOP) or bis(2-oxo-3-oxazolidinyl)phosphine chloride (BOPCl), mediated coupling for from about 1 to about 24 hours at a temperature of between 10° and 50°C. in a solvent such as dichloromethane or DMF.

- When the solid support is 4-(2',4'-dimethoxyphenyl-Fmoc-aminomethyl)phenoxy-acetamidoethyl resin, the Fmoc group is cleaved with a secondary amine, preferably piperidine, prior to coupling with the  $\alpha$ -C-terminal amino acid as described above. The preferred method for coupling to the deprotected 4-(2',4'-dimethoxyphenyl-Fmoc-aminomethyl)phenoxy-acetamidoethyl resin is O-benzotriazol-1-yl-

N,N,N',N'-tetramethyluroniumhexafluoro-phosphate (HBTU, 1 equiv.) and 1-hydroxybenzotriazole (HOBT, 1 equiv.) in DMF. The coupling of successive protected amino acids can be carried out in an automatic polypeptide synthesizer as is well known in the art. In a preferred embodiment, the  $\alpha$ -N-terminal amino acids of the growing peptide chain are protected with Fmoc. The removal of the Fmoc protecting group from the  $\alpha$ -N-terminal side of the growing peptide is accomplished by treatment with a secondary amine, preferably piperidine. Each protected amino acid is then introduced in about 3-fold molar excess, and the coupling is preferably carried out in DMF. The coupling agent is normally O-benzotriazol-1-yl-N,N,N',N'-tetramethyluroniumhexafluorophosphate (HBTU, 1 equiv.) and 1-hydroxybenzotriazole (HOBT, 1 equiv.).

At the end of the solid phase synthesis, the polypeptide is removed from the resin and deprotected, either in successively or in a single operation. Removal of the polypeptide and deprotection can be accomplished in a single operation by treating the resin-bound polypeptide with a cleavage reagent comprising thianisole, water, ethanedithiol and trifluoroacetic acid. In cases wherein the  $\alpha$ -C-terminal of the polypeptide is an alkylamide, the resin is cleaved by aminolysis with an alkylamine. Alternatively, the peptide may be removed by transesterification, e.g. with methanol, followed by aminolysis or by direct transamidation. The protected peptide may be purified at this point or taken to the next step directly. The removal of the side chain protecting groups is accomplished using the cleavage cocktail described above. The fully deprotected peptide is purified by a sequence of chromatographic steps employing any or all of the following types: ion exchange on a weakly basic resin (acetate form); hydrophobic adsorption chromatography on underivitized polystyrene-divinylbenzene (for example, Amberlite XAD); silica gel adsorption chromatography; ion exchange chromatography on carboxymethylcellulose; partition chromatography, e.g. on Sephadex G-25, LH-20 or countercurrent distribution; high performance liquid chromatography (HPLC), especially

reverse-phase HPLC on octyl- or octadecylsilyl-silica bonded phase column packing.

Molecular weights of these therapeutic peptides are determined using Fast Atom Bombardment (FAB) Mass Spectroscopy.

- 5       The therapeutic peptides of the invention may be synthesized with N- and C-terminal protecting groups for use as pro-drugs.

### (1) N-Terminal Protective Groups

- As discussed above, the term "N-protecting group" refers to those
- 10 groups intended to protect the  $\alpha$ -N-terminal of an amino acid or peptide or to otherwise protect the amino group of an amino acid or peptide against undesirable reactions during synthetic procedures. Commonly used N-protecting groups are disclosed in Greene, "Protective Groups In Organic Synthesis," (John Wiley & Sons, New York (1981)), which is
- 15 hereby incorporated by reference. Additionally, protecting groups can be used as pro-drugs which are readily cleaved *in vivo*, for example, by enzymatic hydrolysis, to release the biologically active parent.  $\alpha$ -N-protecting groups comprise loweralkanoyl groups such as formyl, acetyl ("Ac"), propionyl, pivaloyl, t-butylacetyl and the like; other acyl groups
- 20 include 2-chloroacetyl, 2-bromoacetyl, trifluoroacetyl, trichloroacetyl, phthalyl, o-nitrophenoxyacetyl, -chlorobutyl, benzoyl, 4-chlorobenzoyl, 4-bromobenzoyl, 4-nitrobenzoyl and the like; sulfonyl groups such as benzenesulfonyl, p-toluenesulfonyl and the like; carbamate forming groups such as benzyloxycarbonyl, p-chlorobenzyloxycarbonyl, p-
- 25 methoxybenzyloxycarbonyl, p-nitrobenzyloxycarbonyl, 2-nitrobenzyloxycarbonyl, p-bromobenzyloxycarbonyl, 3,4-dimethoxybenzyloxycarbonyl, 3,5-dimethoxybenzyloxycarbonyl, 2,4-dimethoxybenzyloxycarbonyl, 4-ethoxybenzyloxycarbonyl, 2-nitro-4,5-dimethoxybenzyloxycarbonyl, 3,4,5-trimethoxybenzyloxycarbonyl, 1-(p-
- 30 biphenyl)-1-methylethoxycarbonyl,  $\alpha,\alpha$ -dimethyl-3,5-dimethoxybenzyloxycarbonyl, benzhydryloxycarbonyl, t-butyloxycarbonyl, diisopropylmethoxycarbonyl, isopropylloxycarbonyl,



ethoxycarbonyl, methoxycarbonyl, allyloxycarbonyl, 2,2,2,-  
trichloroethoxycarbonyl, phenoxycarbonyl, 4-nitrophenoxycarbonyl,  
fluorenyl-9-methoxycarbonyl, cyclopentylloxycarbonyl,  
adamantylloxycarbonyl, cyclohexylloxycarbonyl, phenylthiocarbonyl and  
the like; arylalkyl groups such as benzyl, triphenylmethyl,  
benzyloxymethyl, 9-fluorenylmethyloxycarbonyl (Fmoc) and the like and  
silyl groups such as trimethylsilyl and the like.

## (2) Carboxy Protective Groups

As discussed above, the term "carboxy protecting group" refers to  
a carboxylic acid protecting ester or amide group employed to block or  
protect the carboxylic acid functionality while the reactions involving  
other functional sites of the compound are performed. Carboxy  
protecting groups are disclosed in Greene, "Protective Groups in  
Organic Synthesis" pp. 152-186 (1981), which is hereby incorporated by  
reference. Additionally, a carboxy protecting group can be used as a  
pro-drug whereby the carboxy protecting group can be readily cleaved *in*  
*vivo*, for example by enzymatic hydrolysis, to release the biologically  
active parent. Such carboxy protecting groups are well known to those  
skilled in the art, having been extensively used in the protection of  
carboxyl groups in the penicillin and cephalosporin fields as described in  
U.S. Pat. Nos. 3,840,556 and 3,719,667, the disclosures of which are  
hereby incorporated herein by reference. Representative carboxy  
protecting groups are C<sub>1</sub>-C<sub>8</sub> loweralkyl (e.g., methyl, ethyl or t-butyl and  
the like); arylalkyl such as phenethyl or benzyl and substituted  
derivatives thereof such as alkoxybenzyl or nitrobenzyl groups and the  
like; arylalkenyl such as phenylethenyl and the like; aryl and substituted  
derivatives thereof such as 5-indanyl and the like; dialkylaminoalkyl such  
as dimethylaminoethyl and the like; alkanoyloxyalkyl groups such as  
acetoxymethyl, butyryloxymethyl, valeryloxymethyl, isobutyryloxymethyl,  
isovaleryloxymethyl, 1-(propionyloxy)-1-ethyl, 1-(pivaloyloxy)-1-ethyl, 1-  
methyl-1-(propionyloxy)-1-ethyl, pivaloyloxymethyl, propionyloxymethyl

- and the like; cycloalkanoyloxyalkyl groups such as cyclopropylcarbonyloxymethyl, cyclobutylcarbonyloxymethyl, cyclopentylcarbonyloxymethyl, cyclohexylcarbonyloxymethyl and the like; aroyloxyalkyl such as benzoyloxymethyl, benzoyloxyethyl and the like;
- 5 like; arylalkylcarbonyloxyalkyl such as benzylcarbonyloxymethyl, 2-benzylcarbonyloxyethyl and the like; alkoxycarbonylalkyl or cycloalkyloxycarbonylalkyl such as methoxycarbonylmethyl, cyclohexyloxycarbonylmethyl, 1-methoxycarbonyl-1-ethyl and the like; alkoxycarbonyloxyalkyl or cycloalkyloxycarbonyloxyalkyl such as
- 10 methoxycarbonyloxymethyl, t-butylloxycarbonyloxymethyl, 1-ethoxycarbonyloxy-1-ethyl, 1-cyclohexyloxycarbonyloxy-1-ethyl and the like; aryloxycarbonyloxyalkyl such as 2-(phenoxycarbonyloxy)ethyl, 2-(5-indanyloxycarbonyloxy)ethyl and the like; alkoxyalkylcarbonyloxyalkyl such as 2-(1-methoxy-2-methylpropan-2-oyloxy)ethyl and like;
- 15 arylalkyloxycarbonyloxyalkyl such as 2-(benzyloxycarbonyloxy)ethyl and the like; arylalkenyloxycarbonyloxyalkyl such as 2-(3-phenylpropen-2-yloxycarbonyloxy)ethyl and the like; alkoxycarbonylaminoalkyl such as t-butylloxycarbonylaminomethyl and the like; alkylaminocarbonylaminoalkyl such as
- 20 methylaminocarbonylaminomethyl and the like; alkanoylaminoalkyl such as acetylaminomethyl and the like; heterocycliccarbonyloxyalkyl such as 4-methylpiperazinyloxymethyl and the like; dialkylaminocarbonylalkyl such as dimethylaminocarbonylmethyl, diethylaminocarbonylmethyl and the like; (5-(loweralkyl)-2-oxo-1,3-
- 25 dioxolen-4-yl)alkyl such as (5-t-butyl-2-oxo-1,3-dioxolen-4-yl)methyl and the like; and (5-phenyl-2-oxo-1,3-dioxolen-4-yl)alkyl such as (5-phenyl-2-oxo-1,3-dioxolen-4-yl)methyl and the like.

Representative amide carboxy protecting groups are

30 aminocarbonyl and loweralkylaminocarbonyl groups.

Preferred carboxy-protected compounds of the invention are compounds wherein the protected carboxy group is a loweralkyl, cycloalkyl or arylalkyl ester, for example, methyl ester, ethyl ester, propyl ester, isopropyl ester, butyl ester, sec-butyl ester, isobutyl ester, amyl ester, isoamyl ester, octyl ester, cyclohexyl ester, phenylethyl ester and the like or an alkanoyloxyalkyl, cycloalkanoyloxyalkyl, aroyloxyalkyl or an arylalkylcarbonyloxyalkyl ester. Preferred amide carboxy protecting groups are loweralkylaminocarbonyl groups. For example, aspartic acid may be protected at the  $\alpha$ -C-terminal by an acid labile group (e.g. t-butyl) and protected at the  $\beta$ -C-terminal by a hydrogenation labile group (e.g. benzyl) then deprotected selectively during synthesis.

Alternatively, it is also possible to obtain fragments of the peptides by fragmenting the naturally occurring amino acid sequence, using, for example, a proteolytic enzyme according to methods well known in the art. Further, it is possible to obtain the desired fragments of the therapeutic peptide through the use of recombinant DNA technology using methods well known in the art.

#### 20 4. Modification of Therapeutic Peptides

The manner of producing the modified therapeutic peptides of the present invention will vary widely, depending upon the nature of the various elements comprising the molecule. The synthetic procedures will be selected so as to be simple, provide for high yields, and allow for a highly purified stable product. Normally, the reactive group will be created as the last stage, for example, with a carboxyl group, esterification to form an active ester will be the last step of the synthesis. Specific methods for the production of modified therapeutic peptides of the present invention are described below.

30 Generally, the modified therapeutic peptides of the present invention may be made using blind or structure activity relationship (SAR) driven substitution. SAR is an analysis which defines the

relationship between the structure of a molecule and its pharmacological activity for a series of compounds. Various studies relative to individual therapeutic peptides show how the activity of the peptide varies according to the variation of chemical structure or chemical properties.

- 5 More specifically, first the therapeutic activity of the free peptide is assayed. Next, the peptide is modified according to the invention, either at the N-terminus, at the C-terminus, or in the interior of the peptide with the linking group only. The linking group will include the reactive group as discussed above. The therapeutic activity of this modified peptide-
- 10 linking group is assayed next, and based on the detected activity a decision is made regarding the modification site. Next, the peptide conjugate is prepared and its therapeutic activity is determined. If the therapeutic activity of the peptide after conjugation is not substantially reduced (i.e. if the therapeutic activity is reduced by less than 10 fold),
- 15 then the stability of the peptide is measured as indicated by its *in vivo* lifetime. If the stability is not improved to a desired level, then the peptide is modified at an alternative site, and the procedure is repeated until a desired level of therapeutic activity and a desired stability are achieved.

- 20 More specifically, each therapeutic peptide selected to undergo the derivatization with a linker and a reactive group will be modified according to the following criteria: if a terminal carboxylic group is available on the therapeutic peptide and is not critical for the retention of pharmacological activity, and no other sensitive functional group is
- 25 present on the therapeutic peptide, then the carboxylic acid will be chosen as attachment point for the linker-reactive group modification. If the terminal carboxylic group is involved in pharmacological activity, or if no carboxylic acids are available, then any other sensitive functional group not critical for the retention of pharmacological activity will be
- 30 selected as the attachment point for the linker-reactive group modification. If several sensitive functional groups are available on a therapeutic peptide, a combination of protecting groups will be used in

such a way that after addition of the linker/reactive group and deprotection of all the protected sensitive functional groups, retention of pharmacological activity is still obtained. If no sensitive functional groups are available on the therapeutic peptide, or if a simpler

- 5 modification route is desired, synthetic efforts will allow for a modification of the original peptide in such a way that retention of biological activity and retention of receptor or target specificity is obtained. In this case the modification will occur at the opposite end of the peptide.

- 10 An NHS derivative may be synthesized from a carboxylic acid in absence of other sensitive functional groups in the therapeutic peptide. Specifically, such a therapeutic peptide is reacted with N-hydroxysuccinimide in anhydrous  $\text{CH}_2\text{Cl}_2$  and EDC, and the product is purified by chromatography or recrystallized from the appropriate solvent system to give the NHS derivative.

- 15 Alternatively, an NHS derivative may be synthesized from a therapeutic peptide that contains an amino and/or thiol group and a carboxylic acid. When a free amino or thiol group is present in the molecule, it is preferable to protect these sensitive functional groups prior to perform the addition of the NHS derivative. For instance, if the molecule contains a free amino group, a transformation of the amine into a Fmoc or preferably into a tBoc protected amine is necessary prior to perform the chemistry described above. The amine functionality will not be deprotected after preparation of the NHS derivative. Therefore this method applies only to a compound whose amine group is not required
- 20 to be freed to induce a pharmacological desired effect. If the amino group needs to be freed to retain the original biological properties of the molecule, then another type of chemistry described in example 3-6 has to be performed.

- 25 In addition, an NHS derivative may be synthesized from a therapeutic peptide containing an amino or a thiol group and no carboxylic acid. When the selected molecule contains no carboxylic acid, an array of bifunctional linkers can be used to convert the molecule
- 30

into a reactive NHS derivative. For instance, ethylene glycol-bis(succinimidyldisuccinate) (EGS) and triethylamine dissolved in DMF and added to the free amino containing molecule (with a ratio of 10:1 in favor of EGS) will produce the mono NHS derivative. To produce an

- 5 NHS derivative from a thiol derivatized molecule, one can use N-[ - maleimidobutyryloxy]succinimide ester (GMBS) and triethylamine in DMF. The maleimido group will react with the free thiol and the NHS derivative will be purified from the reaction mixture by chromatography on silica or by HPLC.

- 10 An NHS derivative may also be synthesized from a therapeutic peptide containing multiple sensitive functional groups. Each case will have to be analyzed and solved in a different manner. However, thanks to the large array of protecting groups and bifunctional linkers that are commercially available, this invention is applicable to any therapeutic
- 15 peptide with preferably one chemical step only to derivatize the therapeutic peptide (as described in example 1 or 3) or two steps (as described in example 2 and involving prior protection of a sensitive group) or three steps (protection, activation and deprotection). Under exceptional circumstances only, would we require to use multiple steps
- 20 (beyond three steps) synthesis to transform a therapeutic peptide into an active NHS or maleimide derivative.

- A maleimide derivative may also be synthesized from a therapeutic peptide containing a free amino group and a free carboxylic acid. To produce a maleimide derivative from an amino derivatized
- 25 molecule, one can use N-[γ-maleimidobutyryloxy]succinimide ester (GMBS) and triethylamine in DMF. The succinimide ester group will react with the free amino and the maleimide derivative will be purified from the reaction mixture by crystallization or by chromatography on silica or by HPLC.

Finally, a maleimide derivative may be synthesized from a therapeutic peptide containing multiple other sensitive functional groups and no free carboxylic acids. When the selected molecule contains no carboxylic acid, an array of bifunctional crosslinking reagents can be

- 5 used to convert the molecule into a reactive NHS derivative. For instance maleimidopropionic acid (MPA) can be coupled to the free amine to produce a maleimide derivative through reaction of the free amine with the carboxylic group of MPA using HBTU/HOBt/DIEA activation in DMF. Alternatively, a lysine residue can be added on the
- 10 C-terminus end of the peptide to allow for conjugation onto the -amino group of the lysine as described in the examples below. This added lysine allows for simple and efficient modification at the C-terminus of the peptide while keeping the terminal end capped by an amide function as designed by the initial choice of the resin


- 15 Many other commercially available heterobifunctional crosslinking reagents can alternatively be used when needed. A large number of bifunctional compounds are available for linking to entities. Illustrative reagents include: azidobenzoyl hydrazide, N-[4-(p-azidosalicylamino)butyl]-3'-[2'-pyridyl(dithio)propionamide), bis-
- 20 sulfosuccinimidyl suberate, dimethyl adipimidate, disuccinimidyl tartrate, N-γ-maleimidobutyryloxysuccinimide ester, N-hydroxy sulfosuccinimidyl-4-azidobenzoate, N-succinimidyl [4-azidophenyl]-1,3'-dithiopropionate, N-succinimidyl [4-iodoacetyl]aminobenzoate, glutaraldehyde, and succinimidyl 4-[N-maleimidomethyl]cyclohexane-1-carboxylate.

Even more specifically, the peptides are preferably modified according to the nature of their substituents and the presence or absence of free cysteines. Most peptides can be gathered into three distinct categories: (1) peptides that contain no cysteines; (2) peptides  
5 that contain one cysteine, (3) peptides that contain two cysteines as a disulfide bridge (cystine); and (4) peptides that contain multiple cysteines.


#### **A. Peptides that Contain No Cysteines**


10 Where the peptide contains no cysteine, addition from the C terminus is performed with all residues cleaved from the support resin and fully protected. Solution phase activation of C-terminus with EDC and NHS can be reacted with an amino-alkyl-maleimide in one pot. The peptide is then fully deprotected. Alternatively, a lysine residue can be  
15 added on the C-terminus of the peptide to allow modification at the epsilon amino group of the lysine while keeping the carboxy terminus capped with an amide group. Such an addition of a lysine residue is preferably performed only where the addition does not substantially affect the therapeutic activity of the peptide. The generalized reaction  
20 scheme for C-terminus modification of peptides that contain no cysteines is illustrated in the schematic diagram below.






- If an N-terminus modification is favored, and again for a peptide containing no cysteine, addition on the N terminus is performed with all residues still on the support resin and fully protected. Addition of activated NHS-Mal bifunctional linker could be performed on deprotected N-terminus with peptide still on resin. The peptide is then fully deprotected. Examples of therapeutic peptides that contain no cysteine and undergo a C-terminus modification are described in examples 7-26.
- Examples of therapeutic peptides that contain no cysteine and undergo a N-terminus modification are described in examples 27-38. The generalized reaction scheme for N-terminus modification of peptides that contain no cysteines is illustrated in the schematic diagrams below, using hetero NHS maleimide (GMBS like) and 3-MPA, respectively.





3-MPA

- Alternatively, the peptide may be modified at an internal amino acid (i.e. neither at the C-terminus nor at the N-terminus). The
- 5 generalized reaction scheme for modification at an internal amino acid of a peptide that contains no free cysteines is illustrated in the schematic diagrams below, using homo bis NHS and hetero NHS maleimide.




5

Homo bis NHS

10

5




Hetero NHS Maleimide (GMBS like)

Peptides that contain no cysteine and can be modified as described above include fragments of the Kringle 5 peptide, of the GLP-1 peptide, of dynorphin A, human growth hormone releasing factor, the 1-24 fragment of human neuropeptide Y, and human secretin. Full description of the chemistry for each of these peptides is reported in the Example section.


## 5

10

15



Homobis Maleimide



Hetero NHS Maleimide (GMBS like)

5

Examples of therapeutic peptides that contain one cysteine include  $\text{G}_\alpha$  (the alpha subunit of Gtherapeutic peptide binding protein), the 724-739 fragment of rat brain nitric oxide synthase blocking peptide, the alpha subunit 1-32 fragment of human [Tyr0] inhibin, the 254-274 fragment of HIV envelope protein, and P34cdc2 kinase fragment.


### C. Peptides that Contain Two Cysteines as a Disulfide Bridge (Cystine)

Where the peptide contains two cysteines as a disulfide bridge, the peptide is cleaved from the support resin before addition of the maleimide. For a modification of the peptide from the C terminus end, all protecting groups are present except at the carboxy terminus (which

stays unprotected due to cleavage from the support resin) and at the two cysteines, which need to be deprotected when peptide is cleaved from resin. Mild air oxidation yields the disulfide bridge, and the peptide can be purified at that stage. Solution phase chemistry is then required to  
5 activate the C-terminus in presence of the disulfide bridge and add the maleimide (through an amino-alkyl-maleimide) to the C-terminus. The peptide is then fully deprotected.


For a modification of the peptide at the N-terminus, the peptide can remain on the support resin. The two cysteines are selectively  
10 deprotected before addition of the maleimide. Air oxidation, potentially helped by a catalyst (heterogeneous) can yield the disulfide with the peptide still on the resin. Maleimide is then added on the N-terminus and peptide cleaved from resin and fully deprotected. The generalized reaction scheme for modification at an internal amino acid of a peptide  
15 that contains two cysteines in a disulfide bridge is illustrated in the schematic diagram below.





- Alternatively, the peptide may be modified at an internal amino acid (i.e. neither at the C-terminus nor at the N-terminus). The
- 5 generalized reaction scheme for modification at an internal amino acid of a peptide that contains two cysteines in a disulfide bridge is illustrated in the schematic diagram below.

Peptide Scheme 10



Examples of therapeutic peptides that contain two cysteines as a disulfide bridge include human osteocalcin 1-49, human diabetes associated peptide, the 5-28 fragment of human/canine atrial natriuretic peptide, bovine bactenecin, and human [Tyr0]-cortistatin 29.

#### D. Peptides Containing Multiple Cysteines

Where the peptide contains multiple cysteines as disulfide bridges, the peptide is cleaved from the support resin before addition of

the maleimide. For a modification of the peptide from the C terminus end, all protecting groups are present except at the carboxy terminus (which stays unprotected due to cleavage from the support resin) and at the two cysteines that are supposed to build a disulfide bridge.

- 5 Cysteines that are involved in other disulfide bridges are deprotected sequentially in pairs using a choice of protecting groups. It is recommended to build and purify each bridge one at a time prior to moving on to the next bridge. Mild air oxidation yields the disulfide bridge, and the peptide should be purified at each stage. Solution phase
- 10 chemistry is then required to activate the C-terminus in presence of the disulfide bridge and add the maleimide (through an amino-alkyl-maleimide) to the C-terminus. The peptide is then fully deprotected.

- For a modification of the peptide from the N terminus end, one can leave the peptide on the support resin and selectively deprotect the
- 15 first two cysteines to build the disulfide under mild air oxidation. Subsequent deprotection will offer the other disulfides before addition of the maleimide. Air oxidation, potentially helped by a catalyst (heterogeneous) can yield the disulfides with the peptide still on the resin. Maleimide is then added on the N-terminus and peptide cleaved
- 20 from resin and fully deprotected.

Alternatively, the peptide may be modified at an internal amino acid (i.e. neither at the C-terminus nor at the N-terminus).

Peptides containing multiple cysteines include human endothelins and [Lys4] Sarafotoxin S6c.

25

## **5. Administration of the Modified Therapeutic Peptides**

- The modified therapeutic peptide will be administered in a physiologically acceptable medium, e.g. deionized water, phosphate buffered saline (PBS), saline, aqueous ethanol or other alcohol, plasma,
- 30 proteinaceous solutions, mannitol, aqueous glucose, alcohol, vegetable oil, or the like. Other additives which may be included include buffers, where the media are generally buffered at a pH in the range of about 5

to 10, where the buffer will generally range in concentration from about 50 to 250 mM, salt, where the concentration of salt will generally range from about 5 to 500 mM, physiologically acceptable stabilizers, and the like. The compositions may be lyophilized for convenient storage and transport.

The modified therapeutic peptides will for the most part be administered orally, parenterally, such as intravascularly (IV), intraarterially (IA), intramuscularly (IM), subcutaneously (SC), or the like. Administration may in appropriate situations be by transfusion. In some instances, where reaction of the functional group is relatively slow, administration may be oral, nasal, rectal, transdermal or aerosol, where the nature of the conjugate allows for transfer to the vascular system. Usually a single injection will be employed although more than one injection may be used, if desired. The modified therapeutic peptides may be administered by any convenient means, including syringe, trocar, catheter, or the like. The particular manner of administration will vary depending upon the amount to be administered, whether a single bolus or continuous administration, or the like. Preferably, the administration will be intravascularly, where the site of introduction is not critical to this invention, preferably at a site where there is rapid blood flow, e.g., intravenously, peripheral or central vein. Other routes may find use where the administration is coupled with slow release techniques or a protective matrix. The intent is that the therapeutic peptides be effectively distributed in the blood, so as to be able to react with the blood components. The concentration of the conjugate will vary widely, generally ranging from about 1 pg/ml to 50 mg/ml. The total administered intravascularly will generally be in the range of about 0.1 mg/ml to about 10 mg/ml, more usually about 1 mg/ml to about 5 mg/ml.

By bonding to long-lived components of the blood, such as immunoglobulin, serum albumin, red blood cells and platelets, a number of advantages ensue. The activity of the modified therapeutic peptides compound is extended for days to weeks. Only one administration need

be given during this period of time. Greater specificity can be achieved, since the active compound will be primarily bound to large molecules, where it is less likely to be taken up intracellularly to interfere with other physiological processes.

5           The formation of the covalent bond between the blood component may occur *in vivo* or *ex vivo*. For *ex vivo* covalent bond formation, the modified therapeutic peptide is added to blood, serum or saline solution containing human serum albumin or IgG to permit covalent bond formation between the modified therapeutic peptide and the blood  
10       component. In a preferred format, the therapeutic peptide is modified with maleimide and it is reacted with human serum albumin in saline solution. Once the modified therapeutic peptide has reacted with the blood component, to form a therapeutic peptide-protein conjugate, the conjugate may be administered to the patient.

15           Alternatively, the modified therapeutic peptide may be administered to the patient directly so that the covalent bond forms between the modified therapeutic peptide and the blood component *in vivo*.

          In addition, where localized delivery of therapeutic peptides is  
20       desired, several methods of delivery may be used:

**A.     Open Surgical Field Lavage**

          There are a number of indications for local therapeutic compounds which would entail administration of the therapeutic compound as an adjunct to open surgery. In these cases, the therapeutic compound would  
25       either be lavaged in the surgical site (or a portion of that site) prior to closure, or the therapeutic compound would be incubated for a short time in a confined space (e.g., the interior of a section of an artery following an endarterectomy procedure or a portion of GI tract during resection) and the excess fluid subsequently evacuated.

30           **B.     Incubation of Tissue Grafts**

          Tissue grafts such as autologous and xenobiotic vein/artery and valve grafts as well as organ grafts can be pretreated with therapeutic

compounds that have been modified to permit covalent bond formation by either incubating them in a therapeutic solution and/or perfusing them with such a solution.

### **C. Catheter Delivery**

- 5           A catheter is used to deliver the therapeutic compound either as part of an endoscopic procedure into the interior of an organ (e.g., bladder, GI tract, vagina/uterus) or adjunctive to a cardiovascular catheter procedure such as a balloon angioplasty. Standard catheters as well as newer drug delivery and iontophoretic catheters can be utilized.

### **D. Direct Injection**

- 10           For certain poorly vascularized spaces such as intra-articular joint spaces, a direct injection of a therapeutic compound may be able to bioconjugate to surface tissues and achieve a desirable duration of drug effect. Other applications could include intra medullary, intratumor,
- 15           intravaginal, intrauterine, intra intestinal, intra eustachian tube, intrathecal, subcutaneous, intrarticular, intraperitoneal or intraocular injections as well as via bronchoscope, via nasogastric tube and via nophrostomy.

## **6. Monitoring the Presence of Modified Therapeutic Peptide Derivatives**

- 20           Another aspect of this invention relates to methods for determining the concentration of the therapeutic peptides and/or analogs, or their derivatives and conjugates in biological samples (such
- 25           as blood) and determining the peptidase stability of the modified peptides. The blood of the mammalian host may be monitored for the presence of the modified therapeutic peptide compounds one or more times. By taking a portion or sample of the blood of the host, one may determine whether the therapeutic peptide has become bound to the
- 30           long-lived blood components in sufficient amount to be therapeutically active and, thereafter, the level of therapeutic peptide compound in the blood. If desired, one may also determine to which of the blood components the therapeutic peptide derivative molecule is bound. This

is particularly important when using non-specific therapeutic peptides. For specific maleimide-therapeutic peptides, it is much simpler to calculate the half life of serum albumin and IgG.

One method for determining the concentration of the therapeutic peptide, analogs, derivatives and conjugates is to use antibodies specific to the therapeutic peptides or therapeutic peptide analogs or their derivatives and conjugates, and to use such antibodies as a treatment for toxicity potentially associated with such therapeutic peptides, analogs, and/or their derivatives or conjugates. This is advantageous because the increased stability and life of the therapeutic peptides *in vivo* in the patient might lead to novel problems during treatment, including increased possibility for toxicity. It should be mentioned, however, that in some cases, the traditional antibody assay may not recognize the difference between cleaved and uncleaved therapeutic peptides. In such cases, other assay techniques may be employed, for example LC/MS (Liquid Chromatography / Mass Spectrometry).

The use of antibodies, either monoclonal or polyclonal, having specificity for a particular therapeutic peptide, analog or derivative thereof, can assist in mediating any such problem. The antibody may be generated or derived from a host immunized with the particular therapeutic peptide, analog or derivative thereof, or with an immunogenic fragment of the agent, or a synthesized immunogen corresponding to an antigenic determinant of the agent. Preferred antibodies will have high specificity and affinity for native, derivatized and conjugated forms of the therapeutic peptide or therapeutic peptide analog. Such antibodies can also be labeled with enzymes, fluorochromes, or radiolabels.

Antibodies specific for derivatized therapeutic peptides may be produced by using purified therapeutic peptides for the induction of derivatized therapeutic peptide-specific antibodies. By induction of antibodies, it is intended not only the stimulation of an immune response by injection into animals, but analogous steps in the production of

synthetic antibodies or other specific binding molecules such as screening of recombinant immunoglobulin libraries. Both monoclonal and polyclonal antibodies can be produced by procedures well known in the art. In some cases, the use of monoclonal antibodies may be preferred over polyclonal antibodies, such as when degradation occurs over an area not covered by epitope/antibody recognition.

The antibodies may be used to treat toxicity induced by administration of the therapeutic peptide, analog or derivative thereof, and may be used *ex vivo* or *in vivo*. *Ex vivo* methods would include immuno-dialysis treatment for toxicity employing antibodies fixed to solid supports. *In vivo* methods include administration of antibodies in amounts effective to induce clearance of antibody-agent complexes.

The antibodies may be used to remove the therapeutic peptides, analogs or derivatives thereof, and conjugates thereof, from a patient's blood *ex vivo* by contacting the blood with the antibodies under sterile conditions. For example, the antibodies can be fixed or otherwise immobilized on a column matrix and the patient's blood can be removed from the patient and passed over the matrix. The therapeutic peptide analogs, derivatives or conjugates, will bind to the antibodies and the blood containing a low concentration of the therapeutic peptide, analog, derivative or conjugate, then may be returned to the patient's circulatory system. The amount of therapeutic peptide compound removed can be controlled by adjusting the pressure and flow rate. Preferential removal of the therapeutic peptides, analogs, derivatives and conjugates from the plasma component of a patient's blood can be affected, for example, by the use of a semipermeable membrane, or by otherwise first separating the plasma component from the cellular component by ways known in the art prior to passing the plasma component over a matrix containing the anti-therapeutic antibodies. Alternatively the preferential removal of therapeutic peptide-conjugated blood cells, including red blood cells, can be effected by collecting and concentrating the blood cells in the patient's blood and contacting those cells with fixed anti-therapeutic



antibodies to the exclusion of the serum component of the patient's blood.

The antibodies can be administered *in vivo*, parenterally, to a patient that has received the therapeutic peptide, analogs, derivatives or conjugates for treatment. The antibodies will bind the therapeutic peptide compounds and conjugates. Once bound the therapeutic peptide, activity will be hindered if not completely blocked thereby reducing the biologically effective concentration of therapeutic peptide compound in the patient's bloodstream and minimizing harmful side effects. In addition, the bound antibody-therapeutic peptide complex will facilitate clearance of the therapeutic peptide compounds and conjugates from the patient's blood stream.

The invention having been fully described is now exemplified by the following non-limiting examples.

## EXAMPLES

### A. General Method of Synthesis of a Modified Therapeutic Peptide

5

Solid phase peptide synthesis of the modified peptide on a 100 µmole scale was performed on a Symphony Peptide Synthesizer using Fmoc protected Rink Amide MBHA resin, Fmoc protected amino acids, O-benzotriazol-1-yl-*N, N, N', N'*-tetramethyl-uronium

10

hexafluorophosphate (HBTU) in *N,N*-dimethylformamide (DMF) solution and activation with *N*-methyl morpholine (NMM), and piperidine deprotection of Fmoc groups (Step 1). The deprotection of the terminal

15

Fmoc group is accomplished using 20% piperidine (Step 2) followed by either the coupling of 3-maleimidopropionic acid (3-MPA), the coupling of acetic acid or the coupling of one or multiple Fmoc-AEEA followed by the coupling of 3-MPA (Step 3). Resin cleavage and products isolation are performed using 86% TFA/5% TIS/5% H<sub>2</sub>O/2% thioanisole and 2% phenol, followed by precipitation by dry-ice cold Et<sub>2</sub>O (Step 4). The products are purified by preparative reverse phase HPLC using a Varian

20

(Rainin) preparative binary HPLC system using a Dynamax C<sub>18</sub>, 60Å, 8 µm, 21 mm x 25 cm column equipped with a Dynamax C<sub>18</sub>, 60Å, 8 µm guard module, 21 mm x 25 cm column and UV detector (Varian Dynamax UVD II) at λ 214 and 254 nm. The product should have >95% purity as determined by RP-HPLC mass spectrometry using a Hewlett

25

Packard LCMS-1100 series spectrometer equipped with a diode array detector and using electro-spray ionization.

### B. Alteration of the Native Peptide Chain

30

To facilitate modification of the peptide, one or more amino acid residues may be added to the peptide as described in examples 1 to 5, and/or one or more amino acid residues may be replaced with other amino acid residues. This alteration aids attachment of the reactive group.

**Example 1 – Addition of Lys at C-Terminus of Kringle-5**  
**Preparation of NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-NH<sub>2</sub>.3TFA**

- Using automated peptide synthesis, the following protected amino acids were sequentially added to Rink Amide MBHA resin: Fmoc-Lys(Boc)-OH, Fmoc-Tyr(tBu)OH, Fmoc-Asp(OtBu)-OH, Fmoc-Tyr(tBu)OH, Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Pro-OH. Deblocking of the Fmoc group the the N-terminal of the resin-bound amino acid was performed with 20% piperidine in DMF for about 15-20 minutes. Coupling of the acetic acid was performed under conditions similar to amino acid coupling. Final cleavage from the resin was performed using cleavage mixture as described above. The product was isolated by precipitation and purified by preparative HPLC to afford the desired product as a white solid upon lyophilization .

**Example 2 - Addition of Lys at C-Terminus of Kringle-5**  
**Preparation of NAc-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-NH<sub>2</sub>.2TFA.3TFA**

- Using automated peptide synthesis, the following protected amino acids were sequentially added to Rink Amide MBHA resin: Fmoc-Lys(Boc)-OH, Fmoc-Tyr(tBu)OH, Fmoc-Asp(OtBu)-OH, Fmoc-Tyr(tBu)OH, Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-Arg(Pbf)-OH. Deblocking of the Fmoc group the the N-terminal of the resin-bound amino acid was performed with 20% piperidine in DMF for about 15-20 minutes. Coupling of the acetic acid was performed under conditions similar to amino acid coupling. Final cleavage from the resin was performed using cleavage mixture as described above. The product was isolated by precipitation and purified by preparative HPLC to afford the desired product as a white solid upon lyophilization.

**Example 3 - Addition of Lys at N-Terminus of Kringle-5**  
**Preparation of NAc-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-NH<sub>2</sub>.3TFA**

Using automated peptide synthesis, the following protected amino acids were sequentially added to Rink Amide MBHA resin: Fmoc-Lys(Boc)-OH, Fmoc-Tyr(tBu)OH, Fmoc-Asp(OtBu)-OH, Fmoc-Tyr(tBu)OH, Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-Arg(Pbf)-OH, 5 Fmoc-Pro-OH, Fmoc-Asn(Trt)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Tyr(tBu)OH. Deblocking of the Fmoc group the N-terminal of the resin-bound amino acid was performed with 20% piperidine in DMF for about 15-20 minutes. Coupling of the acetic acid was performed under conditions similar to amino acid coupling. Final 10 cleavage from the resin was performed using cleavage mixture as described above. The product was isolated by precipitation and purified by preparative HPLC to afford the desired product as a white solid upon lyophilization.

15 **Example 4 - Addition of Lys at N-Terminus of Kringle-5, Substitution of Cys with Ala at Position 524**  
**Preparation of NAc-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Ala<sup>524</sup>-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-NH<sub>2</sub>.4TFA**

20 Using automated peptide synthesis, the following protected amino acids were sequentially added to Rink Amide MBHA resin: Fmoc-Lys(Boc)-OH, Fmoc-Tyr(tBu)OH, Fmoc-Asp(OtBu)-OH, Fmoc-Tyr(tBu)OH, Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Pro-OH, Fmoc-Asn(Trt)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Thr(tBu)-OH, 25 Fmoc-Tyr(tBu)OH, Fmoc-Ala-OH, Fmoc-Trp-OH, Fmoc-Pro-OH, Fmoc-Gly-OH, Fmoc-Gly-OH, Fmoc-Val-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Pro-OH, Fmoc-Asn(Trt)-OH, Fmoc-Arg(Pbf)-OH. Deblocking of the Fmoc group the the N-terminal of the resin-bound amino acid was performed with 20% piperidine in DMF for 30 about 15-20 minutes. Coupling of the acetic acid was performed under conditions similar to amino acid coupling. Final cleavage from the resin was performed using cleavage mixture as described above. The

product was isolated by precipitation and purified by preparative HPLC to afford the desired product as a white solid upon lyophilization.


**5     Example 5 - Addition of Lys at N-Terminus of Kringle-5**  
**Preparation of NAc-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Lys-NH<sub>2</sub>·2TFA**

Using automated peptide synthesis, the following protected amino acids were sequentially added to Rink Amide MBHA resin: Fmoc-Lys(Boc)-OH, Fmoc-Trp-OH, Fmoc-Pro-OH, Fmoc-Gly-OH, Fmoc-Gly-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Gly-OH, Fmoc-Val-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Pro-OH, Fmoc-Asn(Trt)-OH, Fmoc-Arg(Pbf)-OH. Deblocking of the Fmoc group the N-terminal of the resin-bound amino acid was performed with 20% piperidine in DMF for about 15-20 minutes. Coupling of the acetic acid was performed under conditions similar to amino acid coupling. Final cleavage from the resin was performed using cleavage mixture as described above. The product was isolated by precipitation and purified by preparative HPLC to afford the desired product as a white solid upon lyophilization.

**20     Example 6 – Preparation of D-Ala<sub>2</sub> GLP-1 (7-36) Amide**

Solid phase peptide synthesis of the GLP-1 analog on a 100 μmole scale is performed using manual solid-phase synthesis and a Symphony Peptide Synthesizer using Fmoc protected Rink Amide MBHA resin, Fmoc protected amino acids, O-benzotriazol-1-yl-*N*, *N*', *N*'-tetramethyl-uronium hexafluorophosphate (HBTU) in *N,N*-dimethylformamide (DMF) solution and activation with *N*-methyl morpholine (NMM), and piperidine deprotection of Fmoc groups (Step 1). Resin cleavage and product isolation is performed using 85% TFA/5% TIS/5% thioanisole and 5% phenol, followed by precipitation by dry-ice cold Et<sub>2</sub>O (Step 2). The product is purified by preparative reversed phased HPLC using a Varian (Rainin) preparative binary HPLC system: gradient elution of 30-55% B (0.045% TFA in H<sub>2</sub>O (A) and

0.045% TFA in CH<sub>3</sub>CN (B)) over 180 min at 9.5 mL/min using a Phenomenex Luna 10  $\mu$  phenyl-hexyl, 21 mm x 25 cm column and UV detector (Varian Dynamax UVD II) at  $\lambda$  214 and 254 nm to afford the desired peptide in >95% purity, as determined by RP-HPLC. These steps are illustrated in the schematic diagram below.



### C. Preparation of Modified Peptides From Peptides Containing No Cysteines

Preparation of maleimido peptides from therapeutic peptides containing multiple protected functional groups and no Cysteine is exemplified by the synthesis of peptides as described below. The peptide may be modified at the N-terminus, the C-terminus, or at an amino acid located between the N-terminus and the C-terminus. The modified peptide is synthesized by linking off the N-terminus of the natural peptide sequence or by linking off the modified C-terminus of the natural peptide sequence. One or more additional amino acids may be added to the therapeutic peptide to facilitate attachment of the reactive group.

## 1. Modification of the Therapeutic Peptide at the C-Terminus

- Example 7 – Modification of RSV Peptide at the  $\epsilon$ -Amino Group of the Added C-terminus Lysine Residue**  
**Preparation of Val-Ile-Thr-Ile-Glu-Leu-Ser-Asn-Ile-Lys-Glu-Asn-Lys-Met-Asn-Gly-Ala-Lys-Val-Lys-Leu-Ile-Lys-Gln-Glu-Leu-Asp-Lys-Tyr-Lys-Asn-Ala-Val-Lys-(N $\epsilon$ -MPA)**
- 5
- 10 Solid phase peptide synthesis of the DAC analog on a 100  $\mu$ mole scale is performed using manual solid-phase synthesis, a Symphony Peptide Synthesizer and Fmoc protected Rink Amide MBHA. The following protected amino acids are sequentially added to resin: Fmoc-Lys(Aloc)-OH, Fmoc-Val-OH, Fmoc-Ala-OH, Fmoc-Asn(Trt)-OH, Fmoc-
- 15 Lys(Boc)-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Asp(tBu)-OH, Fmoc-Leu-OH, Fmoc-Glu(tBu)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Ile-OH, Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-Val-OH, Fmoc-Lys(Boc)-OH, Fmoc-Ala-OH, Fmoc-Gly-OH, Fmoc-
- 20 Asn(Trt)-OH, Fmoc-Met-OH, Fmoc-Lys(Boc)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Glu(tBu)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Ile-OH, Fmoc-Asn(Trt)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Leu-OH, Fmoc-Glu(tBu)-OH, Fmoc-Ile-OH, Fmoc-Thr(tBu)-OH, Fmoc-Ile-OH, Fmoc-Val-OH. They are dissolved in N,N-dimethylformamide (DMF) and, according to the sequence, activated using O-benzotriazol-1-yl-N, N, N', N'-tetramethyl-uronium
- 25 hexafluorophosphate (HBTU) and Diisopropylethylamine (DIEA). Removal of the Fmoc protecting group is achieved using a solution of 20% (v/v) piperidine in N,N-dimethylformamide (DMF) for 20 minutes (step 1). The selective deprotection of the Lys (Aloc) group is performed manually and accomplished by treating the resin with a solution of 3 eq
- 30 of Pd(PPh<sub>3</sub>)<sub>4</sub> dissolved in 5 mL of CHCl<sub>3</sub>:NMM:HOAc (18:1:0.5) for 2 h (Step 2). The resin is then washed with CHCl<sub>3</sub> (6 x 5 mL), 20% HOAc in DCM (6 x 5 mL), DCM (6 x 5 mL), and DMF (6 x 5 mL). The synthesis is then re-automated for the addition of the 3-maleimidopropionic acid (Step 3). Between every coupling, the resin is washed 3 times with N,N-

dimethylformamide (DMF) and 3 times with isopropanol. The peptide is cleaved from the resin using 85% TFA/5% TIS/5% thioanisole and 5% phenol, followed by precipitation by dry-ice cold Et<sub>2</sub>O (Step 4). The product is purified by preparative reverse phase HPLC using a Varian

- 5 (Rainin) preparative binary HPLC system: gradient elution of 30-55% B (0.045% TFA in H<sub>2</sub>O (A) and 0.045% TFA in CH<sub>3</sub>CN (B)) over 180 min at 9.5 mL/min using a Phenomenex Luna 10  $\mu$  phenyl-hexyl, 21 mm x 25 cm column and UV detector (Varian Dynamax UVD II) at  $\lambda$  214 and 254 nm to afford the desired DAC in >95% purity, as determined by RP-HPLC.
- 10 HPLC.

**Example 8 – Modification of Dyn A 1-13 at the  $\epsilon$ -Amino Group of the Added C-terminus Lysine Residue - Synthesis of Dyn A 1-13(N $\epsilon$ -MPA)-NH<sub>2</sub>**

- 15 **Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-(N $\epsilon$ -MPA)-NH<sub>2</sub>**


Solid phase peptide synthesis of a modified Dyn A 1-13 on a 100  $\mu$ mole scale was performed using manual solid-phase synthesis, a

- 20 Symphony Peptide Synthesizer and Fmoc protected Rink Amide MBHA. The following protected amino acids were sequentially added to resin: Fmoc-Lys(Aloc)-OH, Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-Pro-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Ile-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Leu-OH, Fmoc-Phe-OH, Fmoc-Gly-OH, Fmoc-Gly-OH,
- 25 Fmoc-Tyr(tBu)-OH. They were dissolved in *N,N*-dimethylformamide (DMF) and, according to the sequence, activated using *O*-benzotriazol-1-yl-*N,N,N',N'*-tetramethyl-uronium hexafluorophosphate (HBTU) and Diisopropylethylamine (DIEA). Removal of the Fmoc protecting group is achieved using a solution of 20% (V/V) piperidine in *N,N*-
- 30 dimethylformamide (DMF) for 20 minutes (Step 1). The selective deprotection of the Lys (Aloc) group is performed manually and accomplished by treating the resin with a solution of 3 eq of Pd(PPh<sub>3</sub>)<sub>4</sub> dissolved in 5 mL of CHCl<sub>3</sub>:NMM:HOAc (18:1:0.5) for 2 h (Step 2). The resin is then washed with CHCl<sub>3</sub> (6 x 5 mL), 20% HOAc in DCM (6 x 5



mL), DCM (6 x 5 mL), and DMF (6 x 5 mL). The synthesis is then re-automated for the addition of the 3-maleimidopropionic acid (Step 3). Between every coupling, the resin is washed 3 times with *N,N*-dimethylformamide (DMF) and 3 times with isopropanol. The peptide is  
 5 cleaved from the resin using 85% TFA/5% TIS/5% thioanisole and 5% phenol, followed by precipitation by dry-ice cold Et<sub>2</sub>O (Step 4). The product is purified by preparative reverse phase HPLC using a Varian (Rainin) preparative binary HPLC system: gradient elution of 30-55% B (0.045% TFA in H<sub>2</sub>O (A) and 0.045% TFA in CH<sub>3</sub>CN (B)) over 180 min at  
 10 9.5 mL/min using a Phenomenex Luna 10  $\mu$  phenyl-hexyl, 21 mm x 25 cm column and UV detector (Varian Dynamax UVD II) at  $\lambda$  214 and 254 nm to afford the desired DAC in >95% purity, as determined by RP-HPLC.

The structure of this product is




**Example 9 - Modification of Dyn A 2-13 at the  $\epsilon$ -Amino Group of the Added C-terminus Lysine Residue - Synthesis of Dyn A 2-13(N $\epsilon$ -MPA)-NH<sub>2</sub>**  
 20 **Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-(N $\epsilon$ -MPA)-NH<sub>2</sub>**

Using automated peptide synthesis, the following protected amino acids were sequentially added to Rink Amide MBHA resin: Fmoc-  
 25 Lys(Mtt)-OH, Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-Pro-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Ile-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Leu-OH, Fmoc-Phe-OH, Fmoc-Gly-OH, and Boc-Gly-OH. Manual synthesis was employed for the remaining steps: selective removal of the Mtt group and coupling of MPA using HBTU/HOBt/DIEA activation in

DMF. The target dynorphin analog was removed from the resin; the product was isolated by precipitation and purified by preparative HPLC to afford the desired product as a white solid upon lyophilization in a 35% yield. Anal. HPLC indicated product to be >95% pure with  $R_t =$   
 5 30.42 min. ESI-MS  $m/z$  for  $C_{73}H_{123}N_{25}O_{15}$  ( $MH^+$ ), calcd 1590.0, found  $MH^{3+}$  531.3.

**Example 10 - Modification of Dyn A 1-13 at the  $\epsilon$ -Amino Group of the Added C-terminus Lysine Residue - Synthesis of Dyn A 1-13(AEA<sub>3</sub>-MPA)-NH<sub>2</sub>**  
 10 **Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-(AEA<sub>3</sub>-MPA)-NH<sub>2</sub>**

Using automated peptide synthesis, the following protected amino acids were sequentially added to Rink Amide MBHA resin: Fmoc-  
 15 Lys(Mtt)-OH, Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-Pro-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Ile-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Leu-OH, Fmoc-Phe-OH, Fmoc-Gly-OH, Fmoc-Gly-OH, and Boc-Tyr(Boc)-OH. Manual synthesis was employed for the remaining steps: selective removal of the Mtt group, the coupling of three-Fmoc-AEA-OH  
 20 groups (AEA = aminoethoxyacetic acid) with Fmoc removal in-between each coupling, and MPA acid using HBTU/HOBt/DIEA activation in DMF. The target dynorphin analog was removed from the resin; the product was isolated by precipitation and purified by preparative HPLC to afford the desired product as a white solid upon lyophilization in a  
 25 29% yield. Anal. HPLC indicated product to be >95% pure with  $R_t =$  33.06 min. ESI-MS  $m/z$  for  $C_{94}H_{154}N_{29}O_{23}$  ( $MH^+$ ), calcd 2057.2, found  $MH^{4+}$  515.4,  $MH^{3+}$  686.9,  $MH^{2+}$  1029.7.



**Example 11 – Modification of Dyn A 2-13 at the  $\epsilon$ -Amino Group of the Added C-terminus Lysine Residue - Synthesis of Dyn A 2-13(AEA<sub>3</sub>-MPA)-NH<sub>2</sub>**  
**Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-(AEA<sub>3</sub>-MPA)-NH<sub>2</sub>**


5

Using automated peptide synthesis, the following protected amino acids were sequentially added to Rink Amide MBHA resin: Fmoc-Lys(Mtt)-OH, Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-Pro-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Ile-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Leu-OH, Fmoc-Phe-OH, Fmoc-Gly-OH, and Fmoc-Gly-OH.

10

Manual synthesis was employed for the remaining steps: selective removal of the Mtt group, the coupling of three-Fmoc-AEA-OH groups, with Fmoc removal in-between each coupling, and MPA using HBTU/HOBt/DIEA activation in DMF. The target dynorphin analog was removed from the resin; the product was isolated by precipitation and purified by preparative HPLC to afford the desired product as a white solid upon lyophilization in a 29% yield. Anal. HPLC indicated product to be >95% pure with  $R_t = 31.88$  min. ESI-MS  $m/z$  for C<sub>85</sub>H<sub>146</sub>N<sub>26</sub>O<sub>21</sub> (MH<sup>+</sup>), calcd 1894.3, found MH<sup>4+</sup> 474.6, MH<sup>3+</sup> 632.4, MH<sup>2+</sup> 948.10.

15



20

**Example 12 – Modification of Neuropeptide Y at the  $\epsilon$ -Amino Group of the Added C-terminus Lysine Residue**  
**Preparation of Tyr-Pro-Ser-Lys-Pro-Asp-Asn-Pro-Gly-Glu-Asp-Ala-Pro-Ala-Glu-Asp-Met-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Lys-(N- $\epsilon$ -MPA)-NH<sub>2</sub>**

25

30

Solid phase peptide synthesis of a modified neuropeptide Y analog on a 100  $\mu$ mole scale is performed using manual solid-phase synthesis, a Symphony Peptide Synthesizer and Fmoc protected Rink

Amide MBHA. The following protected amino acids were sequentially added to resin: Fmoc-Lys(Aloc)-OH, Fmoc-Leu-OH, Fmoc-Ala-OH, Fmoc-Ser(tBu)-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Ala-OH, Fmoc-Met-OH, Fmoc-Asp(tBu)-OH, Fmoc-Glu(tBu)-OH, Fmoc-Ala-OH, Fmoc-Pro-OH, Fmoc-Ala-OH, Fmoc-Asp(tBu)-OH, Fmoc-Glu(tBu)-OH, Fmoc-Gly-OH, Fmoc-Pro-OH, Fmoc-Asn(Trt)-OH, Fmoc-Asp(tBu)-OH, Fmoc-Pro-OH, Fmoc-Lys(Boc)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Pro-OH, Fmoc-Tyr(tBu)-OH. They are dissolved in *N,N*-dimethylformamide (DMF) and, according to the sequence, activated using *O*-benzotriazol-1-yl-*N,N,N'*-tetramethyluronium hexafluorophosphate (HBTU) and Diisopropylethylamine (DIEA). Removal of the Fmoc protecting group is achieved using a solution of 20% (V/V) piperidine in *N,N*-dimethylformamide (DMF) for 20 minutes (Step 1). The selective deprotection of the Lys (Aloc) group is performed manually and accomplished by treating the resin with a solution of 3 eq of Pd(PPh<sub>3</sub>)<sub>4</sub> dissolved in 5 mL of CHCl<sub>3</sub>:NMM:HOAc (18:1:0.5) for 2 h (Step 2). The resin is then washed with CHCl<sub>3</sub> (6 x 5 mL), 20% HOAc in DCM (6 x 5 mL), DCM (6 x 5 mL), and DMF (6 x 5 mL). The synthesis is then re-automated for the addition of the 3-maleimidopropionic acid (Step 3). Between every coupling, the resin is washed 3 times with *N,N*-dimethylformamide (DMF) and 3 times with isopropanol. The peptide is cleaved from the resin using 85% TFA/5% TIS/5% thioanisole and 5% phenol, followed by precipitation by dry-ice cold Et<sub>2</sub>O (Step 4). The product is purified by preparative reverse phase HPLC using a Varian (Rainin) preparative binary HPLC system: gradient elution of 30-55% B (0.045% TFA in H<sub>2</sub>O (A) and 0.045% TFA in CH<sub>3</sub>CN (B)) over 180 min at 9.5 mL/min using a Phenomenex Luna 10  $\mu$  phenylhexyl, 21 mm x 25 cm column and UV detector (Varian Dynamax UVD II) at  $\lambda$  214 and 254 nm to afford the desired DAC in >95% purity, as determined by RP-HPLC.


**Example 13 - Modification of GLP-1 (7-36) at the C-Terminus Arginine**

**Preparation of GLP-1 (7-36)-EDA-MPA**

- 5 Solid phase peptide synthesis of a modified GLP-1 analog on a 100  $\mu$ mole scale is performed manually and on a Symphony Peptide Synthesizer SASRIN (super acid sensitive resin). The following protected amino acids are sequentially added to the resin: Fmoc-Arg(Pbf)-OH, Fmoc-Gly-OH, Fmoc-Lys(Boc)-OH, Fmoc-Val-OH, Fmoc-
- 10 Leu-OH, Fmoc-Trp(Boc)-OH, Fmoc-Ala-OH, Fmoc-Ile-OH, Fmoc-Phe-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Ala-OH, Fmoc-Ala-OH, Fmoc-Gln(Trt)-OH, Fmoc-Gly-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Leu-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Val-OH, Fmoc-Asp(tBu)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Thr(tBu)-
- 15 OH, Fmoc-Phe-OH, Fmoc-Thr(tBu)-OH, Fmoc-Gly-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Ala-OH, Boc-His(Trt)-OH. They are dissolved in *N,N*-dimethylformamide (DMF) and, according to the sequence, activated using *O*-benzotriazol-1-yl-*N,N,N*-tetramethyl-uronium hexafluorophosphate (HBTU) and Diisopropylethylamine (DIEA).
- 20 Removal of the Fmoc protecting group is achieved using a solution of 20% (V/V) piperidine in *N,N*-dimethylformamide (DMF) for 20 minutes (Step 1). The fully protected peptide is cleaved from the resin by treatment with 1% TFA / DCM (Step 2). Ethylenediamine and 3-maleimidopropionic acid are then sequentially added to the free C-
- 25 terminus (Step 3). The protecting groups are then cleaved and the product isolated using 86% TFA/5% TIS/5%  $H_2O$ /2% thioanisole and 2% phenol, followed by precipitation by dry-ice cold  $Et_2O$  (Step 4). The product is purified by preparative reverse phase HPLC using a Varian (Rainin) preparative binary HPLC system using a Dynamax  $C_{18}$ , 60Å, 8
- 30  $\mu$ m, 21 mm x 25 cm column equipped with a Dynamax  $C_{18}$ , 60Å, 8  $\mu$ m guard module, 21 mm x 25 cm column and UV detector (Varian Dynamax UVD II) at  $\lambda$  214 and 254 nm to afford the desired DAC in

>95% purity, as determined by RP-HPLC. These steps are illustrated in the schematic diagram below.

5



#### 10 **Example 14 - Modification of Exendin-4 at the C-terminus Serine Preparation of Exendin-4 (1-39)-EDA-MPA**

Solid phase peptide synthesis of a modified Exendin-4 analog on a 100 μmole scale is performed manually and on a Symphony Peptide Synthesizer SASRIN (super acid sensitive resin). The following protected amino acids are sequentially added to the resin: Fmoc-

15 Ser(tBu)-OH, Fmoc-Pro-OH, Fmoc-Pro-OH, Fmoc-Pro-OH, Fmoc-Ala-OH, Fmoc-Gly-OH, Fmoc-Ser(tBu)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Pro-OH, Fmoc-Gly-OH, Fmoc-Gly-OH, Fmoc-Asn(Trt)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Leu-OH, Fmoc-Trp(Boc)-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Ile-

- OH, Fmoc-Phe-OH, Fmoc-Leu-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Val-OH, Fmoc-Ala-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Met-OH, Fmoc-Gln(Trt)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Leu-OH, Fmoc-Asp(OtBu)-OH, Fmoc--
- 5 Ser(tBu)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Phe-OH, Fmoc-Thr(tBu)-OH, Fmoc-Gly-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Gly-OH, Boc-His(Trt)-OH. They are dissolved in *N,N*-dimethylformamide (DMF) and, according to the sequence, activated using *O*-benzotriazol-1-yl-*N,N,N*-tetramethyl-uronium hexafluorophosphate (HBTU) and
- 10 Diisopropylethylamine (DIEA). Removal of the Fmoc protecting group is achieved using a solution of 20% (V/V) piperidine in *N,N*-dimethylformamide (DMF) for 20 minutes (Step 1). The fully protected peptide is cleaved from the resin by treatment with 1% TFA / DCM (Step 2). Ethylenediamine and 3-maleimidopropionic acid are then sequentially
- 15 added to the free C-terminus (Step 3). The protecting groups are then cleaved and the product isolated using 86% TFA/5% TIS/5% H<sub>2</sub>O/2% thioanisole and 2% phenol, followed by precipitation by dry-ice cold Et<sub>2</sub>O (Step 4). The product is purified by preparative reverse phase HPLC using a Varian (Rainin) preparative binary HPLC system using a
- 20 Dynamax C<sub>18</sub>, 60Å, 8 µm, 21 mm x 25 cm column equipped with a Dynamax C<sub>18</sub>, 60Å, 8 µm guard module, 21 mm x 25 cm column and UV detector (Varian Dynamax UVD II) at λ 214 and 254 nm to afford the desired DAC in >95% purity, as determined by RP-HPLC.

SASRIN Resin

Step 1 ↓ SPPS

**Boc**-HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-Resin

Step 2 ↓ 1% TFA / DCM

**Boc**-HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-OH

Step 3 ↓  
1. ethylenediamine  
2. 3-maleimidopropionic acid



Step 4 ↓ 85% TFA/5% TIS/5% thioanisole / 5% phenol



Exendin-4 (1-39)-EDA-MPA



5 **Example 15 – Modification of Secretin Peptide at the  $\epsilon$ -Amino Group of the Added C-terminus Lysine Residue**  
**Preparation of His-Ser-Asp-Gly-Thr-Phe-Thr-Ser-Glu-Leu-Ser-Arg-Leu-Arg-Glu-Ala-Arg-Leu-Glu-Arg-Leu-Leu-Gln-Gly-Leu-Val-Lys-(N $\epsilon$ -MPA)-NH<sub>2</sub>**

10

Solid phase peptide synthesis of a modified secretin peptide analog on a 100  $\mu$ mole scale is performed using manual solid-phase synthesis, a Symphony Peptide Synthesizer and Fmoc protected Rink Amide MBHA. The following protected amino acids are sequentially

15

added to resin: Fmoc-Lys(Aloc)-OH, Fmoc-Val-OH, Fmoc-Leu-OH, Fmoc-Gly-OH, Fmoc-Gln(Trt)-OH, Fmoc-Leu-OH, Fmoc-Leu-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Glu(tBu)-OH, Fmoc-Leu-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Ala-OH, Fmoc-Gly-OH, Fmoc-Glu(tBu)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Leu-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Leu-OH, Fmoc-Glu(tBu)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Phe-OH, Fmoc-Thr(tBu)-OH, Fmoc-Gly-OH, Fmoc-Asp(tBu)-OH, Fmoc-Ser(tBu)-OH, Fmoc-His(Boc)-OH. They are dissolved in *N,N*-dimethylformamide (DMF) and, according to the sequence, activated using *O*-benzotriazol-1-yl-*N,N,N'*-tetramethyl-uronium

25

hexafluorophosphate (HBTU) and Diisopropylethylamine (DIEA). Removal of the Fmoc protecting group is achieved using a solution of 20% (V/V) piperidine in *N,N*-dimethylformamide (DMF) for 20 minutes (Step 1). The selective deprotection of the Lys (Aloc) group is performed manually and accomplished by treating the resin with a solution of 3 eq of Pd(PPh<sub>3</sub>)<sub>4</sub> dissolved in 5 mL of CHCl<sub>3</sub>:NMM:HOAc (18:1:0.5) for 2 h (Step 2). The resin is then washed with CHCl<sub>3</sub> (6 x 5 mL), 20% HOAc in DCM (6 x 5 mL), DCM (6 x 5 mL), and DMF (6 x 5 mL). The synthesis is then re-automated for the addition of the 3-maleimidopropionic acid (Step 3). Between every coupling, the resin is washed 3 times with *N,N*-

35

dimethylformamide (DMF) and 3 times with isopropanol. The peptide is

cleaved from the resin using 85% TFA/5% TIS/5% thioanisole and 5% phenol, followed by precipitation by dry-ice cold Et<sub>2</sub>O (Step 4). The product is purified by preparative reverse phase HPLC using a Varian (Rainin) preparative binary HPLC system: gradient elution of 30-55% B (0.045% TFA in H<sub>2</sub>O (A) and 0.045% TFA in CH<sub>3</sub>CN (B)) over 180 min at 9.5 mL/min using a Phenomenex Luna 10  $\mu$  phenyl-hexyl, 21 mm x 25 cm column and UV detector (Varian Dynamax UVD II) at  $\lambda$  214 and 254 nm to afford the desired DAC in >95% purity, as determined by RP-HPLC.

**Example 16 – Modification of Kringle-5 at the  $\epsilon$ -Amino Group of the Added C-terminus Lysine Residue**  
**Preparation of NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-(N<sub>ε</sub>-MPA)-NH<sub>2</sub>.2TFA**

Solid phase peptide synthesis of a modified Kringle-5 peptide on a 100  $\mu$ mole scale was performed using manual solid-phase synthesis, a Symphony Peptide Synthesizer and Fmoc protected Rink Amide MBHA. The following protected amino acids are sequentially added to resin: Fmoc-Lys(Aloc)-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Asp(tBu)-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Pro-OH. They were dissolved in *N,N*-dimethylformamide (DMF) and, according to the sequence, activated using O-benzotriazol-1-yl-*N,N,N'*-tetramethyl-uronium hexafluorophosphate (HBTU) and Diisopropylethylamine (DIEA). Removal of the Fmoc protecting group is achieved using a solution of 20% (V/V) piperidine in *N,N*-dimethylformamide (DMF) for 20 minutes (step 1). At the end of the synthesis Acetic Anhydride was added to acetylate the N-terminal. The selective deprotection of the Lys (Aloc) group is performed manually and accomplished by treating the resin with a solution of 3 eq of Pd(PPh<sub>3</sub>)<sub>4</sub> dissolved in 5 mL of CHCl<sub>3</sub>:NMM:HOAc (18:1:0.5) for 2 h (Step 2). The resin is then washed with CHCl<sub>3</sub> (6 x 5 mL), 20% HOAc in DCM (6 x 5 mL), DCM (6 x 5 mL), and DMF (6 x 5 mL). The synthesis is then re-automated for the addition of the 3-maleimidopropionic acid (Step 3).

Between every coupling, the resin is washed 3 times with *N,N*-dimethylformamide (DMF) and 3 times with isopropanol. The peptide is cleaved from the resin using 85% TFA/5% TIS/5% thioanisole and 5% phenol, followed by precipitation by dry-ice cold Et<sub>2</sub>O (Step 4). The product is purified by preparative reverse phase HPLC using a Varian (Rainin) preparative binary HPLC system: gradient elution of 30-55% B (0.045% TFA in H<sub>2</sub>O (A) and 0.045% TFA in CH<sub>3</sub>CN (B)) over 180 min at 9.5 mL/min using a Phenomenex Luna 10  $\mu$  phenyl-hexyl, 21 mm x 25 cm column and UV detector (Varian Dynamax UVD II) at  $\lambda$  214 and 254 nm to afford the desired DAC in >95% purity, as determined by RP-HPLC.

**Example 17 – Modification of Kringle-5 at the  $\epsilon$ -Amino Group of the Added C-terminus Lysine Residue**

**Preparation of NAc-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-(N $\epsilon$ -MPA)-NH<sub>2</sub>.2TFA**

Using automated peptide synthesis, the following protected amino acids were sequentially added to Rink Amide MBHA resin: Fmoc-Lys(Aloc)-OH, Fmoc-Tyr(tBu)OH, Fmoc-Asp(OtBu)-OH, Fmoc-Tyr(tBu)OH, Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Pro-OH, Fmoc-Asn(Trt)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Tyr(tBu)OH (step 1). Deblocking of the Fmoc group the N-terminal of the resin-bound amino acid was performed with 20% piperidine in DMF for about 15-20 minutes. Final cleavage from the resin was performed using cleavage mixture as described above. The product was isolated by precipitation and purified by preparative HPLC to afford the desired product as a white solid upon lyophilization. The selective deprotection of the Lys(Aloc) group was performed manually and accomplished by treating the resin with a solution of 3 eq of Pd(PPh<sub>3</sub>)<sub>4</sub> dissolved in 5 mL of CHCl<sub>3</sub>:NMM:HOAc (18:1:0.5) for 2 h (Step 2). The resin was then washed with CHCl<sub>3</sub> (6 x 5 mL), 20% HOAc in DCM (6 x 5 mL), DCM (6 x 5 mL), and DMF (6 x 5 mL). The synthesis

was then re-automated for the addition of the 3-maleimidopropionic acid (Step 3). Resin cleavage and product isolation was performed using 85% TFA/5% TIS/5% thioanisole and 5% phenol, followed by precipitation by dry-ice cold Et<sub>2</sub>O (Step 4). The product was purified by preparative reversed phased HPLC using a Varian (Rainin) preparative binary HPLC system: gradient elution of 30-55% B (0.045% TFA in H<sub>2</sub>O (A) and 0.045% TFA in CH<sub>3</sub>CN (B)) over 180 min at 9.5 mL/min using a Phenomenex Luna 10  $\mu$  phenyl-hexyl, 21 mm x 25 cm column and UV detector (Varian Dynamax UVD II) at  $\lambda$  214 and 254 nm.

**Example 18 - Modification of Kringle-5 at the  $\epsilon$ -Amino Group of the Added C-terminus Lysine Residue**  
**Preparation of NAc-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Ala-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-(N $\epsilon$ -MPA)-NH<sub>2</sub>.3TFA**

Using automated peptide synthesis, the following protected amino acids were sequentially added to Rink Amide MBHA resin: Fmoc-Lys(Aloc)-OH, Fmoc-Tyr(tBu)OH, Fmoc-Asp(OtBu)-OH, Fmoc-Tyr(tBu)OH, Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Pro-OH, Fmoc-Asn(Trt)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Tyr(tBu)OH, Fmoc-Ala-OH, Fmoc-Trp-OH, Fmoc-Pro-OH, Fmoc-Gly-OH, Fmoc-Gly-OH, Fmoc-Val-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Gly-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Pro-OH, Fmoc-Asn(Trt)-OH, Fmoc-Arg(Pbf)-OH (step 1). Deblocking of the Fmoc group the the N-terminal of the resin-bound amino acid was performed with 20% piperidine in DMF for about 15-20 minutes. Coupling of the acetic acid was performed under conditions similar to amino acid coupling. Final cleavage from the resin was performed using cleavage mixture as described above. The product was isolated by precipitation and purified by preparative HPLC to afford the desired product as a white solid upon lyophilization.

The selective deprotection of the Lys(Aloc) group was performed manually and accomplished by treating the resin with a solution of 3 eq of  $\text{Pd}(\text{PPh}_3)_4$  dissolved in 5 mL of  $\text{CHCl}_3$ :NMM:HOAc (18:1:0.5) for 2 h (Step 2). The resin was then washed with  $\text{CHCl}_3$  (6 x 5 mL), 20% HOAc in DCM (6 x 5 mL), DCM (6 x 5 mL), and DMF (6 x 5 mL). The synthesis was then re-automated for the addition of the 3-maleimidopropionic acid (Step 3). Resin cleavage and product isolation was performed using 85% TFA/5% TIS/5% thioanisole and 5% phenol, followed by precipitation by dry-ice cold  $\text{Et}_2\text{O}$  (Step 4). The product was purified by preparative reversed phased HPLC using a Varian (Rainin) preparative binary HPLC system: gradient elution of 30-55% B (0.045% TFA in  $\text{H}_2\text{O}$  (A) and 0.045% TFA in  $\text{CH}_3\text{CN}$  (B)) over 180 min at 9.5 mL/min using a Phenomenex Luna 10  $\mu$  phenyl-hexyl, 21 mm x 25 cm column and UV detector (Varian Dynamax UVD II) at  $\lambda$  214 and 254 nm.

**Example 19 – Modification of Kringle-5 at the  $\epsilon$ -Amino Group of the Added C-terminus Lysine Residue**  
**Preparation of NAc-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Lys-(N $\epsilon$ -MPA)-NH $_2$ .TFA**

Using automated peptide synthesis, the following protected amino acids were sequentially added to Rink Amide MBHA resin: Fmoc-Lys(Aloc)-OH, Fmoc-Trp-OH, Fmoc-Pro-OH, Fmoc-Gly-OH, Fmoc-Gly-OH, Fmoc-Val-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Gly-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Pro-OH, Fmoc-Asn(Trt)-OH, Fmoc-Arg(Pbf)-OH (Step 1). The selective deprotection of the Lys(Aloc) group was performed manually and accomplished by treating the resin with a solution of 3 eq of  $\text{Pd}(\text{PPh}_3)_4$  dissolved in 5 mL of  $\text{CHCl}_3$ :NMM:HOAc (18:1:0.5) for 2 h (Step 2). The resin was then washed with  $\text{CHCl}_3$  (6 x 5 mL), 20% HOAc in DCM (6 x 5 mL), DCM (6 x 5 mL), and DMF (6 x 5 mL). The synthesis was then re-automated for the addition of the 3-maleimidopropionic acid (Step 3). Resin cleavage and product isolation was performed using 85% TFA/5% TIS/5% thioanisole and 5% phenol,

followed by precipitation by dry-ice cold Et<sub>2</sub>O (Step 4). The product was purified by preparative reversed phased HPLC using a Varian (Rainin) preparative binary HPLC system: gradient elution of 30-55% B (0.045% TFA in H<sub>2</sub>O (A) and 0.045% TFA in CH<sub>3</sub>CN (B)) over 180 min at 9.5 mL/min using a Phenomenex Luna 10  $\mu$  phenyl-hexyl, 21 mm x 25 cm column and UV detector (Varian Dynamax UVD II) at  $\lambda$  214 and 254 nm.

**Example 20 – Modification of Kringle-5 at the  $\epsilon$ -Amino Group of the Added C-terminus Lysine Residue**  
**Preparation of NAc-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-(N $\epsilon$ -MPA)-NH<sub>2</sub>.2TFA**

Using automated peptide synthesis, the following protected amino acids were sequentially added to Rink Amide MBHA resin: Fmoc-Lys(Aloc)-OH, Fmoc-Tyr(tBu)OH, Fmoc-Asp(OtBu)-OH, Fmoc-Tyr(tBu)OH, Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-Arg(Pbf)-OH (Step 1). Deblocking of the Fmoc group the N-terminal of the resin-bound amino acid was performed with 20% piperidine in DMF for about 15-20 minutes. Coupling of the acetic acid was performed under conditions similar to amino acid coupling. Final cleavage from the resin was performed using cleavage mixture as described above. The product was isolated by precipitation and purified by preparative HPLC to afford the desired product as a white solid upon lyophilization. The selective deprotection of the Lys(Aloc) group was performed manually and accomplished by treating the resin with a solution of 3 eq of Pd(PPh<sub>3</sub>)<sub>4</sub> dissolved in 5 mL of CHCl<sub>3</sub>:NMM:HOAc (18:1:0.5) for 2 h (Step 2). The resin was then washed with CHCl<sub>3</sub> (6 x 5 mL), 20% HOAc in DCM (6 x 5 mL), DCM (6 x 5 mL), and DMF (6 x 5 mL). The synthesis was then re-automated for the addition of the 3-maleimidopropionic acid (Step 3). Resin cleavage and product isolation was performed using 85% TFA/5% TIS/5% thioanisole and 5% phenol, followed by precipitation by dry-ice cold Et<sub>2</sub>O (Step 4). The product was purified by preparative reversed phased HPLC using a Varian (Rainin) preparative

binary HPLC system: gradient elution of 30-55% B (0.045% TFA in H<sub>2</sub>O (A) and 0.045% TFA in CH<sub>3</sub>CN (B)) over 180 min at 9.5 mL/min using a Phenomenex Luna 10  $\mu$  phenyl-hexyl, 21 mm x 25 cm column and UV detector (Varian Dynamax UVD II) at  $\lambda$  214 and 254 nm.

5

**Example 21 - Modification of Kringle-5 at the  $\epsilon$ -Amino Group of the Added C-terminus Lysine Residue**  
**Preparation of NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Lys-(N $\epsilon$ -MPA)-NH<sub>2</sub>-2TFA**

10

Using automated peptide synthesis, the following protected amino acids were sequentially added to Rink Amide MBHA resin: Fmoc-Lys(Aloc)-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Tyr(tBu)OH, Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Pro-OH (Step 1).

15 Deblocking of the Fmoc group the N-terminal of the resin-bound amino acid was performed with 20% piperidine in DMF for about 15-20 minutes. Coupling of the acetic acid was performed under conditions similar to amino acid coupling. Final cleavage from the resin was performed using cleavage mixture as described above. The product  
20 was isolated by precipitation and purified by preparative HPLC to afford the desired product as a white solid upon lyophilization

The selective deprotection of the Lys(Aloc) group was performed manually and accomplished by treating the resin with a solution of 3 eq of Pd(PPh<sub>3</sub>)<sub>4</sub> dissolved in 5 mL of CHCl<sub>3</sub>:NMM:HOAc (18:1:0.5) for 2 h  
25 (Step 2). The resin was then washed with CHCl<sub>3</sub> (6 x 5 mL), 20% HOAc in DCM (6 x 5 mL), DCM (6 x 5 mL), and DMF (6 x 5 mL). The synthesis was then re-automated for the addition of the 3-maleimidopropionic acid (Step 3). Resin cleavage and product isolation was performed using 85% TFA/5% TIS/5% thioanisole and 5% phenol, followed by  
30 precipitation by dry-ice cold Et<sub>2</sub>O (Step 4). The product was purified by preparative reversed phased HPLC using a Varian (Rainin) preparative binary HPLC system: gradient elution of 30-55% B (0.045% TFA in H<sub>2</sub>O (A) and 0.045% TFA in CH<sub>3</sub>CN (B)) over 180 min at 9.5 mL/min using a

Phenomenex Luna 10  $\mu$  phenyl-hexyl, 21 mm x 25 cm column and UV detector (Varian Dynamax UVD II) at  $\lambda$  214 and 254 nm.

5 **Example 22 – Modification of Kringle-5 at the  $\epsilon$ -Amino Group of the Added C-terminus Lysine Residue**  
**Preparation of NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-(N $\epsilon$ -AEEA-MPA)-NH<sub>2</sub>.2TFA**

Using automated peptide synthesis, the following protected amino  
10 acids were sequentially added to Rink Amide MBHA resin: Fmoc-Lys(Aloc)-OH, Fmoc-Tyr(tBu)OH, Fmoc-Asp(OtBu)-OH, Fmoc-Tyr(tBu)OH, Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Pro-OH (Step 1). Deblocking of the Fmoc group at the N-terminal of the resin-bound amino acid was performed with 20% piperidine in  
15 DMF for about 15-20 minutes. Coupling of the acetic acid was performed under conditions similar to amino acid coupling. The selective deprotection of the Lys(Aloc) group was performed manually and accomplished by treating the resin with a solution of 3 eq of Pd(PPh<sub>3</sub>)<sub>4</sub> dissolved in 5 mL of CHCl<sub>3</sub>:NMM:HOAc (18:1:0.5) for 2 h  
20 (Step 2). The resin was then washed with CHCl<sub>3</sub> (6 x 5 mL), 20% HOAc in DCM (6 x 5 mL), DCM (6 x 5 mL), and DMF (6 x 5 mL). The synthesis was then re-automated for the addition. The synthesis was then re-automated for the addition of the AEEA (aminoethoxyethoxyacetic acid) group and of the 3-maleimidopropionic acid (MPA) (Step 3). Resin  
25 cleavage and product isolation was performed using 85% TFA/5% TIS/5% thioanisole and 5% phenol, followed by precipitation by dry-ice cold Et<sub>2</sub>O (Step 4). The product was purified by preparative reversed phased HPLC using a Varian (Rainin) preparative binary HPLC system: gradient elution of 30-55% B (0.045% TFA in H<sub>2</sub>O (A) and 0.045% TFA  
30 in CH<sub>3</sub>CN (B)) over 180 min at 9.5 mL/min using a Phenomenex Luna 10  $\mu$  phenyl-hexyl, 21 mm x 25 cm column and UV detector (Varian Dynamax UVD II) at  $\lambda$  214 and 254 nm.



**Example 23 – Modification of Kringle-5 at the  $\epsilon$ -Amino Group of the Added C-terminus Lysine Residue**  
**Preparation of NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-(N $\epsilon$ -AEEA<sub>n</sub>-MPA)-NH<sub>2</sub>.2TFA**

5

Using automated peptide synthesis, the following protected amino acids were sequentially added to Rink Amide MBHA resin: Fmoc-Lys(Aloc)-OH, Fmoc-Tyr(tBu)OH, Fmoc-Asp(OtBu)-OH, Fmoc-Tyr(tBu)OH, Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-Arg(Pbf)-OH, 10 Fmoc-Pro-OH (Step 1). Deblocking of the Fmoc group at the N-terminal of the resin-bound amino acid was performed with 20% piperidine in DMF for about 15-20 minutes. Coupling of the acetic acid was performed under conditions similar to amino acid coupling.

The selective deprotection of the Lys(Aloc) group was performed 15 manually and accomplished by treating the resin with a solution of 3 eq of Pd(PPh<sub>3</sub>)<sub>4</sub> dissolved in 5 mL of CHCl<sub>3</sub>:NMM:HOAc (18:1:0.5) for 2 h (Step 2). The resin was then washed with CHCl<sub>3</sub> (6 x 5 mL), 20% HOAc in DCM (6 x 5 mL), DCM (6 x 5 mL), and DMF (6 x 5 mL). The synthesis was then re-automated for the addition. The synthesis was then re- 20 automated for the addition of n AEEA (aminoethoxyethoxyacetic acid) groups and of the 3-maleimidopropionic acid (MPA) (Step 3). Resin cleavage and product isolation was performed using 85% TFA/5% TIS/5% thioanisole and 5% phenol, followed by precipitation by dry-ice cold Et<sub>2</sub>O (Step 4). The product was purified by preparative reversed 25 phased HPLC using a Varian (Rainin) preparative binary HPLC system: gradient elution of 30-55% B (0.045% TFA in H<sub>2</sub>O (A) and 0.045% TFA in CH<sub>3</sub>CN (B)) over 180 min at 9.5 mL/min using a Phenomenex Luna 10  $\mu$  phenyl-hexyl, 21 mm x 25 cm column and UV detector (Varian Dynamax UVD II) at  $\lambda$  214 and 254 nm.

30


**Example 24 – Modification of GLP-1 at the  $\epsilon$ -Amino Group of the Added C-terminus Lysine Residue**  
**Preparation of GLP-1 (1-36)-Lys<sup>37</sup>(N $\epsilon$ -MPA)-NH<sub>2</sub>.5TFA;**

**His-Asp-Glu-Phe-Glu-Arg-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Lys(Nε-MPA)-NH<sub>2</sub>.5TFA**

- 5           Using automated peptide synthesis, the following protected amino acids were sequentially added to Rink Amide MBHA resin: Fmoc-Lys(Aloc)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Gly-OH, Fmoc-Lys(tBoc)-OH, Fmoc-Val-OH, Fmoc-Leu-OH, Fmoc-Trp-OH, Fmoc-Ala-OH, Fmoc-Ile-OH, Fmoc-Phe-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Lys(tBoc)-OH, Fmoc-
- 10   Ala-OH, Fmoc-Ala-OH, Fmoc-Gln(Trt)-OH, Fmoc-Gly-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Leu-OH, Fmoc-Tyr(Pbf)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Val-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Phe-OH, Fmoc-Thr(tBu)-OH, Fmoc-Gly-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Ala-OH, Boc-His(N-Trt)-OH,
- 15   Fmoc-Arg(Pbf)-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Phe-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Asp(OtBu)-OH, Boc-His(N-Trt)-OH (step 1)

- The selective deprotection of the Lys(Aloc) group was performed manually and accomplished by treating the resin with a solution of 3 eq of Pd(PPh<sub>3</sub>)<sub>4</sub> dissolved in 5 mL of CHCl<sub>3</sub>:NMM:HOAc (18:1:0.5) for 2 h
- 20   (Step 2). The resin was then washed with CHCl<sub>3</sub> (6 x 5 mL), 20% HOAc in DCM (6 x 5 mL), DCM (6 x 5 mL), and DMF (6 x 5 mL). The synthesis was then re-automated for the addition of the 3-maleimidopropionic acid (Step 3). Resin cleavage and product isolation was performed using 85% TFA/5% TIS/5% thioanisole and 5% phenol, followed by
- 25   precipitation by dry-ice cold Et<sub>2</sub>O (Step 4). The product was purified by preparative reverse phase HPLC using a Varian (Rainin) preparative binary HPLC system: gradient elution of 30-55% B (0.045% TFA in H<sub>2</sub>O (A) and 0.045% TFA in CH<sub>3</sub>CN (B)) over 180 min at 9.5 mL/min using a Phenomenex Luna 10 μ phenyl-hexyl, 21 mm x 25 cm column and UV
- 30   detector (Varian Dynamax UVD II) at λ 214 and 254 nm. The product had >95% purity as determined by RP-HPLC mass spectrometry using a Hewlett Packard LCMS-1100 series spectrometer equipped with a diode

array detector and using electro-spray ionization. These steps are illustrated in the schematic diagram below.



5

**Example 25 - Modification of GLP-1 at the ε-Amino Group of the Added C-terminus Lysine Residue**  
**Preparation of GLP-1 (1-36)-Lys<sup>37</sup>(N<sub>ε</sub>-AEEA-AEEA-MPA)-NH<sub>2</sub>.5TFA;**  
**His-Asp-Glu-Phe-Glu-Arg-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-**  
**Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-**  
**Val-Lys-Gly-Arg-Lys(N<sub>ε</sub>-AEEA-AEEA-MPA)-NH<sub>2</sub>.5TFA**

10

Using automated peptide synthesis, the following protected amino acids were sequentially added to Rink Amide MBHA resin: Fmoc-

15 Lys(Aloc)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Gly-OH, Fmoc-Lys(tBoc)-OH, Fmoc-Val-OH, Fmoc-Leu-OH, Fmoc-Trp-OH, Fmoc-Ala-OH, Fmoc-Ile-OH, Fmoc-Phe-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Lys(tBoc)-OH, Fmoc-Ala-OH, Fmoc-Ala-OH, Fmoc-Gln(Trt)-OH, Fmoc-Gly-OH, Fmoc-

- Glu(OtBu)-OH, Fmoc-Leu-OH, Fmoc-Tyr(Pbf)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Val-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Phe-OH, Fmoc-Thr(tBu)-OH, Fmoc-Gly-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Ala-OH, Boc-His(N-Trt)-OH,
- 5 Fmoc-Arg(Pbf)-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Phe-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Asp(OtBu)-OH, Boc-His(N-Trt)-OH (step 1).

- The selective deprotection of the Lys(Aloc) group was performed manually and accomplished by treating the resin with a solution of 3 eq of Pd(PPh<sub>3</sub>)<sub>4</sub> dissolved in 5 mL of CHCl<sub>3</sub>:NMM:HOAc (18:1:0.5) for 2 h
- 10 (Step 2). The resin was then washed with CHCl<sub>3</sub> (6 x 5 mL), 20% HOAc in DCM (6 x 5 mL), DCM (6 x 5 mL), and DMF (6 x 5 mL). The synthesis was then re-automated for the addition of the two AEEA (aminoethoxyethoxyacetic acid) groups and the 3-maleimidopropionic acid (Step 3). Resin cleavage and product isolation was performed
- 15 using 85% TFA/5% TIS/5% thioanisole and 5% phenol, followed by precipitation by dry-ice cold Et<sub>2</sub>O (Step 4). The product was purified by preparative reverse phase HPLC using a Varian (Rainin) preparative binary HPLC system: gradient elution of 30-55% B (0.045% TFA in H<sub>2</sub>O (A) and 0.045% TFA in CH<sub>3</sub>CN (B)) over 180 min at 9.5 mL/min using a
- 20 Phenomenex Luna 10 μ phenyl-hexyl, 21 mm x 25 cm column and UV detector (Varian Dynamax UVD II) at λ 214 and 254 nm. The product had >95% purity as determined by RP-HPLC mass spectrometry using a Hewlett Packard LCMS-1100 series spectrometer equipped with a diode array detector and using electro-spray ionization, ESI-MS *m/z* for
- 25 C<sub>174</sub>H<sub>265</sub>N<sub>44</sub>O<sub>56</sub> (MH<sup>+</sup>), calcd 3868, found [M+H<sub>2</sub>]<sup>2+</sup> 1934, [M+H<sub>3</sub>]<sup>3+</sup> 1290, [M+H<sub>4</sub>]<sup>4+</sup> 967. These steps are illustrated in the schematic diagram below.

Step 1 ↓ SPPS

Step 2  $\downarrow$  Pd(PPh<sub>3</sub>)<sub>4</sub>/NMM/HOAc/CHCl<sub>3</sub>

**Step 3**

1. Fmoc-AAAA-OH (2 times)
2. 3-maleimidopropionic acid

Chemical structure of the peptide TSDVSSYLEGQAAKEFI<sup>20</sup>AWLVKGR-PS, showing the N-terminus (TSDVSSYLEGQAAKEFI<sup>20</sup>) and the C-terminus (PS). The structure includes a maleimide group attached to the N-terminus via a linker.

**Step 4** ↓ 85% TFA/5% TIS/5% thioanisole/5% phenol

TFA  
H<sub>2</sub>N-HAEGFTSDVSSYLEGQAAKEFIAWLVKGR-  
GLP-1 (7-36-K(AEEA<sub>2</sub>-MPA))-NH<sub>2</sub>

CCl-1051  
TFA

The reaction scheme shows the conversion of the linear peptide H<sub>2</sub>N-HAEGFTSDVSSYLEGQAAKEFIAWLVKGR-GLP-1 (7-36-K(AEEA<sub>2</sub>-MPA))-NH<sub>2</sub> to its cyclized form. The reagents used are 85% TFA, 5% TIS, 5% thioanisole, and 5% phenol. The product is a cyclic peptide where the N-terminus has been modified to include a CCl-1051 moiety.

5 **Preparation of GLP-1 (7-36)-Lys<sup>37</sup>(Nε-MPA)-NH<sub>2</sub>.4TFA; His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Lys(Nε-MPA)-NH<sub>2</sub>.4TFA**

10 Using automated peptide synthesis, the following protected amino  
acids were sequentially added to Rink Amide MBHA resin: Fmoc-  
Lys(Alloc)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Gly-OH, Fmoc-Lys(tBoc)-OH,  
Fmoc-Val-OH, Fmoc-Leu-OH, Fmoc-Trp-OH, Fmoc-Ala-OH, Fmoc-Ile-  
OH, Fmoc-Phe-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Lys(tBoc)-OH, Fmoc-  
15 Ala-OH, Fmoc-Ala-OH, Fmoc-Gln(Trt)-OH, Fmoc-Gly-OH, Fmoc-  
Glu(OtBu)-OH, Fmoc-Leu-OH, Fmoc-Tyr(Pbf)-OH, Fmoc-Ser(tBu)-OH,  
Fmoc-Ser(tBu)-OH, Fmoc-Val-OH, Fmoc-Asp(OtBu)-OH, Fmoc-  
Ser(tBu)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Phe-OH, Fmoc-Thr(tBu)-OH,

Fmoc-Gly-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Ala-OH, Boc-His(N-Trt)-OH (Step 1).

The selective deprotection of the Lys(Aloc) group was performed manually and accomplished by treating the resin with a solution of 3 eq of Pd(PPh<sub>3</sub>)<sub>4</sub> dissolved in 5 mL of CHCl<sub>3</sub>:NMM:HOAc (18:1:0.5) for 2 h (Step 2). The resin was then washed with CHCl<sub>3</sub> (6 x 5 mL), 20% HOAc in DCM (6 x 5 mL), DCM (6 x 5 mL), and DMF (6 x 5 mL). The synthesis was then re-automated for the addition of the 3-maleimidopropionic acid (Step 3). Resin cleavage and product isolation was performed using 85% TFA/5% TIS/5% thioanisole and 5% phenol, followed by precipitation by dry-ice cold Et<sub>2</sub>O (Step 4). The product was purified by preparative reverse phase HPLC using a Varian (Rainin) preparative binary HPLC system: gradient elution of 30-55% B (0.045% TFA in H<sub>2</sub>O (A) and 0.045% TFA in CH<sub>3</sub>CN (B)) over 180 min at 9.5 mL/min using a Phenomenex Luna 10 μ phenyl-hexyl, 21 mm x 25 cm column and UV detector (Varian Dynamax UVD II) at λ 214 and 254 nm. The product had >95% purity as determined by RP-HPLC mass spectrometry using a Hewlett Packard LCMS-1100 series spectrometer equipped with a diode array detector and using electro-spray ionization.

**Example 27 - Modification of GLP-1 at the ε-Amino Group of the Added C-terminus Lysine Residue**  
**Preparation of GLP-1 (7-36)-Lys<sup>37</sup>(Nε-AEEA-AEEA-MPA)-NH<sub>2</sub>.4TFA**  
**His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Lys(Nε-AEEA-AEEA-MPA)-NH<sub>2</sub>.4TFA**

Using automated peptide synthesis, the following protected amino acids were sequentially added to Rink Amide MBHA resin: Fmoc-Lys(Aloc)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Gly-OH, Fmoc-Lys(tBoc)-OH, Fmoc-Val-OH, Fmoc-Leu-OH, Fmoc-Trp-OH, Fmoc-Ala-OH, Fmoc-Ile-OH, Fmoc-Phe-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Lys(tBoc)-OH, Fmoc-Ala-OH, Fmoc-Ala-OH, Fmoc-Gln(Trt)-OH, Fmoc-Gly-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Leu-OH, Fmoc-Tyr(Pbf)-OH, Fmoc-Ser(tBu)-OH,

Fmoc-Ser(tBu)-OH, Fmoc-Val-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Phe-OH, Fmoc-Thr(tBu)-OH, Fmoc-Gly-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Ala-OH, Boc-His(N-Trt)-OH (Step 1).


- 5       The selective deprotection of the Lys(Aloc) group was performed manually and accomplished by treating the resin with a solution of 3 eq of Pd(PPh<sub>3</sub>)<sub>4</sub> dissolved in 5 mL of CHCl<sub>3</sub>:NMM:HOAc (18:1:0.5) for 2 h (Step 2). The resin was then washed with CHCl<sub>3</sub> (6 x 5 mL), 20% HOAc in DCM (6 x 5 mL), DCM (6 x 5 mL), and DMF (6 x 5 mL). The synthesis
- 10       was then re-automated for the addition of the two AEEA (aminoethoxyethoxyacetic acid) groups and the 3-maleimidopropionic acid (Step 3). Resin cleavage and product isolation was performed using 85% TFA/5% TIS/5% thioanisole and 5% phenol, followed by precipitation by dry-ice cold Et<sub>2</sub>O (Step 4). The product was purified by
- 15       preparative reverse phase HPLC using a Varian (Rainin) preparative binary HPLC system: gradient elution of 30-55% B (0.045% TFA in H<sub>2</sub>O (A) and 0.045% TFA in CH<sub>3</sub>CN (B)) over 180 min at 9.5 mL/min using a Phenomenex Luna 10 μ phenyl-hexyl, 21 mm x 25 cm column and UV detector (Varian Dynamax UVD II) at λ 214 and 254 nm. The product
- 20       had >95% purity as determined by RP-HPLC mass spectrometry using a Hewlett Packard LCMS-1100 series spectrometer equipped with a diode array detector and using electro-spray ionization.

- 25       **Example 28 - Modification of D-Ala<sup>2</sup> GLP-1 at the ε-Amino Group of the Added C-terminus Lysine Residue**  
**Preparation of D-Ala<sup>2</sup> GLP-1 (7-36)-Lys<sup>37</sup>(N<sub>ε</sub>-MPA)-NH<sub>2</sub>.4TFA**  
**His-d-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-**  
**Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-**  
**Val-Lys-Gly-Arg-Lys(N<sub>ε</sub>-MPA)-NH<sub>2</sub>.4TFA**

Using automated peptide synthesis, the following protected amino acids were sequentially added to Rink Amide MBHA resin: Fmoc-Lys(Aloc)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Gly-OH, Fmoc-Lys(tBoc)-OH, 5 Fmoc-Val-OH, Fmoc-Leu-OH, Fmoc-Trp-OH, Fmoc-Ala-OH, Fmoc-Ile-OH, Fmoc-Phe-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Lys(tBoc)-OH, Fmoc-Ala-OH, Fmoc-Ala-OH, Fmoc-Gln(Trt)-OH, Fmoc-Gly-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Leu-OH, Fmoc-Tyr(Pbf)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Val-OH, Fmoc-Asp(OtBu)-OH, Fmoc- 10 Ser(tBu)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Phe-OH, Fmoc-Thr(tBu)-OH, Fmoc-Gly-OH, Fmoc-Glu(OtBu)-OH, Fmoc-d-Ala-OH, Boc-His(N-Trt)-OH (Step1).

The selective deprotection of the Lys(Aloc) group was performed manually and accomplished by treating the resin with a solution of 3 eq 15 of  $\text{Pd}(\text{PPh}_3)_4$  dissolved in 5 mL of  $\text{CHCl}_3$ : $\text{NMM}$ : $\text{HOAc}$  (18:1:0.5) for 2 h (Step 2). The resin was then washed with  $\text{CHCl}_3$  (6 x 5 mL), 20%  $\text{HOAc}$  in  $\text{DCM}$  (6 x 5 mL),  $\text{DCM}$  (6 x 5 mL), and  $\text{DMF}$  (6 x 5 mL). The synthesis was then re-automated for the addition of the 3-maleimidopropionic acid (Step 3). Resin cleavage and product isolation was performed using 20 85%  $\text{TFA}$ /5%  $\text{TIS}$ /5% thioanisole and 5% phenol, followed by precipitation by dry-ice cold  $\text{Et}_2\text{O}$  (Step 4). The product was purified by preparative reverse phase HPLC using a Varian (Rainin) preparative binary HPLC system: gradient elution of 30-55% B (0.045%  $\text{TFA}$  in  $\text{H}_2\text{O}$  (A) and 0.045%  $\text{TFA}$  in  $\text{CH}_3\text{CN}$  (B)) over 180 min at 9.5 mL/min using a 25 Phenomenex Luna 10  $\mu$  phenyl-hexyl, 21 mm x 25 cm column and UV detector (Varian Dynamax UVD II) at  $\lambda$  214 and 254 nm. The product had >95% purity as determined by RP-HPLC mass spectrometry using a Hewlett Packard LCMS-1100 series spectrometer equipped with a diode array detector and using electro-spray ionization. These steps are 30 illustrated in the schematic diagram below.





**Example 29 - Modification of D-Ala<sup>2</sup> GLP-1 at the ε-Amino Group of the Added C-terminus Lysine Residue**

5 **Preparation of D-Ala<sup>2</sup> GLP-1 (7-36)-Lys<sup>37</sup>(Nε-AEEA-AEEA-MPA)-NH<sub>2</sub>.4TFA**  
**His-D-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Lys**  
 10 **(Nε-AEEA-AEEA-MPA)-NH<sub>2</sub>.4TFA**

Using automated peptide synthesis, the following protected amino acids were sequentially added to Rink Amide MBHA resin: Fmoc-Lys(Aloc)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Gly-OH, Fmoc-Lys(tBoc)-OH, Fmoc-Val-OH, Fmoc-Leu-OH, Fmoc-Trp-OH, Fmoc-Ala-OH, Fmoc-Ile-OH, Fmoc-Phe-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Lys(tBoc)-OH, Fmoc-Ala-OH, Fmoc-Ala-OH, Fmoc-Gln(Trt)-OH, Fmoc-Gly-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Leu-OH, Fmoc-Tyr(Pbf)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Val-OH, Fmoc-Asp(OtBu)-OH, Fmoc-

Ser(tBu)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Phe-OH, Fmoc-Thr(tBu)-OH, Fmoc-Gly-OH, Fmoc-Glu(OtBu)-OH, Fmoc-d-Ala-OH, Boc-His(N-Trt)-OH (Step 1).

- The selective deprotection of the Lys(Aloc) group was performed
- 5 manually and accomplished by treating the resin with a solution of 3 eq of  $\text{Pd}(\text{PPh}_3)_4$  dissolved in 5 mL of  $\text{CHCl}_3$ :NMM:HOAc (18:1:0.5) for 2 h (Step 2). The resin was then washed with  $\text{CHCl}_3$  (6 x 5 mL), 20% HOAc in DCM (6 x 5 mL), DCM (6 x 5 mL), and DMF (6 x 5 mL). The synthesis was then re-automated for the addition of the two AEEA
  - 10 (aminoethoxyethoxyacetic acid) groups and the 3-maleimidopropionic acid (Step 3). Resin cleavage and product isolation was performed using 85% TFA/5% TIS/5% thioanisole and 5% phenol, followed by precipitation by dry-ice cold  $\text{Et}_2\text{O}$  (Step 4). The product was purified by preparative reverse phase HPLC using a Varian (Rainin) preparative
  - 15 binary HPLC system: gradient elution of 30-55% B (0.045% TFA in  $\text{H}_2\text{O}$  (A) and 0.045% TFA in  $\text{CH}_3\text{CN}$  (B)) over 180 min at 9.5 mL/min using a Phenomenex Luna 10  $\mu$  phenyl-hexyl, 21 mm x 25 cm column and UV detector (Varian Dynamax UVD II) at  $\lambda$  214 and 254 nm. The product had >95% purity as determined by RP-HPLC mass spectrometry using a
  - 20 Hewlett Packard LCMS-1100 series spectrometer equipped with a diode array detector and using electro-spray ionization. These steps are illustrated in the schematic diagram below.

Step 1 SPPS

**Step 2**  $\text{Pd}(\text{PPh}_3)_4/\text{NMM}/\text{HOAc}/\text{CHCl}_3$

**Step 3**

**Boc-HaEGTFTSDVSSYLEGQAAKEFIAWLVKGR-**

Step 4 ↓ 85% TFA/5% TIS/5% thioanisole/5% phenol


$\text{H}_2\text{N}-\text{HaEGTFTSDVSSYLEGQAAKEFIAWLVKGR}-\text{NH}$   
 TFA                  TFA                  TFA                  TFA                  TFA  
 Asp²                  Ser¹⁰                  Gln¹⁵                  Lys³⁷                  Arg³⁶  
**D-Ala² GLP-1 (7-36)-Lys³⁷(E-AEEA₂-MPA)-NH₂**

5 Preparation of Extensin-4 (1-39)-Lys<sup>40</sup>(N<sub>6</sub>-MPA)-NH<sub>2</sub>;  
His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-  
Glu-Ala-Val-Arg-Leu-Phe-Ile-Gly-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-  
Ser-Gly-Ala-Pro-Pro-Ser-Lys (N<sub>6</sub>-MPA)-NH<sub>2</sub>. 5TFA

10 Using automated peptide synthesis, the following protected amino  
acids were sequentially added to Rink Amide MBHA resin: Fmoc-  
Lys(Aloc)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Pro-OH, Fmoc-Pro-OH, Fmoc-  
Pro-OH, Fmoc-Ala-OH, Fmoc-Gly-OH, Fmoc-Ser-OH, Fmoc-Ser(tBu)-  
OH, Fmoc-Pro-OH, Fmoc-Gly-OH, Fmoc-Gly-OH, Fmoc-Asn(Trt)-OH,  
15 Fmoc-Lys(Boc)-OH, Fmoc-Leu-OH, Fmoc-Trp-OH, Fmoc-Glu(OtBu)-  
OH, Fmoc-Ile-OH, Fmoc-Phe-OH, Fmoc-Leu-OH, Fmoc-Arg(Bpf)-OH,  
Fmoc-Val-OH, Fmoc-Ala-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Glu(OtBu)-  
OH, Fmoc-Glu(OtBu)-OH, Fmoc-Met-OH, Fmoc-Gln(Trt)-OH, Fmoc-  
Lys(Boc)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Leu-OH, Fmoc-Asp(OtBu)-OH,

Fmoc-Ser(tBu)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Phe-OH, Fmoc-Thr(tBu)-OH, Fmoc-Gly-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Gly-OH, Boc-His(Trt)-OH (Step 1).

- The selective deprotection of the Lys(Aloc) group was performed
- 5 manually and accomplished by treating the resin with a solution of 3 eq of  $\text{Pd}(\text{PPh}_3)_4$  dissolved in 5 mL of  $\text{CHCl}_3$ :NMM:HOAc (18:1:0.5) for 2 h (Step 2). The resin was then washed with  $\text{CHCl}_3$  (6 x 5 mL), 20% HOAc in DCM (6 x 5 mL), DCM (6 x 5 mL), and DMF (6 x 5 mL). The synthesis was then re-automated for the addition of the 3-maleimidopropionic acid
- 10 (Step 3). Resin cleavage and product isolation was performed using 85% TFA/5% TIS/5% thioanisole and 5% phenol, followed by precipitation by dry-ice cold  $\text{Et}_2\text{O}$  (Step 4). The product was purified by preparative reverse phase HPLC using a Varian (Rainin) preparative binary HPLC system: gradient elution of 30-55% B (0.045% TFA in  $\text{H}_2\text{O}$
- 15 (A) and 0.045% TFA in  $\text{CH}_3\text{CN}$  (B)) over 180 min at 9.5 mL/min using a Phenomenex Luna 10  $\mu$  phenyl-hexyl, 21 mm x 25 cm column and UV detector (Varian Dynamax UVD II) at  $\lambda$  214 and 254 nm. The product had >95% purity as determined by RP-HPLC mass spectrometry using a Hewlett Packard LCMS-1100 series spectrometer equipped with a diode
- 20 array detector and using electro-spray ionization. These steps are illustrated in the schematic diagram below.



**Example 31 - Modification of Exendin-4(1-39) at the ε-Amino Group of the Added C-terminus Lysine Residue**

- 5 **Preparation of Exendin-4 (1-39)-Lys<sup>40</sup>(Nε-AEEA-AEEA-MPA)-NH<sub>2</sub>.5TFA;**  
**His-Gly-Glu-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-Lys(Nε-AEEA-AEEA-MPA)-NH<sub>2</sub>.5TFA**

10

- Using automated peptide synthesis, the following protected amino acids were sequentially added to Rink Amide MBHA resin: Fmoc-Lys(Aloc)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Pro-OH, Fmoc-Pro-OH, Fmoc-Pro-OH, Fmoc-Ala-OH, Fmoc-Gly-OH, Fmoc-Ser-OH, Fmoc-Ser(tBu)-OH, Fmoc-Pro-OH, Fmoc-Gly-OH, Fmoc-Gly-OH, Fmoc-Asn(Trt)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Leu-OH, Fmoc-Trp-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Ile-OH, Fmoc-Phe-OH, Fmoc-Leu-OH, Fmoc-Arg(Bpf)-OH,
- 15

- Fmoc-Val-OH, Fmoc-Ala-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Met-OH, Fmoc-Gln(Trt)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Leu-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Phe-OH, Fmoc-Thr(tBu)-OH, Fmoc-Gly-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Gly-OH, Boc-His(Trt)-OH (Step 1).


- The selective deprotection of the Lys(Aloc) group was performed manually and accomplished by treating the resin with a solution of 3 eq of Pd(PPh<sub>3</sub>)<sub>4</sub> dissolved in 5 mL of CHCl<sub>3</sub>:NMM:HOAc (18:1:0.5) for 2 h (Step 2). The resin was then washed with CHCl<sub>3</sub> (6 x 5 mL), 20% HOAc in DCM (6 x 5 mL), DCM (6 x 5 mL), and DMF (6 x 5 mL). The synthesis was then re-automated for the addition of the two AEEA (aminoethoxyethoxyacetic acid) groups and the 3-maleimidopropionic acid (Step 3). Resin cleavage and product isolation was performed using 85% TFA/5% TIS/5% thioanisole and 5% phenol, followed by precipitation by dry-ice cold Et<sub>2</sub>O (Step 4). The product was purified by preparative reverse phase HPLC using a Varian (Rainin) preparative binary HPLC system: gradient elution of 30-55% B (0.045% TFA in H<sub>2</sub>O (A) and 0.045% TFA in CH<sub>3</sub>CN (B)) over 180 min at 9.5 mL/min using a Phenomenex Luna 10 μ phenyl-hexyl, 21 mm x 25 cm column and UV detector (Varian Dynamax UVD II) at λ 214 and 254 nm. The product had >95% purity as determined by RP-HPLC mass spectrometry using a Hewlett Packard LCMS-1100 series spectrometer equipped with a diode array detector and using electro-spray ionization. These steps are illustrated in the schematic diagram below.

Step 1 | SPSS

Step 2  $\downarrow$  Pd(PPh<sub>3</sub>)<sub>4</sub>/NMM/HOAc/CHCl<sub>3</sub>

**Step 3**

1. Fmoc-AEEA-OH (2 times)
2. 3-maleimidopropionic acid



Chemical structure of the peptide backbone after Step 3, showing the maleimide ring and the Fmoc-protected serine side chain.

**Step 4** ↓ 85% TFA/5% TIS/5% thioanisole/5% phenol

C(CCC(=O)Nc1ccc(NC(=O)c2ccccc2)cc1)C(=O)NCCSCC


**Example 32 - Modification of Exendin-3(1-39) at the  $\epsilon$ -Amino Group of the Added C-terminus Lysine Residue**

5 **Preparation of Exendin-3 (1-39)-Lys<sup>40</sup>(Nε-MPA)-NH<sub>2</sub>.5TFA; His-Ser-Asp-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-Lys(Nε-MPA)-NH<sub>2</sub>.5TFA**

10 Using automated peptide synthesis, the following protected amino  
acids were sequentially added to Rink Amide MBHA resin: Fmoc-  
Lys(Aloc)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Pro-OH, Fmoc-Pro-OH, Fmoc-  
Pro-OH, Fmoc-Ala-OH, Fmoc-Gly-OH, Fmoc-Ser-OH, Fmoc-Ser(tBu)-  
OH, Fmoc-Pro-OH, Fmoc-Gly-OH, Fmoc-Gly-OH, Fmoc-Asn(Trt)-OH,  
15 Fmoc-Lys(Boc)-OH, Fmoc-Leu-OH, Fmoc-Trp-OH, Fmoc-Glu(OtBu)-  
OH, Fmoc-Ile-OH, Fmoc-Phe-OH, Fmoc-Leu-OH, Fmoc-Arg(Bpf)-OH,  
Fmoc-Val-OH, Fmoc-Ala-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Glu(OtBu)-  
OH, Fmoc-Glu(OtBu)-OH, Fmoc-Met-OH, Fmoc-Gln(Trt)-OH, Fmoc-  
Lys(Boc)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Leu-OH, Fmoc-Asp(OtBu)-OH,

Fmoc-Ser(tBu)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Phe-OH, Fmoc-Thr(tBu)-OH, Fmoc-Gly-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Ser(OtBu)-OH, Boc-His(Trt)-OH (Step 1).

- The selective deprotection of the Lys(Aloc) group was performed manually and accomplished by treating the resin with a solution of 3 eq of  $\text{Pd}(\text{PPh}_3)_4$  dissolved in 5 mL of  $\text{CHCl}_3$ :NMM:HOAc (18:1:0.5) for 2 h (Step 2). The resin was then washed with  $\text{CHCl}_3$  (6 x 5 mL), 20% HOAc in DCM (6 x 5 mL), DCM (6 x 5 mL), and DMF (6 x 5 mL). The synthesis was then re-automated for the addition of the 3-maleimidopropionic acid (Step 3). Resin cleavage and product isolation was performed using 85% TFA/5% TIS/5% thioanisole and 5% phenol, followed by precipitation by dry-ice cold  $\text{Et}_2\text{O}$  (Step 4). The product was purified by preparative reverse phase HPLC using a Varian (Rainin) preparative binary HPLC system: gradient elution of 30-55% B (0.045% TFA in  $\text{H}_2\text{O}$  (A) and 0.045% TFA in  $\text{CH}_3\text{CN}$  (B)) over 180 min at 9.5 mL/min using a Phenomenex Luna 10  $\mu$  phenyl-hexyl, 21 mm x 25 cm column and UV detector (Varian Dynamax UVD II) at  $\lambda$  214 and 254 nm. The product had >95% purity as determined by RP-HPLC mass spectrometry using a Hewlett Packard LCMS-1100 series spectrometer equipped with a diode array detector and using electro-spray ionization. These steps are illustrated in the schematic diagram below.





**Example 33 - Modification of Exendin-3(1-39) at the  $\epsilon$ -Amino Group of the Added C-terminus Lysine Residue**  
**Preparation of Exendin-3 (1-39)-Lys<sup>40</sup>(N $\epsilon$ -AEEA-AEEA-MPA)-**

5    **NH<sub>2</sub>.5TFA;**  
     **His-Ser-Asp-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-**  
     **Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-**  
     **Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-Lys(N $\epsilon$ -AEEA-AEEA-MPA)-**  
10    **NH<sub>2</sub>.5TFA**

Using automated peptide synthesis, the following protected amino acids were sequentially added to Rink Amide MBHA resin: Fmoc-Lys(Aloc)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Pro-OH, Fmoc-Pro-OH, Fmoc-Pro-OH, Fmoc-Ala-OH, Fmoc-Gly-OH, Fmoc-Ser-OH, Fmoc-Ser(tBu)-  
15    OH, Fmoc-Pro-OH, Fmoc-Gly-OH, Fmoc-Gly-OH, Fmoc-Asn(Trt)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Leu-OH, Fmoc-Trp-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Ile-OH, Fmoc-Phe-OH, Fmoc-Leu-OH, Fmoc-Arg(Bpfl)-OH, Fmoc-Val-OH, Fmoc-Ala-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Met-OH, Fmoc-Gln(Trt)-OH, Fmoc-  
20    Lys(Boc)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Leu-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Phe-OH, Fmoc-Thr(tBu)-OH, Fmoc-Gly-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Ser(OtBu)-OH, Boc-His(Trt)-OH (Step 1).

The selective deprotection of the Lys(Aloc) group was performed  
25    manually and accomplished by treating the resin with a solution of 3 eq of Pd(PPh<sub>3</sub>)<sub>4</sub> dissolved in 5 mL of CHCl<sub>3</sub>:NMM:HOAc (18:1:0.5) for 2 h (Step 2). The resin was then washed with CHCl<sub>3</sub> (6 x 5 mL), 20% HOAc in DCM (6 x 5 mL), DCM (6 x 5 mL), and DMF (6 x 5 mL). The synthesis was then re-automated for the addition of the two AEEA  
30    (aminoethoxyethoxyacetic acid) groups and the 3-maleimidopropionic acid (Step 3). Resin cleavage and product isolation was performed using 85% TFA/5% TIS/5% thioanisole and 5% phenol, followed by precipitation by dry-ice cold Et<sub>2</sub>O (Step 4). The product was purified by preparative reverse phase HPLC using a Varian (Rainin) preparative

binary HPLC system: gradient elution of 30-55% B (0.045% TFA in H<sub>2</sub>O (A) and 0.045% TFA in CH<sub>3</sub>CN (B)) over 180 min at 9.5 mL/min using a Phenomenex Luna 10  $\mu$  phenyl-hexyl, 21 mm x 25 cm column and UV detector (Varian Dynamax UVD II) at  $\lambda$  214 and 254 nm. The product

5 had >95% purity as determined by RP-HPLC mass spectrometry using a Hewlett Packard LCMS-1100 series spectrometer equipped with a diode array detector and using electro-spray ionization.

**Example 34 - Modification of HIV-1 DP 178 at the C-Terminus**

- 10 **Preparation of modified HIV-1 DP 178 antifusogenic peptide**  
**Tyr-Thr-Ser-Leu-Ile-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Glu-Glu-**  
**Glu-Lys-Asn-Glu-Glu-Glu-Leu-Leu-Glu-Leu-Asp-Lys-Trp-Ala-Ser-**  
**Leu-Trp-Asn-Trp-Phe-Lys-( N $\epsilon$ -MPA)-NH<sub>2</sub>**
- 15 Using automated peptide synthesis, the following protected amino acids are sequentially added to Rink Amide MBHA resin: Fmoc-Lys(Mtt)-OH, Fmoc-Phe-OH, Fmoc-Trp(Boc)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Trp(Boc)-OH, Fmoc-Leu-OH, Fmoc-Ser(tBu)-OH, Fmoc-Ala-OH, Fmoc-Trp(Boc)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Asp(tBu)-OH, Fmoc-Leu-OH,
- 20 Fmoc-Glu(tBu)-OH, Fmoc-Leu-OH, Fmoc-Leu-OH, Fmoc-Glu(tBu)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Glu(tBu)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Glu(tBu)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Glu(tBu)-OH, Fmoc-Glu(tBu)-OH, Fmoc-Ile-OH, Fmoc-Leu-OH, Fmoc-
- 25 Ser(tBu)-OH, Fmoc-His(Trt)-OH, Fmoc-Ile-OH, Fmoc-Leu-OH, Fmoc-Ser(tBu)-OH, Fmoc-Thr(tBu)-OH and Boc-Tyr(tBu)-OH. Manual synthesis is employed for the remaining steps: selective removal of the Mtt group and coupling of maleimidopropionic acid (MPA) using HBTU/HOBt/DIEA activation in DMF. The target molecule is removed
- 30 from the resin; the product is isolated by precipitation and purified by preparative HPLC to afford the desired product as a white solid upon lyophilization.

**Example 35 – Modification of HIV-1 DP 107 at the C-Terminus**

**Preparation of modified HIV-1 DP 107 antifusogenic peptide**  
**Asn-Asn-Leu-Leu-Arg-Ala-Ile-Glu-Ala-Glu-Glu-His-Leu-Leu-Glu-Leu-**  
**Thr-Val-Trp-Glu-Ile-Lys-Glu-Leu-Glu-Ala-Arg-Ile-Leu-Ala-Val-Glu-**  
**Arg-Tyr-Leu-Lys-Asp-Glu-Lys-(N $\epsilon$ -MPA)NH $_2$**

5

Using automated peptide synthesis, the following protected amino acids are sequentially added to Rink Amide MBHA resin: Fmoc-

Lys(Mtt)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Asp(tBu)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Leu-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-

10 Glu(tBu)-OH, Fmoc-Val-OH, Fmoc-Ala-OH, Fmoc-Leu-OH, Fmoc-Ile-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Ala-OH, Fmoc-Gln(Trt)-OH, Fmoc-Leu-OH, Fmoc-Gln(Trt)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Ile-OH, Fmoc-Gln(Trt)-OH, Fmoc-Trp(Boc)-OH, Fmoc-Val-OH, Fmoc-Thr(tBu)-OH, Fmoc-Leu-OH, Fmoc-Gln(Trt)-OH, Fmoc-Leu-OH, Fmoc-Leu-OH, Fmoc-

15 His(Trt)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Ala-OH, Fmoc-Glu(tBu)-OH, Fmoc-Ile-OH, Fmoc-Ala-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Leu-OH, Fmoc-Leu-OH, Fmoc-Asn(Trt)-OH, Fmoc-Asn(Trt)-OH.

Manual synthesis is employed for the remaining steps: selective removal of the Mtt group and coupling of maleimidopropionic acid (MPA) using

20 HBTU/HOBt/DIEA activation in DMF. The target analog is removed from the resin; the product is isolated by precipitation and purified by preparative HPLC to afford the desired product as a white solid upon lyophilization.

25 **2. Modification of the Therapeutic Peptide at the N-Terminus**

**Example 36 – Modification of RSV Peptide at the  $\epsilon$ -Amino Group of the Added N-terminus Lysine Residue**

30 **Preparation of (N $\epsilon$ -MPA)-Lys-Val-Ile-Thr-Ile-Glu-Leu-Ser-Asn-Ile-Lys-Glu-Asn-Lys-Met-Asn-Gly-Ala-Lys-Val-Lys-Leu-Ile-Lys-Gln-Glu-Leu-Asp-Lys-Tyr-Lys-Asn-Ala-Val**

Solid phase peptide synthesis of a modified RSV peptide on a 100  $\mu$ mole scale is performed using manual solid-phase synthesis, a

35 Symphony Peptide Synthesizer and Fmoc protected Rink Amide MBHA. The following protected amino acids are sequentially added to resin:

Fmoc-Val-OH, Fmoc-Ala-OH, Fmoc-Asn(Trt)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Asp(tBu)-OH, Fmoc-Leu-OH, Fmoc-Glu(tBu)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Ile-OH, Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-Val-OH, Fmoc-Lys(Boc)-OH, Fmoc-Ala-OH, Fmoc-Gly-OH, Fmoc-Asn(Trt)-OH, Fmoc-Met-OH, Fmoc-Lys(Boc)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Glu(tBu)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Ile-OH, Fmoc-Asn(Trt)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Leu-OH, Fmoc-Glu(tBu)-OH, Fmoc-Ile-OH, Fmoc-Thr(tBu)-OH, Fmoc-Ile-OH, Fmoc-Val-OH, Fmoc-Lys(Aloc)-OH. They are dissolved in N,N-dimethylformamide (DMF) and, according to the sequence, activated using O-benzotriazol-1-yl-N, N, N', N'-tetramethyluronium hexafluorophosphate (HBTU) and Diisopropylethylamine (DIEA). Removal of the Fmoc protecting group is achieved using a solution of 20% (V/V) piperidine in N,N-dimethylformamide (DMF) for 20 minutes (Step 1). The selective deprotection of the Lys (Aloc) group is performed manually and accomplished by treating the resin with a solution of 3 eq of Pd(PPh<sub>3</sub>)<sub>4</sub> dissolved in 5 mL of CHCl<sub>3</sub>:NMM:HOAc (18:1:0.5) for 2 h (Step 2). The resin is then washed with CHCl<sub>3</sub> (6 x 5 mL), 20% HOAc in DCM (6 x 5 mL), DCM (6 x 5 mL), and DMF (6 x 5 mL). The synthesis is then re-automated for the addition of the 3-maleimidopropionic acid (Step 3). Between every coupling, the resin is washed 3 times with N,N-dimethylformamide (DMF) and 3 times with isopropanol. The peptide is cleaved from the resin using 85% TFA/5% TIS/5% thioanisole and 5% phenol, followed by precipitation by dry-ice cold Et<sub>2</sub>O (Step 4). The product is purified by preparative reversed phased HPLC using a Varian (Rainin) preparative binary HPLC system: gradient elution of 30-55% B (0.045% TFA in H<sub>2</sub>O (A) and 0.045% TFA in CH<sub>3</sub>CN (B)) over 180 min at 9.5 mL/min using a Phenomenex Luna 10  $\mu$  phenyl-hexyl, 21 mm x 25 cm column and UV detector (Varian Dynamax UVD II) at  $\lambda$  214 and 254 nm to afford the desired DAC in >95% purity, as determined by RP-HPLC.

**Example 37 – Modification of Neuropeptide Y at the  $\epsilon$ -Amino Group of the Added N-terminus Lysine Residue**

**Preparation of (N- $\epsilon$ MPA)-Lys-Tyr-Pro-Ser-Lys-Pro-Glu-Asn-Pro-Gly-Glu-Asp-Ala-Pro-Ala-Glu-Asp-Met-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu**

5

Solid phase peptide synthesis of a modified neuropeptide Y on a 100  $\mu$ mole scale was performed using manual solid-phase synthesis, a Symphony Peptide Synthesizer and Fmoc protected Rink Amide MBHA. The following protected amino acids are sequentially added to resin:

- 10 Fmoc-Leu-OH, Fmoc-Ala-OH, Fmoc-Ser(tBu)-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Ala-OH, Fmoc-Met-OH, Fmoc-Asp(tBu)-OH, Fmoc-Glu(tBu)-OH, Fmoc-Ala-OH, Fmoc-Pro-OH, Fmoc-Ala-OH, Fmoc-Asp(tBu)-OH, Fmoc-Glu(tBu)-OH, Fmoc-Gly-OH, Fmoc-Pro-OH, Fmoc-Asn(Trt)-OH, Fmoc-Glu(tBu)-OH, Fmoc-Pro-OH,
- 15 Fmoc-Lys(Boc)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Pro-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Lys(Aloc)-OH. They are dissolved in N,N-dimethylformamide (DMF) and, according to the sequence, activated using O-benzotriazol-1-yl-N, N, N', N'-tetramethyl-uronium hexafluorophosphate (HBTU) and Diisopropylethylamine (DIEA). Removal of the Fmoc protecting group is
- 20 achieved using a solution of 20% (V/V) piperidine in N,N-dimethylformamide (DMF) for 20 minutes (Step 1). The selective deprotection of the Lys (Aloc) group is performed manually and accomplished by treating the resin with a solution of 3 eq of Pd(PPh<sub>3</sub>)<sub>4</sub> dissolved in 5 mL of CHCl<sub>3</sub>:NMM:HOAc (18:1:0.5) for 2 h (Step 2). The
- 25 resin is then washed with CHCl<sub>3</sub> (6 x 5 mL), 20% HOAc in DCM (6 x 5 mL), DCM (6 x 5 mL), and DMF (6 x 5 mL). The synthesis is then re-automated for the addition of the 3-maleimidopropionic acid (Step 3). Between every coupling, the resin is washed 3 times with N,N-dimethylformamide (DMF) and 3 times with isopropanol. The peptide is
- 30 cleaved from the resin using 85% TFA/5% TIS/5% thioanisole and 5% phenol, followed by precipitation by dry-ice cold Et<sub>2</sub>O (Step 4). The product is purified by preparative reverse phase HPLC using a Varian (Rainin) preparative binary HPLC system: gradient elution of 30-55% B

(0.045% TFA in H<sub>2</sub>O (A) and 0.045% TFA in CH<sub>3</sub>CN (B)) over 180 min at 9.5 mL/min using a Phenomenex Luna 10  $\mu$  phenyl-hexyl, 21 mm x 25 cm column and UV detector (Varian Dynamax UVD II) at  $\lambda$  214 and 254 nm to afford the desired DAC in >95% purity, as determined by RP-

5 HPLC.

**Example 38 – Modification of Neuropeptide Y at the  $\epsilon$ -Amino Group of the Added N-terminus Lysine Residue**  
**Preparation of (N- $\epsilon$ MPA)-Lys-Tyr-Pro-Ser-Lys-Pro-Asp-Asn-Pro-Gly-**  
**10 Glu-Asp-Ala-Pro-Ala-Glu-Asp-Met-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu**

Solid phase peptide synthesis of a modified neuropeptide Y on a 100  $\mu$ mole scale was performed using manual solid-phase synthesis, a Symphony Peptide Synthesizer and Fmoc protected Rink Amide MBHA.

- 15 The following protected amino acids are sequentially added to resin: Fmoc-Leu-OH, Fmoc-Ala-OH, Fmoc-Ser(tBu)-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Ala-OH, Fmoc-Met-OH, Fmoc-Asp(tBu)-OH, Fmoc-Glu(tBu)-OH, Fmoc-Ala-OH, Fmoc-Pro-OH, Fmoc-Ala-OH, Fmoc-Asp(tBu)-OH, Fmoc-Glu(tBu)-OH, Fmoc-Gly-OH,
- 20 Fmoc-Pro-OH, Fmoc-Asn(Trt)-OH, Fmoc-Asp(tBu)-OH, Fmoc-Pro-OH, Fmoc-Lys(Boc)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Pro-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Lys(Aloc)-OH. They are dissolved in N,N-dimethylformamide (DMF) and, according to the sequence, activated using O-benzotriazol-1-yl-N, N, N', N'-tetramethyl-uronium hexafluorophosphate (HBTU) and
- 25 Diisopropylethylamine (DIEA). Removal of the Fmoc protecting group is achieved using a solution of 20% (V/V) piperidine in N,N-dimethylformamide (DMF) for 20 minutes (Step 1). The selective deprotection of the Lys (Aloc) group is performed manually and accomplished by treating the resin with a solution of 3 eq of Pd(PPh<sub>3</sub>)<sub>4</sub>
- 30 dissolved in 5 mL of CHCl<sub>3</sub>:NMM:HOAc (18:1:0.5) for 2 h (Step 2). The resin is then washed with CHCl<sub>3</sub> (6 x 5 mL), 20% HOAc in DCM (6 x 5 mL), DCM (6 x 5 mL), and DMF (6 x 5 mL). The synthesis is then re-automated for the addition of the 3-maleimidopropionic acid (Step 3).

- Between every coupling, the resin is washed 3 times with *N,N*-dimethylformamide (DMF) and 3 times with isopropanol. The peptide is cleaved from the resin using 85% TFA/5% TIS/5% thioanisole and 5% phenol, followed by precipitation by dry-ice cold Et<sub>2</sub>O (Step 4). The product is purified by preparative reverse phase HPLC using a Varian (Rainin) preparative binary HPLC system: gradient elution of 30-55% B (0.045% TFA in H<sub>2</sub>O (A) and 0.045% TFA in CH<sub>3</sub>CN (B)) over 180 min at 9.5 mL/min using a Phenomenex Luna 10  $\mu$  phenyl-hexyl, 21 mm x 25 cm column and UV detector (Varian Dynamax UVD II) at  $\lambda$  214 and 254 nm to afford the desired DAC in >95% purity, as determined by RP-HPLC.

**Example 39 – Modification of Dyn A 1-13 at the  $\epsilon$ -Amino Group of the Added N-terminus Lysine Residue - Synthesis of (N<sub>ε</sub>-MPA)-Dyn A 1-13-NH<sub>2</sub> (N<sub>ε</sub>-MPA)-Lys-Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu**


- Solid phase peptide synthesis of a modified Dyn A 1-13 analog on a 100  $\mu$ mole scale is performed using manual solid-phase synthesis, a Symphony Peptide Synthesizer and Fmoc protected Rink Amide MBHA. The following protected amino acids are sequentially added to resin: Fmoc-Lys(Boc)-OH, Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-Pro-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Ile-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Leu-OH, Fmoc-Phe-OH, Fmoc-Gly-OH, Fmoc-Gly-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Lys(Aloc)-OH. They were dissolved in *N,N*-dimethylformamide (DMF) and, according to the sequence, activated using *O*-benzotriazol-1-yl-*N,N,N'*-tetramethyluronium hexafluorophosphate (HBTU) and Diisopropylethylamine (DIEA). Removal of the Fmoc protecting group is achieved using a solution of 20% (V/V) piperidine in *N,N*-dimethylformamide (DMF) for 20 minutes (Step 1). The selective deprotection of the Lys (Aloc) group is performed manually and accomplished by treating the resin with a solution of 3 eq of Pd(PPh<sub>3</sub>)<sub>4</sub> dissolved in 5 mL of CHCl<sub>3</sub>:NMM:HOAc (18:1:0.5) for 2 h

(Step 2). The resin is then washed with  $\text{CHCl}_3$  (6 x 5 mL), 20% HOAc in DCM (6 x 5 mL), DCM (6 x 5 mL), and DMF (6 x 5 mL). The synthesis is then re-automated for the addition of the 3-maleimidopropionic acid (Step 3). Between every coupling, the resin is washed 3 times with *N,N*-dimethylformamide (DMF) and 3 times with isopropanol. The peptide is cleaved from the resin using 85% TFA/5% TIS/5% thioanisole and 5% phenol, followed by precipitation by dry-ice cold  $\text{Et}_2\text{O}$  (Step 4). The product is purified by preparative reverse phase HPLC using a Varian (Rainin) preparative binary HPLC system: gradient elution of 30-55% B (0.045% TFA in  $\text{H}_2\text{O}$  (A) and 0.045% TFA in  $\text{CH}_3\text{CN}$  (B)) over 180 min at 9.5 mL/min using a Phenomenex Luna 10  $\mu$  phenyl-hexyl, 21 mm x 25 cm column and UV detector (Varian Dynamax UVD II) at  $\lambda$  214 and 254 nm to afford the desired DAC in >95% purity, as determined by RP-HPLC.

**Example 40 - Modification of Dyn A 2-17-NH<sub>2</sub> at the N-terminus  
Glycine - Synthesis of MPA-AEA<sub>3</sub>-Dyn A 2-17-NH<sub>2</sub>  
(MPA-AEA-AEA-AEA)-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-  
Leu-Lys-Trp-Asp-Asn-Glu**

Using automated peptide synthesis, the following protected amino acids and maleimide were sequentially added to Rink Amide MBHA resin: Fmoc-Gln(Trt)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Trp(Boc)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-Pro-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Ile-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Leu-OH, Fmoc-Phe-OH, Fmoc-Gly-OH, Fmoc-Gly-OH, Fmoc-AEA-OH, Fmoc-AEA-OH, Fmoc-AEA-OH, and MPA. The target dynorphin analog was then removed from the resin; the product was isolated by precipitation and purified by preparative HPLC to afford the desired product as a pale yellow solid upon lyophilization in a 32% yield. Anal. HPLC indicated product to be >95% pure with  $R_t$  = 33.44 min. ESI-MS  $m/z$  for  $\text{C}_{109}\text{H}_{172}\text{N}_{35}\text{O}_{29}$  ( $\text{MH}^+$ ), calcd 2436.8, found  $\text{MH}^{3+}$  813.6.





**Example 42 – Modification of Kringle-5 at the  $\epsilon$ -Amino Group of the Added N-Terminus Lysine Residue**  
**Preparation of (N $\epsilon$ -MPA)-Lys-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub>.2TFA**

- Solid phase peptide synthesis of a modified Kringle-5 analog on a
- 10 100  $\mu$ mole scale was performed using manual solid-phase synthesis, a Symphony Peptide Synthesizer and Fmoc protected Rink Amide MBHA. The following protected amino acids are sequentially added to resin: Fmoc-Tyr(tBu)-OH, Fmoc-Asp(tBu)-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Pro-OH, Fmoc-
- 15 Lys(Aloc)-OH. They were dissolved in *N,N*-dimethylformamide (DMF) and, according to the sequence, activated using *O*-benzotriazol-1-yl-*N,N,N',N'*-tetramethyl-uronium hexafluorophosphate (HBTU) and Diisopropylethylamine (DIEA). Removal of the Fmoc protecting group is achieved using a solution of 20% (V/V) piperidine in *N,N*-
- 20 dimethylformamide (DMF) for 20 minutes (step 1). The selective deprotection of the Lys (Aloc) group is performed manually and accomplished by treating the resin with a solution of 3 eq of Pd(PPh<sub>3</sub>)<sub>4</sub> dissolved in 5 mL of CHCl<sub>3</sub>:NMM:HOAc (18:1:0.5) for 2 h (Step 2). The resin is then washed with CHCl<sub>3</sub> (6 x 5 mL), 20% HOAc in DCM (6 x 5
- 25 mL), DCM (6 x 5 mL), and DMF (6 x 5 mL). The synthesis is then re-automated for the addition of the 3-maleimidopropionic acid (Step 3). Between every coupling, the resin is washed 3 times with *N,N*-dimethylformamide (DMF) and 3 times with isopropanol. The peptide is cleaved from the resin using 85% TFA/5% TIS/5% thioanisole and 5%
- 30 phenol, followed by precipitation by dry-ice cold Et<sub>2</sub>O (Step 4). The product is purified by preparative reverse phase HPLC using a Varian

(Rainin) preparative binary HPLC system: gradient elution of 30-55% B (0.045% TFA in H<sub>2</sub>O (A) and 0.045% TFA in CH<sub>3</sub>CN (B)) over 180 min at 9.5 mL/min using a Phenomenex Luna 10  $\mu$  phenyl-hexyl, 21 mm x 25 cm column and UV detector (Varian Dynamax UVD II) at  $\lambda$  214 and 254 nm to afford the desired DAC in >95% purity, as determined by RP-HPLC.

10 **Example 43 – Modification of Kringle-5 at the N-Terminus Proline**  
**Preparation of (MPA-AEEA)-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-**  
**NH<sub>2</sub>-2TFA**

Using automated peptide synthesis, the following protected amino acids were sequentially added to Rink Amide MBHA resin: Fmoc-  
15 Lys(Boc)-OH, Fmoc-Tyr(tBu)OH, Fmoc-Asp(OtBu)-OH, Fmoc-Tyr(tBu)OH, Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Pro-OH (step 1). The deprotection of the terminal Fmoc group is accomplished using 20% piperidine (Step 2) followed by the coupling of Fmoc-AEEA. Deprotection of the resulting Fmoc-AEEA-peptide with  
20 piperidine 20% in DMF allow for the subsequent addition of the 3-MPA (Step 3). Resin cleavage and product isolation was performed using 86% TFA/5% TIS/5% H<sub>2</sub>O/2% thioanisole and 2% phenol, followed by precipitation by dry-ice cold Et<sub>2</sub>O (Step 4). The product was purified by preparative reversed phased HPLC using a Varian (Rainin) preparative  
25 binary HPLC system using a Dynamax C<sub>18</sub>, 60Å, 8  $\mu$ m, 21 mm x 25 cm column equipped with a Dynamax C<sub>18</sub>, 60Å, 8  $\mu$ m guard module, 21 mm x 25 cm column and UV detector (Varian Dynamax UVD II) at  $\lambda$  214 and 254 nm. The product had >95% purity as determined by RP-HPLC mass spectrometry using a Hewlett Packard LCMS-1100 series  
30 spectrometer equipped with a diode array detector and using electrospray ionization.

**Example 44 – Modification of Kringle-5 at the N-Terminus Proline  
Preparation of (MPA)-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-NH<sub>2</sub>.2TFA**

Using automated peptide synthesis, the following protected amino acids were sequentially added to Rink Amide MBHA resin: Fmoc-Lys(Boc)-OH, Fmoc-Tyr(tBu)OH, Fmoc-Asp(OtBu)-OH, Fmoc-Tyr(tBu)OH, Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Pro-OH (step 1). The deprotection of the terminal Fmoc group is accomplished using 20% piperidine (Step 2) followed by the coupling of 3-MPA (Step 3). Resin cleavage and product isolation was performed using 86% TFA/5% TIS/5% H<sub>2</sub>O/2% thioanisole and 2% phenol, followed by precipitation by dry-ice cold Et<sub>2</sub>O (Step 4). The product was purified by preparative reversed phased HPLC using a Varian (Rainin) preparative binary HPLC system using a Dynamax C<sub>18</sub>, 60Å, 8 µm, 21 mm x 25 cm column equipped with a Dynamax C<sub>18</sub>, 60Å, 8 µm guard module, 21 mm x 25 cm column and UV detector (Varian Dynamax UVD II) at λ 214 and 254 nm. The product had >95% purity as determined by RP-HPLC mass spectrometry using a Hewlett Packard LCMS-1100 series spectrometer equipped with a diode array detector and using electro-spray ionization

**Example 45 - Modification of Kringle-5 at the N-Terminus Tyrosine  
Preparation of (MPA-AEEA)-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub>.2TFA**

Using automated peptide synthesis, the following protected amino acids were sequentially added to Rink Amide MBHA resin: Fmoc-Lys(Boc)-OH, Fmoc-Tyr(tBu)OH, Fmoc-Asp(OtBu)-OH, Fmoc-Tyr(tBu)OH, Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Pro-OH, Fmoc-Asn(Trt)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Tyr(tBu)OH (Step 1). The deprotection of the terminal Fmoc group is accomplished using 20% piperidine (Step 2) followed by the coupling of Fmoc-AEEA. Deprotection of the resulting Fmoc-AEEA-peptide with piperidine 20% in DMF allow for the subsequent addition of

the 3-MPA (Step 3). Resin cleavage and product isolation was

performed using 86% TFA/5% TIS/5% H<sub>2</sub>O/2% thioanisole and 2% phenol, followed by precipitation by dry-ice cold Et<sub>2</sub>O (Step 4). The

product was purified by preparative reversed phased HPLC using a

- 5 Varian (Rainin) preparative binary HPLC system using a Dynamax C<sub>18</sub>, 60Å, 8 µm, 21 mm x 25 cm column equipped with a Dynamax C<sub>18</sub>, 60Å, 8 µm guard module, 21 mm x 25 cm column and UV detector (Varian Dynamax UVD II) at λ 214 and 254 nm. The product had >95% purity as determined by RP-HPLC mass spectrometry using a Hewlett Packard
- 10 LCMS-1100 series spectrometer equipped with a diode array detector and using electro-spray ionization.

**Example 46 - Modification of Kringle-5 at the N-Terminus Tyrosine Preparation of (MPA)-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub>.2TFA**

15

Using automated peptide synthesis, the following protected amino acids were sequentially added to Rink Amide MBHA resin: Fmoc-Lys(Boc)-OH, Fmoc-Tyr(tBu)OH, Fmoc-Asp(OtBu)-OH, Fmoc-

- 20 Tyr(tBu)OH, Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Pro-OH, Fmoc-Asn(Trt)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Tyr(tBu)OH (Step 1). The deprotection of the terminal Fmoc group is accomplished using 20% piperidine (Step 2) followed by the coupling of 3-MPA (Step 3). Resin cleavage and product isolation was
- 25 performed using 86% TFA/5% TIS/5% H<sub>2</sub>O/2% thioanisole and 2% phenol, followed by precipitation by dry-ice cold Et<sub>2</sub>O (Step 4). The product was purified by preparative reversed phased HPLC using a Varian (Rainin) preparative binary HPLC system using a Dynamax C<sub>18</sub>, 60Å, 8 µm, 21 mm x 25 cm column equipped with a Dynamax C<sub>18</sub>, 60Å,
- 30 8 µm guard module, 21 mm x 25 cm column and UV detector (Varian Dynamax UVD II) at λ 214 and 254 nm. The product had >95% purity as determined by RP-HPLC mass spectrometry using a Hewlett Packard

LCMS-1100 series spectrometer equipped with a diode array detector and using electro-spray ionization.

5 **Example 47 – Modification of Kringle-5 at the N-Terminus Arginine Preparation of (MPA-AEEA)-Arg-Asn-Pro-Asp-Gly-Asp-Gly-Pro-Trp-Ala-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub>.3TFA**

Using automated peptide synthesis, the following protected amino

- 10 acids were sequentially added to Rink Amide MBHA resin: Fmoc-Lys(Boc)-OH, Fmoc-Tyr(tBu)OH, Fmoc-Asp(OtBu)-OH, Fmoc-Tyr(tBu)OH, Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Pro-OH, Fmoc-Asn(Trt)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Tyr(tBu)OH, Fmoc-Ala-OH, Fmoc-Trp-OH, Fmoc-Pro-OH,
- 15 Fmoc-Gly-OH, Fmoc-Gly-OH, Fmoc-Val-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Gly-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Pro-OH, Fmoc-Asn(Trt)-OH, Fmoc-Arg(Pbf)-OH (step 1). The deprotection of the terminal Fmoc group is accomplished using 20% piperidine (Step 2) followed by the coupling of Fmoc-AEEA. Deprotection of the resulting Fmoc-AEEA-
- 20 peptide with piperidine 20% in DMF allow for the subsequent addition of the 3-MPA (Step 3). Resin cleavage and product isolation was performed using 86% TFA/5% TIS/5% H<sub>2</sub>O/2% thioanisole and 2% phenol, followed by precipitation by dry-ice cold Et<sub>2</sub>O (Step 4). The product was purified by preparative reversed phased HPLC using a
- 25 Varian (Rainin) preparative binary HPLC system using a Dynamax C<sub>18</sub>, 60Å, 8 µm, 21 mm x 25 cm column equipped with a Dynamax C<sub>18</sub>, 60Å, 8 µm guard module, 21 mm x 25 cm column and UV detector (Varian Dynamax UVD II) at λ 214 and 254 nm. The product had >95% purity as determined by RP-HPLC mass spectrometry using a Hewlett Packard
- 30 LCMS-1100 series spectrometer equipped with a diode array detector and using electro-spray ionization.

**Example 48 – Modification of Kringle-5 at the N-Terminus Arginine Preparation of (MPA)-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Ala-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub>.3TFA**

5 Using automated peptide synthesis, the following protected amino acids were sequentially added to Rink Amide MBHA resin: Fmoc-Lys(Boc)-OH, Fmoc-Tyr(tBu)OH, Fmoc-Asp(OtBu)-OH, Fmoc-Tyr(tBu)OH, Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Pro-OH, Fmoc-Asn(Trt)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Thr(tBu)-  
10 OH, Fmoc-Tyr(tBu)OH, Fmoc-Ala-OH, Fmoc-Trp-OH, Fmoc-Pro-OH, Fmoc-Gly-OH, Fmoc-Gly-OH, Fmoc-Val-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Gly-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Pro-OH, Fmoc-Asn(Trt)-OH, Fmoc-Arg(Pbf)-OH (Step 1). The deprotection of the terminal Fmoc group is accomplished using 20% piperidine (Step 2) followed by the  
15 coupling of 3-MPA (Step 3). Resin cleavage and product isolation was performed using 86% TFA/5% TIS/5% H<sub>2</sub>O/2% thioanisole and 2% phenol, followed by precipitation by dry-ice cold Et<sub>2</sub>O (Step 4). The product was purified by preparative reversed phased HPLC using a Varian (Rainin) preparative binary HPLC system using a Dynamax C<sub>18</sub>,  
20 60Å, 8 µm, 21 mm x 25 cm column equipped with a Dynamax C<sub>18</sub>, 60Å, 8 µm guard module, 21 mm x 25 cm column and UV detector (Varian Dynamax UVD II) at λ 214 and 254 nm. The product had >95% purity as determined by RP-HPLC mass spectrometry using a Hewlett Packard LCMS-1100 series spectrometer equipped with a diode array detector  
25 and using electro-spray ionization.

**Example 49 – Modification of Kringle-5 at the N-Terminus Arginine Preparation of (MPA-AEEA)-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-NH<sub>2</sub>.TFA**

30 Using automated peptide synthesis, the following protected amino acids were sequentially added to Rink Amide MBHA resin: Fmoc-Lys(Boc)-OH, Fmoc-Trp-OH, Fmoc-Pro-OH, Fmoc-Gly-OH, Fmoc-Gly-OH, Fmoc-Val-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Gly-OH, Fmoc-  
35 Asp(OtBu)-OH, Fmoc-Pro-OH, Fmoc-Asn(Trt)-OH, Fmoc-Arg(Pbf)-OH

(step 1). The deprotection of the terminal Fmoc group is accomplished using 20% piperidine (Step 2) followed by the coupling of Fmoc-AEEA. Deprotection of the resulting Fmoc-AEEA-peptide with piperidine 20% in DMF allow for the subsequent addition of the 3-MPA (Step 3). Resin cleavage and product isolation was performed using 86% TFA/5% TIS/5% H<sub>2</sub>O/2% thioanisole and 2% phenol, followed by precipitation by dry-ice cold Et<sub>2</sub>O (Step 4). The product was purified by preparative reversed phased HPLC using a Varian (Rainin) preparative binary HPLC system using a Dynamax C<sub>18</sub>, 60Å, 8 µm, 21 mm x 25 cm column equipped with a Dynamax C<sub>18</sub>, 60Å, 8 µm guard module, 21 mm x 25 cm column and UV detector (Varian Dynamax UVD II) at λ 214 and 254 nm. The product had >95% purity as determined by RP-HPLC mass spectrometry using a Hewlett Packard LCMS-1100 series spectrometer equipped with a diode array detector and using electro-spray ionization.

**Example 50 – Modification of Kringle-5 at the N-Terminus Arginine Preparation of (MPA)-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-NH<sub>2</sub>.TFA**

Using automated peptide synthesis, the following protected amino acids were sequentially added to Rink Amide MBHA resin: Fmoc-Lys(Boc)-OH, Fmoc-Trp-OH, Fmoc-Pro-OH, Fmoc-Gly-OH, Fmoc-Gly-OH, Fmoc-Val-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Gly-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Pro-OH, Fmoc-Asn(Trt)-OH, Fmoc-Arg(Pbf)-OH (Step 1). The deprotection of the terminal Fmoc group is accomplished using 20% piperidine (Step 2) followed by the coupling of 3-MPA (Step 3). Resin cleavage and product isolation was performed using 86% TFA/5% TIS/5% H<sub>2</sub>O/2% thioanisole and 2% phenol, followed by precipitation by dry-ice cold Et<sub>2</sub>O (Step 4). The product was purified by preparative reversed phased HPLC using a Varian (Rainin) preparative binary HPLC system using a Dynamax C<sub>18</sub>, 60Å, 8 µm, 21 mm x 25 cm column equipped with a Dynamax C<sub>18</sub>, 60Å, 8 µm guard module, 21 mm x 25 cm column and UV detector (Varian Dynamax UVD II) at λ 214 and

254 nm. The product had >95% purity as determined by RP-HPLC mass spectrometry using a Hewlett Packard LCMS-1100 series spectrometer equipped with a diode array detector and using electro-spray ionization.

5

**Example 51 – Modification of Kringle-5 at the N-Terminus Arginine Preparation of (MPA-AEEA)-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub>.2TFA**

- Using automated peptide synthesis, the following protected amino acids were sequentially added to Rink Amide MBHA resin: Fmoc-Lys(Boc)-OH, Fmoc-Tyr(tBu)OH, Fmoc-Asp(OtBu)-OH, Fmoc-Tyr(tBu)OH, Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-Arg(Pbf)-OH (Step 1). The deprotection of the terminal Fmoc group is accomplished using 20% piperidine (Step 2) followed by the coupling of Fmoc-AEEA.
- 15 Deprotection of the resulting Fmoc-AEEA-peptide with piperidine 20% in DMF allow for the subsequent addition of the 3-MPA (Step 3). Resin cleavage and product isolation was performed using 86% TFA/5% TIS/5% H<sub>2</sub>O/2% thioanisole and 2% phenol, followed by precipitation by dry-ice cold Et<sub>2</sub>O (Step 4). The product was purified by preparative
- 20 reversed phased HPLC using a Varian (Rainin) preparative binary HPLC system using a Dynamax C<sub>18</sub>, 60Å, 8 µm, 21 mm x 25 cm column equipped with a Dynamax C<sub>18</sub>, 60Å, 8 µm guard module, 21 mm x 25 cm column and UV detector (Varian Dynamax UVD II) at λ 214 and 254 nm. The product had >95% purity as determined by RP-HPLC mass
- 25 spectrometry using a Hewlett Packard LCMS-1100 series spectrometer equipped with a diode array detector and using electro-spray ionization

**Example 52 – Modification of Kringle-5 at the N-Terminus Arginine Preparation of (MPA)-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub>.2TFA**

30

Using automated peptide synthesis, the following protected amino acids were sequentially added to Rink Amide MBHA resin: Fmoc-Lys(Boc)-OH, Fmoc-Tyr(tBu)OH, Fmoc-Asp(OtBu)-OH, Fmoc-



Tyr(tBu)OH, Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-Arg(Pbf)-OH (Step 1). The deprotection of the terminal Fmoc group is accomplished using 20% piperidine (Step 2) followed by the coupling of 3-MPA (Step 3). Resin cleavage and product isolation was performed using 86% TFA/5% TIS/5% H<sub>2</sub>O/2% thioanisole and 2% phenol, followed by precipitation by dry-ice cold Et<sub>2</sub>O (Step 4). The product was purified by preparative reversed phased HPLC using a Varian (Rainin) preparative binary HPLC system using a Dynamax C<sub>18</sub>, 60Å, 8 µm, 21 mm x 25 cm column equipped with a Dynamax C<sub>18</sub>, 60Å, 8 µm guard module, 21 mm x 25 cm column and UV detector (Varian Dynamax UVD II) at λ 214 and 254 nm. The product had >95% purity as determined by RP-HPLC mass spectrometry using a Hewlett Packard LCMS-1100 series spectrometer equipped with a diode array detector and using electrospray ionization.

**Example 53 – Modification of Kringle-5 at the N-Terminus Proline Preparation of (MPA-AEEA)-Pro-Arg-Lys-Leu-Tyr-Asp-NH<sub>2</sub>,2TFA**

Using automated peptide synthesis, the following protected amino acids were sequentially added to Rink Amide MBHA resin: Fmoc-Lys(Boc)-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Tyr(tBu)OH, Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Pro-OH (step 1). The deprotection of the terminal Fmoc group is accomplished using 20% piperidine (Step 2) followed by the coupling of Fmoc-AEEA. Deprotection of the resulting Fmoc-AEEA-peptide with piperidine 20% in DMF allow for the subsequent addition of the 3-MPA (Step 3). Resin cleavage and product isolation was performed using 86% TFA/5% TIS/5% H<sub>2</sub>O/2% thioanisole and 2% phenol, followed by precipitation by dry-ice cold Et<sub>2</sub>O (Step 4). The product was purified by preparative reversed phased HPLC using a Varian (Rainin) preparative binary HPLC system using a Dynamax C<sub>18</sub>, 60Å, 8 µm, 21 mm x 25 cm column equipped with a Dynamax C<sub>18</sub>, 60Å, 8 µm guard module, 21 mm x 25 cm column and UV detector (Varian Dynamax UVD II) at λ 214 and 254 nm.

The product had >95% purity as determined by RP-HPLC mass spectrometry using a Hewlett Packard LCMS-1100 series spectrometer equipped with a diode array detector and using electro-spray ionization.

5 **Example 54 – Modification of Kringle-5 at the N-Terminus Proline Preparation of (MPA)-Pro-Arg-Lys-Leu-Tyr-Asp-NH<sub>2</sub>.2TFA**


- Using automated peptide synthesis, the following protected amino acids were sequentially added to Rink Amide MBHA resin: Fmoc-Lys(Boc)-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Tyr(tBu)OH, Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Pro-OH (Step 1). The deprotection of the terminal Fmoc group is accomplished using 20% piperidine (Step 2) followed by the coupling of 3-MPA (Step 3). Resin cleavage and product isolation was performed using 86% TFA/5%
- 10 TIS/5% H<sub>2</sub>O/2% thioanisole and 2% phenol, followed by precipitation by dry-ice cold Et<sub>2</sub>O (Step 4). The product was purified by preparative reversed phased HPLC using a Varian (Rainin) preparative binary HPLC system using a Dynamax C<sub>18</sub>, 60Å, 8 µm, 21 mm x 25 cm column equipped with a Dynamax C<sub>18</sub>, 60Å, 8 µm guard module, 21 mm x 25 cm
- 15 column and UV detector (Varian Dynamax UVD II) at λ 214 and 254 nm. The product had >95% purity as determined by RP-HPLC mass spectrometry using a Hewlett Packard LCMS-1100 series spectrometer equipped with a diode array detector and using electro-spray ionization.
- 20

### 3. Modification at an Internal Amino Acid

#### **Example 55 - Synthesis of Lys<sup>26</sup>( $\epsilon$ -MPA)GLP-1(7-36)-NH<sub>2</sub>**

- 5 Solid phase peptide synthesis of a modified GLP-1 analog on a 100  $\mu$ mole scale was performed manually and on a Symphony Peptide Synthesizer using Fmoc protected Rink amide MBHA resin. The following protected amino acids are sequentially added to the resin: Fmoc-Arg(Pbf)-OH, Fmoc-Gly-OH, Fmoc-Lys(Boc)-OH, Fmoc-Val-OH,
- 10 Fmoc-Leu-OH, Fmoc-Trp(Boc)-OH, Fmoc-Ala-OH, Fmoc-Ile-OH, Fmoc-Phe-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Lys(Aloc)-OH, Fmoc-Ala-OH, Fmoc-Ala-OH, Fmoc-Gln(Trt)-OH, Fmoc-Gly-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Leu-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Val-OH, Fmoc-Asp(tBu)-OH, Fmoc-Ser(tBu)-OH, Fmoc-
- 15 Thr(tBu)-OH, Fmoc-Phe-OH, Fmoc-Thr(tBu)-OH, Fmoc-Gly-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Ala-OH, Boc-His(Trt)-OH. They are dissolved in *N,N*-dimethylformamide (DMF) and, according to the sequence, activated using *O*-benzotriazol-1-yl-*N,N,N'*-tetramethyl-uronium hexafluorophosphate (HBTU) and Diisopropylethylamine (DIEA).
- 20 Removal of the Fmoc protecting group is achieved using a solution of 20% (V/V) piperidine in *N,N*-dimethylformamide (DMF) for 20 minutes (Step 1). Selective deprotection of the Lys(Aloc) group is performed manually and accomplished by treating the resin with a solution of 3eq of Pd(PPh<sub>3</sub>)<sub>4</sub> dissolved in 5mL of CHCl<sub>3</sub>:NMM:HOAc (18:1:0.5) for 2h (Step
- 25 2). The resin is then washed with CHCl<sub>3</sub> (6 x 5mL), 20% HOAc in DCM (6 x 5mL), DCM (6 x 5mL), and DMF (6 x 5mL). The synthesis is then re-automated for the addition of the 3-maleimidopropionic acid (Step 3). Resin cleavage and product isolation is performed using 86% TFA/5% TIS/5% H<sub>2</sub>O/2% thioanisole and 2% phenol, followed by precipitation by
- 30 dry-ice cold Et<sub>2</sub>O (Step 4). The product is purified by preparative reversed phase HPLC using a Varian (Rainin) preparative binary HPLC system using a Dynamax C<sub>18</sub>, 60Å, 8  $\mu$ m, 21 mm x 25 cm column

equipped with a Dynamax C<sub>18</sub>, 60Å, 8 µm guard module, 21 mm x 25 cm column and UV detector (Varian Dynamax UVD II) at λ 214 and 254 nm to afford the desired DAC in >95% purity, as determined by RP-HPLC. These steps are illustrated in the schematic diagram below.



5

#### D. Preparation of Modified Peptides From Peptides Containing One Free Cysteine

10

Preparation of maleimido peptides from therapeutic peptides containing one free Cysteine is exemplified by the synthesis of peptides as described below. The peptide may be modified at the N-terminus, the

C-terminus, or at an amino acid located between the N-terminus and the C-terminus.

- Preparation of maleimido peptides from peptides containing multiple protected functional groups and multiple Cysteine residues all with one free Cysteine residues (*i.e.* all Cysteine residues, except one, are tied up as disulfides). Linking from an internal amino acid in the natural sequence as in Example 5. The free Cysteine residue must be capped or replaced with another amino acid (e.g. Alanine, Methionine, etc.).
- Where the peptide contains one cysteine, the cysteine must stay capped after addition of the maleimide. If the cysteine is involved in binding site, assessment has to be made of how much potency is lost if cysteine is capped by a protecting group. If the cysteine can stay capped, then the synthetic path is similar to example (i) above.
- Examples of therapeutic peptides that contain one cysteine include G<sub>α</sub> (the alpha subunit of Gtherapeutic peptide binding protein), the 724-739 fragment of rat brain nitric oxide synthase blocking peptide, the alpha subunit 1-32 fragment of human [Tyr0] inhibin, the 254-274 fragment of HIV envelope protein, and P34cdc2 kinase fragment.

20

#### 1. Modification at the N-Terminus

##### **Example 56 - Modification of Inhibin Peptide at the Added N-Terminus Lysine**

- Preparation of (N<sub>ε</sub>-MPA)-Lys-Tyr-Ser-Thr-Pro-Leu-Met-Ser-Trp-Pro-Trp-Ser-Pro-Ser-Ala-Leu-Arg-Leu-Gln-Arg-Pro-Pro-Glu-Glu-Pro-Ala-Ala-Ala-His-Ala-Asn-Cys-His-Arg**

- Solid phase peptide synthesis of a modified inhibin peptide analog on a 100 μmole scale is performed using manual solid-phase synthesis, a Symphony Peptide Synthesizer and Fmoc protected Rink Amide MBHA. The following protected amino acids are sequentially added to resin: Fmoc-Arg(Pbf)-OH, Fmoc-His(Boc)-OH, Fmoc-Cys(Trt)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Ala-OH, Fmoc-His(Boc)-OH, Fmoc-Ala-

OH, Fmoc-Ala-OH, Fmoc-Pro-OH, Fmoc-Glu(tBu)-OH, Fmoc-Glu(tBu)-  
OH, Fmoc-Pro-OH, Fmoc-Pro-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Gln(Trt)-  
OH, Fmoc-Leu-OH, Fmoc-Leu-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Leu-OH,  
Fmoc-Ala-OH, Fmoc-Ser(tBu)-OH, Fmoc-Pro-OH, Fmoc-Ser(tBu)-OH,  
5 Fmoc-Trp(Boc)-OH, Fmoc-Pro-OH, Fmoc-Trp(Boc)-OH, Fmoc-Ser(tBu)-  
OH, Fmoc-Met-OH, Fmoc-Leu-OH, Fmoc-Pro-OH, Fmoc-Thr(tBu)-OH,  
Fmoc-Ser(tBu)-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Lys(Aloc)-OH, They are  
dissolved in *N,N*-dimethylformamide (DMF) and, according to the  
sequence, activated using *O*-benzotriazol-1-yl-*N, N, N, N*'-tetramethyl-  
10 uronium hexafluorophosphate (HBTU) and Diisopropylethylamine  
(DIEA). Removal of the Fmoc protecting group is achieved using a  
solution of 20% (V/V) piperidine in *N,N*-dimethylformamide (DMF) for 20  
minutes (Step 1). The selective deprotection of the Lys (Aloc) group is  
performed manually and accomplished by treating the resin with a  
15 solution of 3 eq of Pd(PPh<sub>3</sub>)<sub>4</sub> dissolved in 5 mL of CHCl<sub>3</sub>:NMM:HOAc  
(18:1:0.5) for 2 h (Step 2). The resin is then washed with CHCl<sub>3</sub> (6 x 5  
mL), 20% HOAc in DCM (6 x 5 mL), DCM (6 x 5 mL), and DMF (6 x 5  
mL). The synthesis is then re-automated for the addition of the 3-  
maleimidopropionic acid (Step 3). Between every coupling, the resin is  
20 washed 3 times with *N,N*-dimethylformamide (DMF) and 3 times with  
isopropanol. The peptide is cleaved from the resin using 85% TFA/5%  
TIS/5% thioanisole and 5% phenol, followed by precipitation by dry-ice  
cold Et<sub>2</sub>O (Step 4). The product is purified by preparative reverse phase  
HPLC using a Varian (Rainin) preparative binary HPLC system: gradient  
25 elution of 30-55% B (0.045% TFA in H<sub>2</sub>O (A) and 0.045% TFA in CH<sub>3</sub>CN  
(B)) over 180 min at 9.5 mL/min using a Phenomenex Luna 10  $\mu$  phenyl-  
hexyl, 21 mm x 25 cm column and UV detector (Varian Dynamax UVD  
II) at  $\lambda$  214 and 254 nm to afford the desired DAC in >95% purity, as  
determined by RP-HPLC.

30

**Example 57 – Modification of RSV Antifusogenic Peptide at the N-Terminus**

**Preparation of 3-(MPA)-Val-Ile-Thr-Ile-Glu-Leu-Ser-Asn-Ile-Lys-Glu-Asn-Lys-Cys-Asn-Glu-Ala-Lys-Val-Lys-Leu-Ile-Lys-Glu-Glu-Leu-Asp-Lys-Tyr-Lys-Asn-Ala-Val**

5

Initially, (Cysteine (Cys) was replaced with Methionine (Met) within the native sequence. Solid phase peptide synthesis of a modified anti RSV analog on a 100  $\mu$ mole scale was performed on a Symphony

10

Peptide Synthesizer using Fmoc protected Rink Amide MBHA resin, Fmoc protected amino acids, O-benzotriazol-1-yl-*N, N, N, N*-tetramethyl-uronium hexafluorophosphate (HBTU) in *N, N*-dimethylformamide (DMF) solution and activation with *N*-methylmorpholine (NMM), and piperidine deprotection of Fmoc groups (Step

15


1). The deprotection of the terminal Fmoc group is accomplished using 20% piperidine (Step 2) followed by the coupling of 3-MPA (Step 3). Resin cleavage and product isolation was performed using 85% TFA/5% TIS/5% thioanisole and 5% phenol, followed by precipitation by dry-ice cold Et<sub>2</sub>O (Step 4). The product is purified by preparative reverse phase

20

HPLC using a Varian (Rainin) preparative binary HPLC system: gradient elution of 30-55% B (0.045% TFA in H<sub>2</sub>O (A) and 0.045% TFA in CH<sub>3</sub>CN (B)) over 180 min at 9.5 mL/min using a Phenomenex Luna 10  $\mu$  phenyl-hexyl, 21 mm x 25 cm column and UV detector (Varian Dynamax UVD II) at  $\lambda$  214 and 254 nm to afford the desired DAC in >95% purity, as

25

determined by RP-HPLC. These steps are illustrated by the schematic diagram below.



5

## 2. Modification at the C-Terminus

### **Example 58 - Modification of Inhibin Peptide at the Added C-Terminus Lysine**

**Preparation of (N<sub>ε</sub>-MPA)-Lys-Cys-Asn-Leu-Lys-Glu-Asp-Gly-Ile-Ser-Ala-Ala-Lys-Asp-Val-Lys**

10

Solid phase peptide synthesis of a modified inhibin peptide analog on a 100 μmole scale is performed using manual solid-phase synthesis, a Symphony Peptide Synthesizer and Fmoc protected Rink Amide MBHA. The following protected amino acids are sequentially added to resin: Fmoc-Lys(Boc)-OH, Fmoc-Val-OH, Fmoc-Asp(tBu)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Ala-OH, Fmoc-Ala-OH, Fmoc-Ser(tBu)-OH, Fmoc-Ile-OH, Fmoc-Gly-OH, Fmoc-Asp(tBu)-OH, Fmoc-Glu(tBu)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Leu-OH, Fmoc-Asn(Trt)-OH, Fmoc-Cys(Trt)-

15




OH, Fmoc-Lys(Aloc)-OH, They are dissolved in *N,N*-dimethylformamide (DMF) and, according to the sequence, activated using *O*-benzotriazol-1-yl-*N,N,N'*-tetramethyl-uronium hexafluorophosphate (HBTU) and Diisopropylethylamine (DIEA). Removal of the Fmoc protecting group is achieved using a solution of 20% (V/V) piperidine in *N,N*-dimethylformamide (DMF) for 20 minutes (Step 1). The selective deprotection of the Lys (Aloc) group is performed manually and accomplished by treating the resin with a solution of 3 eq of Pd(PPh<sub>3</sub>)<sub>4</sub> dissolved in 5 mL of CHCl<sub>3</sub>:NMM:HOAc (18:1:0.5) for 2 h (Step 2). The resin is then washed with CHCl<sub>3</sub> (6 x 5 mL), 20% HOAc in DCM (6 x 5 mL), DCM (6 x 5 mL), and DMF (6 x 5 mL). The synthesis is then re-automated for the addition of the 3-maleimidopropionic acid (Step 3). Between every coupling, the resin is washed 3 times with *N,N*-dimethylformamide (DMF) and 3 times with isopropanol. The peptide is cleaved from the resin using 85% TFA/5% TIS/5% thioanisole and 5% phenol, followed by precipitation by dry-ice cold Et<sub>2</sub>O (Step 4). The product is purified by preparative reverse phase HPLC using a Varian (Rainin) preparative binary HPLC system: gradient elution of 30-55% B (0.045% TFA in H<sub>2</sub>O (A) and 0.045% TFA in CH<sub>3</sub>CN (B)) over 180 min at 9.5 mL/min using a Phenomenex Luna 10 μ phenyl-hexyl, 21 mm x 25 cm column and UV detector (Varian Dynamax UVD II) at λ 214 and 254 nm to afford the desired DAC in >95% purity, as determined by RP-HPLC.

**Example 59 – Modification of RSV Fusogenic Peptide at the C-Terminus**  
**Val-Ile-Thr-Ile-Glu-Leu-Ser-Asn-Ile-Lys-Glu-Asn-Lys-Cys-Asn-Gly-Ala-Lys-Val-Lys-Leu-Ile-Lys-Gln-Glu-Leu-Asp-Lys-Tyr-Asn-Ala-Val-(AEEA.MPA)**

Preparation of maleimido peptides from peptides containing multiple protected functional groups and one cysteine is exemplified by the synthesis of a modified RSV fusogenic peptide. The modified RSV fusogenic peptide was synthesized by linking off the C-terminus by the

addition of a lysine residue to the natural peptide sequence as illustrated by the schematic diagram below. In cases where a cysteine residue is contained within the peptide sequence and is not essentially to the biological activity of the peptide, this residue must be replaced with another amino acid (e.g. alanine, methionine, etc.). In the following synthesis, the cysteine (Cys) was replaced with a methionine (Met) within the native RSV sequence.

Solid phase peptide synthesis of the maleimido RSV fusogenic peptide on a 100  $\mu$ mole scale is performed using manual solid-phase synthesis and a Symphony Peptide Synthesizer using Fmoc protected Rink Amide MBHA resin, Fmoc protected amino acids, O-benzotriazol-1-yl-*N, N, N, N*-tetramethyl-uronium hexafluorophosphate (HBTU) in *N,N*-dimethylformamide (DMF) solution and activation with *N*-methylmorpholine (NMM), and piperidine deprotection of Fmoc groups (Step 1). The selective deprotection of the Lys(Aloc) group is performed manually and accomplished by treating the resin with a solution of 3 eq of Pd(PPh<sub>3</sub>)<sub>4</sub> dissolved in 5 mL of CHCl<sub>3</sub>:NMM:HOAc (18:1:0.5) for 2 h (Step 2). The resin is then washed with CHCl<sub>3</sub> (6 x 5 mL), 20% HOAc in DCM (6 x 5 mL), DCM (6 x 5 mL), and DMF (6 x 5 mL). The synthesis is then re-automated for the addition of 3-maleimidopropionic acid (Step 3). Resin cleavage and product isolation is performed using 85% TFA/5% TIS/5% thioanisole and 5% phenol, followed by precipitation by dry-ice cold Et<sub>2</sub>O (Step 4). The product is purified by preparative reverse phase HPLC using a Varian (Rainin) preparative binary HPLC system: gradient elution of 30-55% B (0.045% TFA in H<sub>2</sub>O (A) and 0.045% TFA in CH<sub>3</sub>CN (B)) over 180 min at 9.5 mL/min using a Phenomenex Luna 10  $\mu$  phenyl-hexyl, 21 mm x 25 cm column and UV detector (Varian Dynamax UVD II) at  $\lambda$  214 and 254 nm to afford the desired DAC in >95% purity, as determined by RP-HPLC. These steps are illustrated in the schematic diagram below.



### 3. Modification at an Internal Amino Acid

#### 5 **Example 60 – Modification of G $\alpha$ Peptide at Cys-Asn-Leu-Lys-Glu-Asp-Gly-Ile-Ser-Ala-Ala-Lys-Asp-Val**

Preparation of maleimido peptides from peptides containing multiple protected functional groups and one cysteine is exemplified by the synthesis of a modified G $\alpha$  peptide. The modified G $\alpha$  peptide is synthesized by linking at an internal amino acid as described below.

In cases where a cysteine residue is contained within the peptide sequence and is not essentially to the biological activity of the peptide, this residue must be capped or replaced with another amino acid (e.g. alanine, methionine, etc.). Solid phase peptide synthesis of the modified

G $\alpha$  peptide on a 100  $\mu$ mole scale is performed using manual solid-phase synthesis and a Symphony Peptide Synthesizer using Fmoc protected Rink Amide MBHA resin, Fmoc protected amino acids, O-benzotriazol-1-yl-*N, N, N', N'*-tetramethyl-uronium hexafluorophosphate (HBTU) in *N,N*-dimethylformamide (DMF) solution and activation with *N*-methyl morpholine (NMM), and piperidine deprotection of Fmoc groups (Step 1). The selective deprotection of the Lys(Aloc) group is performed manually and accomplished by treating the resin with a solution of 3 eq of Pd(PPh<sub>3</sub>)<sub>4</sub> dissolved in 5 mL of CHCl<sub>3</sub>:NMM:HOAc (18:1:0.5) for 2 h (Step 2). The resin is then washed with CHCl<sub>3</sub> (6 x 5 mL), 20% HOAc in DCM (6 x 5 mL), DCM (6 x 5 mL), and DMF (6 x 5 mL). The synthesis is then re-automated for the addition of 3-maleimidopropionic acid (Step 3). Resin cleavage and product isolation is performed using 85% TFA/5% TIS/5% thioanisole and 5% phenol, followed by precipitation by dry-ice cold Et<sub>2</sub>O (Step 4). The product is purified by preparative reversed phased HPLC using a Varian (Rainin) preparative binary HPLC system: gradient elution of 30-55% B (0.045% TFA in H<sub>2</sub>O (A) and 0.045% TFA in CH<sub>3</sub>CN (B)) over 180 min at 9.5 mL/min using a Phenomenex Luna 10  $\mu$  phenyl-hexyl, 21 mm x 25 cm column and UV detector (Varian Dynamax UVD II) at  $\lambda$  214 and 254 nm to afford the desired DAC in >95% purity, as determined by RP-HPLC.

#### **E. Preparation of Modified Peptides From Peptides Containing Two Cysteines In Disulfide Bridge**

25

Where the peptide contains two cysteines as a disulfide bridge, the peptide is cleaved from the support resin before addition of the maleimide. We need to add a Lys protected with a Mtt group in order to selectively deprotect the lysine in presence of other t-Boc protected lysine. All protecting groups are present except at the carboxy terminus (which stays unprotected due to cleavage from the support resin) and at the two cysteines, which need to be deprotected when peptide is

30

cleaved from resin. Mild air oxidation yield the disulfide bridge, and the peptide can be purified at that stage. Solution phase chemistry is then required to activate the C-terminus in presence of the disulfide bridge and add the maleimide (through an amino-alkyl-maleimide) to the C-terminus. The peptide is then fully deprotected. Examples of therapeutic peptides that contain two cysteines as a disulfide bridge include human osteocalcin 1-49, human diabetes associated peptide, the 5-28 fragment of human/canine atrial natriuretic peptide, bovine batenecin, and human [Tyr0]-cortistatin 29.

Preparation of maleimido peptides from therapeutic peptides containing two Cysteines in a disulfide bridge is exemplified by the synthesis of peptides as described below. The peptide may be modified at the N-terminus, the C-terminus, or at an amino acid located between the N-terminus and the C-terminus.

#### 1. Modification at the N-Terminus

##### **Example 61 – Modification of TH-1 Peptide at N-Terminus** **Preparation of (Nε-MPA)NH<sub>2</sub>-Lys-Arg-Gly-Asp-Ala-Cys-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Cys**


Preparation of thiol cyclized maleimido peptides from peptides containing multiple protected functional groups and no free cysteine residues (*i.e.* all cysteine residues are tied up as disulfide bridges). is illustrated by the synthesis of a modified TH-1 peptide.

Solid phase peptide synthesis of the modified TH-1 peptide on a 100 μmole scale was performed manually and on a Symphony Peptide Synthesizer using Fmoc protected Rink Amide MBHA resin, Fmoc protected amino acids, O-benzotriazol-1-yl-*N*, *N*', *N*'-tetramethyluronium hexafluorophosphate (HBTU) in *N,N*-dimethylformamide (DMF) solution and activation with *N*-methyl morpholine (NMM), and piperidine deprotection of Fmoc groups (Step 1). The removal of the Ac group and resulting oxidation of the two Cys residues to form the cyclized on

resin DAC was accomplished using  $\text{Ti}(\text{CF}_3\text{CO})_2$  (Step 2). The

deprotection of the terminal Fmoc group is accomplished using 20% piperidine followed by the coupling of 3-MPA (Step 3). Resin cleavage and product isolation was performed using 86% TFA/5% TIS/5%

- 5  $\text{H}_2\text{O}/2\%$  thioanisole and 2% phenol, followed by precipitation by dry-ice cold  $\text{Et}_2\text{O}$  (Step 4). The product was purified by preparative reverse phase HPLC using a Varian (Rainin) preparative binary HPLC system using a Dynamax  $\text{C}_{18}$ , 60Å, 8  $\mu\text{m}$ , 21 mm x 25 cm column equipped with a Dynamax  $\text{C}_{18}$ , 60Å, 8  $\mu\text{m}$  guard module, 21 mm x 25 cm column and
- 10 UV detector (Varian Dynamax UVD II) at  $\lambda$  214 and 254 nm. The product had >95% purity as determined by RP-HPLC mass spectrometry using a Hewlett Packard LCMS-1100 series spectrometer equipped with a diode array detector and using electro-spray ionization, ESI-MS  $m/z$  for  $\text{C}_{66}\text{H}_{95}\text{N}_{20}\text{O}_{26}\text{S}_2$  ( $\text{MH}^+$ ), 1646.8. Found: 1646.7. These steps are
- 15 illustrated in the schematic diagram below.




**Example 62 - Synthesis of *N*-MPA-Ser<sup>1</sup>-Somatostatin-28**

Solid phase peptide synthesis of the DAC:Somatostatin-28

- 5 analog on a 100  $\mu$ mol scale is performed manually and on a Symphony Peptide Synthesizer using Fmoc protected Rink amide MBHA resin. The following protected amino acids are sequentially added to the resin: Fmoc-Cys(Acm)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Phe-OH, Fmoc-Thr(tBu)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Trp(Boc)-OH,
- 10 Fmoc-Phe-OH, Fmoc-Phe-OH, Fmoc-Asn(Trt)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Cys(Acm)-OH, Fmoc-Gly-OH, Fmoc-Ala-OH, Fmoc-Lys(Boc)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Pro-OH, Fmoc-Ala-OH, Fmoc-Met-OH, Fmoc-Ala-OH, Fmoc-Pro-OH, Fmoc-Asn(Trt)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Ala-
- 15 OH, Fmoc-Ser(tBu)-OH. They are dissolved in *N,N*-dimethylformamide (DMF) and, according to the sequence, activated using *O*-benzotriazol-1-yl-*N,N,N',N'*-tetramethyluronium hexafluorophosphate (HBTU) and Diisopropylethylamine (DIEA). Removal of the Fmoc protecting group is achieved using a solution of 20% (V/V) piperidine in *N,N*-
- 20 dimethylformamide (DMF) for 20 minutes (Step 1). Removal of the Acm groups and resulting oxidation of the two Cys residues to form the disulfide bridge is accomplished using iodine (Step 2). Deprotection of the terminal Fmoc group is accomplished using 20% piperidine followed by the coupling of 3-MPA (Step 3). Resin cleavage and product isolation
- 25 is performed using 86% TFA/5% TIS/5% H<sub>2</sub>O/2% thioanisole and 2% phenol, followed by precipitation by dry-ice cold Et<sub>2</sub>O (Step 4). The product is purified by preparative reversed phase HPLC using a Varian (Rainin) preparative binary HPLC system using a Dynamax C<sub>18</sub>, 60Å, 8  $\mu$ m, 21 mm x 25 cm column equipped with a Dynamax C<sub>18</sub>, 60Å, 8  $\mu$ m guard module, 21 mm x 25 cm column and UV detector (Varian
- 30 Dynamax UVD II) at  $\lambda$  214 and 254 nm to afford the desired DAC in

>95% purity, as determined by RP-HPLC. These steps are illustrated in the schematic diagram below.



5


## 2. Modification at the C-Terminus

### Example 63 - Synthesis of Somatostatin-28-EDA-MPA

- Solid phase peptide synthesis of the DAC:Somatostatin-28 analog on a 100  $\mu$ mole scale is performed manually and on a Symphony Peptide Synthesizer using SASRIN (super acid sensitive resin). The following protected amino acids are sequentially added to the resin:
- 10 Fmoc-Cys(Acm)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Phe-OH, Fmoc-Thr(tBu)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Trp(Boc)-OH,
- 15 Fmoc-Phe-OH, Fmoc-Phe-OH, Fmoc-Asn(Trt)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Cys(Acm)-OH, Fmoc-Gly-OH, Fmoc-Ala-OH, Fmoc-Lys(Boc)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-



- Pro-OH, Fmoc-Ala-OH, Fmoc-Met-OH, Fmoc-Ala-OH, Fmoc-Pro-OH, Fmoc-Asn(Trt)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Ala-OH, Boc-Ser(tBu)-OH. They are dissolved in *N,N*-dimethylformamide (DMF) and, according to the sequence, activated using *O*-benzotriazol-1-yl-*N, N, N, N*-tetramethyl-uronium hexafluorophosphate (HBTU) and Diisopropylethylamine (DIEA). Removal of the Fmoc protecting group is achieved using a solution of 20% (V/V) piperidine in *N,N*-dimethylformamide (DMF) for 20 minutes (Step 1). The fully protected peptide is cleaved from the resin by treatment with 1% TFA / DCM (Step
- 2). Removal of the Acn groups and resulting oxidation of the two Cys residues to form the disulfide bridge is accomplished using iodine (Step 3). Ethylenediamine and 3-maleimidopropionic acid are then sequentially added to the free C-terminus (Step 4). The protecting groups are then cleaved and the product isolated using 86% TFA/5% TIS/5% H<sub>2</sub>O/2%
- thioanisole and 2% phenol, followed by precipitation by dry-ice cold Et<sub>2</sub>O (Step 5). The product is purified by preparative reversed phase HPLC using a Varian (Rainin) preparative binary HPLC system using a Dynamax C<sub>18</sub>, 60Å, 8 µm, 21 mm x 25 cm column equipped with a Dynamax C<sub>18</sub>, 60Å, 8 µm guard module, 21 mm x 25 cm column and UV
- detector (Varian Dynamax UVD II) at λ 214 and 254 nm to afford the desired DAC in >95% purity, as determined by RP-HPLC. These steps are illustrated in the schematic diagram below.




### 3. Modification at an Internal Amino Acid

5

#### Example 64 – Synthesis of Lys<sup>14</sup>(ε-MPA)-Somatostatin-28

10 Solid phase peptide synthesis of the DAC:Somatostatin-28 analog on a 100 μmole scale is performed manually and on a Symphony Peptide Synthesizer using Fmoc protected Rink amide MBHA resin. The following protected amino acids are sequentially added to the resin: Fmoc-Cys(Acm)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Phe-OH, Fmoc-Thr(tBu)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Trp(Boc)-OH,

- Fmoc-Phe-OH, Fmoc-Phe-OH, Fmoc-Asn(Trt)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Cys(Acm)-OH, Fmoc-Gly-OH, Fmoc-Ala-OH, Fmoc-Lys(Aloc)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Pro-OH, Fmoc-Ala-OH, Fmoc-Met-OH, Fmoc-Ala-OH, Fmoc-Pro-OH,
- 5 Fmoc-Asn(Trt)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Ala-OH, Fmoc-Ser(tBu)-OH. They are dissolved in *N,N*-dimethylformamide (DMF) and, according to the sequence, activated using *O*-benzotriazol-1-yl-*N, N, N', N'*-tetramethyl-uronium hexafluorophosphate (HBTU) and Diisopropylethylamine (DIEA). Removal of the Fmoc protecting group is
- 10 achieved using a solution of 20% (V/V) piperidine in *N,N*-dimethylformamide (DMF) for 20 minutes (Step 1). Removal of the Acm groups and resulting oxidation of the two Cys residues to form the disulfide bridge is accomplished using iodine (Step 2). Selective deprotection of the Lys(Aloc) group is performed manually and
- 15 accomplished by treating the resin with a solution of 3 eq of Pd(PPh<sub>3</sub>)<sub>4</sub> dissolved in 5mL of CHCl<sub>3</sub>:NMM:HOAc (18:1:0.5) for 2h (Step 3). The resin is then washed with CHCl<sub>3</sub> (6 x 5mL), 20% HOAc in DCM (6 x 5mL), DCM (6 x 5mL), and DMF (6 x 5mL). The synthesis is then re-automated for the addition of the 3-maleimidopropionic acid (Step 4).
- 20 Resin cleavage and product isolation is performed using 86% TFA/5% TIS/5% H<sub>2</sub>O/2% thioanisole and 2% phenol, followed by precipitation by dry-ice cold Et<sub>2</sub>O (Step 5). The product is purified by preparative reversed phase HPLC using a Varian (Rainin) preparative binary HPLC system using a Dynamax C<sub>18</sub>, 60Å, 8 µm, 21 mm x 25 cm column
- 25 equipped with a Dynamax C<sub>18</sub>, 60Å, 8 µm guard module, 21 mm x 25 cm column and UV detector (Varian Dynamax UVD II) at λ 214 and 254 nm to afford the desired DAC in >95% purity, as determined by RP-HPLC. These steps are illustrated in the following schematic diagram.



## F. Preparation of Modified Peptides From Peptides Containing Multiple Cysteines


5

### 1. Modification at the N-Terminus

#### Example 65- Synthesis of N-MPA-Cys<sup>1</sup>-Endothelin-1 (1-21)-OH

Solid phase peptide synthesis of a modified Endothelin-1 analog on a 100  $\mu$ mole scale is performed manually and on a Symphony

- 10 Peptide Synthesizer using Fmoc protected Rink Amide MBHA resin. The following protected amino acids are sequentially added to the resin: Fmoc-Trp(Boc)-OH, Fmoc-Ile-OH, Fmoc-Ile-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Leu-OH, Fmoc-His(Trt)-OH, Fmoc-Cys(Acm)-OH, Fmoc-Phe-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Val-OH, Fmoc-Cys(tBu)-OH, Fmoc-
- 15 Glu(OtBu)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Met-OH, Fmoc-Leu-OH, Fmoc-Ser(tBu)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Cys(tBu)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Cys(Acm)-OH. They are dissolved in *N,N*-dimethylformamide (DMF) and, according to the sequence, activated using *O*-benzotriazol-1-yl-*N, N, N'*, *N'*-tetramethyl-
- 20 uronium hexafluorophosphate (HBTU) and Diisopropylethylamine (DIEA). Removal of the Fmoc protecting groups is achieved using a solution of 20% (V/V) piperidine in *N,N*-dimethylformamide (DMF) for 20 minutes (Step 1). The removal of the Acm groups and resulting oxidation of the first two Cys residues to form the first disulfide bridge on
- 25 resin is accomplished using iodine (Step 2). The removal of the tBu groups and resulting oxidation of the other two Cys residues to form the second disulfide bridge on resin is accomplished using thallium (III) trifluoroacetate (Step 3). The deprotection of the terminal Fmoc group is accomplished using 20% piperidine followed by the coupling of 3-MPA
- 30 (Step 4). Resin cleavage and product isolation is performed using 86% TFA/5% TIS/5% H<sub>2</sub>O/2% thioanisole and 2% phenol, followed by precipitation by dry-ice cold Et<sub>2</sub>O (Step 5). The product is purified by



- 5 preparative reverse phase HPLC using a Varian (Rainin) preparative binary HPLC system using a Dynamax C<sub>18</sub>, 60Å, 8 µm, 21 mm x 25 cm column equipped with a Dynamax C<sub>18</sub>, 60Å, 8 µm guard module, 21 mm x 25 cm column and UV detector (Varian Dynamax UVD II) at λ 214 and

254 nm to afford the desired DAC in >95% purity, as determined by RP-HPLC. These steps are illustrated in the schematic diagram above.

## 2. Modification at the C-Terminus

### 5 **Example 66 - Synthesis of Endothelin-1 (1-21)Lys<sup>22</sup>-(Nε-MPA)-OH**

Solid phase peptide synthesis of a modified Endothelin-1 analog on a 100 μmole scale is performed manually and on a Symphony Peptide Synthesizer using Fmoc protected Rink Amide MBHA resin. The following protected amino acids are sequentially added to the resin:

- 10 Fmoc-Lys(Aloc)-OH, Fmoc-Trp(Boc)-OH, Fmoc-Ile-OH, Fmoc-Ile-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Leu-OH, Fmoc-His(Trt)-OH, Fmoc-Cys(Acm)-OH, Fmoc-Phe-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Val-OH, Fmoc-Cys(tBu)-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Met-OH, Fmoc-Leu-OH, Fmoc-Ser(tBu)-OH,
- 15 Fmoc-Ser(tBu)-OH, Fmoc-Cys(tBu)-OH, Fmoc-Ser(tBu)-OH, Boc-Cys(Acm)-OH. They are dissolved in *N,N*-dimethylformamide (DMF) and, according to the sequence, activated using *O*-benzotriazol-1-yl-*N,N,N',N'*-tetramethyl-uronium hexafluorophosphate (HBTU) and Diisopropylethylamine (DIEA). Removal of the Fmoc protecting group is
- 20 achieved using a solution of 20% (V/V) piperidine in *N,N*-dimethylformamide (DMF) for 20 minutes (Step 1). The removal of the Acm groups and resulting oxidation of the first two Cys residues to form the first disulfide bridge on resin is accomplished using iodine (Step 2). The removal of the tBu groups and resulting oxidation of the other two
- 25 Cys residues to form the second disulfide bridge on resin is accomplished using thallium (III) trifluoroacetate (Step 3). Selective deprotection of the Lys(Aloc) group is performed manually and accomplished by treating the resin with a solution of 3 eq of Pd(PPh<sub>3</sub>)<sub>4</sub> dissolved in 5 mL of CHCl<sub>3</sub>:NMM:HOAc (18:1:0.5) for 2h (Step 4). The
- 30 resin is then washed with CHCl<sub>3</sub> (6 x 5mL), 20% HOAc in DCM (6 x 5mL), DCM (6 x 5mL), and DMF (6 x 5mL). The synthesis is then re-automated for the addition of the 3-maleimidopropionic acid (Step 5).

Resin cleavage and product isolation is performed using 86% TFA/5% TIS/5% H<sub>2</sub>O/2% thioanisole and 2% phenol, followed by precipitation by dry-ice cold Et<sub>2</sub>O (Step 5). The product is purified by preparative reverse phase HPLC using a Varian (Rainin) preparative binary HPLC system using a Dynamax C<sub>18</sub>, 60Å, 8 µm, 21 mm x 25 cm column equipped with a Dynamax C<sub>18</sub>, 60Å, 8 µm guard module, 21 mm x 25 cm column and UV detector (Varian Dynamax UVD II) at λ 214 and 254 nm to afford the desired DAC in >95% purity, as determined by RP-HPLC. These steps are illustrated in the schematic diagram below.

10

10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000  
1001  
1002  
1003  
1004  
1005  
1006  
1007  
1008  
1009  
1010  
1011  
1012  
1013  
1014  
1015  
1016  
1017  
1018  
1019  
1020  
1021  
1022  
1023  
1024  
1025  
1026  
1027  
1028  
1029  
1030  
1031  
1032  
1033  
1034  
1035  
1036  
1037  
1038  
1039  
1040  
1041  
1042  
1043  
1044  
1045  
1046  
1047  
1048  
1049  
1050  
1051  
1052  
1053  
1054  
1055  
1056  
1057  
1058  
1059  
1060  
1061  
1062  
1063  
1064  
1065  
1066  
1067  
1068  
1069  
1070  
1071  
1072  
1073  
1074  
1075  
1076  
1077  
1078  
1079  
1080  
1081  
1082  
1083  
1084  
1085  
1086  
1087  
1088  
1089  
1090  
1091  
1092  
1093  
1094  
1095  
1096  
1097  
1098  
1099  
1100  
1101  
1102  
1103  
1104  
1105  
1106  
1107  
1108  
1109  
1110  
1111  
1112  
1113  
1114  
1115  
1116  
1117  
1118  
1119  
1120  
1121  
1122  
1123  
1124  
1125  
1126  
1127  
1128  
1129  
1130  
1131  
1132  
1133  
1134  
1135  
1136  
1137  
1138  
1139  
1140  
1141  
1142  
1143  
1144  
1145  
1146  
1147  
1148  
1149  
1150  
1151  
1152  
1153  
1154  
1155  
1156  
1157  
1158  
1159  
1160  
1161  
1162  
1163  
1164  
1165  
1166  
1167  
1168  
1169  
1170  
1171  
1172  
1173  
1174  
1175  
1176  
1177  
1178  
1179  
1180  
1181  
1182  
1183  
1184  
1185  
1186  
1187  
1188  
1189  
1190  
1191  
1192  
1193  
1194  
1195  
1196  
1197  
1198  
1199  
1200  
1201  
1202  
1203  
1204  
1205  
1206  
1207  
1208  
1209  
1210  
1211  
1212  
1213  
1214  
1215  
1216  
1217  
1218  
1219  
1220  
1221  
1222  
1223  
1224  
1225  
1226  
1227  
1228  
1229  
1230  
1231  
1232  
1233  
1234  
1235  
1236  
1237  
1238  
1239  
1240  
1241  
1242  
1243  
1244  
1245  
1246  
1247  
1248  
1249  
1250  
1251  
1252  
1253  
1254  
1255  
1256  
1257  
1258  
1259  
1260  
1261  
1262  
1263  
1264  
1265  
1266  
1267  
1268  
1269  
1270  
1271  
1272  
1273  
1274  
1275  
1276  
1277  
1278  
1279  
1280  
1281  
1282  
1283  
1284  
1285  
1286  
1287  
1288  
1289  
1290  
1291  
1292  
1293  
1294  
1295  
1296  
1297  
1298  
1299  
1300  
1301  
1302  
1303  
1304  
1305  
1306  
1307  
1308  
1309  
1310  
1311  
1312  
1313  
1314  
1315  
1316  
1317  
1318  
1319  
1320  
1321  
1322  
1323  
1324  
1325  
1326  
1327  
1328  
1329  
1330  
1331  
1332  
1333  
1334  
1335  
1336  
1337  
1338  
1339  
1340  
1341  
1342  
1343  
1344  
1345  
1346  
1347  
1348  
1349  
1350  
1351  
1352  
1353  
1354  
1355  
1356  
1357  
1358  
1359  
1360  
1361  
1362  
1363  
1364  
1365  
1366  
1367  
1368  
1369  
1370  
1371  
1372  
1373  
1374  
1375  
1376  
1377  
1378  
1379  
1380  
1381  
1382  
1383  
1384  
1385  
1386  
1387  
1388  
1389  
1390  
1391  
1392  
1393  
1394  
1395  
1396  
1397  
1398  
1399  
1400  
1401  
1402  
1403  
1404  
1405  
1406  
1407  
1408  
1409  
1410  
1411  
1412  
1413  
1414  
1415  
1416  
1417  
1418  
1419  
1420  
1421  
1422  
1423  
1424  
1425  
1426  
1427  
1428  
1429  
1430  
1431  
1432  
1433  
1434  
1435  
1436  
1437  
1438  
1439  
1440  
1441  
1442  
1443  
1444  
1445  
1446  
1447  
1448  
1449  
1450  
1451  
1452  
1453  
1454  
1455  
1456  
1457  
1458  
1459  
1460  
1461  
1462  
1463  
1464  
1465  
1466  
1467  
1468  
1469  
1470  
1471  
1472  
1473  
1474  
1475  
1476  
1477  
1478  
1479  
1480  
1481  
1482  
1483  
1484  
1485  
1486  
1487  
1488  
1489  
1490  
1491  
1492  
1493  
1494  
1495  
1496  
1497  
1498  
1499  
1500  
1501  
1502  
1503  
1504  
1505  
1506  
1507  
1508  
1509  
1510  
1511  
1512  
1513  
1514  
1515  
1516  
1517  
1518  
1519  
1520  
1521  
1522  
1523  
1524  
1525  
1526  
1527  
1528  
1529  
1530  
1531  
1532  
1533  
1534  
1535  
1536  
1537  
1538  
1539  
1540  
1541  
1542  
1543  
1544  
1545  
1546  
1547  
1548  
1549  
1550  
1551  
1552  
1553  
1554  
1555  
1556  
1557  
1558  
1559  
1560  
1561  
1562  
1563  
1564  
1565  
1566  
1567  
1568  
1569  
1570  
1571  
1572  
1573  
1574  
1575  
1576  
1577  
1578  
1579  
1580  
1581  
1582  
1583  
1584  
1585  
1586  
1587  
1588  
1589  
1590  
1591  
1592  
1593  
1594  
1595  
1596  
1597  
1598  
1599  
1600  
1601  
1602  
1603  
1604  
1605  
1606  
1607  
1608  
1609  
1610  
1611  
1612  
1613  
1614  
1615  
1616  
1617  
1618  
1619  
1620  
1621  
1622  
1623  
1624  
1625  
1626  
1627  
1628  
1629  
1630  
1631  
1632  
1633  
1634  
1635  
1636  
1637  
1638  
1639  
1640  
1641  
1642  
1643  
1644  
1645  
1646  
1647  
1648  
1649  
1650  
1651  
1652  
1653  
1654  
1655  
1656  
1657  
1658  
1659  
1660  
1661  
1662  
1663  
1664  
1665  
1666  
1667  
1668  
1669  
1670  
1671  
1672  
1673  
1674  
1675  
1676  
1677  
1678  
1679  
1680  
1681  
1682  
1683  
1684  
1685  
1686  
1687  
1688  
1689  
1690  
1691  
1692  
1693  
1694  
1695  
1696  
1697  
1698  
1699  
1700  
1701  
1702  
1703  
1704  
1705  
1706  
1707  
1708  
1709  
1710  
1711  
1712  
1713  
1714  
1715  
1716  
1717  
1718  
1719  
1720  
1721  
1722  
1723  
1724  
1725  
1726  
1727  
1728  
1729  
1730  
1731  
1732  
1733  
1734  
1735  
1736  
1737  
1738  
1739  
1740  
1741  
1742  
1743  
1744  
1745  
1746  
1747  
1748  
1749  
1750  
1751  
1752  
1753  
1754  
1755  
1756  
1757  
1758  
1759  
1760  
1761  
1762  
1763  
1764  
1765  
1766  
1767  
1768  
1769  
1770  
1771  
1772  
1773  
1774  
1775  
1776  
1777  
1778  
1779  
1780  
1781  
1782  
1783  
1784  
1785  
1786  
1787  
1788  
1789  
1790  
1791  
1792  
1793  
1794  
1795  
1796  
1797  
1798  
1799  
1800  
1801  
1802  
1803  
1804  
1805  
1806  
1807  
1808  
1809  
1810  
1811  
1812  
1813  
1814  
1815  
1816  
1817  
1818  
1819  
1820  
1821  
1822  
1823  
1824  
1825  
1826  
1827  
1828  
1829  
1830  
1831  
1832  
1833  
1834  
1835  
1836  
1837  
1838  
1839  
1840  
1841  
1842  
1843  
1844  
1845  
1846  
1847  
1848  
1849  
1850  
1851  
1852  
1853  
1854  
1855  
1856  
1857  
1858  
1859  
1860  
1861  
1862  
1863  
1864  
1865  
1866  
1867  
1868  
1869  
1870  
1871  
1872  
1873  
1874  
1875  
1876  
1877  
1878  
1879  
1880  
1881  
1882  
1883  
1884  
1885  
1886  
1887  
1888  
1889  
1890  
1891  
1892  
1893  
1894  
1895  
1896  
1897  
1898  
1899  
1900  
1901  
1902  
1903  
1904  
1905  
1906  
1907  
1908  
1909  
1910  
1911  
1912  
1913  
1914  
1915  
1916  
1917  
1918  
1919  
1920  
1921  
1922  
1923  
1924  
1925  
1926  
1927  
1928  
1929  
1930  
1931  
1932  
1933  
1934  
1935  
1936  
1937  
1938  
1939  
1940  
1941  
1942  
1943  
1944  
1945  
1946  
1947  
1948  
1949  
1950  
1951  
1952  
1953  
1954  
1955  
1956  
1957  
1958  
1959  
1960  
1961  
1962  
1963  
1964  
1965  
1966  
1967  
1968  
1969  
1970  
1971  
1972  
1973  
1974  
1975  
1976  
1977  
1978  
1979  
1980  
1981  
1982  
1983  
1984  
1985  
1986  
1987  
1988  
1989  
1990  
1991  
1992  
1993  
1994  
1995  
1996  
1997  
1998  
1999  
2000  
2001  
2002  
2003  
2004  
2005  
2006  
2007  
2008  
2009  
2010  
2011  
2012  
2013  
2014  
2015  
2016  
2017  
2018  
2019  
2020  
2021  
2022  
2023  
2024  
2025  
2026  
2027  
2028  
2029  
2030  
2031  
2032  
2033  
2034  
2035  
2036  
2037  
2038  
2039  
2040  
2041  
2042  
2043  
2044  
2045  
2046  
2047  
2048  
2049  
2050  
2051  
2052  
2053  
2054  
2055  
2056  
2057  
2058  
2059  
2060  
2061  
2062  
2063  
2064  
2065  
2066  
2067  
2068  
2069  
2070  
2071  
2072  
2073  
2074  
2075  
2076  
2077  
2078  
2079  
2080  
2081  
2082  
2083  
2084  
2085  
2086  
2087  
2088  
2089  
2090  
2091  
2092  
2093  
2094  
2095  
2096  
2097  
2098  
2099  
2100  
2101  
2102  
2103  
2104  
2105  
2106  
2107  
2108  
2109  
2110  
2111  
2112  
2113  
2114  
2115  
2116  
2117  
2118  
2119  
2120  
2121  
2122  
2123  
2124  
2125  
2126  
2127  
2128  
2129  
2130  
2131  
2132  
2133  
2134  
2135  
2136  
2137  
2138  
2139  
2140  
2141  
2142  
2143  
2144  
2145  
2146  
2147  
2148  
2149  
2150  
2151  
2152  
2153  
2154  
2155  
2156  
2157  
2158  
2159  
2160  
2161  
2162  
2163  
2164  
2165  
2166  
2167  
2168  
2169  
2170  
2171  
2172  
2173  
2174  
2175  
2176  
2177  
2178  
2179  
2180  
2181  
2182  
2183  
2184  
2185  
2186  
2187  
2188  
2189  
2190  
2191  
2192  
2193  
2194  
2195



Fmoc-Rink Amide MBHA Resin

Step 1 ↓ SPPS

Boc-C(Acm)SC(tBu)SSLMDKEC(tBu)VYFC(Acm)HLDIIW-Lys(Aloc)-Resin

Step 2 ↓ I<sub>2</sub>

Boc-CSC(tBu)SSLMDKEC(tBu)VYFCHLDIIW-Lys(Aloc)-Resin


Step 3 ↓ thallium (III) trifluoroacetate

Boc-CSCSSLMDKECVYFCHLDIIW-Lys(Aloc)-Resin


Step 4 ↓ Pd(PPh<sub>3</sub>)<sub>4</sub>/NMM/HOAc/CHCl<sub>3</sub>

Boc-CSCSSLMDKECVYFCHLDIIW-Lys-Resin

Step 5 ↓ 3-maleimidopropionic acid



Step 6 ↓ 85% TFA/5% TIS/5% thioanisole/5% phenol



Endothelin-1 (1-21) Lys<sup>22</sup>(E-MPA)-OH

### 3. Modification at an Internal Amino Acid

#### **Example 67- Synthesis of Lys<sup>4</sup>(N<sub>6</sub>-MPA)Sarafotoxin B(1-21)-OH**

- Solid phase peptide synthesis of a modified Sarafotoxin-B analog
- 5 on a 100  $\mu$ mol scale is performed manually and on a Symphony Peptide Synthesizer using Fmoc protected Rink Amide MBHA resin. The following protected amino acids are sequentially added to the resin: Fmoc-Trp(Boc)-OH, Fmoc-Ile-OH, Fmoc-Val-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Gln(Trt)-OH, Fmoc-His(Trt)-OH, Fmoc-Cys(Acm)-OH, Fmoc-Phe-
- 10 OH, Fmoc-Tyr(tBu)-OH, Fmoc-Leu-OH, Fmoc-Cys(tBu)-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Met-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Lys(Aloc)-OH, Fmoc-Cys(tBu)-OH, Fmoc-Ser(tBu)-OH, Boc-Cys(Acm)-OH. They are dissolved in *N,N*-dimethylformamide (DMF) and, according to the
- 15 sequence, activated using *O*-benzotriazol-1-yl-*N,N,N'*-tetramethyluronium hexafluorophosphate (HBTU) and Diisopropylethylamine (DIEA). Removal of the Fmoc protecting group is achieved using a solution of 20% (V/V) piperidine in *N,N*-dimethylformamide (DMF) for 20 minutes (Step 1). The removal of the Acm groups and resulting
- 20 oxidation of the first two Cys residues to form the first disulfide bridge on resin is accomplished using iodine (Step 2). The removal of the *t*Bu groups and resulting oxidation of the other two Cys residues to form the second disulfide bridge on resin is accomplished using thallium (III) trifluoroacetate (Step 3). Selective deprotection of the Lys(Aloc) group is
- 25 performed manually and accomplished by treating the resin with a solution of 3 eq of Pd(PPh<sub>3</sub>)<sub>4</sub> dissolved in 5 mL of CHCl<sub>3</sub>:NMM:HOAc (18:1:0.5) for 2h (Step 4). The resin is then washed with CHCl<sub>3</sub> (6 x 5mL), 20% HOAc in DCM (6 x 5mL), DCM (6 x 5mL), and DMF (6 x 5mL). The synthesis is then re-automated for the addition of the 3-
- 30 maleimidopropionic acid (Step 5). Resin cleavage and product isolation is performed using 86% TFA/5% TIS/5% H<sub>2</sub>O/2% thioanisole and 2% phenol, followed by precipitation by dry-ice cold Et<sub>2</sub>O (Step 5). The

- product is purified by preparative reverse phase HPLC using a Varian (Rainin) preparative binary HPLC system using a Dynamax C<sub>18</sub>, 60Å, 8 µm, 21 mm x 25 cm column equipped with a Dynamax C<sub>18</sub>, 60Å, 8 µm guard module, 21 mm x 25 cm column and UV detector (Varian
- 5 Dynamax UVD II) at  $\lambda$  214 and 254 nm to afford the desired DAC in >95% purity, as determined by RP-HPLC. These steps are illustrated in the schematic diagram below.

Fmoc-Rink Amide MBHA Resin

Step 1 ↓ SPPS

Boc-C(Acm)SC(tBu)-Lys(Aloc)-DMTDKEC(tBu)LYFCHQDVIW-Resin

Step 2 ↓ I<sub>2</sub>

Boc-CSC(tBu)-Lys(Aloc)-DMTDKEC(tBu)LYFCHQDVIW-Resin


Step 3 ↓ thallium (III) trifluoroacetate

Boc-CSC-Lys(Aloc)-DMTDKECLYFCHQDVIW-Resin


Step 4 ↓ Pd(PPh<sub>3</sub>)<sub>4</sub>/NMM/HOAc/CHCl<sub>3</sub>

Boc-CSC-Lys-DMTDKECLYFCHQDVIW-Resin

Step 5 ↓ 3-maleimidopropionic acid



Step 6 ↓ 85% TFA/5% TIS/5% thioanisole/5% phenol



Lys<sup>4</sup>(E-MPA)Sarafotoxin B (1-21)-OH

## F. Peptide Stability Assays

5

### Example 68 – Peptide Stability Assay of K5

A peptide stability assay was performed. (MPA)-Pro-Arg-Lys-Leu-Tyr-Asp-Lys-NH<sub>2</sub>. 2TFA was synthesized as described above and was identified MPA-K5. The non-modified counterpart peptide Pro-Arg-Lys-Leu-Tyr-Asp-Lys was also synthesized as described in Example 20 without the addition of 3-MPA and identified as K5.

K5 (MW1260.18, 918.12 freebase) was prepared as a 100 mM stock solution in water. MPA-K5 (MW = 1411.17, 1069.11 freebase) was prepared as a 100 mM stock solution in water. Human Serum Albumin (HSA) was obtained as a 25% solution (ca 250 mg/ml, 3.75 mM) as Albutein® available from Alpha Therapeutic. Human plasma was obtained from Golden West Biologicals.

#### (1) Stability of K5 in Human Plasma

K5 was prepared as a 1 µM solution and dissolved in 25% human serum albumin. The mixture was then incubated at 37°C in the presence of human plasma to final concentration of 160 mM K5. Aliquots of 100 µl were withdrawn from the plasma at 0, 4 hours and 24 hours. The 100 µl aliquots were mixed with 100 µl of blocking solution (5 vol. 5%ZnSO<sub>4</sub>/3 vol. Acetonitrile/2 vol. Methanol) in order to precipitate all proteins. The sample was centrifuged for 5 min at 10,000 g and the supernatant containing the peptide was recovered and filtered through a 0.22 µm filter. The presence of free intact K5 peptide was assayed by the HPLC/MS. The results are presented below. The HPLC parameters for detection of K5 peptide in serum were as follows.

The HPLC method was as follows: A Vydac C18 250 X 4.6 mm, 5 µ particle size column was utilized. The column temperature was 30°C

with a flow rate of 0.5 ml/min. Mobile Phase A was 0.1% TFA/water. Mobile Phase B was 0.1% TFA/acetonitrile. The injection volume was 10µl.

The gradient was as follows:

5

<u>Time(Minutes)</u>	<u>%A</u>	<u>%B</u>
0	95	5
20	70	30
25	10	90
30	10	90
35	95	5
45	95	5

10

The proteins were detected at 214, 254 and 334 nm. For mass spectral analysis, the ionization mode was API-electrospray (positive mode) at an M/Z range of 300 to 2000. The gain was 3.0, fragmentor 120v, threshold 20, stepsize 0.1. The gas temp was 350°C and the drying gas volume was 10.0 l/min. The Neb pressure was 24 psi and the Vcap was 3500V. The HPLC method was as follows: A Vydac C18 250 X 4.6 mm, 5 µ particle size column was utilized. The column temperature was 30°C with a flow rate of 0.5 ml/min. Mobile Phase A was 0.1% TFA/water. Mobile Phase B was 0.1% TFA/acetonitrile. The injection volume was 10µl.

15

20

The gradient was as follows:

25

<u>Time(Minutes)</u>	<u>%A</u>	<u>%B</u>
0	95	5
20	70	30
25	10	90
30	10	90
35	95	5
45	95	5

30

00500.01522500

The proteins were detected at 214, 254 and 334 nm. For mass spectral analysis, the ionization mode was API-electrospray (positive mode) at an M/Z range of 300 to 2000. The gain was 3.0, fragmentor 120v, threshold 20, stepsize 0.1. The gas temp was 350°C and the drying gas volume was 10.0 l/min. The Neb pressure was 24 psi and the Vcap was 3500V.

	<u>Time</u>	<u>%K5 peptide in Plasma</u>
10	0 hrs.	100%
	4 hrs	9%
	24 hrs	0%

The results demonstrate that unmodified K5 peptide is unstable in plasma likely as a result of protease activity.

## (2) Stability of MPA-K5-HSA Conjugate in Plasma

MPA-K5 (modified K5 peptide) was incubated with 25% HSA for 2 hours at room temperature. The MPA-K5-HSA conjugate was then incubated at 37° in the presence of human plasma at a final concentration of 160 µm. After the specific incubation period (0, 4 and 24 hours) an aliquot of 100 µl was withdrawn and filtered through a 0.22 µm filter. The presence of intact conjugate was assayed by HPLC-MS.

The column was an Aquapore RP-300, 250 x 4.6 mm, 7µ particle size. The column temperature was 50° C. The mobile phase A was 0.1% TFA/water. The mobile phase B was 0.1% TFA/acetonitrile. The injection volume was 1 µl. The gradient was as follows:

	<u>Time (minutes)</u>	<u>%A</u>	<u>%B</u>	<u>Flow(ml/min)</u>
	0	66	34	0.700
	1	66	34	0.700
5	25	58.8	41.2	0.700
	30	50	50	0.70
	35	5	95	1.00
	41	5	95	1.00
	45	66	34	1.00
10	46	66	34	0.70

The peptide was detected at 214 nm for quantification. For mass spectral analysis of the peptide, the ionization mode was API-electrospray at 1280 to 1500 m/z range, gain 1.0, fragmentor 125V, threshold 100, stepsize 0.40. The gas temperature was 350°C the drying gas was 13.0 l/min. The pressure was 60psi and the Vcap was 6000V. The results are presented below.

Approximately 33% of circulating albumin in the bloodstream is mercaptalbumin (SH-albumin) which is not blocked by endogenous sulfhydryl compounds such as cysteine or glutathione and is therefore available for reaction with maleimido groups. The remaining 66% of the circulating albumin is capped or blocked by sulfhydryl compounds. The HPLC MS assay permits the identification of capped-HSA, SH-albumin and K5-MPA-albumin. The MPA covalently bonds to the free thiol on the albumin. The stability of the three forms of albumin in plasma is presented below.

	<u>Time</u>	<u>%capped HSA</u>	<u>% SH-Albumin</u>	<u>%K5-MPA-HSA</u>
	0 hrs.	61.3	16.6	22.1
30	4 hrs.	64.6	16.05	19.35
	24 hrs.	63	16.8	20.2



- The percentage of K5-MPA-HSA remained relatively constant throughout the 24 hour plasma assay in contrast to unmodified K5 which decreased to 9% of the original amount of K5 in only 4 hours in plasma. The results demonstrate that in contrast to K5 which is quite unstable in plasma, K5-MPA-HSA is quite stable from peptidase activity in plasma.

**Example 70 - Peptide Stability Assay of Dynorphin**

- In order to determine the stability of peptide conjugates in the presence of serum peptidases the serum stability of Dyn A-(1-13)-OH, Dyn A-(1-13)-NH<sub>2</sub> and Dyn A 1-13(MPA)-NH<sub>2</sub> were compared. Dyn A-(1-13)-OH, Dyn A-(1-13)-NH<sub>2</sub> and Dyn A 1-13(MPA)-NH<sub>2</sub> were synthesized as described above. The Dynorphin peptides were mixed with human heparinized plasma to a final concentration of 4 mg/mL. After the required incubation time at 37 °C, 0, 20, 60, 120, 180, 360 and 480 minutes) a 100 µL-aliquot was added to 100 µL of blocking solution (5 vol. of a 5% aqueous ZnSO<sub>4</sub> solution, 3 vol. of acetonitrile, 2 vol. of methanol) that precipitates all proteins. After centrifugation (10,000 g for 2.5 min), clear supernatant was recovered, filtered through a 0.45 µm filter and stored on ice until LC/MS analysis.
- The samples were analyzed using an LC at 214 nm to detect the presence of the different compounds and MS to determine the identity of the detected compound. The integrated area % for each peak from the LC chromatogram was then plotted against time and the relative stabilities determined in human plasma.
- The stability data for Dyn A-(1-13)-OH and Dyn A-(1-13)-NH<sub>2</sub> were consistent with that reported in literature: the proteolytic breakdown of the dynorphin peptides is quite rapid. Dyn A-(1-13)-OH had a half life of about 10 minutes. Dyn A-(1-13)-NH<sub>2</sub> had a half life of about 30 minutes. In contrast Dyn A 1-13(MPA)-NH<sub>2</sub> exhibited striking stabilization in the presence of serum peptidase activity. Unmodified dynorphin peptides are degraded within 60 minutes. In contrast, modified dynorphin

peptides (Dyn A 1-13(MPA)-NH<sub>2</sub>) are stable from serum peptidase activity for up to 480 minutes.

- The stability determination of the dynorphin conjugate is determined by ELISA. In order to determine if the observed signal is due to a dynorphin conjugate and what the conjugate is, LC mass spectrometry analysis of the reaction mixture after 8 h was performed. The use of mass spectrometry permits a determination of the molecular weight of the conjugate and allows the determination whether there are any truncated forms of the dynorphin conjugate.
- 10 Mass spectrometry of human plasma shows the two forms of albumin, the free thiol at 66436 Da and the oxidized form at 66557 Da. Also, mass spectrometry can distinguish between a Dyn 2-13 truncated conjugate (68046 Da) and the intact Dyn 1-13 conjugate, (68207 Da) in an equal mixture.
- 15 Mass spectrometry analysis of dynorphin samples taken from the serum after 480 minutes of exposure to the serum peptidases identifies only the presence of the intact conjugate (68192 Da) and not the breakdown products thereby demonstrating the stability of the dynorphin conjugate from serum peptidase activity.

20

**TABLE 1**  
**NATURAL AMINO ACIDS AND THEIR ABBREVIATIONS**

Name	3-Letter Abbreviation	1-Letter Abbreviation	Protected Amino Acids
Alanine	Ala	A	Fmoc-Ala-OH
Arginine	Arg	R	Fmoc-Arg(Pbf)-OH
Asparagine	Asn	N	Fmoc-Asn(Trt)-OH
Aspartic acid	Asp	D	Asp(tBu)-OH
Cysteine	Cys	C	Fmoc-Cys(Trt)
Glutamic acid	Glu	E	Fmoc-Glu(tBu)-OH
Glutamine	Gln	Q	Fmoc-Gln(Trt)-OH
Glycine	Gly	G	Fmoc-Gly-OH
Histidine	His	H	Fmoc-His(Trt)-OH
Isoleucine	Ile	I	Fmoc-Ile-OH
Leucine	Leu	L	Fmoc-Leu-OH
Lysine	Lys	K	Fmoc-Lys(Mtt)-OH
Methionine	Met	M	Fmoc-Met-OH
Phenylalanine	Phe	F	Fmoc-Phe-OH
Proline	Pro	P	Fmoc-Pro-OH
Serine	Ser	S	Fmoc-Ser(tBu)-OH
Threonine	Thr	T	Fmoc-Thr(tBu)-OH
Tryptophan	Trp	W	Fmoc-Trp(Boc)-OH
Tyrosine	Tyr	Y	Boc-Tyr(tBu)-OH
Valine	Val	V	Fmoc-Val-OH

We claim:

1. A modified therapeutic peptide capable of forming a peptidase stabilized therapeutic peptide composed of between 3 and 50 amino acids, said peptide having a carboxy terminal amino acid, an amino terminal amino acid, a therapeutically active region of amino acids and a less therapeutically active region of amino acids, said peptide comprising:
  - a reactive group which reacts with amino groups, hydroxyl groups, or thiol groups on blood components to form a stable covalent bond thereby forming the peptidase stabilized therapeutic peptide wherein the reactive group is selected from the group consisting of succinimidyl and maleimido groups and wherein the reactive group is attached to an amino acid positioned in said less therapeutically active region of amino acids.
2. The peptide of claim 1 wherein said therapeutically active region of amino acids includes said carboxy terminal amino acid and said reactive group is attached to said amino terminal amino acid.
3. The peptide of claim 1 wherein said therapeutically active region of amino acids includes said amino terminal amino acid and said reactive group is attached to said carboxy terminal amino acid.
4. The peptide of claim 1 wherein said therapeutically active region of amino acids includes said carboxy terminal amino acid and said reactive group is attached to an amino acid positioned between said amino terminal amino acid and said carboxy terminal amino acid.
5. The peptide of claim 1 wherein said therapeutically active region of amino acids includes said amino terminal amino acid and said

reactive group is attached to an amino acid positioned between said amino terminal amino acid and said carboxy terminal amino acid.

6. A method of synthesizing the modified therapeutic peptide of claim 1, comprising:
- a) if said therapeutic peptide does not contain a cysteine, then synthesizing said peptide from said carboxy terminal amino acid and adding said reactive group to said carboxy terminal amino acid, or adding a terminal lysine to said carboxy terminal amino acid and adding said reactive group to said terminal lysine;
- b) if said therapeutic peptide contains only one cysteine, then reacting said cysteine with a protective group prior to addition of said reactive group to an amino acid in said less therapeutically active region of said peptide;
- c) if said therapeutic peptide contains two cysteines as a disulfide bridge, then oxidizing said two cysteines and adding said reactive group to said amino terminal amino acid, or to said carboxy terminal amino acid, or to an amino acid positioned between said carboxy terminal amino acid and said amino terminal amino acid of said therapeutic peptide; and
- d) if said therapeutic peptide contains more than two cysteines as disulfide bridges, then sequentially oxidizing said cysteines in said disulfide bridges and purifying said peptide prior to the addition of said reactive groups to said carboxy terminal amino acid.
7. A method for protecting a therapeutic peptide from peptidase activity in vivo, said peptide being composed of between 3 and 50 amino acids and having a carboxy terminus and an amino terminus and a carboxy terminal amino acid amino acid and an amino terminal amino acid, comprising:
- (a) modifying said peptide by attaching a reactive group to the carboxy terminal amino acid, to the amino terminal amino acid, or to an

amino acid located between the amino terminal amino acid and the carboxy terminal amino acid, such that said modified peptide is capable of forming a covalent bond in vivo with a reactive functionality on a blood component;

- 5 (b) forming a covalent bond between said reactive group and a reactive functionality on a blood component to form a peptide-blood component conjugate, thereby protecting said peptide from peptidase activity; and
- (c) analyzing the stability of said peptide-blood component
- 10 conjugate to assess the protection of said peptide from peptidase activity.

8. A method according to claim 7, further comprising the step of administering said modified peptide in vivo before step (b), such that the
- 15 peptide-blood component conjugate is formed in vivo.

10. A method according to claim 7, wherein step (b) occurs ex vivo.

11. A method according to claim 7 wherein step (c) is performed in
- 20 vivo.

12. A method according to claim 7, wherein said reactive group is a maleimido group.
- 25

13. A method according to claim 7, wherein said reactive group is attached to said peptide via a linking group.

- 30 14. A method according to claim 7, wherein said blood component is albumin.

15. A method according to claim 7, wherein one or more of said amino acids is synthetic.

16. A method for protecting a therapeutic peptide from peptidase activity in vivo, said peptide being composed of between 3 and 50 amino acids and having a therapeutically active region of amino acids and a less therapeutically active region of amino acids, comprising:

- (a) determining said therapeutically active region of amino acids;
- 10 (b) modifying said peptide at an amino acid included in said less therapeutically active region of amino acids by attaching a reactive group to said amino acid to form a modified peptide, such that said modified peptide has therapeutic activity and is capable of forming a covalent bond in vivo with a reactive functionality on a blood component;
- 15 (c) forming a covalent bond between said reactive entity and a reactive functionality on a blood component to form a peptide-blood component conjugate, thereby protecting said peptide from peptidase activity; and
- (d) analyzing the stability of said peptide-blood component
- 20 conjugate to assess the protection of said peptide from peptidase activity.

17. A method according to claim 16, further comprising the step of administering said modified peptide in vivo before step (c), such that the peptide-blood component conjugate is formed in vivo.

18. A method according to claim 18, wherein step (c) occurs ex vivo.

19. A method according to claim 19, wherein step (d) is performed in vivo.

20. A method according to claim 18, wherein step (c) is performed in vivo.

21. A method according to claim 20, wherein step (d) is performed ex vivo.

22. A method according to claim 16, wherein said peptide has a carboxy terminus, an amino terminus, a carboxy terminal amino acid and an amino terminal amino acid, and wherein step (b) further comprises:

(a) if said less therapeutically active portion is located at the carboxy terminus of said peptide, then modifying said peptide at the carboxy terminal amino acid of said peptide;

(b) if said less active portion is located at the amino terminus of said peptide, then modifying said peptide at the amino terminal amino acid of said peptide; and

(c) if said less active portion is located at neither the amino terminus nor the carboxy terminus of said peptide, then modifying said peptide at an amino acid located between the carboxy terminus and the amino terminus.

23. A method according to claim 16, wherein said reactive group is a maleimido group.

24. A method according to claim 16, wherein said reactive entity is attached to said peptide via a linking group.

25. A method according to claim 16, wherein said blood component is albumin.

26. A method according to claim 16, wherein one or more of said amino acids is synthetic.



ABSTRACT OF THE DISCLOSURE

5           A method for protecting a peptide from peptidase activity *in vivo*,  
the peptide being composed of between 2 and 50 amino acids and  
having a C-terminus and an N-terminus and a C-terminus amino acid  
and an N-terminus amino acid is described. In the first step of the  
method, the peptide is modified by attaching a reactive group to the C-  
10 terminus amino acid, to the N-terminus amino acid, or to an amino acid  
located between the N-terminus and the C-terminus, such that the  
modified peptide is capable of forming a covalent bond *in vivo* with a  
reactive functionality on a blood component. In the next step, a covalent  
bond is formed between the reactive group and a reactive functionality  
15 on a blood component to form a peptide-blood component conjugate,  
thereby protecting said peptide from peptidase activity. The final step of  
the method involves the analyzing of the stability of the peptide-blood  
component conjugate to assess the protection of the peptide from  
peptidase activity.  
20

● 09/623548 !

SEQUENCE LISTING

EXPRESS MAIL LABEL NO. EL387347704US  
Attorney Docket No. REDC-2110 USA

533 Rec'd PCT/PTO 0 5 SEP 2000

<110> Conjuchem, Inc.  
Bridon, Dominique  
Ezrin, Alan  
Milner, Peter  
Holmes, Darren  
Thibaudeau, Karen

<120> PROTECTION OF ENDOGENOUS THERAPEUTIC PEPTIDES FROM  
PEPTIDASE ACTIVITY THROUGH CONJUGATION TO BLOOD  
COMPONENTS

<130> 2110

<140>

<141>

<150> 60/134,406

<151> 1999-05-17

<150> 60/153,406

<151> 1999-09-10

<150> 60/159,783

<151> 1999-10-18

<160> 1617

<170> PatentIn Ver. 2.1

<210> 1

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1

His Phe Arg Trp Gly Lys Pro Val Gly Lys Lys Arg Arg Pro Val Lys

1

5

10

15

Val Tyr Pro

<210> 2  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 2  
Met Glu His Phe Arg Trp Gly Lys  
1 5

<210> 3  
<211> 39  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 3  
Ser Tyr Ser Met Glu His Phe Arg Trp Gly Lys Pro Val Gly Lys Lys  
1 5 10 15  
Arg Arg Pro Val Lys Val Tyr Pro Asn Gly Ala Glu Asp Glu Ser Ala  
20 25 30  
Glu Ala Phe Pro Leu Glu Phe  
35

<210> 4  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 4  
Ser Tyr Ser Met Glu His Phe Arg Trp Gly Lys Pro Val  
1 5 10

<210> 5  
<211> 16  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 5  
Ser Tyr Ser Met Glu His Phe Arg Trp Gly Lys Pro Val Gly Lys Lys  
1 5 10 15

<210> 6  
<211> 17  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 6  
Ser Tyr Ser Met Glu His Phe Arg Trp Gly Lys Pro Val Gly Lys Lys  
1 5 10 15

Arg

<210> 7  
<211> 24  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 7  
Ser Tyr Ser Met Glu His Phe Arg Trp Gly Lys Pro Val Gly Lys Lys  
1 5 10 15

Arg Arg Pro Val Lys Val Tyr Pro  
20

<210> 8  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 8  
Met Glu His Phe Arg Trp Gly  
1 5

<210> 9  
<211> 32  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 9  
Phe Arg Trp Gly Lys Pro Val Gly Lys Lys Arg Arg Pro Val Lys Val  
1 5 10 15  
Tyr Pro Asn Gly Ala Glu Asp Glu Ser Ala Glu Ala Phe Pro Leu Glu  
20 25 30

<210> 10  
<211> 22  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 10  
Arg Pro Val Lys Val Tyr Pro Asn Gly Ala Glu Asp Glu Ser Ala Glu  
1 5 10 15

Ala Phe Pro Leu Glu Phe

<210> 11  
 <211> 39  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 11  
 Ser Tyr Ser Met Glu His Phe Arg Trp Gly Lys Pro Val Gly Lys Lys  
 1 5 10 15  
 Arg Arg Pro Val Lys Val Tyr Pro Asn Val Ala Glu Asn Glu Ser Ala  
 20 25 30

Glu Ala Phe Pro Leu Glu Phe  
 35

<210> 12  
 <211> 28  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 12  
 Pro Val Gly Lys Lys Arg Arg Pro Val Lys Val Tyr Pro Asn Val Ala  
 1 5 10 15  
 Glu Asn Glu Ser Ala Glu Ala Phe Pro Leu Glu Phe  
 20 25

<210> 13  
 <211> 18  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 13

Val Tyr Pro Asn Gly Ala Glu Asp Glu Ser Ala Glu Ala Phe Pro Leu  
1 5 10 15

Glu Phe

<210> 14

<211> 39

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 14

Ser Tyr Ser Met Glu His Phe Arg Trp Gly Lys Pro Val Gly Lys Lys  
1 5 10 15

Arg Arg Pro Val Lys Val Tyr Pro Asn Val Ala Glu Asn Glu Ser Ala  
20 25 30

Glu Ala Phe Pro Leu Glu Phe  
35

<210> 15

<211> 28

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 15

Pro Val Gly Lys Lys Arg Arg Pro Val Lys Val Tyr Pro Asn Val Ala  
1 5 10 15

Glu Asn Glu Ser Ala Glu Ala Phe Pro Leu Glu Phe  
20 25

<210> 16

<211> 18

<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 16  
Val Tyr Pro Asn Gly Ala Glu Asp Glu Ser Ala Glu Ala Phe Pro Leu  
1 5 10 15

Glu Phe

<210> 17  
<211> 33  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 17  
Val Cys Ser Cys Arg Leu Val Phe Cys Arg Arg Thr Glu Leu Arg Val  
1 5 10 15

Gly Asn Cys Leu Ile Gly Gly Val Ser Phe Thr Tyr Cys Cys Thr Arg  
20 25 30

Val

<210> 18  
<211> 34  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 18  
Gly Ile Cys Ala Cys Arg Arg Arg Phe Cys Pro Asn Ser Glu Arg Phe  
1 5 10 15



Ser Gly Tyr Cys Arg Val Asn Gly Ala Arg Tyr Val Arg Cys Cys Ser  
 20 25 30

Arg Arg

<210> 19

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 19

Met Glu His Phe Phe

1 5

<210> 20

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 20

Met Glu His Phe Phe

1 5

<210> 21

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 21

Ser Tyr Ser Met Glu His Phe Arg Trp Gly Lys Pro Val Gly Lys Lys

1 5 10 15

Arg

<210> 22

<211> 30

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 22

Arg Lys Tyr Val Met Gly His Phe Arg Trp Asp Arg Phe Gly Arg Arg  
1 5 10 15

Asn Ser Ser Ser Ser Gly Ser Ser Gly Ala Gly Gln Lys Arg  
20 25 30

<210> 23

<211> 43

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 23

Phe Pro Thr Ile Pro Leu Ser Arg Leu Phe Asp Asn Ala Met Leu Arg  
1 5 10 15

Ala His Arg Leu His Gln Leu Ala Phe Asp Thr Tyr Gln Glu Phe Glu  
20 25 30

Glu Ala Tyr Ile Pro Lys Glu Gln Lys Tyr Ser  
35 40

<210> 24

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

Peptide

<400> 24

Leu Ser Arg Leu Phe Asp Asn Ala

1

5

<210> 25

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 25

Cys Glu His Arg Trp Cys Lys Pro Val

1

5

<210> 26

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 26

Ser Tyr Ser Met Glu His Phe Arg Trp Gly Lys Pro Val

1

5

10

<210> 27

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 27

Ser Tyr Ser Met Glu His Phe Arg Trp Gly Lys Pro Val

1

5

10

<210> 28  
<211> 18  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 28  
Asp Glu Gly Pro Tyr Lys Met Glu His Phe Arg Trp Gly Ser Pro Pro  
1 5 10 15

Lys Asp

<210> 29  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 29  
Ser Tyr Ser Met Glu His Phe Arg Trp Gly Lys Pro Val  
1 5 10

<210> 30  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 30  
Ser Tyr Ser Met Glu His Arg Trp Gly Lys Pro Val  
1 5 10

<210> 31  
<211> 11

<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 31  
Tyr Val Met Gly His Phe Arg Trp Asp Arg Phe  
1 5 10

<210> 32  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 32  
Lys Tyr Val Met Gly His Phe Arg Trp Asp Arg Phe  
1 5 10

<210> 33  
<211> 3  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 33  
Pro Leu Gly  
1

<210> 34  
<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 34

Asp His Phe Arg Trp Lys

1

5

<210> 35

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 35

Ser Tyr Ser Glu His Phe Arg Trp Gly Lys Pro Val

1

5

10

<210> 36

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 36

Ser Tyr Ser Glu His Phe Arg Trp Gly Lys Pro Val

1

5

10

<210> 37

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 37

Glu His Phe Arg Trp Gly

1

5

<210> 38  
<211> 22  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 38  
Ala Glu Lys Lys Asp Glu Gly Pro Tyr Arg Met Glu His Phe Arg Trp  
1 5 10 15

Gly Ser Pro Pro Lys Asp  
20

<210> 39  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 39  
Tyr Val Met Gly His Phe Arg Trp Asp Arg Phe Gly  
1 5 10

<210> 40  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 40  
Tyr Ile Gln Asn Pro Leu Gly  
1 5

<210> 41  
<211> 9  
<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 41

Cys Tyr Ile Gln Asn Cys Pro Leu Gly  
1 5

<210> 42

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 42

Tyr Ile Thr Asn Cys Pro Tyr  
1 5

<210> 43

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 43

Cys Tyr Ile Gln Asn Cys  
1 5

<210> 44

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide



<400> 44  
Cys Tyr Ile Gln Asn Cys Pro Leu Gly  
1 5

<210> 45  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 45  
Met Asn Ile Lys Gly Ser Pro Trp Lys  
1 5

<210> 46  
<211> 7  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 46  
Tyr Phe Gln Asn Pro Arg Gly  
1 5

<210> 47  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 47  
Tyr Ile Gln Asn Pro Arg Gly  
1 5

<210> 48

<211> 9  
 <212> PRT  
 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence: Synthetic  
       Peptide  
  
 <400> 48  
 Cys Tyr Phe Gln Asn Cys Pro Lys Gly  
       1                              5  
  
  
 <210> 49  
 <211> 6  
 <212> PRT  
 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence: Synthetic  
       Peptide  
  
 <400> 49  
 Cys Tyr Phe Gln Asn Cys  
       1                              5  
  
  
 <210> 50  
 <211> 7  
 <212> PRT  
 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence: Synthetic  
       Peptide  
  
 <400> 50  
 Tyr Phe Val Asn Cys Pro Gly  
       1                              5  
  
  
 <210> 51  
 <211> 7  
 <212> PRT  
 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence: Synthetic

Peptide

<400> 51

Tyr Phe Gln Asn Cys Pro Arg

1

5

<210> 52

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 52

Cys Tyr Phe Gln Asn Cys Pro Arg Gly

1

5

<210> 53

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 53

Cys Tyr Phe Gln Asn Cys Pro Arg

1

5

<210> 54

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 54

Cys Tyr Phe Gln Asn Cys Pro Arg Gly

1

5

<210> 55  
<211> 8  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide  
  
<400> 55  
Tyr Phe Gln Asn Cys Pro Arg Gly  
1 5

<210> 56  
<211> 8  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide  
  
<400> 56  
Tyr Phe Gln Asn Cys Pro Arg Gly  
1 5

<210> 57  
<211> 8  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide  
  
<400> 57  
Ala Phe Gln Asn Cys Pro Arg Gly  
1 5

<210> 58  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 58

Tyr Phe Val Asn Cys Pro Gly  
1 5

<210> 59

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 59

Tyr Phe Gln Asn Cys Pro Arg Tyr  
1 5

<210> 60

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 60

Ile Phe Ile Asn Cys Pro Arg  
1 5

<210> 61

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 61

Tyr Phe Val Asn Cys Pro Arg Gly

1

5

<210> 62

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 62

Tyr Phe Gln Asn Cys Pro Arg Gly

1

5

<210> 63

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 63

Glu Asn Cys Cys Pro Arg

1

5

<210> 64

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 64

Phe Phe Ile Asn Cys Pro Arg Ala

1

5

<210> 65

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 65

Tyr Phe Gln Asn Cys Pro Lys

1

5

<210> 66

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 66

Phe Phe Ile Asn Cys Pro Arg Ala

1

5

<210> 67

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 67

Cys Tyr Phe Gln Asn Cys Pro Lys Gly

1

5

<210> 68

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 68

Tyr Phe Val Asn Cys Pro Gly

1

5

<210> 69

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 69

Cys Phe Ile Gln Asn Cys Pro Gly

1

5

<210> 70

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 70

Cys Tyr Ile Gln Asn Cys Pro Arg Gly

1

5

<210> 71

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 71

Tyr Ile Gln Asn Cys Pro Gly

1

5

<210> 72



<211> 25  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 72  
Ser Glu Ala Ala Ala Leu Pro Arg Ala Ser Ala Ala Ala Met Arg Ala  
1 5 10 15  
Ala Trp Pro Ser Pro Ser Val Glu Gly  
20 25

<210> 73  
<211> 28  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 73  
Phe His Leu Leu Arg Glu Val Leu Glu Ala Arg Ala Glu Gln Leu Ala  
1 5 10 15  
Gln Glu Ala His Lys Asn Arg Lys Leu Glu Ile Ile  
20 25

<210> 74  
<211> 30  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 74  
Phe His Leu Leu Arg Glu Met Leu Glu Met Ala Lys Ala Glu Gln Glu  
1 5 10 15  
Ala Glu Gln Ala Ala Leu Asn Arg Leu Leu Glu Glu Ala  
20 25 30

<210> 75  
<211> 41  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 75  
Ser Gln Glu Pro Pro Ile Ser Leu Asp Leu Thr Phe His Leu Leu Arg  
1 5 10 15  
Glu Val Leu Glu Met Thr Lys Ala Asp Gln Leu Ala Gln Gln Ala His  
20 25 30

Asn Asn Arg Lys Leu Leu Asp Ile Ala  
35 40

<210> 76  
<211> 41  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 76  
Ser Glu Glu Pro Pro Ile Ser Leu Asp Leu Thr Phe His Leu Leu Arg  
1 5 10 15  
Glu Val Leu Glu Met Ala Arg Ala Glu Gln Leu Ala Gln Gln Ala His  
20 25 30

Ser Asn Arg Lys Leu Met Glu Ile Ile  
35 40

<210> 77  
<211> 41  
<212> PRT  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 77

Ser Gln Glu Pro Ile Ser Leu Asp Leu Thr Phe His Leu Leu Arg  
1 5 10 15

Glu Val Leu Glu Met Thr Lys Ala Asp Gln Leu Ala Gln Gln Ala His  
20 25 30

Ser Asn Arg Lys Leu Leu Asp Ile Ala  
35 40

<210> 78

<211> 41

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 78

Ser Glu Glu Pro Pro Ile Ser Leu Asp Leu Thr Phe His Leu Leu Arg  
1 5 10 15

Glu Val Leu Glu Met Ala Arg Ala Glu Gln Leu Ala Gln Gln Ala His  
20 25 30

Ser Asn Arg Lys Leu Met Glu Asn Phe  
35 40

<210> 79

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 79

Ser Glu Glu Pro Pro Ile Ser Leu Asp Leu Thr Phe His Leu Leu Arg  
1 5 10 15

Glu Val Leu Glu Cys

<210> 80  
 <211> 33  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 80  
 Asp Leu Thr Phe His Leu Leu Arg Glu Met Leu Glu Met Ala Lys Ala  
 1 5 10 15  
 Glu Gln Glu Ala Glu Gln Ala Ala Leu Asn Arg Leu Leu Leu Glu Glu  
 20 25 30

Ala

<210> 81  
 <400> 81  
 000

<210> 82  
 <211> 28  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 82  
 Phe His Leu Leu Arg Glu Val Leu Glu Ala Arg Ala Glu Gln Leu Ala  
 1 5 10 15  
 Gln Gln Ala His Ser Asn Arg Lys Leu Glu Ile Ile  
 20 25

<210> 83  
 <211> 28  
 <212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 83

Phe His Leu Leu Arg Glu Val Leu Glu Ala Arg Ala Glu Gln Leu Ala  
1 5 10 15  
Gln Glu Ala His Lys Asn Arg Lys Leu Glu Ile Ile  
20 25

<210> 84

<211> 40

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 84

Ser Glu Glu Pro Ile Ser Leu Asp Leu Thr Phe His Leu Leu Arg Glu  
1 5 10 15  
Val Leu Glu Met Ala Arg Ala Glu Gln Leu Ala Gln Gln Ala His Ser  
20 25 30  
Asn Arg Lys Leu Met Glu Ile Ile  
35 40

<210> 85

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 85

Val Gly Ser Glu  
1

<210> 86  
<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 86  
Ala Gly Ser Glu  
1

<210> 87  
<211> 41  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 87  
Ser Gln Glu Pro Pro Ile Ser Leu Asp Leu Thr Phe His Leu Leu Arg  
1 5 10 15  
Glu Val Leu Glu Met Thr Lys Ala Asp Gln Leu Ala Gln Gln Ala His  
20 25 30  
Ser Asn Arg Lys Leu Leu Asp Ile Ala  
35 40

<210> 88  
<211> 40  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 88  
Ser Gln Glu Pro Pro Ile Ser Leu Asp Leu Thr Phe His Leu Leu Arg  
1 5 10 15  
Glu Val Leu Glu Thr Lys Ala Asp Gln Leu Ala Gln Gln Ala Tyr Ser

Asn Arg Lys Leu Leu Asp Ile Ala  
 35 40

<210> 89

<211> 27

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 89

Ser Leu Asp Ser Pro Ala Ala Leu Ala Glu Arg Gly Ala Arg Asn Ala  
 1 5 10 15

Leu Gly Gly His Gln Glu Ala Pro Glu Arg Glu  
 20 25

<210> 90

<211> 40

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 90

Glu Gly Pro Pro Ile Ser Ile Asp Leu Ser Leu Glu Leu Leu Arg Lys  
 1 5 10 15

Met Ile Glu Ile Glu Lys Gln Glu Lys Glu Lys Gln Gln Ala Ala Asn  
 20 25 30

Asn Arg Leu Leu Leu Asp Thr Ile  
 35 40

<210> 91

<211> 42

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 91

Tyr Ser Glu Glu Pro Pro Ile Ser Leu Asp Leu Thr Phe His Leu Leu  
1 5 10 15

Arg Glu Val Leu Glu Met Ala Arg Ala Glu Gln Leu Ala Gln Gln Ala  
20 25 30

His Ser Asn Arg Lys Leu Met Glu Ile Ile  
35 40

<210> 92

<211> 42

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 92

Tyr Ser Gln Glu Pro Pro Ile Ser Leu Asp Leu Thr Phe His Leu Leu  
1 5 10 15

Arg Glu Val Leu Glu Met Thr Lys Ala Asp Gln Leu Ala Gln Gln Ala  
20 25 30

His Ser Asn Arg Lys Leu Leu Asp Ile Ala  
35 40

<210> 93

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 93

Tyr Asn Arg Lys Leu Leu Asp Ile Ala  
1 5



<210> 94  
 <211> 41  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 94  
 Tyr Asp Asp Pro Pro Leu Ser Ile Asp Leu Thr Phe His Leu Leu Arg  
 1 5 10 15  
 Thr Leu Leu Glu Leu Ala Arg Thr Gln Ser Gln Arg Glu Arg Ala Glu  
 20 25 30  
 Gln Asn Arg Ile Ile Phe Asp Ser Val  
 35 40

<210> 95  
 <211> 41  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 95  
 Tyr Asp Asp Pro Pro Leu Ser Ile Asp Leu Thr Phe His Leu Leu Arg  
 1 5 10 15  
 Thr Leu Leu Glu Leu Ala Arg Thr Gln Ser Gln Arg Glu Arg Ala Glu  
 20 25 30  
 Gln Asn Arg Ile Ile Phe Asp Ser Val  
 35 40

<210> 96  
 <211> 40  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic

# Peptide

<400> 96

Asp Asn Pro Pro Leu Ser Ile Asp Leu Thr Phe His Leu Leu Arg Thr  
1 5 10 15

Leu Leu Glu Leu Ala Arg Thr Gln Ser Gln Arg Glu Arg Ala Glu Gln  
20 25 30

Asn Arg Ile Ile Phe Asp Ser Val  
35 40

<210> 97

<211> 40

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 97

Asp Asp Pro Pro Leu Ser Ile Asp Leu Thr Phe His Leu Leu Arg Thr  
1 5 10 15

Leu Leu Glu Leu Ala Arg Thr Gln Ser Gln Arg Glu Arg Ala Glu Gln  
20 25 30

Asn Arg Ile Ile Phe Asp Ser Val  
35 40

<210> 98

<211> 41

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 98

Asn Asp Asp Pro Pro Ile Ser Ile Asp Leu Thr Phe His Leu Leu Arg  
1 5 10 15

Asn Met Ile Glu Met Ala Arg Ile Glu Asn Glu Arg Glu Gln Ala Gly  
20 25 30

Leu Asn Arg Lys Tyr Leu Asp Glu Val  
35 40

<210> 99  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 99  
Ala Gly Thr Ala Asp Cys Phe Trp Lys Tyr Cys Val  
1 5 10

<210> 100  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 100  
Ala Gly Asn Leu Ser Glu Cys Phe Trp Lys Tyr Cys Val  
1 5 10

<210> 101  
<211> 46  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 101  
Thr Gly Ser Gly Pro Ser Leu Ser Ile Val Asn Pro Leu Asp Val Leu  
1 5 10 15

Arg Gln Arg Leu Leu Glu Ile Ala Arg Arg Arg Met Arg Gln Ser  
20 25 30

Gln Asp Gln Ile Gln Ala Asn Arg Glu Ile Leu Gln Thr Ile  
 35 40 45

<210> 102

<211> 41

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 102

Ser Glu Asp Pro Pro Met Ser Ile Asp Leu Thr Phe His Met Leu Arg  
 1 5 10 15

Asn Met Ile His Met Ala Lys Met Glu Gly Glu Arg Glu Gln Ala Gln  
 20 25 30

Ile Asn Arg Asn Leu Leu Asp Glu Val  
 35 40

<210> 103

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 103

Phe Glu Cys Thr Thr His Gln Pro Arg Ser Pro Leu Arg Asp Leu Lys  
 1 5 10 15

Gly Ala Leu Glu Ser Leu Ile Glu Glu Glu Thr Gly Gln  
 20 25

<210> 104

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 104

Phe Glu Cys Thr Thr His Gln Pro Arg Ser Pro Leu Arg Asp Leu Lys  
1 5 10 15

Gly Ala Leu Glu Ser Leu Ile Glu Glu Glu Thr Gly Gln  
20 25

<210> 105

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 105

Asp Ala Glu Asn Leu Ile Asp Ser Phe Gln Glu Ile Val  
1 5 10

<210> 106

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 106

Asn Thr Glu His Leu Val Asp Ser Phe Gln Glu Met Gly  
1 5 10

<210> 107

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 107  
 Asp Thr Ser His His Asp Gln Asp His Pro Thr Phe Asp  
           1                  5                  10

<210> 108  
 <400> 108  
 000

<210> 109  
 <211> 26  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
           Peptide

<400> 109  
 Trp Cys Leu Glu Ser Ser Gln Cys Gln Asp Leu Ser Thr Glu Ser Asn  
           1                  5                  10                  15  
 Leu Leu Ala Cys Ile Arg Ala Cys Lys Pro  
                   20                  25

<210> 110  
 <211> 10  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
           Peptide

<400> 110  
 Gln His Trp Ser Tyr Gly Leu Ser Pro Gly  
           1                  5                  10

<210> 111  
 <211> 44  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic

# Peptide

<400> 111

Tyr Ala Asp Ala Ile Phe Thr Asn Ser Tyr Arg Lys Val Leu Gly Gln  
1 5 10 15

Leu Ser Ala Arg Lys Leu Leu Gln Asp Ile Met Ser Arg Gln Gln Gly  
20 25 30

Glu Ser Asn Gln Glu Arg Gly Ala Arg Ala Arg Leu  
35 40

<210> 112

<211> 44

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 112

Tyr Ala Asp Ala Ile Phe Thr Asn Ser Tyr Arg Lys Val Leu Gly Gln  
1 5 10 15

Leu Ser Ala Arg Lys Leu Leu Gln Asp Ile Met Asn Arg Gln Gln Gly  
20 25 30

Glu Arg Asn Gln Glu Gln Gly Ala Lys Val Arg Leu  
35 40

<210> 113

<211> 44

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 113

Tyr Ala Asp Ala Ile Phe Thr Asn Ser Tyr Arg Lys Val Leu Gly Gln  
1 5 10 15

Leu Ser Ala Arg Lys Leu Leu Gln Asp Ile Met Ser Arg Gln Gln Gly  
20 25 30

Glu Arg Asn Gln Glu Gln Gly Ala Arg Val Arg Leu  
35 40

<210> 114  
<211> 29  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 114  
His Ala Asp Ala Ile Phe Thr Ser Ser Tyr Arg Arg Ile Leu Gly Gln  
1 5 10 15

Leu Tyr Ala Arg Lys Leu Leu His Glu Ile Met Asn Arg  
20 25

<210> 115  
<211> 30  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 115  
Val Asp Ser Met Trp Ala Glu Gln Lys Gln Met Glu Leu Glu Ser Ile  
1 5 10 15

Leu Val Ala Leu Leu Gln Lys His Ser Arg Asn Ser Gln Gly  
20 25 30

<210> 116  
<211> 29  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide



<400> 116  
Tyr Ala Asp Ala Ile Phe Thr Asn Ser Tyr Arg Lys Val Leu Gly Gln  
1 5 10 15

Leu Ser Ala Arg Lys Leu Leu Gln Asp Ile Met Ser Arg  
20 25

<210> 117  
<211> 29  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 117  
Tyr Ala Asp Ala Ile Phe Thr Asn Ser Tyr Arg Lys Val Leu Gly Gln  
1 5 10 15

Leu Ser Ala Arg Lys Leu Leu Gln Asp Ile Met Ser Arg  
20 25

<210> 118  
<211> 29  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 118  
Tyr Arg Asp Ala Ile Phe Thr Asn Ser Tyr Arg Lys Val Leu Gly Gln  
1 5 10 15

Leu Ser Ala Arg Lys Leu Leu Gln Asp Ile Met Ser Arg  
20 25

<210> 119  
<211> 31  
<212> PRT  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 119

His Ala Asp Ala Ile Phe Thr Asn Ser Tyr Arg Lys Val Leu Gly Gln  
1 5 10 15

Leu Ser Ala Arg Lys Leu Leu Gln Asp Ile Ser Arg Gln Gln Gly  
20 25 30

<210> 120

<211> 37

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 120

Tyr Ala Asp Ala Ile Phe Thr Asn Ser Tyr Arg Lys Val Leu Gly Gln  
1 5 10 15

Leu Ser Ala Arg Lys Leu Leu Gln Asp Ile Met Ser Arg Gln Gln Gly  
20 25 30

Glu Ser Asn Gln Glu  
35

<210> 121

<211> 40

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 121

Tyr Ala Asp Ala Ile Phe Thr Asn Ser Tyr Arg Lys Val Leu Gly Gln  
1 5 10 15

Leu Ser Ala Arg Lys Leu Leu Gln Asp Ile Met Ser Arg Gln Gln Gly  
20 25 30

Glu Ser Asn Gln Glu Arg Gly Ala

<210> 122  
 <211> 40  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 122  
 Tyr Ala Asp Ala Ile Phe Thr Asn Ser Tyr Arg Lys Val Leu Gly Gln  
 1 5 10 15

Leu Ser Ala Arg Lys Leu Leu Gln Asp Ile Met Ser Arg Gln Gln Gly  
 20 25 30

Glu Ser Asn Gln Glu Arg Gly Ala  
 35 40

<210> 123  
 <211> 15  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 123  
 Glu Gln Gly Glu Ser Asn Gln Glu Arg Gly Ala Arg Ala Arg Leu  
 1 5 10 15

<210> 124  
 <211> 42  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 124  
 His Val Asp Ala Ile Phe Thr Thr Asn Tyr Arg Lys Leu Leu Ser Gln

1                      5                      10                      15

Leu Tyr Ala Arg Lys Val Ile Gln Asp Ile Met Asn Lys Gln Gly Glu  
                     20                      25                      30

Arg Ile Gln Glu Gln Arg Ala Arg Leu Ser  
                     35                      40

<210> 125  
 <211> 44  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
                     Peptide

<400> 125  
 Tyr Ala Asp Ala Ile Phe Thr Asn Ser Tyr Arg Lys Ile Leu Gly Gln  
                     1                      5                      10                      15

Leu Ser Ala Arg Lys Leu Leu Gln Asp Ile Met Asn Arg Gln Gln Gly  
                     20                      25                      30

Glu Arg Asn Gln Glu Gln Gly Ala Lys Val Arg Leu  
                     35                      40

<210> 126  
 <211> 43  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
                     Peptide

<400> 126  
 His Ala Asp Ala Ile Phe Thr Ser Ser Tyr Arg Arg Ile Leu Gly Gln  
                     1                      5                      10                      15

Leu Tyr Ala Arg Lys Leu Leu His Glu Ile Met Asn Arg Gln Gln Gly  
                     20                      25                      30

Glu Arg Asn Gln Glu Gln Arg Ser Arg Phe Asn  
                     35                      40

<210> 127  
<211> 6  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 127  
His Trp Ala Trp Phe Lys  
1 5

<210> 128  
<211> 6  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 128  
His Trp Ala Trp Phe Lys  
1 5

<210> 129  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 129  
Ala Ala Trp Phe Lys  
1 5

<210> 130  
<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 130

His Trp Lys Trp Phe Lys

1

5

<210> 131

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 131

Ala Ala Ala Trp Phe Leu

1

5

<210> 132

<211> 45

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 132

His Ala Asp Gly Met Phe Asn Lys Ala Tyr Arg Lys Ala Leu Gly Gln

1

5

10

15

Leu Ser Ala Arg Lys Tyr Leu His Thr Leu Met Ala Lys Arg Val Gly

20

25

30

Gly Gly Ser Met Ile Glu Asp Asp Asn Glu Pro Leu Ser

35

40

45

<210> 133

<211> 44

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 133

Tyr Ala Asp Ala Ile Phe Thr Asn Ser Tyr Arg Lys Val Leu Gly Gln  
1 5 10 15

Leu Ser Ala Arg Lys Leu Leu Gln Asp Ile Asn Ser Arg Gln Gln Gly  
20 25 30

Glu Ser Asn Gln Glu Arg Gly Ala Arg Ala Arg Leu  
35 40

<210> 134

<211> 28

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 134

Tyr Ala Asp Ala Ile Phe Thr Asn Cys Tyr Arg Lys Val Leu Cys Gln  
1 5 10 15

Leu Ser Ala Arg Lys Leu Leu Gln Asp Ile Ser Arg  
20 25

<210> 135

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 135

Phe Ser Lys Lys Leu Lys Pro Ala  
1 5

<210> 136

<211> 10

<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 136  
Glu His Trp Ser His Gly Trp Tyr Pro Gly  
1 5 10

<210> 137  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 137  
Glu His Trp Ser Tyr Gly Leu Arg Pro Gly  
1 5 10

<210> 138  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 138  
Phe Ser Tyr Leu Arg Pro Ala  
1 5

<210> 139  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide



<400> 139

Glu His Trp Ser Tyr Ala Leu Arg Pro Gly

1 5 10

<210> 140

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 140

Glu His Trp Ser Tyr Gly Leu Gln Pro Gly

1 5 10

<210> 141

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 141

His Trp Ser Tyr Val Arg Pro

1 5

<210> 142

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 142

Glu His Trp Ser Tyr Lys Leu Arg Pro Gly

1 5 10

<210> 143  
<211> 10  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 143  
Glu Phe Pro Ser Tyr Phe Leu Arg Pro Gly  
1 5 10

<210> 144  
<211> 9  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 144  
Phe Trp Ser Tyr Ala Leu Arg Pro Gly  
1 5

<210> 145  
<211> 10  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 145  
Glu Phe Trp Ser Tyr Trp Leu Arg Pro Gly  
1 5 10

<210> 146  
<211> 9  
<212> PRT  
<213> Artificial Sequence  
  
<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 146

Glu His Trp Ser Tyr Gly Leu Arg Pro

1

5

<210> 147

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 147

Glu His Trp Ser Tyr Ala Leu Arg Pro

1

5

<210> 148

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 148

His Trp Ser Tyr Trp Leu Arg Pro Gly

1

5

<210> 149

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 149

Glu His Trp Ser Tyr Trp Leu Arg Pro

1

5

<210> 150  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 150  
His Trp Ser Tyr Ser Leu Arg Pro  
1 5

<210> 151  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 151  
Glu His Trp Ser Tyr Arg Trp Leu Pro  
1 5

<210> 152  
<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 152  
Leu Arg Pro Gly  
1

<210> 153  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 153  
His Trp Ser Tyr Gly Leu Arg Pro Gly  
1 5

<210> 154  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 154  
Glu His Tyr Ser Leu Glu Trp Lys Pro Gly  
1 5 10

<210> 155  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 155  
Glu His Trp Ser Tyr Gly Trp Leu Pro Gly  
1 5 10

<210> 156  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 156

Ser Tyr Gly Leu Arg Pro Gly  
1 5

<210> 157  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 157  
His Trp Ser Tyr Gly Leu Lys Pro Gly  
1 5

<210> 158  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 158  
Phe Phe Ser Tyr Leu Arg Pro  
1 5

<210> 159  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 159  
His Trp Ser Tyr Gly Trp Leu Pro Gly  
1 5

<210> 160  
<211> 9

<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 160  
His Trp Ser Tyr Ser Leu Arg Pro Gly  
1 5

<210> 161  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 161  
Ala Phe Trp Ser Tyr Ser Leu Arg Pro  
1 5

<210> 162  
<211> 31  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 162  
Glu Pro Asp Cys Cys Arg Gln Lys Thr Cys Ser Cys Arg Leu Tyr Glu  
1 5 10 15

Leu Leu His Gly Ala Gly Asn His Ala Ala Gly Ile Leu Thr Leu  
20 25 30

<210> 163  
<211> 28  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 163  
Arg Ser Gly Pro Pro Gly Leu Gln Gly Arg Leu Gln Arg Leu Leu Gln  
1 5 10 15

Ala Ser Gly Asn His Ala Ala Gly Ile Leu Thr Met  
20 25

<210> 164

<211> 28

<212> PRT

<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 164  
Arg Pro Gly Pro Pro Gly Leu Gln Gly Arg Leu Gln Arg Leu Leu Gln  
1 5 10 15

Ala Asn Gly Asn His Ala Ala Gly Ile Leu Thr Met  
20 25

<210> 165

<211> 31

<212> PRT

<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 165  
Ser Arg Thr His Arg His Ser Met Glu Ile Arg Thr Pro Asp Ile Asn  
1 5 10 15

Pro Ala Trp Tyr Ala Ser Arg Gly Ile Arg Pro Val Gly Arg Phe  
20 25 30

<210> 166

<211> 20



<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 166  
Thr Pro Asp Ile Asn Pro Ala Trp Tyr Ala Ser Arg Gly Ile Arg Pro  
1 5 10 15  
Val Gly Arg Phe  
20

<210> 167  
<211> 31  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 167  
Ser Arg Ala His Gln His Ser Met Glu Thr Arg Thr Pro Asp Ile Asn  
1 5 10 15  
Pro Ala Trp Tyr Thr Gly Arg Gly Ile Arg Pro Val Gly Arg Phe  
20 25 30

<210> 168  
<211> 20  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 168  
Thr Pro Asp Ile Asn Pro Ala Trp Tyr Thr Gly Arg Gly Ile Arg Pro  
1 5 10 15  
Val Gly Arg Phe  
20

<210> 169  
<211> 31  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 169  
Ser Arg Ala His Gln His Ser Met Glu Ile Arg Thr Pro Asp Ile Asn  
1 5 10 15  
Pro Ala Trp Tyr Ala Ser Arg Gly Ile Arg Pro Val Gly Arg Phe  
20 25 30

<210> 170  
<211> 20  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 170  
Thr Pro Asp Ile Asn Pro Ala Trp Tyr Ala Gly Arg Gly Ile Arg Pro  
1 5 10 15  
Val Gly Arg Phe  
20

<210> 171  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 171  
Ala Tyr Trp Lys Phe  
1 5

<210> 172  
<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 172  
Pro Cys Lys Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys Lys  
1 5 10

<210> 173  
<211> 17  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 173  
Asp Arg Met Pro Cys Arg Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys  
1 5 10 15

Lys

<210> 174  
<211> 17  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 174  
Asp Arg Met Pro Cys Arg Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys  
1 5 10 15

Lys

<210> 175  
<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 175  
Ala Gly Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys  
1 5 10

<210> 176  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 176  
Ala Gly Cys Lys Asn Phe Phe Lys Thr Phe Thr Ser Cys  
1 5 10

<210> 177  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 177  
Ala Gly Cys Lys Asn Phe Phe Lys Thr Tyr Thr Ser Cys  
1 5 10

<210> 178  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 178  
Cys His His Phe Phe Lys Thr Phe Thr Ser Cys  
1 5 10

<210> 179  
<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 179  
Ala Gly Cys Lys Asn Phe Phe Trp Lys Thr Trp Thr Ser Cys  
1 5 10

<210> 180  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 180  
Phe Cys Tyr Thr Thr  
1 5

<210> 181  
<211> 27  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 181  
Ser Ala Asn Ser Asn Pro Ala Ala Pro Arg Glu Arg Lys Ala Gly Cys

1

5

10

15

Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys  
20 25

&lt;210&gt; 182

&lt;211&gt; 7

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Synthetic  
Peptide

&lt;400&gt; 182

Phe Cys Phe Lys Thr Cys Thr  
1 5

&lt;210&gt; 183

&lt;211&gt; 32

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Synthetic  
Peptide

&lt;400&gt; 183

Ala Pro Ser Asp Pro Arg Leu Arg Gln Phe Leu Gln Lys Ser Leu Ala  
1 5 10 15

Ala Ala Ala Gly Lys Gln Glu Leu Ala Lys Tyr Phe Leu Ala Glu Leu  
20 25 30

&lt;210&gt; 184

&lt;211&gt; 15

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 184  
Tyr Ala Gly Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys  
1 5 10 15

<210> 185  
<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 185  
Tyr Gly Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys  
1 5 10

<210> 186  
<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 186  
Ser Ala Asn Ser Asn Pro Ala Met Ala Pro Arg Tyr Arg Lys  
1 5 10

<210> 187  
<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 187  
Ala Gly Cys Lys Asn Phe Phe Trp Lys Thr Tyr Thr Ser Cys  
1 5 10

<210> 188  
<211> 15  
<212> PRT  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 188

Tyr Ala Gly Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys  
1 5 10 15

<210> 189

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 189

Ala Gly Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys  
1 5 10

<210> 190

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 190

Phe Trp Lys Thr  
1

<210> 191

<211> 25

<212> PRT

<213> Artificial Sequence

<220>



<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 191

Ser Asn Pro Ala Met Ala Pro Arg Glu Arg Lys Ala Gly Cys Lys Asn  
1 5 10 15

Phe Phe Trp Lys Thr Phe Thr Ser Cys  
20 25

<210> 192

<211> 28

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 192

Ser Ala Asn Ser Asn Pro Ala Met Ala Pro Arg Glu Arg Lys Ala Gly  
1 5 10 15

Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys  
20 25

<210> 193

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 193

Ser Ala Asn Ser Asn Pro Ala Met Ala Pro Arg Glu  
1 5 10

<210> 194

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 194

Tyr Ser Ala Asn Ser Asn Pro Ala Met Ala Pro Arg Glu Arg Lys Ala  
1 5 10 15

Gly Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys  
20 25

<210> 195

<211> 28

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 195

Ser Ala Asn Ser Asn Pro Ala Leu Ala Pro Arg Glu Arg Lys Ala Gly  
1 5 10 15

Cys Lys Asn Phe Phe Trp Lys Thr Tyr Thr Ser Cys  
20 25

<210> 196

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 196

Ser Ala Asn Ser Asn Pro Ala Met Ala Pro Arg Glu Arg Lys  
1 5 10

<210> 197

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 197

Phe Cys Tyr Trp Lys Val Cys Trp  
1 5

<210> 198

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 198

Phe Cys Tyr Trp Lys Val Cys Trp  
1 5

<210> 199

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 199

Phe Cys Tyr Trp Thr Thr  
1 5

<210> 200

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 200

Ala Cys Tyr Trp Leu Val Cys Thr  
1 5

<210> 201  
<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 201  
Ala Gly Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys  
1 5 10

<210> 202  
<211> 3  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 202  
His Pro Gly  
1

<210> 203  
<211> 1  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 203  
Thr  
1

<210> 204  
<211> 3  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 204  
Thr His Pro  
1

<210> 205  
<211> 3  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 205  
Glu His Pro  
1

<210> 206  
<211> 3  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 206  
Glu Gln Pro  
1

<210> 207  
<211> 2  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 207

Glu His

1

<210> 208

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 208

His Pro Gly Lys

1

<210> 209

<211> 3

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 209

His Pro Gly

1

<210> 210

<211> 2

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 210

Glu Pro

1

<210> 211

<211> 2

<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 211  
Phe Pro  
1

<210> 212  
<211> 22  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 212  
Phe Leu Trp Lys Asp Leu Gln Arg Val Arg Gly Asp Leu Gly Ala Ala  
1 5 10 15  
Leu Asp Ser Trp Ile Thr  
20

<210> 213  
<211> 24  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 213  
Glu Glu Glu Glu Lys Asp Ile Glu Ala Glu Glu Arg Gly Asp Leu Gly  
1 5 10 15  
Glu Gly Gly Ala Trp Arg Leu His  
20

<210> 214  
<211> 10

<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 214  
Ser Phe Pro Trp Met Glu Ser Asp Val Thr  
1 5 10

<210> 215  
<211> 32  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 215  
Cys Ala Ser Leu Ser Thr Cys Val Leu Gly Lys Leu Ser Gln Glu Leu  
1 5 10 15  
His Lys Leu Gln Thr Tyr Pro Arg Thr Asp Val Gly Ala Gly Thr Pro  
20 25 30

<210> 216  
<211> 32  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 216  
Cys Ser Asn Leu Ser Thr Cys Val Leu Gly Lys Leu Ser Gln Glu Leu  
1 5 10 15  
His Lys Leu Gln Thr Tyr Pro Arg Thr Asp Val Gly Ala Gly Thr Pro  
20 25 30



<210> 217  
<211> 32  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 217  
Cys Gly Asn Leu Ser Thr Cys Met Leu Gly Thr Tyr Thr Gln Asp Phe  
1 5 10 15  
Asn Lys Phe His Thr Phe Pro Gln Thr Ala Ile Gly Val Gly Ala Pro  
20 25 30

<210> 218  
<211> 32  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 218  
Cys Ser Asn Leu Ser Thr Cys Val Leu Ser Ala Tyr Trp Arg Asn Leu  
1 5 10 15  
Asn Asn Phe His Arg Phe Ser Gly Met Gly Phe Gly Pro Glu Thr Pro  
20 25 30

<210> 219  
<211> 32  
<212> PRT  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 219

Cys Gly Asn Leu Ser Thr Cys Met Leu Gly Thr Tyr Thr Gln Asp Leu  
1 5 10 15

Asn Lys Phe His Thr Phe Pro Gln Thr Ser Ile Gly Val Gly Ala Pro  
20 25 30

<210> 220

<211> 32

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 220

Cys Ser Asn Leu Ser Thr Cys Val Leu Gly Lys Leu Ser Gln Glu Leu  
1 5 10 15

His Lys Leu Gln Thr Tyr Pro Arg Thr Asn Thr Gly Ser Gly Thr Pro  
20 25 30

<210> 221

<211> 25

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 221

Val Leu Gly Lys Leu Ser Gln Glu Leu His Lys Leu Gln Thr Tyr Pro  
1 5 10 15

Arg Thr Asn Thr Gly Ser Gly Thr Pro  
20 25

<210> 222  
<211> 21  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 222  
Asp Met Ser Ser Asp Leu Glu Arg Asp His Arg Pro His Val Ser Met  
1 5 10 15

Pro Gln Asn Ala Asn  
20

<210> 223  
<211> 57  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 223  
Ala Pro Phe Arg Ser Ala Leu Glu Ser Ser Pro Ala Asp Pro Ala Thr  
1 5 10 15

Leu Ser Glu Asp Glu Ala Arg Leu Leu Leu Ala Ala Leu Val Gln Asp  
20 25 30

Tyr Val Gln Met Lys Ala Ser Glu Leu Glu Gln Glu Gln Glu Arg Glu  
35 40 45

Gly Ser Ser Leu Asp Ser Pro Arg Ser  
50 55

<210> 224  
<211> 37  
<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 224

Ser Cys Asn Thr Ala Thr Cys Val Thr His Arg Leu Ala Gly Leu Leu  
1 5 10 15

Ser Arg Ser Gly Gly Val Val Lys Ser Asn Phe Val Pro Thr Asn Val  
20 25 30

Gly Ser Gln Ala Phe  
35

<210> 225

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 225

Ser Gly Gly Val Val Lys Asn Asn Phe Val Pro Thr Asn Val Gly Ser  
1 5 10 15

Lys Ala Phe

<210> 226

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 226

Ser Gly Gly Val Val Lys Asn Asn Phe Val Pro Thr Asn Val Gly Ser  
1 5 10 15

Lys Ala Phe

<210> 227  
<211> 15  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 227  
Val Lys Asn Asn Phe Val Pro Thr Asn Val Gly Ser Lys Ala Phe  
1 5 10 15

<210> 228  
<211> 37  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 228  
Ser Cys Asn Thr Ala Thr Cys Val Thr His Arg Leu Ala Gly Leu Leu  
1 5 10 15

Ser Arg Ser Gly Gly Val Val Lys Asp Asn Phe Val Pro Thr Asn Val  
20 25 30

Gly Ser Lys Ala Phe  
35

<210> 229  
<211> 37  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 229  
Ala Cys Asn Thr Ala Thr Cys Val Thr His Arg Leu Ala Asp Phe Leu

1

5

10

15

Ser Arg Ser Gly Gly Val Gly Lys Asn Asn Phe Val Pro Thr Asn Val  
 20 25 30

Gly Ser Lys Ala Phe  
 35

<210> 230

<211> 37

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 230

Ala Cys Asp Thr Ala Thr Cys Val Thr His Arg Leu Ala Gly Leu Leu  
 1 5 10 15

Ser Arg Ser Gly Gly Val Val Lys Asn Asn Phe Val Pro Thr Asn Val  
 20 25 30

Gly Ser Lys Ala Phe  
 35

<210> 231

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 231

Cys Gly Asn Leu Ser Thr Cys  
 1 5

<210> 232

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 232

Asp Met Ala Lys Asp Leu Glu Thr Asn His His Pro Tyr Phe Gly Asn  
1 5 10 15

<210> 233

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 233

Ala Cys Asp Thr Ala Thr Cys Val Thr His Arg Leu Ala Gly Leu Leu  
1 5 10 15

Ser Arg Ser

<210> 234

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 234

Gly Gly Val Val Lys Asn Asn Phe Val Pro Thr Asn Val Gly Ser Lys  
1 5 10 15

Ala Phe

<210> 235

<211> 30

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 235

Val Thr His Arg Leu Ala Gly Leu Leu Ser Arg Ser Gly Gly Val Val  
1 5 10 15

Lys Asn Asn Phe Val Pro Thr Asn Val Gly Ser Lys Ala Phe  
20 25 30

<210> 236

<211> 37

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 236

Ala Cys Asn Thr Ala Thr Cys Val Thr His Arg Leu Ala Gly Leu Leu  
1 5 10 15

Ser Arg Ser Gly Gly Met Val Lys Ser Asn Phe Val Pro Thr Asn Val  
20 25 30

Gly Ser Lys Ala Phe  
35

<210> 237

<211> 37

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 237

Ser Cys Asn Thr Ala Thr Cys Val Thr His Arg Leu Ala Gly Leu Leu  
1 5 10 15

Ser Arg Ser Gly Gly Val Val Lys Asp Asn Phe Val Pro Thr Asn Val  
20 25 30



Gly Ser Glu Ala Phe  
35

<210> 238  
<211> 37  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 238  
Ser Cys Asn Thr Ala Thr Cys Val Thr His Arg Leu Ala Gly Leu Leu  
1 5 10 15

Ser Arg Ser Gly Gly Val Val Lys Asp Asn Phe Val Pro Thr Asn Val  
20 25 30

Gly Ser Glu Ala Phe  
35

<210> 239  
<211> 30  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 239  
Val Thr His Arg Leu Ala Gly Leu Leu Ser Arg Ser Gly Gly Val Val  
1 5 10 15

Lys Asp Asn Phe Val Pro Thr Asn Val Gly Ser Glu Ala Phe  
20 25 30

<210> 240  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic

Peptide

<400> 240

Pro Thr Asn Val Gly Ser Glu Ala Phe

1

5

<210> 241

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 241

Thr Asn Val Gly Ser Glu Ala Phe

1

5

<210> 242

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 242

Asn Val Gly Ser Glu Ala Phe

1

5

<210> 243

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 243

Val Gly Ser Glu Ala Phe

1

5

<210> 244  
<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 244  
Val Gly Ser Glu Ala Phe  
1 5

<210> 245  
<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 245  
Ser Glu Ala Phe  
1

<210> 246  
<211> 37  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 246  
Ala Cys Asp Thr Ala Thr Cys Val Thr His Arg Leu Ala Gly Leu Leu  
1 5 10 15

Ser Arg Ser Gly Gly Val Val Lys Asn Asn Phe Val Pro Thr Asn Val  
20 25 30

Gly Ser Lys Ala Phe  
35

<210> 247  
<211> 30  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 247  
Ser Asn Leu Ser Thr Val Leu Gly Lys Leu Ser Gln Glu Leu His Lys  
1 5 10 15  
Leu Gln Thr Tyr Pro Arg Thr Asp Val Gly Ala Gly Thr Pro  
20 25 30

<210> 248  
<211> 38  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 248  
Tyr Ala Cys Asp Thr Ala Thr Cys Val Thr His Arg Leu Ala Gly Leu  
1 5 10 15  
Leu Ser Arg Ser Gly Gly Val Val Lys Asn Asn Phe Val Pro Thr Asn  
20 25 30  
Val Gly Ser Lys Ala Phe  
35

<210> 249  
<211> 38  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 249

Tyr Ala Cys Asn Thr Ala Thr Cys Val Thr His Arg Leu Ala Gly Leu  
 1 5 10 15

Leu Ser Arg Ser Gly Gly Met Val Lys Ser Asn Phe Val Pro Thr Asn  
 20 25 30

Val Gly Ser Lys Ala Phe  
 35

<210> 250  
 <211> 11  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 250  
 Tyr Val Pro Thr Asn Val Gly Ser Glu Ala Phe  
 1 5 10

<210> 251  
 <211> 38  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 251  
 Tyr Ser Cys Asn Thr Ala Thr Cys Val Thr His Arg Leu Ala Gly Leu  
 1 5 10 15

Leu Ser Arg Ser Gly Gly Val Val Lys Asp Asn Phe Val Pro Thr Asn  
 20 25 30

Val Gly Ser Glu Ala Phe  
 35

<210> 252  
 <211> 16  
 <212> PRT  
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 252

Tyr Val Lys Asp Asn Phe Val Pro Thr Asn Val Gly Ser Glu Ala Phe  
1 5 10 15

<210> 253

<211> 37

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 253

Ser Cys Asn Thr Ala Thr Cys Val Thr His Arg Leu Ala Gly Leu Leu  
1 5 10 15

Ser Arg Ser Gly Gly Val Val Lys Asp Asn Phe Val Pro Thr Asn Val  
20 25 30

Gly Ser Glu Ala Phe  
35

<210> 254

<211> 46

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 254

Ala Pro Leu Ala Pro Arg Asp Ala Gly Ser Gln Arg Pro Arg Lys Lys  
1 5 10 15

Glu Asp Asn Val Leu Val Glu Ser His Glu Lys Ser Leu Gly Glu Ala  
20 25 30

Asp Lys Ala Asp Val Asn Val Leu Thr Lys Ala Lys Ser Gln  
35 40 45

<210> 255  
 <211> 32  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 255  
 Lys Lys Glu Asp Asn Val Leu Val Glu Ser His Glu Lys Ser Leu Gly  
 1 5 10 15  
 Glu Ala Asp Lys Ala Asp Val Asp Val Leu Thr Lys Ala Lys Ser Gln  
 20 25 30

<210> 256  
 <211> 84  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 256  
 Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn  
 1 5 10 15  
 Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His  
 20 25 30  
 Asn Phe Val Ala Leu Gly Ala Pro Leu Ala Pro Arg Asp Ala Gly Ser  
 35 40 45  
 Gln Arg Pro Arg Lys Lys Glu Asp Asn Val Leu Val Glu Ser His Glu  
 50 55 60  
 Lys Ser Leu Gly Glu Ala Asp Lys Ala Asp Val Asn Val Leu Thr Lys  
 65 70 75 80  
 Ala Lys Ser Gln

<210> 257  
<211> 21  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 257  
Glu Lys Ser Leu Gly Glu Ala Asp Lys Ala Asp Val Asn Val Leu Thr  
1 5 10 15  
  
Lys Ala Lys Ser Gln  
20

<210> 258  
<211> 34  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 258  
Ser Val Ser Glu Ile Gln Leu Asn His Asn Leu Gly Lys His Leu Asn  
1 5 10 15  
  
Ser Leu Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His  
20 25 30  
  
Asn Phe

<210> 259  
<211> 34  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide



<400> 259

Ser Val Ser Glu Cys Gln Leu Met His Asn Leu Gly Lys His Leu Asn  
1 5 10 15

Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Cys Gln Asp Val His  
20 25 30

Asn Phe

<210> 260

<211> 40

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 260

Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile Gln  
1 5 10 15

Asp Leu Arg Arg Arg Phe Phe Leu His His Leu Ile Ala Glu Ile His  
20 25 30

Thr Ala Glu Ile Arg Ala Thr Ser  
35 40

<210> 261

<211> 34

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 261

Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn  
1 5 10 15

Ser Leu Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His  
20 25 30

Asn Phe

<210> 262

<211> 32

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 262

Ala Val Ser Glu Ile Gln Phe His Asn Leu Gly Lys His Leu Ser Ser  
1 5 10 15

Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His Asn Tyr  
20 25 30

<210> 263

<211> 30

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 263

Ser Glu Ile Gln Phe His Asn Leu Gly Lys His Leu Ser Ser Glu Arg  
1 5 10 15

Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His Asn Tyr  
20 25 30

<210> 264

<211> 32

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

Peptide

<400> 264

Ser Val Ser Glu Ile Gln Leu His Asn Leu Gly Lys His Leu Asn Ser  
1 5 10 15

Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His Asn Tyr  
20 25 30

<210> 265

<211> 32

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 265

Ser Val Ser Glu Ile Gln Leu His Asn Leu Gly Lys His Leu Asn Ser  
1 5 10 15

Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His Asn Tyr  
20 25 30

<210> 266

<211> 30

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 266

Ser Glu Ile Gln Leu His Asn Leu Gly Lys His Leu Asn Ser Glu Arg  
1 5 10 15

Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His Asn Tyr  
20 25 30

<210> 267  
<211> 26  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 267  
Phe His Asn Leu Gly Lys His Leu Ser Ser Glu Arg Val Glu Trp Leu  
1 5 10 15  
Arg Lys Lys Leu Gln Asp Val His Asn Tyr  
20 25

<210> 268  
<211> 32  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 268  
Ala Val Ser Glu Ile Gln Leu His Asn Leu Gly Lys His Leu Ala Ser  
1 5 10 15  
Val Glu Arg Gln Trp Leu Arg Lys Lys Leu Gln Asp Val His Asn Tyr  
20 25 30

<210> 269  
<211> 25  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 269

Arg Asp Ala Gly Ser Gln Arg Pro Arg Lys Lys Glu Asp Asn Val Leu  
1 5 10 15

Val Glu Ser His Glu Lys Ser Leu Gly  
20 25

<210> 270

<211> 32

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 270

Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser Ser Met  
1 5 10 15

Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His Asn Phe  
20 25 30

<210> 271

<211> 31

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 271

Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn  
1 5 10 15

Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val  
20 25 30

<210> 272

<211> 34

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 272

Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn  
1 5 10 15

Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His  
20 25 30

Asn Phe

<210> 273

<211> 22

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 273

Lys His Leu Asn Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu  
1 5 10 15

Gln Asp Val His Asn Phe  
20

<210> 274

<211> 34

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 274

Ala Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Ala  
1 5 10 15

Ser Val Glu Arg Met Gln Trp Leu Arg Lys Lys Leu Gln Asp Val His

Asn Phe

<210> 275

<211> 38

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 275

Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn  
1 5 10 15

Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His  
20 25 30

Asn Phe Val Ala Leu Gly  
35

<210> 276

<211> 44

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 276

Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn  
1 5 10 15

Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His  
20 25 30

Asn Phe Val Ala Leu Gly Ala Pro Leu Ala Pro Arg  
35 40

<210> 277

<211> 21

<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 277  
Leu Gln Asp Val His Asn Phe Val Ala Leu Gly Ala Pro Leu Ala Pro  
1 5 10 15  
  
Arg Asp Ala Gly Ser  
20

<210> 278  
<211> 30  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 278  
Ala Pro Leu Ala Pro Arg Asp Ala Gly Ser Gln Arg Pro Arg Lys Lys  
1 5 10 15  
  
Glu Asp Asn Val Leu Val Glu Ser His Glu Lys Ser Leu Gly  
20 25 30

<210> 279  
<211> 46  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 279  
Ala Pro Leu Ala Pro Arg Asp Ala Gly Ser Gln Arg Pro Arg Lys Lys  
1 5 10 15  
  
Glu Asp Asn Val Leu Val Glu Ser His Glu Lys Ser Leu Gly Glu Ala  
20 25 30



Asp Lys Ala Asp Val Asn Val Leu Thr Lys Ala Lys Ser Gln  
35 40 45

<210> 280

<211> 32

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 280

Lys Lys Glu Asp Asn Val Leu Val Glu Ser His Glu Lys Ser Leu Gly  
1 5 10 15

Glu Ala Asp Lys Ala Asp Val Asp Val Leu Thr Lys Ala Lys Ser Gln  
20 25 30

<210> 281

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 281

Glu Ala Asp Lys Ala Asp Val Asn Val Leu Thr Lys Ala Lys Ser Gln  
1 5 10 15

<210> 282

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 282

Ala Asp Lys Ala Asp Val Asn Val Leu Thr Lys Ala Lys Ser Gln  
 1 5 10 15

<210> 283

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 283

Tyr Pro Ile Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu  
 1 5 10 15

Leu Asn Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Leu Val Thr  
 20 25 30

Arg Pro Arg Tyr  
 35

<210> 284

<211> 41

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 284

Tyr Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile  
 1 5 10 15

Gln Asp Leu Arg Arg Arg Phe Phe Leu His His Leu Ile Ala Glu Ile  
 20 25 30

His Thr Ala Glu Ile Arg Ala Thr Ser  
 35 40

<210> 285

<211> 45

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 285

Tyr Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu  
1 5 10 15

Asn Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val  
20 25 30

His Asn Phe Val Ala Leu Gly Ala Pro Leu Ala Pro Arg  
35 40 45

<210> 286

<211> 35

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 286

Tyr Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu  
1 5 10 15

Asn Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val  
20 25 30

His Asn Phe  
35

<210> 287

<211> 34

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 287

Tyr Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn  
1 5 10 15

Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His  
 20 25 30

Asn Phe

<210> 288

<211> 22

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 288

Tyr Leu Gln Asp Val His Asn Phe Val Ala Leu Gly Ala Pro Leu Ala  
 1 5 10 15

Pro Arg Asp Ala Gly Ser  
 20

<210> 289

<211> 28

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 289

Phe Met His Asn Leu Gly Lys His Leu Ser Ser Met Glu Arg Val Glu  
 1 5 10 15

Trp Leu Arg Lys Lys Leu Gln Asp Val His Asn Tyr  
 20 25

<210> 290

<211> 26

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 290

Tyr Arg Asp Ala Gly Ser Gln Arg Pro Arg Lys Lys Glu Asp Asn Val  
1 5 10 15

Leu Val Glu Ser His Glu Lys Ser Leu Gly  
20 25

<210> 291

<211> 33

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 291

Tyr Lys Lys Glu Asp Asn Val Leu Val Glu Ser His Glu Lys Ser Leu  
1 5 10 15

Gly Glu Ala Asp Lys Ala Asp Val Asn Val Leu Thr Lys Ala Lys Ser  
20 25 30

Gln

<210> 292

<211> 22

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 292

Tyr Glu Lys Ser Leu Gly Glu Ala Asp Lys Ala Asp Val Asn Val Leu  
1 5 10 15

Thr Lys Ala Lys Ser Gln  
20

<210> 293  
<211> 34  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 293  
Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile Gln  
1 5 10 15  
Asp Leu Arg Arg Arg Phe Phe Leu His His Leu Ile Ala Glu Ile His  
20 25 30

Thr Ala

<210> 294  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 294  
Ala Arg Ser Ala Trp  
1 5

<210> 295  
<211> 34  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 295  
Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile Gln  
1 5 10 15  
Asp Leu Arg Arg Arg Phe Phe Leu His His Leu Ile Ala Glu Ile His

Thr Ala

<210> 296

<211> 33

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 296

Val	Ser	Glu	His	Gln	Leu	Leu	His	Asp	Lys	Gly	Lys	Ser	Ile	Gln	Asp
1				5				10					15		

Leu	Arg	Arg	Arg	Phe	Phe	Leu	His	His	Leu	Ile	Ala	Glu	Ile	His	Thr
				20				25					30		

Ala

<210> 297

<211> 35

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 297

Tyr	Ala	Val	Ser	Glu	His	Gln	Leu	Leu	His	Asp	Lys	Gly	Lys	Ser	Ile
1				5				10					15		

Gln	Asp	Leu	Arg	Arg	Arg	Phe	Phe	Leu	His	His	Leu	Ile	Ala	Glu	Ile
						20			25				30		

His Thr Ala

35

<210> 298

<211> 34

<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 298  
Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile Gln  
1 5 10 15

Asp Leu Arg Arg Arg Phe Phe Leu His His Leu Ile Ala Glu Ile His  
20 25 30

Thr Tyr

<210> 299  
<211> 37  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 299  
Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile Gln  
1 5 10 15

Asp Leu Arg Arg Arg Phe Phe Leu His His Leu Ile Ala Glu Ile His  
20 25 30

Thr Ala Glu Ile Arg  
35

<210> 300  
<211> 28  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 300



Leu Leu His Asp Lys Gly Lys Ser Ile Gln Asp Leu Arg Arg Arg Phe  
1 5 10 15

Phe Leu His His Leu Ile Ala Glu Ile His Thr Ala  
20 25

<210> 301

<211> 27

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 301

Ala Thr Ser Glu Val Ser Pro Asn Ser Lys Pro Ser Pro Asn Thr Lys  
1 5 10 15

Asn His Pro Val Arg Phe Gly Ser Asp Asp Glu  
20 25

<210> 302

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 302

Tyr Leu Thr Gln Glu Thr Asn Lys Val Glu Thr Tyr Lys Glu Gln Pro  
1 5 10 15

Leu Lys Thr Pro  
20

<210> 303

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

Peptide

<400> 303

Thr Arg Ser Ala Trp

1

5

<210> 304

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 304

Thr Arg Ser Ala Trp

1

5

<210> 305

<211> 32

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 305

Thr Arg Ser Ala Trp Leu Asp Ser Gly Val Thr Gly Ser Gly Leu Glu

1

5

10

15

Gly Asp His Leu Ser Asp Thr Ser Thr Thr Ser Leu Glu Leu Asp Ser

20

25

30

<210> 306

<211> 33

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

# Peptide

<400> 306

Ser Ala Trp Leu Asp Ser Gly Val Thr Gly Ser Gly Leu Glu Gly Asp  
1 5 10 15

His Leu Ser Asp Thr Ser Thr Thr Ser Leu Glu Leu Asp Ser Arg Arg  
20 25 30

His

<210> 307

<211> 34

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 307

Thr Ala Leu Leu Trp Gly Leu Lys Lys Lys Lys Glu Asn Asn Arg Arg  
1 5 10 15

Thr His His Met Gln Leu Met Ile Ser Leu Phe Lys Ser Pro Leu Leu  
20 25 30

Leu Leu

<210> 308

<211> 31

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 308

Met Ile Pro Ala Lys Asp Met Ala Lys Val Met Ile Val Met Leu Ala  
1 5 10 15

Ile Arg Phe Leu Thr Lys Ser Asp Gly Lys Ser Val Lys Lys Arg  
20 25 30

<210> 309  
<211> 27  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 309  
Thr Ala Leu Leu Trp Gly Leu Lys Lys Lys Lys Gly Lys Gln Gln Lys  
1 5 10 15  
Asn Thr Ser Tyr Ala Thr Asn Asp Leu Ile Ile  
20 25

<210> 310  
<211> 30  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 310  
Ala Thr Gln Arg Leu Ala Asn Phe Leu Val His Ser Ser Asn Asn Phe  
1 5 10 15  
Gly Ala Ile Leu Ser Ser Thr Asn Val Gly Ser Asn Thr Tyr  
20 25 30

<210> 311  
<211> 30  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 311  
Ala Thr Gln Arg Leu Ala Asn Phe Leu Val Arg Ser Ser Asn Asn Leu  
1 5 10 15

Gly Pro Val Leu Pro Pro Thr Asn Val Gly Ser Asn Thr Tyr  
 20 25 30

<210> 312  
 <211> 25  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 312  
 Val Leu Gly Lys Leu Ser Gln Glu Leu His Lys Leu Gln Thr Tyr Pro  
 1 5 10 15

Arg Thr Asn Thr Gly Ser Asn Thr Tyr  
 20 25

<210> 313  
 <211> 24  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 313  
 Leu Gly Arg Leu Ser Gln Glu Leu His Arg Leu Gln Thr Tyr Pro Arg  
 1 5 10 15

Thr Asn Thr Gly Ser Asn Thr Tyr  
 20

<210> 314  
 <211> 25  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 314

Ala Thr Gln Arg Leu Ala Asn Glu Leu Val Arg Leu Gln Thr Tyr Pro  
1 5 10 15

Arg Thr Asn Val Gly Ser Asn Thr Tyr  
20 25

<210> 315

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 315

Thr Gln Arg Leu Ala Asn Phe Leu Val His Ser Ser Asn Asn Phe Gly  
1 5 10 15

Ala Ile Leu Ser Ser Thr Asn Val Gly Ser Asn Thr Tyr  
20 25

<210> 316

<211> 37

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 316

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu  
1 5 10 15

Ile Arg Ser Ser Asn Asn Leu Gly Ala Ile Leu Ser Pro Thr Asn Val  
20 25 30

Gly Ser Asn Thr Tyr  
35

<210> 317

<211> 37

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 317

Lys	Cys	Asn	Thr	Ala	Thr	Cys	Ala	Thr	Gln	Arg	Leu	Ala	Asn	Phe	Leu
1				5					10					15	

Val	His	Ser	Ser	Asn	Asn	Phe	Gly	Ala	Ile	Leu	Ser	Ser	Thr	Asn	Val
				20				25						30	

Gly	Ser	Asn	Thr	Tyr
				35

<210> 318

<211> 37

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 318

Lys	Cys	Asn	Thr	Ala	Thr	Cys	Ala	Thr	Gln	Arg	Leu	Ala	Asn	Phe	Leu
1				5					10					15	

Val	His	Ser	Ser	Asn	Asn	Phe	Gly	Ala	Ile	Leu	Ser	Ser	Thr	Asn	Val
				20				25						30	

Gly	Ser	Asn	Thr	Tyr
				35

<210> 319

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 319

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala

<210> 320  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 320  
Ser Asn Asn Phe Gly Ala Ile Leu Ser Ser  
1 5 10

<210> 321  
<211> 37  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 321  
Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu  
1 5 10 15

Val Arg Ser Ser Asn Asn Leu Gly Pro Val Leu Pro Pro Thr Asn Val  
20 25 30

Gly Ser Asn Thr Tyr  
35

<210> 322  
<211> 30  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 322  
Ala Thr Gln Arg Leu Ala Asn Phe Leu Val Arg Ser Ser Asn Asn Leu



1

5

10

15

Gly Pro Val Leu Pro Pro Thr Asn Val Gly Ser Asn Thr Tyr  
 20 25 30

<210> 323

<211> 30

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 323

Ala Thr Gln Arg Leu Ala Asn Phe Leu Val His Ser Ser Asn Asn Phe  
 1 5 10 15

Gly Ala Ile Leu Ser Ser Thr Asn Val Gly Ser Asn Thr Tyr  
 20 25 30

<210> 324

<211> 30

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 324

Ala Thr Gln Arg Leu Ala Asn Phe Leu Val Arg Ser Ser Asn Asn Leu  
 1 5 10 15

Gly Pro Val Leu Pro Pro Thr Asn Val Gly Ser Asn Thr Tyr  
 20 25 30

<210> 325

<211> 25

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 325

Val Leu Gly Lys Leu Ser Gln Glu Leu His Lys Leu Gln Thr Tyr Pro  
1 5 10 15

Arg Thr Asn Thr Gly Ser Asn Thr Tyr  
20 25

<210> 326

<211> 24

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 326

Leu Gly Arg Leu Ser Gln Glu Leu His Arg Leu Gln Thr Tyr Pro Arg  
1 5 10 15

Thr Asn Thr Gly Ser Asn Thr Tyr  
20

<210> 327

<211> 25

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 327

Ala Thr Gln Arg Leu Ala Asn Glu Leu Val Arg Leu Gln Thr Tyr Pro  
1 5 10 15

Arg Thr Asn Val Gly Ser Asn Thr Tyr  
20 25

<210> 328

<211> 29

<212> PRT

<213> Artificial Sequence



Gly Ser Asn Thr Tyr

35

<210> 331

<211> 37

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 331

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu

1

5

10

15

Val His Ser Ser Asn Asn Phe Gly Ala Ile Leu Ser Ser Thr Asn Val

20

25

30

Gly Ser Asn Thr Tyr

35

<210> 332

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 332

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala

1

5

10

<210> 333

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 333

Ser Asn Asn Phe Gly Ala Ile Leu Ser Ser  
1 5 10

<210> 334  
<211> 37  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 334  
Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu  
1 5 10 15

Val Arg Ser Ser Asn Asn Leu Gly Pro Val Leu Pro Pro Thr Asn Val  
20 25 30

Gly Ser Asn Thr Tyr  
35

<210> 335  
<211> 30  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 335  
Ala Thr Gln Arg Leu Ala Asn Phe Leu Val Arg Ser Ser Asn Asn Leu  
1 5 10 15

Gly Pro Val Leu Pro Pro Thr Asn Val Gly Ser Asn Thr Tyr  
20 25 30

<210> 336  
<211> 28  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic

# Peptide

<400> 336

Ser Gln Gly Thr Phe Thr Ser Glu Tyr Ser Lys Tyr Leu Asp Ser Arg  
1 5 10 15

Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr  
20 25

<210> 337

<211> 35

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 337

His Gly Glu Gly Thr Ser Asp Leu Ser Lys Gln Met Glu Glu Ala Arg  
1 5 10 15

Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro  
20 25 30

Pro Pro Ser  
35

<210> 338

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 338

His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser  
1 5 10 15

Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr  
20 25

<210> 339

<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 339  
Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr  
1 5 10

<210> 340  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 340  
Phe Val Gln Trp Leu Met Asn Thr  
1 5

<210> 341  
<211> 28  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 341  
Ser Gln Gly Thr Phe Thr Ser Glu Tyr Ser Lys Tyr Leu Asp Ser Arg  
1 5 10 15

Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr  
20 25

<210> 342  
<211> 36  
<212> PRT  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 342

His Asp Glu Phe Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val  
1 5 10 15

Ser Ser Tyr Leu Glu Gly Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu  
20 25 30

Val Lys Gly Arg  
35

<210> 343

<211> 37

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 343

His Asp Glu Phe Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val  
1 5 10 15

Ser Ser Tyr Leu Glu Gly Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu  
20 25 30

Val Lys Gly Arg Gly  
35

<210> 344

<211> 30

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 344

His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly  
1 5 10 15



Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg  
 20 25 30

<210> 345  
 <211> 33  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 345  
 His Ala Asp Gly Ser Phe Ser Asp Glu Met Asn Thr Ile Leu Asp Asn  
 1 5 10 15

Leu Ala Thr Arg Asp Phe Ile Asn Trp Leu Ile Gln Thr Lys Ile Thr  
 20 25 30

Asp

<210> 346  
 <211> 34  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 346  
 His Ala Asp Gly Ser Phe Ser Asp Glu Met Asn Thr Ile Leu Asp Asn  
 1 5 10 15

Leu Ala Ala Arg Asp Phe Ile Asn Trp Leu Ile Gln Thr Lys Ile Thr  
 20 25 30

Asp Arg

<210> 347  
 <211> 37  
 <212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 347

His	Ser	Glu	Gly	Thr	Phe	Thr	Ser	Asp	Tyr	Ser	Lys	Tyr	Leu	Asp	Ser
1				5					10					15	

Arg	Arg	Ala	Glu	Asp	Phe	Val	Glu	Trp	Leu	Met	Asn	Thr	Lys	Arg	Asn
			20					25						30	

Lys	Asn	Asn	Ile	Ala
			35	

<210> 348

<211> 37

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 348

His	Ser	Glu	Gly	Thr	Phe	Thr	Ser	Asp	Tyr	Ser	Lys	Tyr	Leu	Asp	Ser
1				5					10					15	

Arg	Arg	Ala	Glu	Asp	Phe	Val	Glu	Trp	Leu	Met	Asn	Thr	Lys	Arg	Asn
			20					25						30	

Lys	Asn	Asn	Ile	Ala
			35	

<210> 349

<211> 39

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 349

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu

1

5

10

15

Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser  
20 25 30

Ser Gly Ala Pro Pro Pro Ser  
35

&lt;210&gt; 350

&lt;211&gt; 34

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Synthetic  
Peptide

&lt;400&gt; 350

His Ala Asp Gly Thr Leu Thr Ser Asp Ile Ser Ser Phe Leu Glu Lys  
1 5 10 15

Gln Ala Thr Lys Glu Phe Ile Ala Trp Leu Val Ser Gly Arg Gly Arg  
20 25 30

Arg Gln

&lt;210&gt; 351

&lt;211&gt; 29

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Synthetic  
Peptide

&lt;400&gt; 351

His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser  
1 5 10 15

Lys Lys Ala Gln Glu Phe Val Gln Trp Leu Met Asn Thr  
20 25

&lt;210&gt; 352

&lt;211&gt; 39

<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 352  
His Gly Glu Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu  
1 5 10 15

Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser  
20 25 30

Ser Gly Ala Pro Pro Pro Ser  
35

<210> 353  
<211> 33  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 353  
His Ala Asp Gly Ser Phe Thr Ser Asp Ile Asn Lys Val Leu Asp Thr  
1 5 10 15

Ile Ala Ala Lys Glu Phe Leu Asn Trp Leu Ile Ser Thr Lys Val Thr  
20 25 30

Glu

<210> 354  
<211> 36  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 354

His Asp Glu Phe Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val  
 1 5 10 15

Ser Ser Tyr Leu Glu Gly Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu  
 20 25 30

Val Lys Gly Arg  
 35

<210> 355

<211> 30

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 355

His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly  
 1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg  
 20 25 30

<210> 356

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 356

Ser Tyr Leu Glu Gly Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val  
 1 5 10 15

Xaa Gly Arg

<210> 357

<211> 4

<212> PRT

<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 357  
Ser Asp Val Ser  
1

<210> 358  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 358  
Thr Ser Asp Val Ser  
1 5

<210> 359  
<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 359  
Phe Thr Ser Asp Val Ser  
1 5

<210> 360  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 360

Thr Phe Thr Ser Asp Val Ser  
1 5

<210> 361

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 361

Gly Thr Phe Thr Ser Asp Val Ser  
1 5

<210> 362

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 362

Glu Gly Thr Phe Thr Ser Asp Val Ser  
1 5

<210> 363

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 363

Ala Glu Gly Thr Phe Thr Ser Asp Val Ser  
1 5 10

<210> 364

<211> 39

<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 364  
His Ser Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu  
1 5 10 15

Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser  
20 25 30

Ser Gly Ala Pro Pro Pro Ser  
35

<210> 365  
<211> 39  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 365  
His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu  
1 5 10 15

Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser  
20 25 30

Ser Gly Ala Pro Pro Pro Ser  
35

<210> 366  
<211> 31  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 366



His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu  
 1 5 10 15  
 Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Tyr  
 20 25 30

<210> 367  
 <211> 31  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 367  
 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu  
 1 5 10 15  
 Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Tyr  
 20 25 30

<210> 368  
 <211> 31  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 368  
 Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Met Ile Glu  
 1 5 10 15  
 Trp Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro Pro Pro Ser  
 20 25 30

<210> 369  
 <211> 37  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic

# Peptide

<400> 369

His Asp Glu Phe Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val  
1 5 10 15

Ser Ser Tyr Leu Glu Gly Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu  
20 25 30

Val Lys Gly Arg Lys  
35

<210> 370

<211> 31

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 370

His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly  
1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg Lys  
20 25 30

<210> 371

<211> 40

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 371

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu  
1 5 10 15

Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser  
20 25 30

Ser Gly Ala Pro Pro Pro Ser Lys  
35 40

<210> 372  
<211> 40  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 372  
His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu  
1 5 10 15  
Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser  
20 25 30  
Ser Gly Ala Pro Pro Pro Ser Lys  
35 40

<210> 373  
<211> 40  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 373  
His Ser Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu  
1 5 10 15  
Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser  
20 25 30  
Ser Gly Ala Pro Pro Pro Ser Lys  
35 40

<210> 374  
<211> 31  
<212> PRT  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 374

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Glu Met Glu Glu  
1 5 10 15

Glu Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Tyr  
20 25 30

<210> 375

<211> 30

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 375

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Glu Met Glu Glu  
1 5 10 15

Glu Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Tyr  
20 25 30

<210> 376

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 376

Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu  
1 5 10 15

Trp Leu Lys Gly Gly Pro Ser Ser Gly Pro Pro Pro Ser  
20 25

<210> 377

<211> 31

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 377

Glu Ala Glu Asp Leu Gln Val Gly Gln Val Glu Leu Gly Gly Gly Pro  
1 5 10 15

Gly Ala Gly Ser Leu Gln Pro Leu Ala Leu Glu Gly Ser Leu Gln  
20 25 30

<210> 378

<211> 32

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 378

Tyr Glu Ala Glu Asp Leu Gln Val Gly Gln Val Glu Leu Gly Gly Gly  
1 5 10 15

Pro Gly Ala Gly Ser Leu Gln Pro Leu Ala Leu Glu Gly Ser Leu Gln  
20 25 30

<210> 379

<211> 51

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 379

Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr Gln Leu  
1 5 10 15

Glu Asn Tyr Cys Asn Phe Val Asn Gln His Leu Cys Gly Ser His Leu

Val Glu Ala Leu Tyr Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr Thr  
 35 40 45

Pro Lys Thr  
 50

<210> 380

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 380

Asp Val Ser Thr Pro Pro Thr Val Leu Pro Asp Asn Phe Pro Arg Tyr  
 1 5 10 15

<210> 381

<211> 35

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 381

Arg Asp Val Ser Thr Pro Pro Thr Val Leu Pro Asp Asn Phe Pro Arg  
 1 5 10 15

Tyr Pro Val Gly Lys Phe Phe Gln Tyr Asp Thr Trp Lys Gln Ser Thr  
 20 25 30

Gln Arg Leu  
 35

<210> 382

<211> 24

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 382

Gly Leu Pro Ala Leu Leu Arg Ala Arg Arg Gly His Val Leu Ala Lys  
1 5 10 15

Glu Leu Glu Ala Phe Arg Glu Ala  
20

<210> 383

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 383

Tyr Pro Ser Lys Pro Asp Asn Pro Gly Glu Asp Ala Pro Ala Glu Asp  
1 5 10 15

Met Ala Arg Tyr Tyr Ser Ala Leu Arg His Tyr Ile Asn Leu Leu Thr  
20 25 30

Arg Pro Arg Tyr  
35

<210> 384

<211> 39

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 384

Pro Asp Lys Asp Phe Ile Val Asn Pro Ser Asp Leu Val Leu Asp Asn  
1 5 10 15

Lys Ala Ala Leu Arg Asp Tyr Leu Arg Gln Ile Asn Glu Tyr Phe Ala  
20 25 30

Ile Ile Gly Arg Pro Arg Phe  
35

<210> 385  
<211> 3  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 385  
Phe Met Arg  
1

<210> 386  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 386  
Cys Trp Arg Tyr Cys Trp Arg Tyr  
1 5

<210> 387  
<211> 36  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 387  
Tyr Pro Ser Lys Pro Asp Asn Pro Gly Glu Asp Ala Pro Ala Glu Asp  
1 5 10 15  
Met Ala Arg Tyr Tyr Ser Ala Leu Arg His Tyr Ile Asn Leu Ile Thr  
20 25 30



Arg Gln Arg Tyr  
35

<210> 388  
<211> 24  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 388  
Tyr Pro Ser Lys Pro Asp Asn Pro Gly Glu Asp Ala Pro Ala Glu Asp  
1 5 10 15

Met Ala Arg Tyr Tyr Ser Ala Leu  
20

<210> 389  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 389  
Ile Gly Pro Tyr Arg Leu Arg Tyr  
1 5

<210> 390  
<211> 36  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 390  
Gly Pro Ser Gln Pro Thr Tyr Pro Gly Asp Asp Ala Pro Val Glu Asp  
1 5 10 15

Leu Ile Arg Phe Tyr Asp Asn Leu Gln Gln Tyr Leu Asn Val Val Thr  
 20 25 30

Arg His Arg Tyr  
 35

<210> 391  
 <211> 36  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 391  
 Ala Pro Leu Glu Pro Val Tyr Pro Gly Asp Asn Ala Thr Pro Glu Gln  
 1 5 10 15

Met Ala Gln Tyr Ala Ala Asp Leu Arg Arg Tyr Ile Asn Met Leu Thr  
 20 25 30

Arg Pro Arg Tyr  
 35

<210> 392  
 <211> 6  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 392  
 Leu Thr Arg Pro Arg Tyr  
 1 5

<210> 393  
 <211> 6  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic

Peptide

<400> 393

Leu Thr Arg Pro Arg Tyr

1

5

<210> 394

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 394

Ala Pro Ser Glu Pro His His Pro Gly Asp Gln Ala Thr Gln Asp Gln

1

5

10

15

Leu Ala Gln Tyr Tyr Ser Asp Leu Tyr Gln Tyr Ile Thr Phe Val Thr

20

25

30

Arg Pro Arg Phe

35

<210> 395

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 395

Ala Pro Leu Glu Pro Met Tyr Pro Gly Asp Tyr Ala Thr His Glu Gln

1

5

10

15

Arg Ala Gln Tyr Glu Thr Gln Leu Arg Arg Tyr Ile Asn Thr Leu Thr

20

25

30

Arg Pro Arg Tyr

35

<210> 396

<211> 36  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 396  
Tyr Pro Pro Lys Pro Glu Asn Pro Gly Glu Asp Ala Pro Pro Glu Glu  
1 5 10 15

Leu Ala Lys Tyr Tyr Thr Ala Leu Arg His Tyr Ile Asn Leu Ile Thr  
20 25 30

Arg Gln Arg Tyr  
35

<210> 397  
<211> 36  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 397  
Tyr Pro Ile Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu  
1 5 10 15

Leu Asn Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Leu Val Thr  
20 25 30

Arg Gln Arg Tyr  
35

<210> 398  
<211> 34  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 398

Ile Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu Leu Asn  
1 5 10 15

Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Leu Val Thr Arg Gln  
20 25 30

Arg Tyr

<210> 399

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 399

Tyr Pro Ala Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu  
1 5 10 15

Leu Ser Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Leu Val Thr  
20 25 30

Arg Gln Arg Tyr  
35

<210> 400

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 400

Tyr Pro Ile Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu  
1 5 10 15

Leu Asn Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Leu Leu Thr  
20 25 30

Arg Pro Arg Tyr

<210> 401  
 <211> 10  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 401  
 Glu Gln Asp Tyr Thr Gly Trp Met Asp Phe  
 1 5 10

<210> 402  
 <211> 33  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 402  
 Lys Ala Pro Ser Gly Arg Met Ser Ile Val Lys Asn Leu Gln Asn Leu  
 1 5 10 15  
 Asp Pro Ser His Arg Ile Ser Asp Arg Asp Tyr Met Gly Trp Met Asp  
 20 25 30

Phe

<210> 403  
 <211> 4  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 403  
 Asp Tyr Met Gly

1

<210> 404  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 404  
Asp Tyr Met Gly Trp Met Asp Phe  
1 5

<210> 405  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 405  
Asp Tyr Met Gly Trp Met Asp Phe  
1 5

<210> 406  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 406  
Tyr Met Gly Trp Met Asp Phe  
1 5

<210> 407  
<211> 4  
<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 407

Trp Met Asp Phe

1

<210> 408

<211> 33

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 408

Lys Ala Pro Ser Gly Arg Val Ser Met Ile Lys Asn Leu Gln Ser Leu

1

5

10

15

Asp Pro Ser His Arg Ile Ser Asp Arg Asp Tyr Met Gly Trp Met Asp

20

25

30

Phe

<210> 409

<400> 409

000

<210> 410

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 410

Ser Ala Glu Glu Tyr Glu Tyr Pro Ser

1

5



<210> 411  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 411  
Asp Tyr Met Gly Trp  
1 5

<210> 412  
<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 412  
Asp Tyr Met Gly Trp Met  
1 5

<210> 413  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 413  
Val Pro Val Glu Ala Val Asp Pro Met  
1 5

<210> 414  
<400> 414  
000

<210> 415  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 415  
Asp Tyr Met Gly Trp Met Asp Phe  
1 5

<210> 416  
<211> 23  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 416  
Met Lys Val Ala Ile Ile Phe Leu Leu Ser Ala Leu Ala Leu Leu Asn  
1 5 10 15

Leu Ala Gly Asn Thr Thr Ala  
20

<210> 417  
<211> 27  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 417  
Val Pro Leu Pro Ala Gly Gly Gly Thr Val Leu Thr Lys Met Tyr Pro  
1 5 10 15

Arg Gly Asn His Trp Ala Val Gly His Leu Met  
20 25

<210> 418  
<211> 16  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 418  
Val Pro Leu Pro Ala Gly Gly Gly Thr Val Leu Thr Lys Met Tyr Pro  
1 5 10 15

<210> 419  
<211> 27  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 419  
Ala Pro Val Ser Val Gly Gly Gly Thr Val Leu Ala Lys Met Tyr Pro  
1 5 10 15

Arg Gly Asn His Trp Ala Val Gly His Leu Met  
20 25

<210> 420  
<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 420  
Met Tyr Pro Arg Gly Asn His Trp Ala Val Gly His Leu Met  
1 5 10

<210> 421  
<211> 36

<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 421  
Phe Leu Pro His Val Phe Ala Glu Leu Ser Asp Arg Lys Gly Phe Val  
1 5 10 15

Gln Gly Asn Gly Ala Val Glu Ala Leu His Asp His Phe Tyr Pro Asp  
20 25 30

Trp Met Asp Phe  
35

<210> 422  
<211> 17  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 422  
Glu Gly Pro Trp Leu Glu Glu Glu Glu Ala Tyr Gly Trp Met Asp  
1 5 10 15

Phe

<210> 423  
<211> 34  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 423  
Glu Leu Gly Pro Gln Gly Pro Pro His Leu Val Ala Asp Pro Ser Lys  
1 5 10 15

Lys Gln Gly Pro Trp Leu Glu Glu Glu Glu Glu Ala Tyr Gly Trp Met  
20 25 30

Asp Phe

<210> 424

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 424

Glu Arg Pro Pro Met Glu Glu Glu Glu Glu Ala Tyr Gly Trp Met Asp  
1 5 10 15

Phe

<210> 425

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 425

Ala Trp Met Asp Phe  
1 5

<210> 426

<211> 42

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 426

Tyr Ala Glu Gly Thr Phe Ile Ser Asp Tyr Ser Ile Ala Met Asp Lys  
 1 5 10 15

Ile His Gln Gln Asp Phe Val Asn Trp Leu Leu Ala Gln Lys Gly Lys  
 20 25 30

Lys Asn Asp Trp Lys His Asn Ile Thr Gln  
 35 40

<210> 427

<211> 42

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 427

Tyr Ala Glu Gly Thr Phe Ile Ser Asp Tyr Ser Ile Ala Met Asp Lys  
 1 5 10 15

Ile Arg Gln Gln Asp Phe Val Asn Trp Leu Leu Ala Gln Lys Gly Lys  
 20 25 30

Lys Ser Asp Trp Lys His Asn Ile Thr Gln  
 35 40

<210> 428

<211> 30

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 428

Tyr Ala Glu Gly Thr Phe Ile Ser Asp Tyr Ser Ile Ala Met Asp Lys  
 1 5 10 15

Ile Arg Gln Gln Asp Phe Val Asn Trp Leu Leu Ala Gln Lys  
 20 25 30

<210> 429

<211> 30  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 429  
Tyr Ala Glu Gly Thr Phe Ile Ser Asp Tyr Ser Ile Ala Met Asp Lys  
1 5 10 15  
Ile Arg Gln Gln Asp Phe Val Asn Trp Leu Leu Ala Gln Lys  
20 25 30

<210> 430  
<211> 22  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 430  
Phe Val Pro Ile Phe Thr His Ser Glu Leu Gln Lys Ile Arg Glu Lys  
1 5 10 15  
Glu Arg Asn Lys Gly Gln  
20

<210> 431  
<211> 22  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 431  
Phe Val Pro Ile Phe Thr Tyr Gly Glu Leu Gln Arg Met Gln Glu Lys  
1 5 10 15  
Glu Arg Asn Lys Gly Gln  
20

<210> 432  
<211> 22  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 432  
Phe Val Pro Ile Phe Thr Tyr Gly Glu Leu Gln Arg Leu Gln Glu Lys  
1 5 10 15

Glu Arg Asn Lys Gly Gln  
20

<210> 433  
<211> 21  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 433  
Phe Val Pro Ile Phe Thr Tyr Gly Glu Leu Arg Leu Gln Glu Lys Glu  
1 5 10 15

Arg Asn Lys Gly Gln  
20

<210> 434  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 434  
Ile Ala Arg Arg His Pro Tyr Phe Leu  
1 5



<210> 435  
<211> 27  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 435  
His Ser Asp Gly Thr Phe Thr Ser Glu Leu Ser Arg Leu Arg Glu Ser  
1 5 10 15  
Ala Arg Leu Gln Arg Leu Leu Gln Gly Leu Val  
20 25

<210> 436  
<211> 27  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 436  
His Ser Asp Gly Leu Phe Thr Ser Glu Tyr Ser Lys Met Arg Gly Asn  
1 5 10 15  
Ala Gln Val Gln Lys Phe Ile Gln Asn Leu Met  
20 25

<210> 437  
<211> 27  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 437  
His Ser Asp Gly Thr Phe Thr Ser Glu Leu Ser Arg Leu Arg Glu Gly  
1 5 10 15

Ala Arg Leu Gln Arg Leu Leu Gln Gly Leu Val  
20 25

<210> 438  
<211> 27  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 438  
His Ser Asp Gly Thr Phe Thr Ser Glu Leu Ser Arg Leu Arg Asp Ser  
1 5 10 15

Ala Arg Leu Gln Arg Leu Leu Gln Gly Leu Val  
20 25

<210> 439  
<211> 27  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 439  
His Ser Asp Gly Thr Phe Thr Ser Glu Leu Ser Arg Leu Gln Asp Ser  
1 5 10 15

Ala Arg Leu Gln Arg Leu Leu Gln Gly Leu Val  
20 25

<210> 440  
<211> 26  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 440

Ser Asp Gly Thr Phe Thr Ser Glu Leu Ser Arg Leu Arg Asp Ser Ala  
1 5 10 15

Arg Leu Gln Arg Leu Leu Gly Gly Leu Val  
20 25

<210> 441

<211> 32

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 441

Ala Ala Met Leu Ala Ser Gln Thr Glu Ala Phe Val Pro Ile Phe Thr  
1 5 10 15

Tyr Gly Glu Leu Gln Arg Met Gln Glu Lys Glu Arg Asn Lys Gly Gln  
20 25 30

<210> 442

<211> 28

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 442

His Ser Asp Ala Val Phe Thr Asp Asn Tyr Thr Arg Leu Arg Arg Gln  
1 5 10 15

Leu Ala Val Arg Arg Tyr Leu Asn Ser Ile Leu Asn  
20 25

<210> 443

<211> 31

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 443

His	Ser	Asp	Ala	Val	Phe	Thr	Asp	Asn	Tyr	Thr	Arg	Leu	Arg	Arg	Gln
1				5					10					15	

Leu	Ala	Val	Arg	Arg	Tyr	Leu	Asn	Ser	Ile	Leu	Asn	Gly	Lys	Arg
			20				25						30	

<210> 444

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 444

Met	Ala	Val	Lys	Lys	Tyr	Leu	Asn	Ser	Ile	Leu	Asn
1				5					10		

<210> 445

<211> 27

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 445

His	Ala	Asp	Gly	Val	Phe	Thr	Ser	Asp	Phe	Ser	Arg	Leu	Leu	Gly	Gln
1					5					10				15	

Leu	Ser	Ala	Lys	Lys	Tyr	Leu	Glu	Ser	Leu	Ile
			20				25			

<210> 446

<211> 27

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 446

His	Ala	Asp	Gly	Val	Phe	Thr	Ser	Asp	Tyr	Ser	Arg	Leu	Leu	Gly	Gln
1				5					10					15	

Ile	Ser	Ala	Lys	Lys	Tyr	Leu	Glu	Ser	Leu	Ile
			20				25			

<210> 447

<211> 27

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 447

His	Ala	Asp	Gly	Val	Phe	Thr	Ser	Asp	Phe	Ser	Lys	Leu	Leu	Gly	Gln
1				5					10					15	

Leu	Ser	Ala	Lys	Lys	Tyr	Leu	Glu	Ser	Leu	Met
			20				25			

<210> 448

<211> 42

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 448

His	Ala	Asp	Gly	Val	Phe	Thr	Ser	Asp	Phe	Ser	Lys	Leu	Leu	Gly	Gln
1				5					10					15	

Leu	Ser	Ala	Lys	Lys	Tyr	Leu	Glu	Ser	Leu	Met	Gly	Lys	Arg	Val	Ser
			20				25					30			

Ser Asn Ile Ser Glu Asp Pro Val Pro Val

<210> 449  
 <211> 12  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 449  
 Val Ser Ser Asn Ile Ser Glu Asp Pro Val Pro Val  
 1 5 10

<210> 450  
 <211> 15  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 450  
 Ser Ser Glu Gly Glu Ser Pro Asp Phe Pro Glu Glu Leu Glu Lys  
 1 5 10 15

<210> 451  
 <211> 21  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 451  
 Cys Ser Cys Asn Ser Trp Leu Asp Lys Glu Cys Val Tyr Phe Cys His  
 1 5 10 15

Leu Asp Ile Ile Trp  
 20

<210> 452  
<211> 28  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 452  
His Ser Asp Ala Val Phe Thr Asp Asn Tyr Ser Arg Phe Arg Lys Gln  
1 5 10 15  
Met Ala Val Lys Lys Tyr Leu Asn Ser Val Leu Thr  
20 25

<210> 453  
<211> 28  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 453  
His Ser Asp Ala Leu Phe Thr Asp Thr Tyr Thr Arg Leu Arg Lys Gln  
1 5 10 15  
Met Ala Met Lys Lys Tyr Leu Asn Ser Val Leu Asn  
20 25

<210> 454  
<211> 28  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 454  
His Ser Asp Ala Val Phe Thr Asp Asn Tyr Thr Arg Leu Arg Lys Gln  
1 5 10 15  
Met Ala Val Lys Lys Tyr Leu Asn Ser Ile Leu Asn

<210> 455  
 <211> 28  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 455  
 His Ser Asp Ala Val Phe Thr Asp Asn Tyr Thr Arg Leu Arg Lys Gln  
 1 5 10 15  
 Met Ala Val Lys Lys Tyr Leu Asn Ser Ile Leu Asn  
 20 25

<210> 456  
 <211> 12  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 456  
 His Ser Asp Ala Val Phe Thr Asp Asn Tyr Thr Arg  
 1 5 10

<210> 457  
 <211> 19  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 457  
 Tyr Thr Arg Leu Arg Lys Gln Met Ala Val Lys Lys Tyr Leu Asn Ser  
 1 5 10 15  
 Ile Leu Asn



<210> 458  
<211> 18  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 458  
Thr Arg Leu Arg Lys Gln Met Ala Val Lys Lys Tyr Leu Asn Ser Ile  
1 5 10 15

Leu Asn

<210> 459  
<211> 27  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 459  
His Ser Asp Ala Val Phe Thr Asp Asn Ser Arg Phe Arg Lys Gln Met  
1 5 10 15

Ala Ala Lys Lys Tyr Leu Asn Ser Val Leu Ala  
20 25

<210> 460  
<211> 23  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 460  
Phe Thr Asp Asn Tyr Thr Arg Leu Arg Lys Gln Met Ala Val Lys Lys

1

5

10

15

Tyr Leu Asn Ser Ile Leu Asn  
20

&lt;210&gt; 461

&lt;211&gt; 28

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Synthetic  
Peptide

&lt;400&gt; 461

Lys Pro Arg Arg Pro Tyr Thr Asp Asn Tyr Thr Arg Leu Arg Lys Gln  
1 5 10 15

Met Ala Val Lys Lys Tyr Leu Asn Ser Ile Leu Asn  
20 25

&lt;210&gt; 462

&lt;211&gt; 29

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Synthetic  
Peptide

&lt;400&gt; 462

Tyr Phe Asp Ala Ile Phe Thr Asn Ser Tyr Arg Lys Val Leu Gly Gln  
1 5 10 15

Leu Ser Ala Arg Lys Leu Leu Gln Asp Ile Met Ser Arg  
20 25

&lt;210&gt; 463

&lt;211&gt; 28

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 463

His Ser Asp Ala Val Phe Thr Asp Asn Tyr Thr Arg Leu Arg Lys Gln  
1 5 10 15

Leu Ala Val Lys Lys Tyr Leu Asn Ser Ile Leu Asn  
20 25

<210> 464

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 464

Leu Met Tyr Pro Thr Tyr Leu Lys  
1 5

<210> 465

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 465

Met Met Arg Asp Ser Gly Cys Phe Gly Arg Arg Ile Asp Arg Ile Gly  
1 5 10 15

Ser Leu Ser Gly Met Gly Cys Asn Gly Ser Arg Lys Asn  
20 25

<210> 466

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 466

Gly Phe Ile Trp Gly Asn Ile Phe Gly His Tyr Ser Gly Asp Phe  
1 5 10 15

<210> 467

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 467

Ser Leu Arg Arg Ser Ser Cys Phe Gly Gly Arg  
1 5 10

<210> 468

<211> 24

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 468

Ser Ser Asp Cys Phe Gly Ser Arg Ile Asp Arg Ile Gly Ala Gln Ser  
1 5 10 15

Gly Met Gly Cys Gly Arg Arg Phe  
20

<210> 469

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 469

Cys Phe Gly Ser Arg Ile Asp Arg Ile Gly Ala Gln Ser Gly Met Gly

1

5

10

15

Cys Gly Arg Phe  
20

&lt;210&gt; 470

&lt;211&gt; 21

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Synthetic  
Peptide

&lt;400&gt; 470

Cys Phe Gly Ser Arg Ile Asp Arg Ile Gly Ala Gln Ser Gly Met Gly  
1 5 10 15

Cys Gly Arg Phe  
20

&lt;210&gt; 471

&lt;211&gt; 24

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Synthetic  
Peptide

&lt;400&gt; 471

Ser Ser Asp Cys Phe Gly Ser Arg Ile Asp Arg Ile Gly Ala Gln Ser  
1 5 10 15

Gly Met Gly Cys Gly Arg Arg Phe  
20

&lt;210&gt; 472

&lt;211&gt; 30

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 472

Ala Pro Arg Ser Met Arg Arg Ser Ser Asp Cys Phe Gly Ser Arg Ile  
1 5 10 15

Asp Arg Ile Gly Ala Gln Ser Gly Met Gly Cys Gly Arg Phe  
20 25 30

<210> 473

<211> 24

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 473

Ser Ser Cys Phe Gly Gly Arg Met Asp Arg Ile Gly Ala Gln Ser Gly  
1 5 10 15

Leu Gly Cys Asn Ser Phe Arg Tyr  
20

<210> 474

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 474

Cys Phe Gly Gly Arg Met Asp Arg Ile Gly Ala Gln Ser Gly Leu Gly  
1 5 10 15

Cys

<210> 475

<211> 22

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 475

Cys Phe Gly Gly Arg Met Asp Arg Ile Gly Ala Gln Ser Gly Leu Gly  
1 5 10 15

Cys Asn Ser Phe Arg Tyr  
20

<210> 476

<211> 28

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 476

Ser Leu Arg Arg Ser Ser Cys Phe Gly Gly Arg Met Asp Arg Ile Gly  
1 5 10 15

Ala Gln Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr  
20 25

<210> 477

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 477

Arg Cys Gly Gly Arg Ile Asp Arg Ile Arg Cys  
1 5 10

<210> 478

<211> 26

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 478

Arg Arg Ser Ser Cys Phe Gly Gly Arg Ile Asp Arg Ile Gly Ala Gln  
1 5 10 15

Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr  
20 25

<210> 479

<211> 26

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 479

Arg Arg Ser Ser Cys Phe Gly Gly Arg Met Asp Arg Ile Gly Ala Gln  
1 5 10 15

Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr  
20 25

<210> 480

<211> 25

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 480

Arg Ser Ser Cys Phe Gly Gly Arg Met Asp Arg Ile Gly Ala Gln Ser  
1 5 10 15

Gly Leu Gly Cys Asn Ser Phe Arg Tyr  
20 25

<210> 481

<211> 23



<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 481  
Ser Ser Cys Phe Gly Gly Arg Met Asp Arg Ile Gly Ala Gln Ser Gly  
1 5 10 15

Leu Gly Cys Asn Ser Phe Arg  
20

<210> 482  
<211> 27  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 482  
Ser Lys Ser Ser Ser Pro Cys Phe Gly Gly Lys Leu Asp Arg Ile Gly  
1 5 10 15

Ser Tyr Ser Gly Leu Gly Cys Asn Ser Arg Lys  
20 25

<210> 483  
<211> 21  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 483  
Ser Ser Cys Phe Gly Gly Arg Ile Asp Arg Ile Gly Ala Gln Ser Gly  
1 5 10 15

Leu Gly Cys Asn Ser  
20

<210> 484  
<211> 23  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 484  
Ser Ser Cys Phe Gly Gly Arg Ile Asp Arg Ile Gly Ala Gln Ser Gly  
1 5 10 15

Leu Gly Cys Asn Ser Phe Arg  
20

<210> 485  
<211> 24  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 485  
Ser Ser Cys Phe Gly Gly Arg Ile Asp Arg Ile Gly Ala Gln Ser Gly  
1 5 10 15

Leu Gly Cys Asn Ser Phe Arg Tyr  
20

<210> 486  
<211> 28  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 486  
Ser Leu Arg Arg Ser Ser Cys Phe Gly Gly Arg Ile Asp Arg Ile Gly  
1 5 10 15

Ala Gln Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr  
20 25

<210> 487

<211> 24

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 487

Arg Ser Ser Cys Phe Gly Gly Arg Ile Asp Arg Ile Gly Ala Gln Ser  
1 5 10 15

Gly Leu Gly Cys Asn Ser Phe Arg  
20

<210> 488

<211> 25

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 488

Arg Ser Ser Cys Phe Gly Gly Arg Ile Asp Arg Ile Gly Ala Gln Ser  
1 5 10 15

Gly Leu Gly Cys Asn Ser Phe Arg Tyr  
20 25

<210> 489

<211> 56

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 489

Ser Leu Arg Arg Ser Ser Cys Phe Gly Gly Arg Met Asp Arg Ile Gly  
 1 5 10 15

Ala Gln Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr Ser Leu Arg Arg  
 20 25 30

Ser Ser Cys Phe Gly Gly Arg Met Asp Arg Ile Gly Ala Gln Ser Gly  
 35 40 45

Leu Gly Cys Asn Ser Phe Arg Tyr  
 50 55

<210> 490

<211> 32

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 490

Ala Gly Pro Arg Ser Leu Arg Arg Ser Ser Cys Phe Gly Gly Arg Ile  
 1 5 10 15

Asp Arg Ile Gly Ala Gln Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr  
 20 25 30

<210> 491

<211> 27

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 491

Ser Lys Ser Ser Ser Pro Cys Phe Gly Gly Lys Leu Asp Arg Ile Gly  
 1 5 10 15

Ser Tyr Ser Gly Leu Gly Cys Asn Ser Arg Lys  
 20 25

<210> 492  
<211> 16  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 492  
Asn Pro Met Tyr Asn Ala Val Ser Asn Ala Asp Leu Met Asp Phe Lys  
1 5 10 15

<210> 493  
<211> 15  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 493  
Arg Ser Ser Cys Phe Gly Gly Arg Ile Asp Arg Ile Gly Ala Cys  
1 5 10 15

<210> 494  
<211> 21  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 494  
Ser Phe Gly Gly Arg Ile Asp Arg Ile Gly Ala Gln Ser Gly Leu Gly  
1 5 10 15

Asn Ser Phe Arg Tyr  
20

<210> 495

<211> 28  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 495  
Ser Leu Arg Arg Ser Ser Cys Phe Gly Gly Arg Met Asp Arg Ile Gly  
1 5 10 15

Ala Gln Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr  
20 25

<210> 496  
<211> 21  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 496  
Phe Ala Gly Arg Ile Asp Arg Ile Gly Ala Gln Ser Gly Leu Gly Cys  
1 5 10 15

Asn Ser Phe Arg Tyr  
20

<210> 497  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 497  
Ser Ser Asp Arg Ser Ala Leu Leu Lys Ser Lys Leu Arg  
1 5 10

<210> 498

<211> 30  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 498  
Asn Pro Met Tyr Asn Ala Val Ser Asn Ala Asp Leu Met Asp Phe Lys  
1 5 10 15  
Asn Leu Leu Asp His Leu Glu Glu Lys Met Pro Leu Glu Asp  
20 25 30

<210> 499  
<211> 37  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 499  
Glu Val Val Pro Pro Gln Val Leu Ser Glu Pro Asn Glu Glu Ala Gly  
1 5 10 15  
Ala Ala Leu Ser Pro Leu Pro Glu Val Pro Pro Trp Thr Gly Glu Val  
20 25 30  
Ser Pro Ala Gln Arg  
35

<210> 500  
<211> 20  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 500  
Ser Ser Asp Arg Ser Ala Leu Leu Lys Ser Lys Leu Arg Ala Leu Leu  
1 5 10 15

Thr Ala Pro Arg  
20

<210> 501  
<211> 27  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 501  
Ser Lys Ser Ser Ser Pro Cys Phe Gly Gly Lys Leu Asp Arg Ile Gly  
1 5 10 15

Ser Tyr Ser Gly Leu Gly Cys Asn Ser Arg Lys  
20 25

<210> 502  
<211> 24  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 502  
Tyr Ser Ser Cys Phe Gly Gly Arg Ile Asp Arg Ile Gly Ala Gln Ser  
1 5 10 15

Gly Leu Gly Cys Asn Ser Phe Arg  
20

<210> 503  
<211> 21  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide



<400> 503

Tyr Ser Ser Asp Arg Ser Ala Leu Leu Lys Ser Lys Leu Arg Ala Leu  
1 5 10 15

Leu Thr Ala Pro Arg  
20

<210> 504

<211> 32

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 504

Thr Ala Pro Arg Ser Leu Arg Arg Ser Ser Cys Phe Gly Gly Arg Met  
1 5 10 15

Asp Arg Ile Gly Ala Gln Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr  
20 25 30

<210> 505

<211> 24

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 505

Tyr Ser Ser Cys Phe Gly Gly Arg Ile Asp Arg Ile Gly Ala Gln Ser  
1 5 10 15

Gly Leu Gly Cys Asn Ser Phe Arg  
20

<210> 506

<211> 35

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 506

Ser Phe Asn Ser Cys Phe Gly Asn Arg Ile Glu Arg Ile Gly Ser Trp  
1 5 10 15

Ser Gly Leu Gly Cys Asn Asn Val Lys Thr Gly Asn Lys Lys Arg Ile  
20 25 30

Phe Gly Asn  
35

<210> 507

<211> 32

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 507

Ser Pro Lys Met Met His Lys Ser Gly Cys Phe Gly Arg Arg Leu Asp  
1 5 10 15

Arg Ile Gly Ser Leu Ser Gly Leu Gly Cys Asn Val Leu Arg Lys Tyr  
20 25 30

<210> 508

<211> 22

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 508

Gly Trp Asn Arg Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser

1

5

10

15

Leu Ser Gly Leu Gly Cys  
20

&lt;210&gt; 509

&lt;211&gt; 32

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Synthetic  
Peptide

&lt;400&gt; 509

Ser Pro Lys Met Val Gln Gly Ser Gly Cys Phe Gly Arg Lys Met Asp  
1 5 10 15

Arg Ile Ser Ser Ser Ser Gly Leu Gly Cys Lys Val Leu Arg Arg His  
20 25 30

&lt;210&gt; 510

&lt;211&gt; 45

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Synthetic  
Peptide

&lt;400&gt; 510

Ser Gln Gly Ser Thr Leu Arg Val Gln Gln Arg Pro Gln Asn Ser Lys  
1 5 10 15

Val Thr His Ile Ser Ser Cys Phe Gly His Lys Ile Asp Arg Ile Gly  
20 25 30

Ser Val Ser Arg Leu Gly Cys Asn Ala Leu Lys Leu Leu  
35 40 45

&lt;210&gt; 511

&lt;211&gt; 26

<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 511  
Asp Ser Gly Cys Phe Gly Arg Arg Leu Asp Arg Ile Gly Ser Leu Ser  
1 5 10 15

Gly Leu Gly Cys Asn Val Leu Arg Arg Tyr  
20 25

<210> 512  
<211> 32  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 512  
Ser Pro Lys Thr Met Arg Asp Ser Gly Cys Phe Gly Arg Arg Leu Asp  
1 5 10 15

Arg Ile Gly Ser Leu Ser Gly Leu Gly Cys Asn Val Leu Arg Arg Tyr  
20 25 30

<210> 513  
<211> 32  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 513  
Asn Ser Lys Met Ala His Ser Ser Ser Cys Phe Gly Gln Lys Ile Asp  
1 5 10 15

Arg Ile Gly Ala Val Ser Arg Leu Gly Cys Asp Gly Leu Arg Leu Phe  
 20 25 30

<210> 514

<211> 45

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 514

Ser Gln Asp Ser Ala Phe Arg Ile Gln Glu Arg Leu Arg Asn Ser Lys  
 1 5 10 15

Met Ala His Ser Ser Ser Cys Phe Gly Gln Lys Ile Asp Arg Ile Gly  
 20 25 30

Ala Val Ser Arg Leu Gly Cys Asp Gly Leu Arg Leu Phe  
 35 40 45

<210> 515

<211> 33

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 515

Tyr Ser Pro Lys Met Val Gln Gly Ser Gly Cys Phe Gly Arg Lys Met  
 1 5 10 15

Asp Arg Leu Ser Ser Ser Ser Gly Leu Gly Cys Lys Val Leu Arg Arg  
 20 25 30

His

<210> 516

<211> 32  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 516  
Ser Pro Lys Met Val Gln Gly Ser Gly Cys Phe Gly Arg Lys Met Asp  
1 5 10 15  
Arg Ile Ser Ser Ser Gly Leu Gly Cys Lys Val Leu Arg Arg His  
20 25 30

<210> 517  
<211> 22  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 517  
Gly Leu Ser Lys Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser  
1 5 10 15  
Met Ser Gly Leu Gly Cys  
20

<210> 518  
<211> 22  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 518  
Gly Leu Ser Arg Ser Cys Phe Gly Val Lys Leu Asp Arg Ile Gly Ser  
1 5 10 15

Met Ser Gly Leu Gly Cys  
20

<210> 519  
<211> 53  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 519  
Asp Leu Arg Val Asp Thr Lys Ser Arg Ala Ala Trp Ala Arg Leu Leu  
1 5 10 15  
Gln Glu His Pro Asn Ala Arg Lys Tyr Lys Gly Ala Asn Lys Lys Gly  
20 25 30  
Leu Ser Lys Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser Met  
35 40 45  
Ser Gly Leu Gly Cys  
50

<210> 520  
<211> 53  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 520  
Asp Leu Arg Val Asp Thr Lys Ser Arg Ala Ala Trp Ala Arg Leu Leu  
1 5 10 15  
His Glu His Pro Asn Ala Arg Lys Tyr Lys Gly Gly Asn Lys Lys Gly  
20 25 30  
Leu Ser Lys Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser Met  
35 40 45  
Ser Gly Leu Gly Cys

<210> 521  
 <211> 27  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 521  
 Lys Pro Gly Thr Pro Pro Lys Val Pro Arg Thr Pro Pro Gly Glu Glu  
 1 5 10 15  
 Leu Ala Glu Pro Gln Ala Ala Gly Gly Asn Gln  
 20 25

<210> 522  
 <211> 21  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 522  
 Gly Asp Lys Thr Pro Gly Gly Gly Gly Ala Asn Leu Lys Gly Asp Arg  
 1 5 10 15  
 Ser Arg Leu Leu Arg  
 20

<210> 523  
 <211> 27  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 523  
 Gly Leu Ser Lys Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser



1

5

10

15

Met Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr

20

25

&lt;210&gt; 524

&lt;211&gt; 23

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Synthetic  
Peptide

&lt;400&gt; 524

Tyr Gly Leu Ser Lys Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly

1

5

10

15

Ser Met Ser Gly Leu Gly Cys

20

&lt;210&gt; 525

&lt;211&gt; 7

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Synthetic  
Peptide

&lt;400&gt; 525

Asp Ala Phe Val Ala Leu Met

1

5

&lt;210&gt; 526

&lt;211&gt; 7

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Synthetic  
Peptide

&lt;400&gt; 526

Asp Ala Phe Val Ala Leu Met

<210> 527  
<211> 11  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide  
  
<400> 527  
Glu Pro Ser Lys Asp Ala Phe Ile Gly Leu Met  
1 5 10

<210> 528  
<211> 9  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide  
  
<400> 528  
Gly Pro Ser Gly Phe Tyr Gly Val Arg  
1 5

<210> 529  
<211> 10  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide  
  
<400> 529  
Ala Pro Leu Ser Gly Phe Tyr Gly Val Arg  
1 5 10

<210> 530  
<211> 7  
<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 530

Asp Ser Phe Val Gly Leu Met  
1 5

<210> 531

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 531

His Lys Thr Asp Ser Phe Val Gly Leu Met  
1 5 10

<210> 532

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 532

His Lys Ile Asn Ser Phe Val Gly Leu Met  
1 5 10

<210> 533

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 533  
Tyr His Lys Thr Asp Ser Phe Val Gly Leu Met  
1 5 10

<210> 534  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 534  
His Lys Thr Asp Ser Tyr Val Gly Leu Met  
1 5 10

<210> 535  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 535  
Lys Asp Ser Phe Val Gly Met  
1 5

<210> 536  
<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 536  
Arg Ala Trp Phe Pro Pro  
1 5

<210> 537

<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 537  
Ala Ala Trp Phe Pro Pro  
1 5

<210> 538  
<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 538  
Ala Ala Trp Phe Pro Pro  
1 5

<210> 539  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 539  
Asp Ser Phe Val Ala Leu Met  
1 5

<210> 540  
<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic

Peptide

<400> 540

Asp Ser Phe Val Gly Leu

1

5

<210> 541

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 541

Asp Ser Phe Trp Ala Leu Met

1

5

<210> 542

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 542

Asp Tyr Trp Val Trp Trp Arg

1

5

<210> 543

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 543

Asp Tyr Trp Val Trp Trp Lys

1

5

<210> 544  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 544  
Asp Met His Asp Phe Phe Val Gly Leu Met  
1 5 10

<210> 545  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 545  
Asp Met His Asp Phe Phe Gly Leu Met  
1 5

<210> 546  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 546  
Asp Met His Asp Phe Phe Pro Gly Leu Met  
1 5 10

<210> 547  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 547  
Tyr Asp Met His Asp Phe Phe Val Gly Leu Met  
1 5 10

<210> 548  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 548  
Asp Pro His Asp Phe Trp Val Trp Leu  
1 5

<210> 549  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 549  
Gly Asn Leu Trp Ala Thr Gly His Phe Met  
1 5 10

<210> 550  
<211> 30  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 550  
Leu Ser Trp Asp Leu Pro Glu Pro Arg Ser Arg Ala Gly Lys Ile Arg



1

5

10

15

Val His Pro Arg Gly Asn Leu Trp Ala Thr Gly His Phe Met  
20 25 30

&lt;210&gt; 551

&lt;211&gt; 32

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Synthetic  
Peptide

&lt;400&gt; 551

Ala Pro Leu Ser Trp Asp Leu Pro Glu Pro Arg Ser Arg Ala Gly Lys  
1 5 10 15

Ile Arg Val His Pro Arg Gly Asn Leu Trp Ala Thr Gly His Phe Met  
20 25 30

&lt;210&gt; 552

&lt;211&gt; 5

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Synthetic  
Peptide

&lt;400&gt; 552

Cys Tyr Trp Val Cys  
1 5

&lt;210&gt; 553

&lt;211&gt; 10

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 553  
Gly Asn His Trp Ala Val Gly His Leu Met  
1 5 10

<210> 554  
<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 554  
Lys Ile Pro Tyr Ile Leu  
1 5

<210> 555  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 555  
Tyr Phe Leu Phe Arg Pro Arg Asn  
1 5

<210> 556  
<211> 25  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 556  
Phe Lys Val Asp Glu Glu Phe Gln Gly Pro Ile Val Ser Gln Asn Arg  
1 5 10 15

Arg Tyr Phe Leu Phe Arg Pro Arg Asn

<210> 557  
 <211> 23  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 557  
 Tyr Lys Val Asn Glu Tyr Gln Gly Pro Val Ala Pro Ser Gly Gly Phe  
 1 5 10 15

Phe Leu Phe Arg Pro Arg Asn  
 20

<210> 558  
 <211> 21  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 558  
 Asp Ala Gly His Gly Gln Ile Ser His Lys Arg His Lys Thr Asp Ser  
 1 5 10 15

Phe Val Gly Leu Met  
 20

<210> 559  
 <211> 10  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 559  
 Pro Asn Pro Asp Glu Phe Val Gly Leu Met

<210> 560

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 560

Glu Leu Trp Ala Val Gly Ser Phe Met

1

5

<210> 561

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 561

Glu Leu Trp Ala Val Gly Ser Leu Met

1

5

<210> 562

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 562

Glu Ala Asp Pro Asn Lys Phe Tyr Gly Leu Met

1

5

10

<210> 563

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 563

Glu Ala Asp Pro Asn Lys Phe Tyr  
1 5

<210> 564

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 564

Ser Pro Ser Asn Ser Lys Cys Pro Asp Gly Pro Asp Cys Phe Val Gly  
1 5 10 15

Leu Met

<210> 565

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 565

Asp Phe Gly Leu Met  
1 5

<210> 566

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 566

Asp Asp Phe Gly Leu Met  
1 5

<210> 567

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 567

Gly Ser His Trp Ala Val Gly His Leu Met  
1 5 10

<210> 568

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 568

Gly Lys Arg Asp Ala Asp Ser Ser Ile Glu Lys Gln Val Ala Leu Leu  
1 5 10 15

Lys Ala Leu Tyr Gly His Gly  
20

<210> 569

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 569

Ala Leu Asn Ser Val Ala Tyr Glu Arg Ser Ala Met Gln Asn Tyr Glu  
1 5 10 15

Arg Arg Arg

<210> 570

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 570

Lys Trp Cys Phe Arg Val Cys Tyr Arg Gly Ile Cys Tyr Arg Arg Cys  
1 5 10 15

Arg

<210> 571

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 571

Glu Gly Lys Arg Pro Trp Ile Leu  
1 5

<210> 572

<211> 25

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 572  
Met Leu Thr Lys Phe Glu Thr Lys Ser Ala Arg Val Lys Gly Leu Ser  
1 5 10 15

Phe His Pro Lys Arg Pro Trp Ile Leu  
20 25

<210> 573  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 573  
Asp Met His Asp Phe Phe Val Gly Leu Met  
1 5 10

<210> 574  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 574  
His Lys Thr Asp Ser Phe Val Gly Leu Met  
1 5 10

<210> 575  
<211> 24  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 575  
Asp Ala Asp Ser Ser Ile Glu Lys Gln Val Ala Leu Leu Lys Ala Leu  
1 5 10 15



Tyr Gly His Gly Gln Ile Ser His  
20

<210> 576

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 576

Glu Gln Trp Phe Trp Trp Met  
1 5

<210> 577

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 577

Arg Phe Phe Leu Met  
1 5

<210> 578

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 578

Arg Pro Arg Pro Gln Gln Phe Phe Gly Leu Met  
1 5 10

<210> 579

<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 579  
Arg Trp Phe Trp Leu Met  
1 5

<210> 580  
<211> 2  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 580  
Trp Met  
1

<210> 581  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 581  
Arg Phe Phe Leu Met  
1 5

<210> 582  
<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic

Peptide

<400> 582

Arg Trp Phe Trp Leu Met

1

5

<210> 583

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 583

Ala Gln Gln Phe Phe Gly Leu Met

1

5

<210> 584

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 584

Tyr Phe Phe His Leu Met

1

5

<210> 585

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 585

Arg Pro Lys Pro Gln Gln Phe Tyr Gly Leu Met

1

5

10

<210> 586  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 586  
Arg Pro Lys Pro Gln Gln Phe Phe Leu Met  
1 5 10

<210> 587  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 587  
Arg Pro Lys Pro Gln Gln Phe Phe His Leu Met  
1 5 10

<210> 588  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 588  
Arg Pro Lys Pro Gln Gln Phe Phe Trp Leu Met  
1 5 10

<210> 589  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 589  
Arg Pro Lys Pro Gln Gln Trp Phe Trp Leu Met  
1 5 10

<210> 590  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 590  
Arg Pro Lys Pro Phe Gln Trp Phe Trp Leu Leu  
1 5 10

<210> 591  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 591  
Arg Pro Lys Pro Gln Gln Phe Phe Pro Leu Met  
1 5 10

<210> 592  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 592  
Pro Gln Gln Phe Phe Gly Leu Met

<210> 593  
<211> 5  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide  
  
<400> 593  
Gln Phe Phe Leu Met  
1 5

<210> 594  
<211> 5  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide  
  
<400> 594  
Gln Phe Phe Leu Met  
1 5

<210> 595  
<211> 6  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide  
  
<400> 595  
Gln Phe Phe Gly Leu Met  
1 5

<210> 596  
<211> 7  
<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 596

Gln Gln Phe Phe Gly Leu Met  
1 5

<210> 597

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 597

Gln Phe Phe Gly Leu Met  
1 5

<210> 598

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 598

Arg Pro Lys Pro Gln Gln Phe Phe Leu Met  
1 5 10

<210> 599

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 599

Arg Pro Lys Pro Gln Gln Phe Phe Gly Leu  
1 5 10

<210> 600

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 600

Pro Gln Gln Phe Phe Gly Leu Met  
1 5

<210> 601

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 601

Glu Phe Phe Gly Leu Met  
1 5

<210> 602

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 602

Glu Phe Phe Pro Leu Met  
1 5

<210> 603



<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 603  
Arg Pro Lys Pro Gln Gln Phe Phe Gly Leu  
1 5 10

<210> 604  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 604  
Phe Phe Gly Leu Met  
1 5

<210> 605  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 605  
Arg Pro Lys Pro Gln Gln Phe Phe Pro Leu Met  
1 5 10

<210> 606  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic

Peptide

<400> 606

Phe Phe Pro Leu Met

1

5

<210> 607

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 607

Gln Gln Phe Phe Gly Leu Met

1

5

<210> 608

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 608

Arg Pro Lys Pro Gln Gln Phe Phe Leu Met

1

5

10

<210> 609

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 609

Glu Phe Phe Pro Leu Met

1

5

<210> 610  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 610  
Arg Pro Lys Pro Gln Gln Trp Phe Trp Leu Leu  
1 5 10

<210> 611  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 611  
Lys Pro Pro Phe Asn Trp Phe Trp Leu  
1 5

<210> 612  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 612  
Arg Pro Lys Pro Gln Gln Phe Phe Gly Leu Met  
1 5 10

<210> 613  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 613  
Lys Pro Arg Pro Gln Gln Phe Ile Gly Leu Met  
1 5 10

<210> 614  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 614  
Lys Pro Arg Pro His Gln Phe Phe Gly Leu Met  
1 5 10

<210> 615  
<211> 3  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 615  
Gln Trp Phe  
1

<210> 616  
<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 616  
Arg Pro Lys Pro Gln Gln Phe Phe Gly Leu Met Gly Lys Arg

1

5

10

&lt;210&gt; 617

&lt;211&gt; 4

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Synthetic  
Peptide

&lt;400&gt; 617

Arg Pro Lys Pro

1

&lt;210&gt; 618

&lt;211&gt; 6

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Synthetic  
Peptide

&lt;400&gt; 618

Arg Pro Lys Pro Gln Gln

1

5

&lt;210&gt; 619

&lt;211&gt; 7

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Synthetic  
Peptide

&lt;400&gt; 619

Arg Pro Lys Pro Gln Gln Phe

1

5

&lt;210&gt; 620

&lt;211&gt; 9

&lt;212&gt; PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 620

Arg Pro Lys Pro Gln Gln Phe Phe Gly  
1 5

<210> 621

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 621

Pro Lys Pro Gln Gln Phe Phe Gly Leu Met  
1 5 10

<210> 622

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 622

Lys Pro Gln Gln Phe Phe Gly Leu Met  
1 5

<210> 623

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 623  
Phe Gly Leu Met  
1

<210> 624  
<211> 3  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 624  
Gly Leu Met  
1

<210> 625  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 625  
Arg Pro Lys Pro Gln Gln Phe Phe Gly Leu Met  
1 5 10

<210> 626  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 626  
Arg Pro Lys Pro Gln Gln Phe Phe Gly Leu Met  
1 5 10

<210> 627

<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 627  
Arg Pro Lys Pro Gln Gln Phe Tyr Gly Leu  
1 5 10

<210> 628  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 628  
Asp Arg Val Tyr Ile His Ala  
1 5

<210> 629  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 629  
Ala Pro Gly Asp Arg Ile Tyr Val His Pro Phe  
1 5 10

<210> 630  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic



Peptide

<400> 630

Gly Val Tyr Val His Pro Val

1

5

<210> 631

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 631

Glu Asn Gly Leu Pro Val His Leu Asp Gln Ser Ile Phe Arg Arg

1

5

10

15

<210> 632

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 632

Glu Asn Gly Leu Pro Val His Leu Asp Gln Ser Ile Phe Arg Arg

1

5

10

15

<210> 633

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 633

Gly Leu Pro Pro Arg Pro Lys Ile Pro Pro

1

5

10

<210> 634  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 634  
Gly Leu Pro Pro Gly Pro Pro Ile Pro Pro  
1 5 10

<210> 635  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 635  
Arg Pro Gly Phe Ser Pro Phe Arg  
1 5

<210> 636  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 636  
Arg Pro Gly Phe Ser Pro Phe Arg  
1 5

<210> 637  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 637

Asp Arg Val Tyr Ile His Pro Phe His Leu  
1 5 10

<210> 638

<211> 3

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 638

Gly Gly Gly  
1

<210> 639

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 639

Asp Arg Val Tyr Ile His Pro  
1 5

<210> 640

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 640

Cys Tyr Trp Lys Val Cys Thr

<210> 641

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 641

Asp Arg Val Tyr Ile His Pro Phe

1

5

<210> 642

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 642

Glu Gly Val Tyr Val His Pro Val

1

5

<210> 643

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 643

Asp Arg Val Tyr

1

<210> 644

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 644

Val Tyr Ile His Pro Phe  
1 5

<210> 645

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 645

Tyr Ile His Pro Phe  
1 5

<210> 646

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 646

Ile His Pro Phe  
1

<210> 647

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 647  
Arg Val Tyr Ile His Pro Phe  
1 5

<210> 648  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 648  
Arg Val Tyr Ile His Pro Ile  
1 5

<210> 649  
<211> 8  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 649  
Pro Thr His Ile Lys Trp Gly Asp  
1 5

<210> 650  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 650  
Glu Trp Pro Arg Pro Gln Ile Pro Pro  
1 5

<210> 651

<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 651  
Asn Arg Val Tyr Val His Pro Phe His Leu  
1 5 10

<210> 652  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 652  
Asn Arg Val Tyr Val His Pro Phe Asn Leu  
1 5 10

<210> 653  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 653  
Asn Arg Val Tyr Val His Pro Phe Gly Leu  
1 5 10

<210> 654  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic

Peptide

<400> 654

Asn Arg Val Tyr Val His Pro

1

5

<210> 655

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 655

Asn Arg Val Tyr Val His Pro Phe

1

5

<210> 656

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 656

Arg Val Tyr Ile His Pro Phe His Leu

1

5

<210> 657

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 657

Tyr Lys Arg His Pro Ile

1

5



<210> 658  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 658  
Asp Arg Val Tyr Ile Phe Pro Phe  
1 5

<210> 659  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 659  
Asp Arg Val Tyr Ile His Pro Phe His Leu Val Ile His  
1 5 10

<210> 660  
<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 660  
Asp Arg Val Tyr Ile His Pro Phe His Leu Val Ile His Asn  
1 5 10

<210> 661  
<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 661  
Asp Arg Val Tyr Ile His Pro Phe His Leu Leu Val Tyr Ser  
1 5 10

<210> 662  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 662  
Arg Val Tyr Ile His Pro Phe  
1 5

<210> 663  
<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 663  
Arg Val Tyr Ile His Pro  
1 5

<210> 664  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 664  
Arg Val Tyr Ile His Pro Ala

<210> 665

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 665

Arg Val Tyr Ile His Pro Ile

1

5

<210> 666

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 666

Arg Val Tyr Ile His Pro Thr

1

5

<210> 667

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 667

Arg Val Tyr Ile His Pro Phe

1

5

<210> 668

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 668

Arg Val Tyr Val His Pro Ala  
1 5

<210> 669

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 669

Val Tyr Ile His Pro Ile  
1 5

<210> 670

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 670

Asp Arg Val Tyr Ile His Pro Phe His Leu Val Ile His Ser  
1 5 10

<210> 671

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 671  
Arg Val Tyr Val His Pro Phe  
1 5

<210> 672  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 672  
Asp Arg Val Tyr Val His Pro Phe  
1 5

<210> 673  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 673  
Asp Arg Val Tyr Val His Pro Phe  
1 5

<210> 674  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 674  
Asp Arg Val Tyr Val His Pro Phe His Leu  
1 5 10

<210> 675

<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 675  
Asp Arg Val Tyr Val His Pro Phe Asn Leu  
1 5 10

<210> 676  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 676  
Asp Arg Val Tyr Val His Pro Phe Ser Leu  
1 5 10

<210> 677  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 677  
Asp Arg Val Tyr Val His Pro Phe His Leu  
1 5 10

<210> 678  
<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic

Peptide

<400> 678

Asp Arg Val Tyr Ile His Pro Phe His Leu Val Ile His Asn  
1 5 10

<210> 679

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 679

Asp Arg Val Tyr Ile His Pro Phe His Leu Leu Val Tyr Ser  
1 5 10

<210> 680

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 680

Pro His Pro Phe His Phe Phe Val Tyr Lys  
1 5 10

<210> 681

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 681

Asp Arg Val Tyr Ile His Pro Phe His Leu Leu Tyr Tyr Ser  
1 5 10

<210> 682  
<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 682  
Asp Arg Val Tyr Ile His Pro Cys His Leu Leu Tyr Tyr Ser  
1 5 10

<210> 683  
<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 683  
Asp Arg Val Tyr Ile His Pro Leu His Leu Leu Tyr Tyr Ser  
1 5 10

<210> 684  
<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 684  
Asp Arg Val Tyr Ile His Pro Val His Leu Leu Tyr Tyr Ser  
1 5 10

<210> 685  
<211> 38  
<212> PRT  
<213> Artificial Sequence



<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 685

Cys Ser Cys Ser Ser Leu Met Asp Lys Glu Cys Val Tyr Phe Cys His  
1 5 10 15

Leu Asp Ile Ile Trp Val Asn Thr Pro Glu His Val Val Pro Tyr Gly  
20 25 30

Leu Gly Ser Pro Arg Ser  
35

<210> 686

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 686

Ile Asn Thr Pro Glu Gln Thr Val Pro Tyr Gly Leu Ser Asn Tyr Arg  
1 5 10 15

Gly Ser Phe Arg  
20

<210> 687

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 687

Val Asn Thr Pro Glu Arg Val Val Pro Tyr Gly Leu Gly Ser Pro Ser  
1 5 10 15

Arg Ser

<210> 688  
<211> 39  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 688  
Cys Ser Cys Ser Ser Leu Met Asp Lys Glu Cys Val Tyr Phe Cys His  
1 5 10 15  
Leu Asp Ile Ile Trp Val Asn Thr Pro Glu His Val Val Pro Tyr Gly  
20 25 30

Leu Gly Ser Pro Ser Arg Ser  
35

<210> 689  
<211> 18  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 689  
Val Asn Thr Pro Glu His Val Val Pro Tyr Gly Leu Gly Ser Pro Ser  
1 5 10 15

Arg Ser

<210> 690  
<211> 20  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 690

Ile Ile Trp Val Asn Thr Pro Glu His Val Val Pro Tyr Gly Leu Gly  
 1 5 10 15  
 Ser Pro Arg Ser  
 20

<210> 691  
 <211> 17  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 691  
 Val Asn Thr Pro Glu His Val Val Pro Tyr Gly Leu Gly Ser Pro Arg  
 1 5 10 15  
 Ser

<210> 692  
 <211> 37  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 692  
 Cys Ser Cys Ser Ser Trp Leu Asp Lys Glu Cys Val Tyr Phe Cys His  
 1 5 10 15

Leu Asp Ile Ile Trp Val Asn Thr Pro Glu Gln Thr Ala Pro Tyr Gly  
 20 25 30

Leu Gly Asn Pro Pro  
 35

<210> 693  
 <211> 16  
 <212> PRT  
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 693

Val Asn Thr Pro Glu Gln Thr Ala Pro Tyr Gly Leu Gly Asn Pro Pro  
1 5 10 15

<210> 694

<211> 41

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 694

Cys Thr Cys Phe Thr Tyr Lys Asp Lys Glu Cys Val Tyr Tyr Cys His  
1 5 10 15

Leu Asp Ile Ile Trp Ile Asn Thr Pro Glu Gln Thr Val Pro Tyr Gly  
20 25 30

Leu Ser Asn Tyr Arg Gly Ser Phe Arg  
35 40

<210> 695

<211> 39

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 695

Cys Ser Cys Ser Ser Leu Met Asp Lys Glu Cys Val Tyr Phe Cys His  
1 5 10 15

Leu Asp Ile Ile Trp Val Asn Thr Pro Glu His Ile Val Pro Tyr Gly  
20 25 30

Leu Gly Ser Pro Ser Arg Ser  
35

<210> 696  
<211> 18  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 696  
Val Asn Thr Pro Glu His Val Val Pro Tyr Gly Leu Gly Ser Pro Ser  
1 5 10 15

Arg Ser

<210> 697  
<211> 39  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 697  
Cys Ser Cys Ser Ser Leu Met Asp Lys Glu Cys Val Tyr Phe Cys His  
1 5 10 15

Leu Asp Ile Ile Trp Val Asn Thr Pro Glu Arg Val Val Pro Tyr Gly  
20 25 30

Leu Gly Ser Pro Ser Arg Ser  
35

<210> 698  
<211> 38  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 698

Cys Ser Cys Ser Ser Trp Leu Asp Lys Glu Cys Val Tyr Phe Cys His  
1 5 10 15

Leu Asp Ile Ile Trp Val Asn Thr Pro Glu Gln Thr Ala Pro Tyr Gly  
20 25 30

Leu Gly Asn Pro Pro Arg  
35

<210> 699

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 699

Val Asn Thr Pro Glu Gln Thr Ala Pro Tyr Gly Leu Gly Asn Pro Pro  
1 5 10 15

Arg

<210> 700

<211> 41

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 700

Cys Thr Cys Phe Thr Tyr Lys Asp Lys Glu Cys Val Tyr Tyr Cys His  
1 5 10 15

Leu Asp Ile Ile Trp Ile Asn Thr Pro Glu Gln Thr Val Pro Tyr Gly  
20 25 30

Leu Ser Asn His Arg Gly Ser Leu Arg  
35 40

<210> 701  
<211> 20  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 701  
Cys Gln Cys Ala Ser Gln Lys Asp Lys Lys Trp Ser Tyr Cys Gln Ala  
1 5 10 15  
Gly Lys Glu Ile  
20

<210> 702  
<211> 21  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 702  
Cys Ser Cys Ser Ser Leu Met Asp Lys Glu Cys Val Tyr Phe Cys His  
1 5 10 15  
Leu Asp Ile Ile Trp  
20

<210> 703  
<211> 15  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 703  
Cys Ser Cys Ser Ser Leu Met Asp Lys Glu Cys Val Tyr Phe Cys  
1 5 10 15

<210> 704  
<211> 15  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 704  
Cys Ser Cys Ser Ser Leu Met Asp Lys Glu Cys Val Tyr Phe Cys  
1 5 10 15

<210> 705  
<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 705  
Trp Leu Asp Ile Ile Trp  
1 5

<210> 706  
<211> 21  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 706  
Cys Ser Ala Ser Ser Leu Met Asp Lys Glu Ala Val Tyr Phe Cys His  
1 5 10 15

Leu Asp Ile Ile Trp  
20

<210> 707  
<211> 20  
<212> PRT



<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 707

Ser	Cys	Ser	Ser	Leu	Met	Asp	Lys	Glu	Cys	Val	Tyr	Phe	Asp	His	Leu
1				5				10						15	

Asp Ile Ile Trp  
20

<210> 708

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 708

Ala	Ser	Ala	Ser	Ser	Leu	Met	Asp	Lys	Glu	Ala	Val	Tyr	Phe	Ala	His
1				5				10						15	

Leu Asp Ile Ile Trp  
20

<210> 709

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 709

Leu	Met	Asp	Lys	Glu	Ala	Val	Tyr	Phe	Ala	His	Leu	Asp	Ile	Ile	Trp
1				5				10						15	

<210> 710

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 710

Cys Ala Cys Phe Thr Tyr Lys Asp Lys Glu Cys Val Tyr Tyr Cys His  
1 5 10 15

Leu Asp Ile Ile Trp  
20

<210> 711

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 711

Cys Ser Ala Ser Ser Leu Asp Lys Glu Ala Val Tyr Phe Cys His Leu  
1 5 10 15

Ala Ile Ile Trp  
20

<210> 712

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 712

Cys Ser Cys Ser Ser Leu Met Asp Lys Glu Cys Val Tyr Phe Cys His  
1 5 10 15

Leu Asn Ile Ile Trp  
20

<210> 713  
<211> 15  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 713  
Asn Trp His Gly Thr Ala Pro Asp Trp Phe Phe Asn Tyr Tyr Trp  
1 5 10 15

<210> 714  
<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 714  
Asp Glu Glu Ala Val Tyr Phe Ala His Leu Asp Ile Ile Trp  
1 5 10

<210> 715  
<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 715  
His Leu Asp Ile Ile Trp  
1 5

<210> 716  
<211> 23  
<212> PRT  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 716

His Leu Asp Ile Ile Trp Val Asn Thr Pro Glu His Val Val Pro Tyr  
1 5 10 15

Gly Leu Gly Ser Pro Arg Ser  
20

<210> 717

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 717

Cys Ser Cys Ser Ser Trp Leu Asp Lys Glu Cys Val Tyr Phe Cys His  
1 5 10 15

Leu Asp Ile Ile Trp  
20

<210> 718

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 718

Cys Thr Cys Phe Thr Tyr Lys Asp Lys Glu Cys Val Tyr Tyr Cys His  
1 5 10 15

Leu Asp Ile Ile Trp  
20

<210> 719

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 719

Ser Leu Lys Asp Leu Phe Pro Ala Lys Ala Ala Asp Arg Arg Asp Arg  
1 5 10 15

<210> 720

<211> 3

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 720

Leu Trp Trp  
1

<210> 721

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 721

Met Leu Met Trp  
1

<210> 722

<211> 1

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 722

Arg

1

<210> 723

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 723

Asp Pro Ile Leu Trp

1

5

<210> 724

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 724

Ser Pro Val Leu Trp

1

5

<210> 725

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 725

Leu Asp Ile Ile Trp

1

5

<210> 726

<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 726  
Leu Asp Ile Ile Trp  
1 5

<210> 727  
<211> 21  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 727  
Cys Ser Cys Lys Asp Met Thr Asp Lys Glu Cys Leu Asn Phe Cys His  
1 5 10 15

Gln Asp Val Ile Trp  
20

<210> 728  
<211> 21  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 728  
Cys Ser Cys Lys Asp Met Thr Asp Lys Glu Cys Leu Tyr Phe Cys His  
1 5 10 15

Gln Asp Val Ile Trp  
20

<210> 729

<211> 21  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 729  
Cys Thr Cys Asn Asp Met Thr Asp Glu Glu Cys Leu Asn Phe Cys His  
1 5 10 15

Gln Asp Val Ile Trp  
20

<210> 730  
<211> 16  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 730  
Gly Asn Trp His Gly Thr Ala Pro Asp Trp Phe Phe Asn Tyr Tyr Trp  
1 5 10 15

<210> 731  
<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 731  
His Leu Asp Ile Ile Trp  
1 5

<210> 732  
<211> 45  
<212> PRT  
<213> Artificial Sequence



<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 732

Thr Leu Asp Glu Glu Asp Leu Val Asp Ser Leu Ser Glu Gly Asp Ala

1

5

10

15

Tyr Thr Asn Gly Leu Gln Val Asn Phe His Ser Pro Arg Ser Gly Gln

20

25

30

Arg Cys Trp Ala Ala Arg Thr Gln Val Glu Lys Arg Leu

35

40

45

<210> 733

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 733

Cys Pro Pro Gly Ser Pro Met Asn Pro His His Lys Cys Glu Val Trp

1

5

10

15

<210> 734

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 734

Asp Pro Val Leu Trp

1

5

<210> 735

<211> 5

<212> PRT

<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 735  
Glu Ala Ile Trp Leu  
1 5

<210> 736  
<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 736  
Ala Val Leu Trp  
1

<210> 737  
<211> 3  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 737  
Leu Trp Trp  
1

<210> 738  
<211> 2  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 738

Leu Trp

1

<210> 739

<211> 3

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 739

Leu Trp Tyr

1

<210> 740

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 740

Leu Trp Ala Ala Tyr Phe

1

5

<210> 741

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 741

Gly Asn Trp His Gly Thr Ser Pro Asp Trp Phe Phe Asn Tyr Trp

1

5

10

15

<210> 742

<211> 14

<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 742  
Asp Lys Glu Ala Val Tyr Phe Ala His Leu Asp Ile Ile Trp  
1 5 10

<210> 743  
<211> 21  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 743  
Cys Thr Cys Lys Asp Met Thr Asp Lys Glu Cys Leu Tyr Phe Cys His  
1 5 10 15  
Gln Asp Ile Ile Trp  
20

<210> 744  
<211> 21  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 744  
Cys Thr Cys Lys Asp Met Thr Asp Glu Glu Cys Leu Asn Phe Cys His  
1 5 10 15  
Gln Asp Val Ile Trp  
20

<210> 745  
<211> 7

<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 745  
Tyr Pro Phe Val Glu Pro Ile  
1 5

<210> 746  
<211> 3  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 746  
Tyr Pro Phe  
1

<210> 747  
<211> 3  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 747  
Tyr Pro Phe  
1

<210> 748  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 748  
Tyr Pro Phe Pro Gly Pro Ile  
1 5

<210> 749  
<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 749  
Tyr Pro Phe Pro  
1

<210> 750  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 750  
Tyr Pro Phe Pro Gly  
1 5

<210> 751  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 751  
Tyr Pro Phe Pro Gly  
1 5

<210> 752  
<211> 5  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide  
  
<400> 752  
Tyr Pro Phe Pro Gly  
1 5

<210> 753  
<211> 7  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide  
  
<400> 753  
Tyr Pro Phe Val Glu Pro Ile  
1 5

<210> 754  
<211> 2  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide  
  
<400> 754  
Tyr Phe  
1

<210> 755  
<211> 3  
<212> PRT  
<213> Artificial Sequence  
  
<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 755  
Tyr Phe Tyr  
1

<210> 756  
<211> 3  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 756  
Tyr Phe Tyr  
1

<210> 757  
<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 757  
Tyr Phe Pro Tyr  
1

<210> 758  
<211> 3  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 758  
Tyr Phe Pro  
1



<210> 759  
<211> 3  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 759  
Tyr Phe Pro  
1

<210> 760  
<211> 3  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 760  
Tyr Phe Pro  
1

<210> 761  
<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 761  
Tyr Phe Pro Gly  
1

<210> 762  
<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 762  
Tyr Phe Pro Gly  
1

<210> 763  
<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 763  
Tyr Phe Pro Gly  
1

<210> 764  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 764  
Tyr Phe Pro Gly Pro  
1 5

<210> 765  
<211> 3  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 765

Tyr Phe Pro

1

<210> 766

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 766

Pro Phe Pro Gly Pro Ile

1

5

<210> 767

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 767

Pro Phe Pro Gly Pro Ile

1

5

<210> 768

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 768

Tyr Pro Val Pro

1

<210> 769

<211> 4

<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 769  
Tyr Pro Phe Pro  
1

<210> 770  
<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 770  
Tyr Pro Phe Pro  
1

<210> 771  
<211> 3  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 771  
Tyr Pro Pro  
1

<210> 772  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 772  
Tyr Ala Phe Gly Tyr Pro Ser  
1 5

<210> 773  
<211> 3  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 773  
Tyr Arg Phe  
1

<210> 774  
<211> 32  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 774  
Tyr Gly Gly Phe Leu Arg Arg Ile Arg Pro Lys Leu Lys Trp Asp Asn  
1 5 10 15  
Gln Lys Arg Tyr Gly Gly Phe Leu Arg Arg Gln Phe Lys Val Val Thr  
20 25 30

<210> 775  
<211> 17  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 775

Tyr Gly Gly Phe Leu Arg Arg Ile Arg Pro Lys Leu Lys Trp Asp Asn  
1 5 10 15

Gln

<210> 776

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 776

Tyr Gly Phe Leu Arg Ile Arg Pro Lys Leu Lys  
1 5 10

<210> 777

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 777

Tyr Ala Gly Phe Leu Arg Arg Ile Arg Pro Lys Leu Lys Trp Asp Asn  
1 5 10 15

Gln

<210> 778

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 778

Tyr Ala Gly Phe Leu Arg Arg Ile Arg Pro Lys Leu Lys Trp Asp Asn  
1 5 10 15

Gln

<210> 779

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 779

Tyr Ala Gly Phe Leu Arg Arg Ile Arg Pro Lys Leu Lys Trp Asp Asn  
1 5 10 15

Gln

<210> 780

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 780

Tyr Gly Phe Leu Arg Arg Ile Arg Pro Lys Leu Lys  
1 5 10

<210> 781

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 781  
Tyr Gly Phe Leu Arg Arg Ile Arg  
1 5

<210> 782  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 782  
Tyr Gly Gly Phe Leu Arg Ile Arg Pro Lys Leu Lys  
1 5 10

<210> 783  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 783  
Tyr Gly Gly Phe Leu Arg Arg Arg Pro Lys Leu Lys  
1 5 10

<210> 784  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 784  
Gly Gly Phe Leu Arg Arg Ile  
1 5



<210> 785  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 785  
Tyr Gly Gly Phe Leu Arg Arg Ile Arg Pro Lys Leu  
1 5 10

<210> 786  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 786  
Tyr Gly Gly Phe Leu Arg Arg Ile Arg Pro Lys Leu Lys  
1 5 10

<210> 787  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 787  
Tyr Gly Gly Phe Leu Arg Arg Ile Arg Pro Lys Leu Lys  
1 5 10

<210> 788  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 788

Tyr Gly Gly Phe Leu Arg Arg Ile Arg Pro  
1 5 10

<210> 789

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 789

Tyr Gly Gly Phe Leu Arg Arg Ile Arg Pro Arg Leu Arg Gly  
1 5 10

<210> 790

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 790

Gly Gly Phe Leu Arg Arg Ile Arg Pro Lys Leu Lys Trp Asp Asn Gln  
1 5 10 15

<210> 791

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 791

Gly Gly Phe Leu Arg Arg Ile Arg Pro Lys Leu Lys Trp Asp Asn Gln  
1 5 10 15

<210> 792  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 792  
Gly Gly Phe Leu Arg Arg Ile Arg Pro Lys Leu  
1 5 10

<210> 793  
<211> 15  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 793  
Gly Phe Leu Arg Arg Ile Arg Pro Lys Leu Lys Trp Asp Asn Gln  
1 5 10 15

<210> 794  
<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 794  
Gly Phe Leu Arg Arg Ile  
1 5

<210> 795  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 795

Gly Phe Leu Arg Arg Ile Arg Pro Lys Leu Lys

1

5

10

<210> 796

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 796

Gly Phe Leu Arg Arg Ile Arg Pro Lys Leu Lys Trp Asp Asn Gln

1

5

10

15

<210> 797

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 797

Arg Ile Arg Pro Lys Leu Lys Trp Asp Asn Gln

1

5

10

<210> 798

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 798

Ile Arg Pro Lys Leu Lys Trp Asp Asn Gln  
1 5 10

<210> 799

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 799

Arg Arg Ile Arg Pro Lys Leu Lys Trp Asp Asn Gln  
1 5 10

<210> 800

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 800

Tyr Pro Phe Pro Arg Arg Ile Arg Pro Lys Leu Lys Trp Asp Asn Gln  
1 5 10 15

<210> 801

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 801

Arg Pro Lys Leu Lys Trp Asp Asn Gln  
1 5

<210> 802

<211> 5

<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 802  
Lys Trp Asp Asn Gln  
1 5

<210> 803  
<211> 17  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 803  
Tyr Gly Gly Phe Leu Arg Arg Ile Arg Pro Lys Leu Lys Trp Asp Asn  
1 5 10 15  
Gln

<210> 804  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 804  
Tyr Gly Gly Phe Leu Arg Arg Gln Phe Lys Val Val Thr  
1 5 10

<210> 805  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 805

Tyr Gly Gly Phe Leu Arg Arg Gln Phe  
1 5

<210> 806

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 806

Tyr Gly Gly Phe Leu Arg Arg Gln Phe Lys Val Val Thr Arg Ser Gln  
1 5 10 15

Glu Asp Pro Asn Ala Tyr Ser Gly Glu Leu Phe Asp Ala  
20 25

<210> 807

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 807

Tyr Gly Gly Phe Leu Arg Lys Tyr Pro Lys  
1 5 10

<210> 808

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 808  
Tyr Gly Gly Phe Leu Arg Lys Tyr Pro  
1 5

<210> 809  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 809  
Tyr Gly Gly Phe Leu Arg Arg Ile Arg Pro Lys Leu Lys  
1 5 10

<210> 810  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 810  
Tyr Gly Gly Phe Leu Arg Phe  
1 5

<210> 811  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 811  
Tyr Gly Gly Phe Leu Arg Phe  
1 5



<210> 812  
<211> 29  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 812  
Tyr Gly Gly Phe Leu Arg Arg Gln Phe Lys Val Val Thr Arg Ser Gln  
1 5 10 15  
Glu Asp Pro Asn Ala Tyr Tyr Glu Glu Leu Phe Asp Val  
20 25

<210> 813  
<211> 31  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 813  
Tyr Gly Gly Phe Met Thr Ser Glu Lys Ser Gln Thr Pro Leu Val Thr  
1 5 10 15  
Leu Phe Lys Asn Ala Ile Ile Lys Asn Ala His Lys Lys Gly Gln  
20 25 30

<210> 814  
<211> 27  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 814  
Tyr Gly Gly Phe Met Thr Ser Glu Lys Ser Gln Thr Pro Leu Val Thr  
1 5 10 15  
Leu Phe Lys Asn Ala Ile Ile Lys Asn Ala His

<210> 815  
 <211> 31  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 815  
 Tyr Gly Gly Phe Met Thr Ser Glu Lys Ser Gln Thr Pro Leu Val Thr  
 1 5 10 15  
 Leu Phe Lys Asn Ala Ile Ile Lys Asn Ala Tyr Lys Lys Gly Glu  
 20 25 30

<210> 816  
 <211> 26  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 816  
 Tyr Gly Gly Phe Met Thr Ser Glu Lys Ser Gln Thr Pro Leu Val Thr  
 1 5 10 15  
 Leu Phe Lys Asn Ala Ile Ile Lys Asn Ala  
 20 25

<210> 817  
 <211> 27  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 817  
 Tyr Gly Gly Phe Met Thr Ser Glu Lys Ser Gln Thr Pro Leu Val Thr

1

5

10

15

Leu Phe Lys Asn Ala Ile Ile Lys Asn Ala Tyr  
20 25

&lt;210&gt; 818

&lt;211&gt; 17

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Synthetic  
Peptide

&lt;400&gt; 818

Tyr Gly Gly Phe Met Thr Ser Glu Lys Ser Gln Thr Pro Leu Val Thr  
1 5 10 15

Leu

&lt;210&gt; 819

&lt;211&gt; 16

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Synthetic  
Peptide

&lt;400&gt; 819

Tyr Gly Gly Phe Met Thr Ser Glu Lys Ser Gln Thr Pro Leu Val Thr  
1 5 10 15

&lt;210&gt; 820

&lt;211&gt; 16

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Synthetic  
Peptide

&lt;400&gt; 820

Tyr Gly Gly Phe Met Thr Ser Glu Lys Ser Gln Thr Pro Leu Val Thr

<210> 821

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 821

Tyr Gly Gly Phe Leu Arg Lys Tyr Arg Pro Lys

1

5

10

<210> 822

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 822

Tyr Gly Gly Phe Leu Arg Lys

1

5

<210> 823

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 823

Tyr Gly Gly Phe Leu Arg Lys Arg

1

5

<210> 824

<211> 31

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 824

Tyr Gly Gly Phe Met Thr Ser Glu Lys Ser Gln Thr Pro Leu Val Thr  
1 5 10 15

Leu Phe Lys Asn Ala Ile Ile Lys Asn Ala His Lys Lys Gly Gln  
20 25 30

<210> 825

<211> 27

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 825

Tyr Gly Gly Phe Met Thr Ser Glu Lys Ser Gln Thr Pro Leu Val Thr  
1 5 10 15

Leu Phe Lys Asn Ala Ile Ile Lys Asn Ala His  
20 25

<210> 826

<211> 31

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 826

Tyr Gly Gly Phe Met Ser Ser Glu Lys Ser Gln Thr Pro Leu Val Thr  
1 5 10 15

Leu Phe Lys Asn Ala Ile Ile Lys Asn Ala His Lys Lys Gly Gln  
20 25 30

<210> 827  
<211> 31  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 827  
Tyr Gly Gly Phe Met Thr Ser Glu Lys Ser Gln Thr Pro Leu Val Thr  
1 5 10 15  
Leu Phe Lys Asn Ala Ile Ile Lys Asn Ala Tyr Lys Lys Gly Glu  
20 25 30

<210> 828  
<211> 21  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 828  
Tyr Gly Gly Phe Met Thr Leu Phe Lys Asn Ala Ile Ile Lys Asn Ala  
1 5 10 15  
Tyr Lys Lys Gly Glu  
20

<210> 829  
<211> 26  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 829  
Tyr Gly Gly Phe Met Thr Ser Glu Lys Ser Gln Thr Pro Leu Val Thr  
1 5 10 15  
Leu Phe Lys Asn Ala Ile Ile Lys Asn Ala

<210> 830  
 <211> 27  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 830  
 Tyr Gly Gly Phe Met Thr Ser Glu Lys Ser Gln Thr Pro Leu Val Thr  
           1                  5                  10                  15  
 Leu Phe Lys Asn Ala Ile Ile Lys Asn Ala Tyr  
                   20                  25

<210> 831  
 <211> 26  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 831  
 Thr Ser Glu Lys Ser Gln Thr Pro Leu Val Thr Leu Phe Lys Asn Ala  
           1                  5                  10                  15  
 Ile Ile Lys Asn Ala Tyr Lys Lys Gly Glu  
                   20                  25

<210> 832  
 <211> 14  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 832  
 Phe Lys Asn Ala Ile Ile Lys Asn Ala Tyr Lys Lys Gly Glu

<210> 833

<211> 31

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 833

Tyr Gly Gly Phe Met Thr Ser Glu Lys Ser Gln Thr Pro Leu Val Thr  
1 5 10 15

Leu Phe Lys Asn Ala Ile Val Lys Asn Ala His Lys Lys Gly Gln  
20 25 30

<210> 834

<211> 31

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 834

Tyr Gly Gly Phe Met Thr Ser Glu Lys Ser Gln Thr Pro Leu Val Thr  
1 5 10 15

Leu Phe Lys Asn Ala Ile Ile Lys Asn Val His Lys Lys Gly Gln  
20 25 30

<210> 835

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 835

Glu Leu Ala Gly Ala Pro Pro Glu Pro Ala



<210> 836

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 836

Tyr Gly Gly Phe

1

<210> 837

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 837

Tyr Gly Gly Phe Met Thr Ser Glu Lys

1

5

<210> 838

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 838

Lys Lys Gly Glu

1

<210> 839

<211> 31

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 839

Tyr	Gly	Gly	Phe	Met	Thr	Ser	Glu	Lys	Ser	Gln	Thr	Pro	Leu	Val	Thr
1				5					10					15	

Leu	Phe	Lys	Asn	Ala	Ile	Ile	Lys	Asn	Ala	Tyr	Lys	Lys	Gly	Glu
				20				25					30	

<210> 840

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 840

Tyr	Gly	Gly	Phe	Met	Thr	Ser	Glu	Lys	Ser	Gln	Thr	Pro	Leu	Val	Thr
1				5					10					15	

Leu

<210> 841

<211> 1

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 841

Tyr  
1

<210> 842

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 842

Tyr Phe Met Thr Ser Glu Lys  
1 5

<210> 843

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 843

Tyr Gly Phe Met Thr Ser Glu Lys  
1 5

<210> 844

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 844

Tyr Gly Phe Met Thr Ser Glu Lys Ser Gln Thr Pro Leu Val Thr Leu  
1 5 10 15

<210> 845

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 845

Gly Gly Phe Met Thr Ser Glu Lys Ser Gln Thr Pro Leu Val Thr Leu  
1 5 10 15

<210> 846

<211> 31

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 846

Tyr Gly Gly Phe Leu Thr Ser Glu Lys Ser Gln Thr Pro Leu Val Thr  
1 5 10 15

Leu Phe Lys Asn Ala Ile Ile Lys Asn Ala His Lys Lys Gly Gln  
20 25 30

<210> 847

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 847

Tyr Gly Gly Phe Met Lys  
1 5

<210> 848

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 848

Tyr Gly Gly Phe Met Lys Lys  
1 5

<210> 849  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 849  
Tyr Gly Gly Phe Met Lys Arg  
1 5

<210> 850  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 850  
Tyr Gly Gly Phe Met Arg Arg Val  
1 5

<210> 851  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 851  
Ala Ala Ala Tyr Gly Gly Phe Met  
1 5

<210> 852  
<211> 26  
<212> PRT  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 852

Tyr Gly Gly Phe Met Lys Lys Met Asp Glu Leu Tyr Pro Leu Glu Val  
1 5 10 15

Glu Glu Glu Ala Asn Gly Gly Glu Val Leu  
20 25

<210> 853

<211> 26

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 853

Tyr Gly Gly Phe Met Lys Lys Met Asp Glu Leu Tyr Pro Leu Glu Val  
1 5 10 15

Glu Glu Glu Ala Asn Gly Gly Glu Val Leu  
20 25

<210> 854

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 854

Tyr Gly Gly Phe Met Arg Arg Val Gly Arg Pro Glu  
1 5 10

<210> 855

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 855

Tyr Gly Gly Phe Met Arg Arg Val Gly Arg Pro Glu

1

5

10

<210> 856

<211> 22

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 856

Tyr Gly Gly Phe Met Arg Arg Val Gly Arg Pro Glu Trp Trp Met Asp

1

5

10

15

Tyr Gln Lys Arg Tyr Gly

20

<210> 857

<211> 3

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 857

Phe Ala Arg

1

<210> 858

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

Peptide

<400> 858

Tyr Ala Gly Phe Gly

1

5

<210> 859

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 859

Tyr Ala Gly Phe Leu

1

5

<210> 860

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 860

Tyr Ala Gly Phe Met

1

5

<210> 861

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 861

Tyr Gly Phe Leu

1



<210> 862  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 862  
Tyr Gly Phe Leu Arg  
1 5

<210> 863  
<211> 2  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 863  
Gly Phe  
1

<210> 864  
<211> 2  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 864  
Gly Phe  
1

<210> 865  
<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 865  
Gly Gly Phe Leu  
1

<210> 866  
<211> 3  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 866  
Tyr Gly Phe  
1

<210> 867  
<211> 3  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 867  
Tyr Gly Phe  
1

<210> 868  
<211> 3  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 868  
Phe Leu Arg

1

<210> 869  
<211> 3  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 869  
Tyr Gly Phe  
1

<210> 870  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 870  
Tyr Gly Gly Phe Leu  
1 5

<210> 871  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 871  
Tyr Gly Gly Phe Leu  
1 5

<210> 872  
<211> 5  
<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 872

Tyr Gly Gly Phe Leu

1

5

<210> 873

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 873

Tyr Ala Gly Phe Leu

1

5

<210> 874

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 874

Tyr Ser Gly Phe Leu Thr

1

5

<210> 875

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 875

Tyr Thr Gly Phe Leu Thr

1

5

<210> 876

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 876

Tyr Gly Gly Phe Leu Lys

1

5

<210> 877

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 877

Tyr Gly Gly Phe Met Arg

1

5

<210> 878

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 878

Tyr Gly Gly Phe Met Arg Arg

1

5

<210> 879

<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 879  
Tyr Gly Gly Phe Met Arg Arg Val Gly  
1 5

<210> 880  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 880  
Tyr Gly Gly Phe Met Arg Gly Leu  
1 5

<210> 881  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 881  
Tyr Gly Gly Phe Met Arg Phe  
1 5

<210> 882  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic

Peptide

<400> 882

Tyr Gly Gly Phe Met

1

5

<210> 883

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 883

Tyr Gly Gly Phe Met

1

5

<210> 884

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 884

Tyr Ala Gly Phe Met

1

5

<210> 885

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 885

Tyr Ala Gly Phe Met

1

5

<210> 886  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 886  
Tyr Gly Gly Phe Met Arg Phe  
1 5

<210> 887  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 887  
Tyr Gly Gly Phe Met  
1 5

<210> 888  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 888  
Tyr Ala Gly Phe Met  
1 5

<210> 889  
<211> 4  
<212> PRT  
<213> Artificial Sequence



<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 889

Tyr Gly Phe Pro

1

<210> 890

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 890

Tyr Gly Phe Met

1

<210> 891

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 891

Tyr Gly Gly Phe Met Arg Arg Val

1

5

<210> 892

<211> 31

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 892

Phe Ala Glu Pro Leu Pro Ser Glu Glu Glu Gly Glu Ser Tyr Ser Lys

1

5

10

15

Glu Val Pro Glu Met Glu Lys Arg Tyr Gly Gly Phe Met Arg Phe  
20 25 30

&lt;210&gt; 893

&lt;211&gt; 25

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Synthetic  
Peptide

&lt;400&gt; 893

Tyr Gly Gly Phe Met Arg Arg Val Gly Arg Pro Glu Trp Trp Met Asp  
1 5 10 15

Tyr Gln Lys Arg Tyr Gly Gly Phe Leu  
20 25

&lt;210&gt; 894

&lt;211&gt; 34

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Synthetic  
Peptide

&lt;400&gt; 894

Tyr Gly Gly Phe Met Lys Lys Met Asp Glu Leu Tyr Pro Leu Glu Val  
1 5 10 15

Glu Glu Glu Ala Asn Gly Gly Glu Val Leu Gly Lys Arg Tyr Gly Gly  
20 25 30

Phe Met

&lt;210&gt; 895

&lt;211&gt; 19

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 895

Ser Ser Glu Val Ala Gly Glu Gly Asp Gly Asp Ser Met Gly His Glu  
1 5 10 15

Asp Leu Tyr

<210> 896

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 896

Leu Val Val Tyr Pro Trp  
1 5

<210> 897

<211> 2

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 897

Pro Gly  
1

<210> 898

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 898  
Tyr Pro Phe Pro  
1

<210> 899  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 899  
Tyr Pro Phe Pro Pro  
1 5

<210> 900  
<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 900  
Tyr Pro Pro Pro  
1

<210> 901  
<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 901  
Arg Tyr Leu Gly Tyr Leu  
1 5

<210> 902  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 902  
Ala Ala Ala Tyr Gly Gly Phe Leu  
1 5

<210> 903  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 903  
Ala Ala Ala Tyr Gly Gly Phe Leu  
1 5

<210> 904  
<211> 18  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 904  
Tyr Gly Gly Phe Met Arg Arg Val Gly Arg Pro Glu Trp Trp Met Asp  
1 5 10 15

Tyr Gln

<210> 905  
<211> 6  
<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 905

Tyr Pro Phe Pro Pro Leu  
1 5

<210> 906

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 906

Tyr Val Pro Phe Pro Pro Phe  
1 5

<210> 907

<211> 2

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 907

Trp Gly  
1

<210> 908

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 908  
Tyr Arg Phe Lys  
1

<210> 909  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 909  
Tyr Met Phe His Leu Met Asp  
1 5

<210> 910  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 910  
Tyr Ala Phe Asp Val Val Gly  
1 5

<210> 911  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 911  
Tyr Ala Phe Glu Val Val Gly  
1 5

<210> 912

<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 912  
Tyr Pro Trp Phe  
1

<210> 913  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 913  
Tyr Pro Trp Phe Phe  
1 5

<210> 914  
<211> 2  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 914  
Tyr Arg  
1

<210> 915  
<211> 1  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic



Peptide

<400> 915

Tyr

1

<210> 916

<211> 2

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 916

Leu Gly

1

<210> 917

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 917

Pro Gln Arg Phe

1

<210> 918

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 918

Ala Gly Glu Gly Leu Ser Ser Pro Phe Trp Ser Leu Ala Ala Pro Gln

1

5

10

15

Arg Phe

<210> 919

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 919

Phe Gly Gly Phe Thr Gly Ala Arg Lys Ser Ala Arg Lys Leu Ala Asn

1

5

10

15

Gln

<210> 920

<211> 3

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 920

Tyr Phe Phe

1

<210> 921

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 921

Tyr Pro Leu Gly

1

<210> 922  
<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 922  
Tyr Pro Trp Gly  
1

<210> 923  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 923  
Val Val Tyr Pro Trp Thr Gln  
1 5

<210> 924  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 924  
Leu Val Val Tyr Pro Trp Thr Gln Arg  
1 5

<210> 925  
<211> 2  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 925  
Pro Leu  
1

<210> 926  
<211> 17  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 926  
Phe Gly Gly Phe Thr Gly Ala Arg Lys Ser Ala Arg Lys Leu Ala Asn  
1 5 10 15  
Gln

<210> 927  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 927  
Tyr Gly Gly Phe Met Arg Arg Val  
1 5

<210> 928  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 928  
Ala Lys Ser Gln Gly Gly Ser Asn  
1 5

<210> 929  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 929  
Leu Glu Asp Gly Pro Lys Phe Leu  
1 5

<210> 930  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 930  
Arg Lys Asp Val Tyr  
1 5

<210> 931  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 931  
Gly Glu Gln Arg Lys Asp Val Tyr Val Gln Leu Tyr Leu  
1 5 10

<210> 932  
<211> 28  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 932  
Ser Asp Ala Ala Val Asp Thr Ser Ser Glu Ile Thr Thr Lys Asp Leu  
1 5 10 15  
  
Lys Glu Lys Lys Glu Val Val Glu Glu Ala Glu Asn  
20 25

<210> 933  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 933  
Tyr Gln Ala Lys Ser Gln Gly Gly Ser Asn  
1 5 10

<210> 934  
<211> 28  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 934  
Ser Asp Ala Ala Val Asp Thr Ser Ser Glu Ile Thr Thr Lys Asp Leu  
1 5 10 15  
  
Lys Glu Lys Lys Glu Val Val Glu Glu Ala Glu Asn  
20 25

<210> 935  
<211> 52  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 935  
Tyr Arg Gln Ser Met Asn Asn Phe Gln Gly Leu Arg Ser Phe Gly Cys  
1 5 10 15

Arg Phe Gly Thr Cys Thr Val Gln Lys Leu Ala His Gln Ile Tyr Gln  
20 25 30

Phe Thr Asp Lys Asp Lys Asp Asn Val Ala Pro Arg Ser Lys Ile Ser  
35 40 45

Pro Gln Gly Tyr  
50

<210> 936  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 936  
Tyr Arg Gln Ser Met Asn Asn Phe Gln Gly Leu Arg  
1 5 10

<210> 937  
<211> 37  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 937  
Ser Phe Gly Cys Arg Phe Gly Thr Cys Thr Val Gln Lys Leu Ala His

1

5

10

15

Gln Ile Tyr Phe Thr Asp Lys Asp Asn Val Ala Pro Arg Ser Lys Ile  
 20 25 30

Ser Pro Gln Gly Tyr  
 35

<210> 938

<211> 31

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 938

Thr Val Gln Lys Leu Ala His Gln Ile Tyr Gln Phe Thr Asp Lys Asp  
 1 5 10 15

Lys Asp Asn Val Ala Pro Arg Ser Lys Ile Ser Pro Gln Gly Tyr  
 20 25 30

<210> 939

<211> 48

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 939

Glu Leu Arg Met Ser Ser Ser Tyr Pro Thr Gly Leu Ala Asp Val Lys  
 1 5 10 15

Ala Gly Pro Ala Gln Thr Leu Ile Arg Pro Gln Asp Met Lys Gly Ala  
 20 25 30

Ser Arg Ser Pro Glu Asp Ser Ser Pro Asp Ala Ala Arg Ile Arg Val  
 35 40 45



<210> 940  
<211> 33  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 940  
Ser Leu Pro Glu Ala Gly Pro Gly Arg Thr Leu Val Ser Ser Lys Pro  
1 5 10 15  
Gln Ala His Gly Ala Pro Ala Pro Pro Ser Gly Ser Ala Pro His Phe  
20 25 30

Leu

<210> 941  
<211> 52  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 941  
Tyr Arg Gln Ser Met Asn Phe Gln Gly Leu Arg Ser Phe Gly Cys Arg  
1 5 10 15  
Phe Gly Thr Cys Thr Val Gln Lys Leu Ala His Gln Ile Tyr Gln Phe  
20 25 30  
Thr Asp Lys Asp Gly Val Ala Pro Arg Ser Lys Ile Ser Lys Ile Ser  
35 40 45  
Pro Gln Gly Tyr  
50

<210> 942  
<211> 20  
<212> PRT  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 942

Ala Arg Leu Asp Val Ala Ala Glu Phe Arg Lys Lys Trp Asn Lys Trp

1

5

10

15

Ala Leu Ser Arg

20

<210> 943

<211> 53

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 943

Tyr Arg Gln Ser Met Asn Gln Gly Ser Arg Ser Thr Gly Cys Arg Phe

1

5

10

15

Gly Thr Cys Thr Met Gln Lys Leu Ala His Gln Ile Tyr Gln Ile Tyr

20

25

30

Gln Phe Thr Asp Lys Asp Lys Asp Gly Met Ala Pro Arg Asn Lys Ile

35

40

45

Ser Pro Gln Gly Tyr

50

<210> 944

<211> 40

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 944

Ser Thr Gly Cys Arg Phe Gly Thr Cys Thr Met Gln Lys Leu Ala His

1

5

10

15

Gln Ile Tyr Gln Phe Thr Asp Lys Asp Lys Asp Gly Met Ala Pro Arg  
 20 25 30

Asn Lys Ile Ser Pro Gln Gly Tyr  
 35 40

<210> 945

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 945

Ala Arg Leu Asp Thr Ser Ser Gln Phe Arg Lys Lys Trp Asn Lys Trp  
 1 5 10 15

Ala Leu Ser Arg  
 20

<210> 946

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 946

Ala Pro Ser Gly Ala Gln Arg Leu Tyr Gly Phe Gly Leu  
 1 5 10

<210> 947

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 947

Gly Asp Gly Arg Leu Tyr Ala Phe Gly Leu  
1 5 10

<210> 948

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 948

Gly Gly Ser Leu Tyr Ser Phe Gly Leu  
1 5

<210> 949

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 949

Asp Arg Leu Tyr Ser Phe Gly Leu  
1 5

<210> 950

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 950

Val His His Gln Lys Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn  
1 5 10 15

Lys

<210> 951  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 951  
Gly Ser Asn Lys Gly Ala Ile Ile Gly Leu Met  
1 5 10

<210> 952  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 952  
Arg Glu Arg Met Ser  
1 5

<210> 953  
<211> 17  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 953  
Ala Lys Glu Arg Leu Glu Ala Lys His Arg Glu Arg Met Ser Gln Val  
1 5 10 15

Met

<210> 954

<211> 43  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 954  
Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys  
1 5 10 15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile  
20 25 30

Gly Leu Met Val Gly Gly Val Val Ile Ala Thr  
35 40

<210> 955  
<211> 42  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 955  
Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys  
1 5 10 15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile  
20 25 30

Gly Leu Met Val Gly Gly Val Val Ile Ala  
35 40

<210> 956  
<211> 40  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 956

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys  
1 5 10 15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile  
20 25 30

Gly Leu Met Val Gly Gly Val Val  
35 40

<210> 957

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 957

Tyr Glu Val His His Gln Lys Leu Val Phe Phe  
1 5 10

<210> 958

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 958

Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile Gly Leu Met  
1 5 10

<210> 959

<211> 28

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 959

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys  
1 5 10 15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys  
20 25

<210> 960

<211> 40

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 960

Val Val Gly Gly Val Met Leu Gly Ile Ile Ala Gly Lys Asn Ser Gly  
1 5 10 15

Val Asp Glu Ala Phe Phe Val Leu Lys Gln His His Val Glu Tyr Gly  
20 25 30

Ser Asp His Arg Phe Glu Ala Asp  
35 40

<210> 961

<211> 42

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 961

Asp Ala Glu Phe Gly His Asp Ser Gly Phe Glu Val Arg His Gln Lys  
1 5 10 15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile  
20 25 30

Gly Leu Met Val Gly Gly Val Val Ile Ala  
35 40



<210> 962  
<211> 40  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 962  
Asp Ala Glu Phe Phe Gly His Asp Ser Gly Phe Glu Val Arg His Gln Lys  
1 5 10 15  
Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile  
20 25 30  
Gly Leu Met Val Gly Gly Val Val  
35 40

<210> 963  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 963  
Tyr Glu Val His His Gln Lys Leu Val Phe Phe  
1 5 10

<210> 964  
<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 964  
Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile Gly Leu Met  
1 5 10

<210> 965  
<211> 28  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 965  
Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys  
1 5 10 15  
  
Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys  
20 25

<210> 966  
<211> 40  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 966  
Val Val Gly Gly Val Met Leu Gly Ile Ile Ala Gly Lys Asn Ser Gly  
1 5 10 15  
  
Val Asp Glu Ala Phe Phe Val Leu Lys Gln His His Val Glu Tyr Gly  
20 25 30  
  
Ser Asp His Arg Phe Glu Ala Asp  
35 40

<210> 967  
<211> 42  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 967  
Asp Ala Glu Phe Gly His Asp Ser Gly Phe Glu Val Arg His Gln Lys

1                    5                    10                    15  
 Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile  
                   20                    25                    30

Gly Leu Met Val Gly Gly Val Val Ile Ala  
                   35                    40

<210> 968

<211> 40

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 968

Asp Ala Glu Phe Gly His Asp Ser Gly Phe Glu Val Arg His Gln Lys  
                   1                    5                    10                    15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile  
                   20                    25                    30

Gly Leu Met Val Gly Gly Val Val  
                   35                    40

<210> 969

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 969

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu  
                   1                    5                    10

<210> 970

<211> 5

<212> PRT

<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 970  
Ile Ile Gly Leu Met  
1 5

<210> 971  
<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 971  
Ile Gly Leu Met  
1

<210> 972  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 972  
Met Leu Gly Ile Ile Ala Gly Lys Asn Ser Gly  
1 5 10

<210> 973  
<211> 15  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 973  
Asn Trp Cys Lys Arg Gly Arg Lys Gln Cys Lys Thr His Pro His

<210> 974

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 974

His His Gly Val Val Glu Val Asp Ala Ala Val Thr Pro Glu Glu Arg  
1 5 10 15

His Leu Ser Lys  
20

<210> 975

<211> 38

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 975

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys  
1 5 10 15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile  
20 25 30

Gly Leu Met Val Gly Gly  
35

<210> 976

<211> 28

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 976

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Gln Val His His Gln Lys  
1 5 10 15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys  
20 25

<210> 977

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 977

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Gln Val His His Gln Lys  
1 5 10 15

<210> 978

<211> 40

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 978

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys  
1 5 10 15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile  
20 25 30

Gly Leu Met Val Gly Gly Val Val  
35 40

<210> 979

<211> 35

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 979

His Asp Ser Gly Tyr Glu Val His His Gln Lys Leu Val Phe Phe Ala  
1 5 10 15

Gln Asp Val Gly Ser Asn Lys Gly Ala Ile Ile Gly Leu Met Val Gly  
20 25 30

Gly Val Val  
35

<210> 980

<211> 35

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 980

Glu Gln Val Thr Asn Val Gly Gly Ala Val Val Thr Gly Val Thr Ala  
1 5 10 15

Val Ala Gln Lys Thr Val Glu Gly Ala Gly Ser Ile Ala Ala Ala Thr  
20 25 30

Gly Phe Val  
35

<210> 981

<211> 24

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 981

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile  
1 5 10 15

Gly Leu Met Val Gly Gly Val Val

20

<210> 982

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 982

Gly Tyr Val Ile Ile Lys Pro Leu Val Trp Val

1

5

10

<210> 983

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 983

Val His His Gln Lys Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn

1

5

10

15

Lys

<210> 984

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 984

Gly Ser Asn Lys Gly Ala Ile Ile Gly Leu Met

1

5

10



<210> 985  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 985  
Arg Glu Arg Met Ser  
1 5

<210> 986  
<211> 17  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 986  
Ala Lys Glu Arg Leu Glu Ala Lys His Arg Glu Arg Met Ser Gln Val  
1 5 10 15

Met

<210> 987  
<211> 43  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 987  
Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys  
1 5 10 15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile  
20 25 30

Gly Leu Met Val Gly Gly Val Val Ile Ala Thr  
35 40

<210> 988

<211> 42

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 988

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys  
1 5 10 15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile  
20 25 30

Gly Leu Met Val Gly Gly Val Val Ile Ala  
35 40

<210> 989

<211> 40

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 989

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys  
1 5 10 15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile  
20 25 30

Gly Leu Met Val Gly Gly Val Val  
35 40

<210> 990

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 990

Tyr Glu Val His His Gln Lys Leu Val Phe Phe

1

5

10

<210> 991

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 991

Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile Gly Leu Met

1

5

10

<210> 992

<211> 28

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 992

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys

1

5

10

15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys

20

25

<210> 993

<211> 40

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

# Peptide

<400> 993

Val Val Gly Gly Val Met Leu Gly Ile Ile Ala Gly Lys Asn Ser Gly  
1 5 10 15

Val Asp Glu Ala Phe Phe Val Leu Lys Gln His His Val Glu Tyr Gly  
20 25 30

Ser Asp His Arg Phe Glu Ala Asp  
35 40

<210> 994

<211> 42

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 994

Asp Ala Glu Phe Gly His Asp Ser Gly Phe Glu Val Arg His Gln Lys  
1 5 10 15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile  
20 25 30

Gly Leu Met Val Gly Gly Val Val Ile Ala  
35 40

<210> 995

<211> 40

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 995

Asp Ala Glu Phe Gly His Asp Ser Gly Phe Glu Val Arg His Gln Lys  
1 5 10 15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile  
20 25 30

Gly Leu Met Val Gly Gly Val Val  
35 40

<210> 996  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 996  
Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu  
1 5 10

<210> 997  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 997  
Ile Ile Gly Leu Met  
1 5

<210> 998  
<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 998  
Ile Gly Leu Met  
1

<210> 999

<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 999  
Met Leu Gly Ile Ile Ala Gly Lys Asn Ser Gly  
1 5 10

<210> 1000  
<211> 15  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1000  
Asn Trp Cys Lys Arg Gly Arg Lys Gln Cys Lys Thr His Pro His  
1 5 10 15

<210> 1001  
<211> 20  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1001  
His His Gly Val Val Glu Val Asp Ala Ala Val Thr Pro Glu Glu Arg  
1 5 10 15  
  
His Leu Ser Lys  
20

<210> 1002  
<211> 38  
<212> PRT  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1002

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys  
1 5 10 15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile  
20 25 30

Gly Leu Met Val Gly Gly  
35

<210> 1003

<211> 28

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1003

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Gln Val His His Gln Lys  
1 5 10 15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys  
20 25

<210> 1004

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1004

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Gln Val His His Gln Lys  
1 5 10 15

<210> 1005

<211> 40  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1005  
Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys  
1 5 10 15  
Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile  
20 25 30  
Gly Leu Met Val Gly Gly Val Val  
35 40

<210> 1006  
<211> 35  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1006  
His Asp Ser Gly Tyr Glu Val His His Gln Lys Leu Val Phe Phe Ala  
1 5 10 15  
Gln Asp Val Gly Ser Asn Lys Gly Ala Ile Ile Gly Leu Met Val Gly  
20 25 30  
Gly Val Val  
35

<210> 1007  
<211> 35  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide



<400> 1007  
Glu Gln Val Thr Asn Val Gly Gly Ala Val Val Thr Gly Val Thr Ala  
1 5 10 15

Val Ala Gln Lys Thr Val Glu Gly Ala Gly Ser Ile Ala Ala Thr  
20 25 30

Gly Phe Val  
35

<210> 1008  
<211> 24  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1008  
Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile  
1 5 10 15

Gly Leu Met Val Gly Gly Val Val  
20

<210> 1009  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1009  
Gly Tyr Val Ile Ile Lys Pro Leu Val Trp Val  
1 5 10

<210> 1010  
<211> 63  
<212> PRT  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1010

Arg Leu Glu Lys Arg Asp Val Lys Ala Val Cys Ser Gln Glu Ala Met  
1 5 10 15

Thr Gly Pro Cys Arg Ala Val Met Pro Arg Trp Tyr Phe Asp Leu Ser  
20 25 30

Lys Gly Lys Cys Val Arg Phe Ile Tyr Gly Gly Cys Gly Gly Asn Arg  
35 40 45

Asn Asn Phe Glu Ser Glu Asp Tyr Cys Met Ala Val Cys Lys Ala  
50 55 60

<210> 1011

<211> 39

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1011

Asn Ser Ser Cys Gly Glu Gly Asn His Leu Pro Thr Thr Pro Cys Tyr  
1 5 10 15

Leu Gln Trp Gly Thr His Arg Glu Phe Leu Arg Arg Phe Ser Ile Trp  
20 25 30

Asn His Gly His Leu His Met  
35

<210> 1012

<211> 39

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1012

Ala Gly Arg Gly Lys Gln Gly Gly Lys Val Arg Ala Lys Ala Lys Thr

1

5

10

15

Arg Ser Ser Arg Ala Gly Leu Gln Phe Pro Val Gly Arg Val His Arg  
 20 25 30

Leu Leu Arg Lys Gly Asn Tyr  
 35

<210> 1013

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 1013

Thr Arg Ser Ser Arg Ala Gly Leu Gln Phe Pro Val Gly Arg Val His  
 1 5 10 15

Arg Leu Leu Arg Lys  
 20

<210> 1014

<211> 37

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 1014

Lys Trp Lys Leu Phe Lys Lys Ile Glu Lys Val Gly Gln Asn Ile Arg  
 1 5 10 15

Asp Gly Ile Ile Lys Ala Gly Pro Ala Val Ala Val Val Gly Gln Ala  
 20 25 30

Thr Gln Ile Ala Lys  
 35

<210> 1015

<211> 32

<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1015  
Ser Trp Leu Ser Lys Thr Ala Lys Lys Leu Glu Asn Ser Ala Lys Lys  
1 5 10 15  
Arg Ile Ser Glu Gly Ile Ala Ile Ala Ile Gln Gly Gly Pro Arg Cys  
20 25 30

<210> 1016  
<211> 31  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1016  
Gly Ile Met Ser Ile Val Lys Asp Val Ala Lys Asn Ala Ala Lys Gly  
1 5 10 15  
Ala Leu Ser Thr Leu Ser Thr Leu Ser Cys Lys Leu Ala Lys Thr  
20 25 30

<210> 1017  
<211> 24  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1017  
Phe Leu Gly Ala Leu Phe Lys Val Ala Ser Lys Val Leu Pro Ser Val  
1 5 10 15

Lys Cys Ala Ile Thr Lys Lys Cys

20

<210> 1018

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1018

Ile Leu Pro Trp Lys Trp Pro Trp Trp Pro Trp Arg Arg

1

5

10

<210> 1019

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1019

Arg Gly Gly Arg Leu Cys Tyr Cys Arg Arg Arg Phe Cys Val Cys Val

1

5

10

15

Gly Arg

<210> 1020

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1020

Arg Arg Trp Cys Tyr Arg Lys Cys Tyr Lys Gly Tyr Cys Tyr Arg Lys

1

5

10

15

Cys Arg

<210> 1021

<211> 35

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1021

Arg Trp Lys Ile Phe Lys Lys Ile Glu Lys Val Gly Gln Asn Ile Arg  
1 5 10 15

Asp Gly Ile Val Lys Ala Gly Pro Ala Val Ala Val Val Gly Gln Ala  
20 25 30

Ala Thr Ile  
35

<210> 1022

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1022

Arg Leu Cys Arg Ile Val Val Ile Arg Val Cys Arg  
1 5 10

<210> 1023

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1023

Thr	Arg	Ser	Ser	Arg	Ala	Gly	Leu	Gln	Phe	Pro	Val	Gly	Arg	Val	His
1				5					10					15	

Arg	Leu	Leu	Arg	Lys
				20

<210> 1024  
 <211> 14  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

Tyr	Pro	Pro	Gly	Pro	Leu	Ala	Pro	Pro	Gln	Pro	Phe	Gly	Pro
1					5					10			

<210> 1025  
 <211> 22  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

Val	Asn	Pro	Gly	Val	Val	Val	Arg	Ile	Ser	Gln	Lys	Gly	Leu	Asp	Tyr
1					5					10				15	

Ala	Ser	Gln	Gln	Gly	Arg
					20

<210> 1026  
 <211> 15  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 1026

Ala Asp Val Leu Thr Thr Gly Ala Gly Asn Pro Val Gly Asp Lys  
1 5 10 15

<210> 1027

<211> 42

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1027

Met Ala Ala Val Ser Met Ser Val Ala Leu Arg Gln Ala Leu Trp Gly  
1 5 10 15

Arg Arg Val Ala Thr Val Ala Ala Val Ser Val Ser Lys Val Ser Thr  
20 25 30

Arg Ser Leu Ser Thr Ser Thr Trp Arg Leu  
35 40

<210> 1028

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1028

Gly Ile Gly Lys Phe Lys His Ser Ala Gly Lys Phe Gly Lys Ala Phe  
1 5 10 15

Val Gly Glu Ile Met Lys Ser  
20

<210> 1029

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic



Peptide

<400> 1029

Leu Arg Asp Leu Val Ser Tyr Cys Arg Ala Arg Gly Lys Gly Arg Glu  
1 5 10 15

Arg Met Asn Gly Thr Arg Lys Gly His Leu Leu Tyr Met  
20 25

<210> 1030

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1030

Ser Gln Asn Tyr  
1

<210> 1031

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1031

Arg Leu Cys Arg Ile Val Val Ile Arg Val Cys Arg  
1 5 10

<210> 1032

<211> 25

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1032

Asn	Gln	Gly	Arg	His	Phe	Cys	Gly	Gly	Ala	Leu	Ile	His	Ala	Arg	Phe
1				5					10					15	

Val	Met	Thr	Ala	Ala	Ser	Cys	Phe	Gln
			20					25

<210> 1033

<211> 2

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1033

Pro Phe

1

<210> 1034

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1034

Cys	Asn	Leu	Ala	Val	Ala	Ala	Ala	Ser	His	Ile	Tyr	Gln	Asn	Gln	Phe
1				5					10					15	

Val Gln

<210> 1035

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1035

Tyr Arg Val Arg Phe Leu Ala Lys Glu Asn Val Thr Gln Asp Ala Glu  
 1 5 10 15

Asp Asn Cys

<210> 1036

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 1036

Lys Trp Lys Leu Phe Lys Lys Ile Gly Ala Val Leu Lys Val Leu  
 1 5 10 15

<210> 1037

<211> 35

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 1037

Lys Trp Lys Val Phe Lys Lys Ile Glu Lys Met Gly Arg Asn Ile Arg  
 1 5 10 15

Asn Gly Ile Val Lys Ala Gly Pro Ala Ile Ala Val Leu Gly Glu Ala  
 20 25 30

Lys Ala Leu  
 35

<210> 1038

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

Peptide

<400> 1038

Thr Tyr Ile Cys Glu Val Glu Asp Gln Lys Glu Glu

1 5 10

<210> 1039

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1039

Cys Tyr Cys Arg Ile Pro Ala Cys Ile Ala Gly Glu Arg Arg Tyr Gly

1 5 10 15

Thr Cys Ile Tyr Gln Gly Arg Leu Trp Ala Phe Cys Cys

20 25

<210> 1040

<211> 34

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1040

Ala Leu Trp Lys Thr Met Leu Lys Lys Leu Gly Thr Met Ala Leu His

1 5 10 15

Ala Gly Lys Ala Ala Leu Gly Ala Ala Ala Asp Thr Ile Ser Gln Gly

20 25 30

Thr Gln

<210> 1041

<211> 24

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1041

Gly Val Leu Ser Asn Val Ile Gly Tyr Leu Lys Lys Leu Gly Thr Gly  
1 5 10 15

Ala Leu Asn Ala Val Leu Lys Gln  
20

<210> 1042

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1042

Val Glu Pro Ile Pro Tyr  
1 5

<210> 1043

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1043

Arg Arg Trp Gln Trp Arg Met Lys Lys Leu Gly  
1 5 10

<210> 1044

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

Peptide

<400> 1044

Asp Ala Glu Ala Val Gly Pro Glu Ala Phe Ala Asp Gln Asp Leu Asp  
1 5 10 15

Glu Arg Glu Val Arg  
20

<210> 1045

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1045

Ser Ile Gly Ser Leu Ala Lys  
1 5

<210> 1046

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1046

Gly Ile Gly Lys Phe Leu His Ser Ala Gly Lys Phe Gly Lys Ala Phe  
1 5 10 15

Val Gly Glu Ile Met Lys Ser  
20

<210> 1047

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

Peptide

<400> 1047

Gly Ile Gly Lys Phe Leu His Ser Ala Lys Lys Phe Gly Lys Ala Phe  
1 5 10 15

Val Gly Glu Ile Met Asn Ser

20

<210> 1048

<211> 27

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1048

Tyr Leu Val Leu Phe Phe Tyr Pro Leu Asp Phe Thr Phe Val Cys Pro  
1 5 10 15

Thr Glu Ile Ile Cys Pro Thr Glu Ile Ile Gly  
20 25

<210> 1049

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1049

Leu Val Gln Ala Phe Gln Gly Lys Val Asn Val Phe Leu Gln Phe  
1 5 10 15

<210> 1050

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

Peptide

<400> 1050

Gly Leu Phe Ile Ile Asp Tyr Thr Asp Glu Met Gly Glu Val Pro Ala  
1 5 10 15

Gly Gly Lys

<210> 1051

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1051

Asp Glu Val Asp  
1

<210> 1052

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1052

Asp Glu Val Asp  
1

<210> 1053

<211> 3

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1053



Val Ala Asp

1

<210> 1054

<211> 3

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1054

Val Ala Asp

1

<210> 1055

<211> 27

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1055

Asp Pro Met Ser Ser Thr Tyr Ile Glu Glu Leu Gly Lys Arg Glu Val

1

5

10

15

Thr Ile Pro Pro Lys Tyr Arg Glu Leu Leu Ala

20

25

<210> 1056

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1056

Val Ala Asp Met

1

<210> 1057  
<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1057  
Asp Glu Val Asp  
1

<210> 1058  
<211> 20  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1058  
Ala Ala Val Ala Leu Leu Pro Ala Val Leu Leu Ala Leu Leu Ala Pro  
1 5 10 15

Tyr Val Ala Asp  
20

<210> 1059  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1059  
Tyr Val Ala Asp Ala Pro Lys  
1 5

<210> 1060  
<211> 20

<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide  
  
<400> 1060  
Ala Ala Val Ala Leu Leu Pro Ala Val Leu Leu Ala Leu Leu Ala Pro  
1 5 10 15  
  
Asp Glu Val Asp  
20

<210> 1061  
<211> 4  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide  
  
<400> 1061  
Tyr Val Ala Asp  
1  
  
<210> 1062  
<211> 4  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1062  
Tyr Val Ala Asp  
1

<210> 1063  
<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1063  
Tyr Val Ala Asp  
1

<210> 1064  
<211> 2  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1064  
Val Phe  
1

<210> 1065  
<211> 3  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1065  
Leu Leu Leu  
1

<210> 1066  
<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1066  
Tyr Val Ala Asp

1

<210> 1067

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1067

Val Glu Ile Asp

1

<210> 1068

<211> 1

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1068

Asp

1

<210> 1069

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1069

Asp Glu Val Asp Ala Pro Lys

1

5

<210> 1070

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1070

Asp Met Phe Ser Asp Gly Asn Phe Asn Trp Val Arg Val Val Ala Leu  
1 5 10 15

Phe Tyr Phe Ala Ser  
20

<210> 1071

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1071

Ala Asn Arg Leu Phe Gly Glu Lys  
1 5

<210> 1072

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1072

Gly Gly Gly Gly Asp Ile His Gln Gly Phe Gln Ser Leu Leu Thr Glu  
1 5 10 15

Val Asn Lys

<210> 1073

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1073

Gly Asn Thr Ala Ala Gln Met Ala Gln Ile Leu Ser Phe Asn  
1 5 10

<210> 1074

<211> 25

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1074

Gln Gly Leu Trp Leu Met Asn Val Leu Arg Val Gly Trp His His His  
1 5 10 15

Leu Gln Pro Arg Thr Val Pro Glu Asn  
20 25

<210> 1075

<211> 35

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1075

Thr Gly His Gly Gly Pro Gln Phe Val Ala Asp His Pro Phe Leu Phe  
1 5 10 15

Leu Ile Met His Lys Ile Thr Asn Cys Ile Leu Phe Phe Gly Arg Phe  
20 25 30

Ser Ser Pro  
35

<210> 1076  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1076  
Ala Pro Arg Leu Arg Phe Tyr Ser Leu  
1 5

<210> 1077  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1077  
Ala Pro Arg Leu Arg Phe Tyr Ser  
1 5

<210> 1078  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1078  
Ala Pro Arg Leu Arg Phe Tyr  
1 5

<210> 1079  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>



<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1079  
Arg Leu Arg Phe His  
1 5

<210> 1080  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1080  
Arg Leu Arg Phe Asp  
1 5

<210> 1081  
<211> 23  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1081  
Leu Lys Lys Tyr Lys Val Pro Gln Leu Glu Ile Val Pro Asn Ser Ala  
1 5 10 15

Glu Glu Arg Leu His Ser Met  
20

<210> 1082  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1082

Gln Lys Leu Gly Asn Gln Trp Ala Val Gly His Leu Met  
1 5 10

<210> 1083

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1083

Trp Ala Val Gly His Leu Met  
1 5

<210> 1084

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1084

Glu Gln Arg Leu Gly Asn Gln Trp Ala Val Gly His Leu Met  
1 5 10

<210> 1085

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1085

Glu Gln Arg Leu Gly Asn Gln Trp Ala Val Gly His Leu Leu  
1 5 10

<210> 1086

<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1086  
Phe Gln Trp Ala Val Gly His Leu  
1 5

<210> 1087  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1087  
Gln Arg Leu Gly Asn Gln Trp Ala Val Gly Phe Leu Met  
1 5 10

<210> 1088  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1088  
Gln Arg Leu Gly Asn Gln Trp Ala Val Gly Phe Leu Leu  
1 5 10

<210> 1089  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic

Peptide

<400> 1089

Gln Arg Tyr Gly Asn Gln Trp Ala Val Gly His Leu Met  
1 5 10

<210> 1090

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1090

Gln Arg Tyr Gly Asn Gln Trp Ala Val Gly Phe Leu Met  
1 5 10

<210> 1091

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1091

Met Pro Leu Pro Pro His Pro Gly His Pro Gly Tyr Ile Asn Phe Ser  
1 5 10 15

Tyr Glu Val Leu Thr

20

<210> 1092

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1092

Pro Phe Tyr Gly Pro Val

1

5

<210> 1093

<211> 47

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1093

Tyr Leu Tyr Gln Trp Leu Gly Ala Pro Val Pro Tyr Pro Asp Pro Leu

1

5

10

15

Glu Pro Arg Arg Val Cys Leu Asn Pro Asp Cys Asp Glu Leu Ala Asp

20

25

30

His Ile Gly Phe Gln Glu Ala Tyr Arg Arg Phe Tyr Gly Pro Val

35

40

45

<210> 1094

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1094

Leu Val Val Tyr Pro Trp

1

5

<210> 1095

<211> 46

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1095

Tyr Leu Tyr Gln Trp Leu Gly Ala Pro Val Pro Tyr Pro Asp Pro Leu  
 1 5 10 15  
 Pro Arg Arg Val Cys Leu Asn Pro Asp Cys Asp Glu Leu Ala Asp His  
 20 25 30  
 Ile Gly Phe Gln Glu Ala Tyr Arg Arg Phe Tyr Gly Pro Val  
 35 40 45

<210> 1096

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 1096

Gly Phe Gln Glu Ala Tyr Arg Arg Phe Tyr Gly Pro Val  
 1 5 10

<210> 1097

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 1097

Pro Tyr Gln Glu Ala Phe Arg Arg Phe Phe Gly Pro Val  
 1 5 10

<210> 1098

<211> 48

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 1098

Val Pro Ile Tyr Glu Lys Lys Tyr Gly Gln Val Pro Met Cys Asp Ala  
 1 5 10 15  
 Gly Glu Gln Cys Ala Val Arg Lys Gly Ala Arg Ile Gly Lys Leu Cys  
 20 25 30  
 Asp Cys Pro Arg Gly Thr Ser Cys Asn Ser Phe Leu Leu Lys Cys Leu  
 35 40 45

<210> 1099

<211> 48

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 1099

Val Pro Ile Tyr Glu Lys Lys Tyr Gly Gln Val Pro Met Cys Asp Ala  
 1 5 10 15  
 Gly Glu Gln Cys Ala Val Arg Lys Gly Ala Arg Ile Gly Lys Leu Cys  
 20 25 30  
 Asp Cys Pro Arg Gly Thr Ser Cys Asn Ser Phe Leu Leu Lys Cys Leu  
 35 40 45

<210> 1100

<211> 48

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 1100

Val Pro Ile Tyr Glu Lys Lys Tyr Gly Gln Val Pro Met Cys Asp Ala  
 1 5 10 15

Gly Glu Gln Cys Ala Val Arg Lys Gly Ala Arg Ile Gly Lys Leu Cys  
 20 25 30

Asp Cys Pro Arg Gly Thr Ser Cys Asn Ser Phe Leu Leu Lys Cys Leu  
 35 40 45

<210> 1101  
 <211> 28  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 1101  
 Ala Gly Ala Thr Val Gln Val Thr Leu Asp Gly Val Pro Ala Ala Ala  
 1 5 10 15

Pro Gly Gln Pro Ala Gln Leu Gln Leu Asn Ala Thr  
 20 25

<210> 1102  
 <211> 5  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 1102  
 Phe Leu Phe Leu Phe  
 1 5

<210> 1103  
 <211> 30  
 <212> PRT  
 <213> Artificial Sequence

<220>



<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1103

Ala Cys Tyr Cys Arg Ile Pro Ala Cys Ile Ala Gly Glu Arg Arg Tyr  
1 5 10 15

Gly Thr Cys Ile Tyr Gln Gly Arg Leu Trp Ala Phe Cys Cys  
20 25 30

<210> 1104

<211> 3

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1104

Met Leu Phe  
1

<210> 1105

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1105

Met Leu Phe Lys  
1

<210> 1106

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1106  
Met Leu Phe Lys  
1

<210> 1107  
<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1107  
Trp His Val Ala Ala Asn  
1 5

<210> 1108  
<211> 25  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1108  
Met Leu Thr Glu Leu Glu Lys Ala Leu Asn Ser Ile Ile Asp Val Tyr  
1 5 10 15  
His Lys Tyr Ser Leu Ile Lys Gly Asn  
20 25

<210> 1109  
<211> 19  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1109  
His Trp Asp Thr Thr Gln Ser Leu Lys Gln Leu Glu Glu Arg Ala Ala  
1 5 10 15

Trp Asn Val

<210> 1110  
<211> 20  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1110  
Gly Pro Val Ser Ala Val Leu Thr Glu Leu Arg Cys Thr Cys Leu Arg  
1 5 10 15

Val Thr Leu Arg  
20

<210> 1111  
<211> 21  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1111  
Ile Gln Arg Thr Pro Lys Ile Gln Val Tyr Ser Arg His Pro Ala Glu  
1 5 10 15

Asn Gly Lys Ser Asn  
20

<210> 1112  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1112

Arg Glu Gly Ser Tyr Phe Phe Gly Asp Asn Ala  
1 5 10

<210> 1113

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1113

Tyr Ser Asp Asp Glu Gly Ala Ser Trp Ser Asp Leu Asp Ile Val Ser  
1 5 10 15

Phe Ser Lys

<210> 1114

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1114

Val Ala Arg Thr Leu Leu Val Phe Glu Val Gln Gln Pro Phe Leu Phe  
1 5 10 15

Val Leu

<210> 1115

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1115  
Asp Phe Arg Phe Leu Arg Cys Ser Thr Arg Gln Cys Trp Asn  
1 5 10

<210> 1116  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1116  
Cys Asn Thr Gly Gln Leu Cys Pro Val Glu  
1 5 10

<210> 1117  
<211> 18  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1117  
Ser Val Asp Arg Ser Gly Asn Val His His Gln Phe Gln Lys Leu Thr  
1 5 10 15

Leu Glu

<210> 1118  
<211> 19  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1118  
Leu His Glu Trp Thr Lys Pro Glu Asn Leu Asp Phe Ile Glu Val Asn  
1 5 10 15

Val Leu Pro

<210> 1119  
<211> 29  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1119  
Val Leu Glu Leu Pro Tyr Gln Gly Glu Glu Leu Ser Met Val Ile Leu  
1 5 10 15

Leu Pro Asp Asp Ile Glu Asp Glu Ser Thr Gly Leu Lys  
20 25

<210> 1120  
<211> 19  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1120  
Thr Tyr Gly Ala Asp Leu Ala Ser Val Asp Phe Gln His Ala Ser Glu  
1 5 10 15

Asp Ala Arg

<210> 1121  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1121  
Glu Arg Pro Pro Leu Gln Gln Pro Pro His Arg Asp  
1 5 10

<210> 1122  
<211> 29  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1122  
Tyr Glu Arg Pro Pro Leu Gln Gln Pro Pro His Arg Asp Lys Lys Pro  
1 5 10 15  
Cys Lys Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys Lys  
20 25

<210> 1123  
<211> 20  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1123  
Ser Ala Leu Pro Leu Glu Ser Gly Pro Thr Gly Gln Asp Ser Val Gln  
1 5 10 15  
Asp Ala Thr Gly  
20

<210> 1124  
<211> 31  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1124  
Thr Gly Leu Leu Thr Phe Leu Ala Trp Trp His Glu Trp Ala Ser Gln  
1 5 10 15

Asp Ser Ser Ser Thr Ala Phe Glu Gly Gly Thr Pro Glu Leu Ser  
20 25 30

<210> 1125  
<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1125  
Arg Gly Asp Cys  
1

<210> 1126  
<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1126  
Arg Gly Asp Ser  
1

<210> 1127  
<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1127  
Arg Gly Asp Val  
1



<210> 1128  
<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1128  
Arg Gly Glu Ser  
1

<210> 1129  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1129  
Gly Arg Gly Asp Ser Pro Ala  
1 5

<210> 1130  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1130  
Arg Gly Asp Phe Val  
1 5

<210> 1131  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1131

Pro Leu Tyr Lys Lys Ile Ile Lys Lys Leu Leu Ser

1

5

10

<210> 1132

<211> 49

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1132

Glu Cys Glu Ser Gly Pro Cys Cys Arg Asn Cys Lys Phe Leu Lys Glu

1

5

10

15

Gly Thr Ile Cys Lys Arg Ala Arg Gly Asp Asp Met Asp Asp Tyr Cys

20

25

30

Asn Gly Lys Thr Cys Asp Cys Pro Arg Asn Pro His Lys Gly Pro Ala

35

40

45

Thr

<210> 1133

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1133

Gly Arg Ala Asp Ser Pro Lys

1

5

<210> 1134

<211> 37  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1134  
Phe Asn Lys His Thr Glu Ile Ile Glu Glu Asp Thr Asn Lys Asp Lys  
1 5 10 15  
Pro Ser Tyr Gln Phe Gly Gly His Asn Ser Val Asp Phe Glu Glu Asp  
20 25 30  
Thr Leu Pro Lys Val  
35

<210> 1135  
<211> 16  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1135  
Ala Asp Ser Gly Glu Gly Asp Phe Leu Ala Glu Gly Gly Val Arg  
1 5 10 15

<210> 1136  
<211> 17  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1136  
Tyr Ala Asp Ser Gly Glu Gly Asp Phe Leu Ala Glu Gly Gly Val  
1 5 10 15

Arg

<210> 1137  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1137  
Gly Val Asn Asp Asn Glu Glu Gly Phe Phe Ser Ala Arg  
1 5 10

<210> 1138  
<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1138  
Glu Gly Val Asn Asp Asn Glu Glu Gly Phe Phe Ser Ala Arg  
1 5 10

<210> 1139  
<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1139  
Gly Val Asn Asp Asn Glu Glu Gly Phe Phe Ser Ala Arg Tyr  
1 5 10

<210> 1140  
<211> 18  
<212> PRT  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1140

Tyr Glu Lys Pro Gly Ser Pro Pro Arg Glu Val Val Pro Arg Pro Arg  
1 5 10 15

Gly Val

<210> 1141

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1141

Trp Gln Pro Pro Arg Ala Arg Ile  
1 5

<210> 1142

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1142

Glu Ile Leu Asp Val  
1 5

<210> 1143

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

Peptide

<400> 1143

Glu Ile Leu Asp Val Pro Ser Thr

1

5

<210> 1144

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1144

Gly Arg Ala Asp Ser Pro

1

5

<210> 1145

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1145

Gly Arg Gly Asp Ser

1

5

<210> 1146

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1146

Gly Arg Gly Asp Ser Pro

1

5

<210> 1147  
<211> 7  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1147  
Gly Arg Gly Asp Ser Pro Cys  
1 5

<210> 1148  
<211> 6  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1148  
Gly Arg Gly Asp Thr Pro  
1 5

<210> 1149  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1149  
Gly Arg Gly Glu Ser  
1 5

<210> 1150  
<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1150  
Gly Arg Gly Glu Ser Pro  
1 5

<210> 1151  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1151  
Gly Gly Asp Ser Pro  
1 5

<210> 1152  
<211> 15  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1152  
Gly Gln Gln His His Leu Gly Gly Ala Lys Gln Ala Gly Asp Val  
1 5 10 15

<210> 1153  
<211> 3  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1153  
Gly Pro Arg



1

<210> 1154

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1154

Gly Arg Gly Asp Ser Pro Ala Ser Ser Lys  
1 5 10

<210> 1155

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1155

Gly Gly Arg Gly Asp Ser Pro Cys Ala  
1 5

<210> 1156

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1156

Gly Arg Gly Asp Ser Pro  
1 5

<210> 1157

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1157

Gly Arg Gly Asp Asn Pro  
1 5

<210> 1158

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1158

Trp Gln Pro Pro Arg Ala Arg Ile  
1 5

<210> 1159

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1159

Tyr Ile Gly Ser Arg  
1 5

<210> 1160

<211> 3

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1160  
Leu Asp Val  
1

<210> 1161  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1161  
Leu Asp Val Pro Ser  
1 5

<210> 1162  
<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1162  
Lys Gly Asp Ser  
1

<210> 1163  
<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1163  
Gly Ala Val Ser Thr Ala  
1 5

<210> 1164

<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1164  
Trp Thr Val Pro Thr Ala  
1 5

<210> 1165  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1165  
Arg Gly Asp Ser Pro  
1 5

<210> 1166  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1166  
Thr Asp Val Asn Gly Asp Gly Arg His Asp Leu  
1 5 10

<210> 1167  
<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic

Peptide

<400> 1167

Arg Glu Asp Val

1

<210> 1168

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1168

Arg Gly Asp Ser Pro Ala Ser Ser Lys Pro

1

5

10

<210> 1169

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1169

Arg Gly Asp Thr

1

<210> 1170

<211> 3

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1170

Arg Asp Ser

1

<210> 1171  
<211> 5  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1171  
Ser Asp Gly Arg Gly  
1 5

<210> 1172  
<211> 4  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1172  
Ser Asp Gly Arg  
1

<210> 1173  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1173  
Tyr Arg Gly Asp Ser  
1 5

<210> 1174  
<211> 42  
<212> PRT  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1174

Tyr Ala Lys Leu Leu Gly His Gln Asn Leu Lys Gln Lys Ile Lys His  
1 5 10 15

Val Val Lys Leu Lys Asp Glu Asn Ser Gln Leu Lys Ser Glu Val Ser  
20 25 30

Lys Leu Arg Cys Gln Leu Ala Lys Lys Lys  
35 40

<210> 1175

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1175

Phe Met Arg Phe  
1

<210> 1176

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1176

Phe Met Arg Phe  
1

<210> 1177

<211> 4

<212> PRT

<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1177  
Phe Met Arg Phe  
1

<210> 1178  
<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1178  
Phe Met Arg Phe  
1

<210> 1179  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1179  
Leu Pro Leu Arg Phe  
1 5

<210> 1180  
<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1180  
Tyr Leu Pro Leu Arg Phe



<210> 1181  
<211> 3  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1181  
Trp Arg Phe  
1

<210> 1182  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1182  
Tyr Phe Met Arg Phe  
1 5

<210> 1183  
<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1183  
Tyr Met Arg Phe  
1

<210> 1184  
<211> 8  
<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 1184

Ser Asp Arg Asn Phe Leu Arg Phe  
1 5

<210> 1185

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 1185

Ser Asp Arg Asn Phe Leu Arg Phe  
1 5

<210> 1186

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 1186

Asp Pro Phe Leu Arg Phe  
1 5

<210> 1187

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 1187

Glu Ile Leu Glu Val Pro Ser Thr

1

5

<210> 1188

<211> 30

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1188

Gly Trp Thr Leu Asn Ser Ala Gly Tyr Leu Leu Gly Pro His Ala Val

1

5

10

15

Gly Asn His Arg Ser Phe Ser Asp Lys Asn Gly Leu Thr Ser

20

25

30

<210> 1189

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1189

Gly Trp Thr Leu Asn Ser Ala Gly Tyr Leu Leu Gly Pro His Ala Val

1

5

10

15

Gly Asn His

<210> 1190

<211> 30

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1190

Met Ala Arg Gly Ser Ala Leu Leu Leu Ala Ser Leu Leu Leu Ala Ala  
1 5 10 15

Ala Leu Ser Ala Ser Ala Gly Leu Trp Ser Pro Ala Lys Glu  
20 25 30

<210> 1191

<211> 24

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1191

Glu Leu Arg Pro Glu Asp Asp Met Lys Pro Gly Ser Phe Asp Arg Ser  
1 5 10 15

Ile Pro Glu Asn Asn Ile Met Arg  
20

<210> 1192

<211> 35

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1192

Thr Ile Ile Glu Phe Leu Ser Phe Leu His Leu Lys Glu Ala Gly Ala  
1 5 10 15

Leu Asp Arg Leu Leu Asp Leu Pro Ala Ala Ala Ser Ser Glu Asp Ile  
20 25 30

Glu Arg Ser  
35

<210> 1193

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1193

Gly Trp Thr Leu Asn Ser Ala Gly Tyr Leu Leu Gly Pro His Ala Ile  
1 5 10 15

Asp Asn His Arg Ser Phe His Asp Lys Tyr Gly Leu Ala  
20 25

<210> 1194

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1194

Gly Trp Thr Leu Asn Ser Ala Gly Tyr Leu Leu Gly Pro His Ala Ile  
1 5 10 15

<210> 1195

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1195

Gly Trp Thr Leu Asn Ser Ala Gly Tyr Leu Leu Gly Pro His Ala Ile  
1 5 10 15

Asp Asn His Arg Ser Phe Ser Asp Lys His Gly Leu Thr  
20 25

<210> 1196

<211> 40

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1196

Thr Lys Glu Lys Arg Gly Trp Thr Leu Asn Ser Ala Gly Tyr Leu Leu  
1 5 10 15

Gly Pro His Ala Ile Asp Asn His Arg Ser Phe Ser Asp Lys His Gly  
20 25 30

Leu Thr Gly Lys Arg Glu Leu Pro  
35 40

<210> 1197

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1197

Gly Trp Thr Leu Asn Ser Ala Gly Tyr Leu Leu Gly Pro Pro Pro Gly  
1 5 10 15

Phe Ser Pro Phe Arg  
20

<210> 1198

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1198

Gly Trp Thr Leu Asn Ser Ala Gly Tyr Leu Leu Gly Pro Pro Pro Ala  
1 5 10 15

Leu Ala Leu Ala

<210> 1199  
 <211> 24  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 1199  
 Gly Trp Thr Leu Asn Ser Ala Gly Tyr Leu Leu Gly Pro Arg Pro Lys  
 1 5 10 15  
 Pro Gln Gln Trp Phe Trp Leu Leu  
 20

<210> 1200  
 <211> 41  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 1200  
 Glu Leu Glu Pro Glu Asp Glu Ala Arg Pro Gly Gly Phe Asp Arg Leu  
 1 5 10 15  
 Gln Ser Glu Asp Lys Ala Ile Arg Thr Ile Met Glu Phe Leu Ala Phe  
 20 25 30  
 Leu His Leu Lys Glu Ala Gly Ala Leu  
 35 40

<210> 1201  
 <211> 26  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 1201

Leu Gln Ser Glu Asp Lys Ala Ile Arg Thr Ile Met Glu Phe Leu Ala  
1 5 10 15

Phe Leu His Leu Lys Glu Ala Gly Ala Leu  
20 25

<210> 1202

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1202

Thr Ile Met Glu Phe Leu Ala Phe Leu His Leu Lys Glu Ala Gly Ala  
1 5 10 15

Leu

<210> 1203

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1203

Gly Trp Thr Leu Asn Ser Ala Gly Tyr Leu Leu Gly Pro Gln Gln Phe  
1 5 10 15

Phe Gly Leu Met  
20

<210> 1204

<211> 15

<212> PRT

<213> Artificial Sequence



<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1204

Gly Trp Thr Leu Asn Thr Ala Trp Trp Leu Leu Gly Pro His Ala  
1 5 10 15

<210> 1205

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1205

Gly Trp Thr Leu Asn Thr Ala Trp Trp Leu Leu Gly Pro His Ala  
1 5 10 15

<210> 1206

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1206

Gly Trp Thr Leu Asn Ser Ala Gly Tyr Leu Leu Gly Pro Pro Ala  
1 5 10 15

Leu Ala Leu Ala

20

<210> 1207

<211> 24

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1207

Gly Trp Thr Leu Asn Ser Ala Gly Tyr Leu Leu Gly Pro Arg Pro Lys  
1 5 10 15

Pro Gln Gln Trp Phe Trp Leu Leu  
20

<210> 1208

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1208

Asp Glu Pro Asn Ser Asp Gln Phe Ile Gly Leu Met  
1 5 10

<210> 1209

<211> 120

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1209

Lys Lys Lys Asp Lys Val Lys Lys Gly Gly Pro Gly Ser Glu Cys Ala  
1 5 10 15

Glu Trp Ala Trp Gly Pro Cys Thr Pro Ser Ser Lys Asp Cys Gly Val  
20 25 30

Gly Phe Arg Glu Gly Thr Cys Gly Ala Gln Thr Gln Arg Ile Arg Cys  
35 40 45

Arg Val Pro Cys Asn Trp Lys Lys Glu Phe Gly Ala Asp Cys Lys Lys  
50 55 60

Phe Glu Asn Trp Gly Ala Cys Asp Gly Gly Thr Gly Thr Lys Val Arg  
65 70 75 80

Gln Gly Thr Leu Lys Lys Ala Arg Tyr Asn Ala Gln Cys Gln Glu Thr  
85 90 95

Ile Arg Val Thr Lys Pro Cys Thr Pro Lys Thr Lys Ala Lys Ala Lys  
100 105 110

Ala Lys Lys Gly Lys Gly Lys Asp  
115 120

<210> 1210  
<211> 61  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1210  
Ala Asp Cys Lys Lys Phe Glu Asn Trp Gly Ala Cys Asp Gly Gly Thr  
1 5 10 15

Gly Thr Lys Val Arg Gln Gly Thr Leu Lys Lys Ala Arg Tyr Asn Ala  
20 25 30

Gln Cys Gln Glu Thr Ile Arg Val Thr Lys Pro Cys Thr Pro Lys Thr  
35 40 45

Lys Ala Lys Ala Lys Ala Lys Lys Gly Lys Gly Lys Asp  
50 55 60

<210> 1211  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1211  
Cys His Ser Gly Tyr Val Gly Val Arg Cys  
1 5 10

<210> 1212

<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1212  
Ala Asn Phe Leu Val Trp Glu Ile Val Arg Lys Lys Pro  
1 5 10

<210> 1213  
<211> 50  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1213  
Val Val Ser His Phe Asn Asp Cys Pro Asp Ser His Thr Gln Phe Cys  
1 5 10 15

Phe His Gly Thr Cys Arg Phe Leu Val Gln Glu Asp Lys Pro Ala Cys  
20 25 30

Val Cys His Ser Gly Tyr Val Gly Ala Arg Cys Glu His Ala Asp Leu  
35 40 45

Leu Ala  
50

<210> 1214  
<211> 50  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1214  
Val Val Ser His Phe Asn Lys Cys Pro Asp Ser His Thr Gln Tyr Cys  
1 5 10 15

Phe His Gly Thr Cys Arg Phe Leu Val Gln Glu Glu Lys Pro Ala Cys  
20 25 30

Val Cys His Ser Gly Tyr Val Gly Val Arg Cys Glu His Ala Asp Leu  
35 40 45

Leu Ala  
50

<210> 1215

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1215

Cys His Ser Gly Tyr Val Gly Val Arg Cys  
1 5 10

<210> 1216

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1216

Cys His Ser Gly Tyr Val Gly Val Arg Cys  
1 5 10

<210> 1217

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1217  
Pro Pro Gly His Phe Lys  
1 5

<210> 1218  
<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1218  
Arg Thr Gly Gln Tyr Lys  
1 5

<210> 1219  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1219  
Phe Asn Leu Pro Leu Gly Asn Tyr Lys Lys Pro  
1 5 10

<210> 1220  
<211> 24  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1220  
Pro Ala Leu Pro Glu Asp Gly Gly Ser Gly Ala Phe Pro Pro Gly His  
1 5 10 15

Phe Lys Asp Pro Lys Arg Leu Tyr  
20

<210> 1221  
<211> 10  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1221  
His Ala Glu Lys His Trp Phe Val Gly Leu  
1 5 10

<210> 1222  
<211> 12  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1222  
Cys Met His Ile Glu Ser Leu Asp Ser Tyr Thr Cys  
1 5 10

<210> 1223  
<211> 12  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1223  
Asp Val Val Asp Ala Asp Glu Tyr Leu Ile Pro Gln  
1 5 10

<210> 1224  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1224

Cys Tyr Ala Ala Pro Leu Lys Pro Ala Lys Ser Cys

1

5

10

<210> 1225

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1225

Tyr Phe Asn Lys Pro Thr Gly Tyr Gly Ser Ser Ser Arg Arg Ala Pro

1

5

10

15

Gln Thr

<210> 1226

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1226

Ala Leu Leu Glu Thr Tyr Cys Ala Thr Pro Ala Lys Ser Glu

1

5

10

<210> 1227

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic



Peptide

<400> 1227

Gly Tyr Gly Ser Ser Ser Arg Arg Ala Pro Gln Thr

1

5

10

<210> 1228

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1228

Ser Arg Val Ser Arg Arg Ser Arg

1

5

<210> 1229

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1229

Tyr Ser Arg Val Ser Arg Arg Ser Arg

1

5

<210> 1230

<211> 3

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1230

Gly His Lys

1

<210> 1231  
<211> 22  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1231  
Ser Val Arg Val Glu Gln Val Val Lys Pro Pro Gln Asp Lys Thr Glu  
1 5 10 15

Ser Glu Asn Thr Ser Asp  
20

<210> 1232  
<211> 24  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1232  
Gly Lys Lys Glu Lys Pro Glu Lys Lys Val Lys Lys Ser Asp Cys Gly  
1 5 10 15

Glu Trp Gln Trp Ser Val Cys Val  
20

<210> 1233  
<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1233  
Ser Phe Leu Pro Ser Ser  
1 5

<210> 1234  
<211> 15  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1234  
Ser Ala Gln Thr Asn Arg His Ile Leu Arg Phe Asn Arg Pro Phe  
1 5 10 15

<210> 1235  
<211> 18  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1235  
Ile Pro Val Lys Gln Ala Val His Gly Gln Phe Leu Leu Pro Lys Gln  
1 5 10 15

Glu Lys

<210> 1236  
<211> 18  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1236  
Leu Ala Gly Glu Thr Gly Gln Glu Ala Ala Pro Leu Asp Gly Val Leu  
1 5 10 15

Ala Asn

<210> 1237  
<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1237  
Ala Leu Lys Arg Gln Gly Arg Thr Leu Tyr Gly Phe Gly Gly  
1 5 10

<210> 1238  
<211> 30  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1238  
Gly Met Asp Val Leu Gly Arg Pro Lys Ile Pro Leu Glu Thr Pro Ala  
1 5 10 15  
Tyr Thr Gly Gln Pro Trp His Cys Gln His Cys Phe Leu Leu  
20 25 30

<210> 1239  
<211> 43  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1239  
Met Asn Thr Ile Thr Ile Cys Lys Phe Asp Val Leu Asp Ala Glu Leu  
1 5 10 15  
Leu Ser Thr Val Glu Gly Gly Tyr Ser Gly Lys Asp Cys Leu Lys Asp  
20 25 30

Met Gly Gly Tyr Ala Leu Ala Gly Ala Gly Ser  
35 40

<210> 1240

<211> 38

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1240

Gly Ala Asp Lys Thr Val Lys Gly Pro Asp Gly Leu Thr Ala Leu Glu  
1 5 10 15

Ala Thr Asp Asn Gln Ala Ile Asp Tyr Gly Gly Phe Met Glu Val Val  
20 25 30

Tyr Val Asp Ala Thr Lys  
35

<210> 1241

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1241

Cys Lys Gln Leu Gln Arg Asp Arg Gln Val Tyr Arg Ala Thr His Arg  
1 5 10 15

<210> 1242

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1242

Cys Glu Gly Asn Val Arg Val Ser Arg Glu Leu Ala Gly His Thr Gly  
 1 5 10 15  
 Tyr

<210> 1243  
 <211> 16  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 1243  
 Cys Gly Ala Gly Glu Ser Gly Lys Ser Thr Ile Val Lys Gln Met Lys  
 1 5 10 15

<210> 1244  
 <211> 15  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 1244  
 Cys Asn Leu Lys Glu Asp Gly Ile Ser Ala Ala Lys Asp Val Lys  
 1 5 10 15

<210> 1245  
 <211> 16  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 1245  
 Cys Lys Gln Leu Gln Lys Asp Lys Gln Val Tyr Arg Ala Thr His Arg  
 1 5 10 15

<210> 1246  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1246  
Glu Glu Gln Gly Met Leu Pro Glu Asp Leu Ser  
1 5 10

<210> 1247  
<211> 15  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1247  
Pro Gly Thr Cys Glu Ile Cys Ala Tyr Ala Ala Cys Thr Gly Cys  
1 5 10 15

<210> 1248  
<211> 15  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1248  
Pro Asn Thr Cys Glu Ile Cys Ala Tyr Ala Ala Cys Thr Gly Cys  
1 5 10 15

<210> 1249  
<211> 16  
<212> PRT  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1249

Asn Asp Asp Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu  
1 5 10 15

<210> 1250

<211> 32

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1250

Ser Thr Pro Leu Met Ser Trp Pro Trp Ser Pro Ser Ala Leu Arg Leu  
1 5 10 15

Leu Gln Arg Pro Pro Glu Glu Pro Ala Ala His Ala Asn Cys His Arg  
20 25 30

<210> 1251

<211> 33

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1251

Tyr Ser Thr Pro Leu Met Ser Trp Pro Trp Ser Pro Ser Ala Leu Arg  
1 5 10 15

Leu Leu Gln Arg Pro Pro Glu Glu Pro Ala Ala His Ala Asn Cys His  
20 25 30

Arg



<210> 1252  
<211> 31  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1252  
His Asn Lys Gln Glu Gly Arg Asp His Asp Lys Ser Lys Gly His Phe  
1 5 10 15  
His Arg Val Val Ile His His Lys Gly Gly Lys Ala His Arg Gly  
20 25 30

<210> 1253  
<211> 32  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1253  
Tyr His Asn Lys Gln Glu Gly Arg Asp His Asp Lys Ser Lys Gly His  
1 5 10 15  
Phe His Arg Val Val Ile His His Lys Gly Gly Lys Ala His Arg Gly  
20 25 30

<210> 1254  
<211> 32  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1254



<211> 72  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1257  
Ala Pro Val Ala Asn Glu Leu Arg Cys Gln Cys Leu Gln Thr Val Ala  
1 5 10 15

Gly Ile His Phe Lys Asn Ile Gln Ser Leu Lys Val Met Pro Pro Gly  
20 25 30

Pro His Cys Thr Gln Thr Glu Val Ile Ala Thr Leu Lys Asn Gly Arg  
35 40 45

Glu Ala Cys Leu Asp Pro Glu Ala Pro Met Val Gln Lys Ile Val Gln  
50 55 60

Lys Met Leu Lys Gly Val Pro Lys  
65 70

<210> 1258  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1258  
Val Gln Gly Glu Glu Ser Asn Asp Lys  
1 5

<210> 1259  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1259

Ile Leu Asn Gly Ile Asn Asn Tyr Lys Asn Pro Lys Leu  
1 5 10

<210> 1260

<211> 22

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1260

Phe Val Gln Gly Glu Ala Ile Pro Met Ser Ile Pro Pro Glu Asp Lys  
1 5 10 15

Ile Pro Val Ala Leu Gly  
20

<210> 1261

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1261

Ala Pro Val Pro Pro Gly Glu Asp Ser Lys Asp Val Ala  
1 5 10

<210> 1262

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1262

Met Val Lys Gln Ile Glu Ser Lys Thr Ala Phe Gln Glu Ala Leu Asp  
1 5 10 15

Ala Ala Gly Asp Lys

20

<210> 1263

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1263

Ala Tyr Val His Asp Ala Pro Val Arg Ser

1

5

10

<210> 1264

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1264

Pro Arg Lys Leu Tyr Asp Lys

1

5

<210> 1265

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1265

Tyr Thr Thr Asn Pro Arg Lys Leu Tyr Asp Tyr Lys

1

5

10

<210> 1266

<211> 24  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1266  
Arg Asn Pro Asp Gly Asp Val Gly Gly Pro Trp Ala Tyr Thr Thr Asn  
1 5 10 15  
Pro Arg Lys Leu Tyr Asp Tyr Lys  
20

<210> 1267  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1267  
Arg Asn Pro Asp Gly Asp Val Gly Gly Pro Trp Lys  
1 5 10

<210> 1268  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1268  
Pro Arg Lys Leu Tyr Asp Tyr Lys  
1 5

<210> 1269  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1269  
Tyr Thr Thr Asn Pro Arg Lys Leu Tyr Asp Tyr Lys  
1 5 10

<210> 1270  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1270  
Tyr Thr Thr Asn Pro Arg Lys Leu Tyr Asp Tyr  
1 5 10

<210> 1271  
<211> 24  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1271  
Arg Asn Pro Asp Gly Asp Val Gly Gly Pro Trp Ala Tyr Thr Thr Asn  
1 5 10 15

Pro Arg Lys Leu Tyr Asp Tyr Lys  
20

<210> 1272  
<211> 23  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic

Peptide

<400> 1272

Arg Asn Pro Asp Gly Asp Val Gly Gly Pro Trp Ala Tyr Thr Thr Asn  
1 5 10 15

Pro Arg Lys Leu Tyr Asp Tyr

20

<210> 1273

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1273

Arg Lys Leu Tyr Asp Tyr Lys  
1 5

<210> 1274

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1274

Arg Lys Leu Tyr Asp Tyr  
1 5

<210> 1275

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1275



Pro Arg Lys Leu Tyr Asp Lys

1

5

<210> 1276

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1276

Pro Arg Lys Leu Tyr Asp

1

5

<210> 1277

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1277

Pro Arg Lys Leu Tyr Asp Tyr Lys

1

5

<210> 1278

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1278

Asp Gly Glu Ala

1

<210> 1279

<211> 6

<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1279  
Leu Gly Thr Ile Pro Gly  
1 5

<210> 1280  
<211> 23  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1280  
Asn Ile Ser Ser Glu Glu Lys Ala Ser Trp Thr Arg Pro Glu Lys Gln  
1 5 10 15

Glu Thr Leu Asp Gly His Met  
20

<210> 1281  
<211> 17  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1281  
Phe Asn Leu Asp Val Arg Phe Leu Val Val Lys Glu Ala Val Asn Pro  
1 5 10 15

Gly

<210> 1282  
<211> 17

<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1282  
Ala Pro Arg Gln Arg Gln Thr Leu Val Leu Phe Pro Gly Asp Leu Arg  
1 5 10 15

Thr

<210> 1283  
<211> 24  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1283  
Cys Ser Cys Ser Pro Val His Pro Gln Gln Ala Phe Cys Asn Ala Asp  
1 5 10 15

Val Val Ile Arg Ala Lys Ala Val  
20

<210> 1284  
<211> 24  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1284  
Cys Ser Cys Ser Pro Val His Pro Gln Gln Ala Phe Cys Asn Ala Asp  
1 5 10 15

Val Val Ile Arg Ala Lys Ala Val  
20

<210> 1285  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1285  
Asn Val Ile Gln Ile Ser Asn Asp Leu Glu Asn Leu Arg  
1 5 10

<210> 1286  
<211> 35  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1286  
Val Pro Ile Gln Lys Val Gln Asp Asp Thr Lys Thr Leu Ile Lys Thr  
1 5 10 15

Ile Val Thr Arg Ile Asn Asp Ile Ser His Thr Gln Ser Val Ser Ser  
20 25 30

Lys Gln Lys  
35

<210> 1287  
<211> 15  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1287  
Tyr Lys Val Gln Asp Asp Thr Lys Thr Leu Ile Lys Thr Ile Val  
1 5 10 15

<210> 1288  
<211> 15  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1288  
Ser Cys Ser Leu Pro Gln Thr Ser Gly Leu Gln Lys Pro Glu Ser  
1 5 10 15

<210> 1289  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1289  
Glu Asp Val Asp His Val Phe Leu Arg Phe  
1 5 10

<210> 1290  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1290  
Thr Ser Phe Thr Pro Arg Leu  
1 5

<210> 1291  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1291  
Asp Pro Ala Phe Asn Ser Trp Gly  
1 5

<210> 1292  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1292  
Asp Pro Gly Phe Ser Ser Trp Gly  
1 5

<210> 1293  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1293  
Asp Gln Gly Phe Asn Ser Trp Gly  
1 5

<210> 1294  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1294  
Asp Ala Ser Phe His Ser Trp Gly

<210> 1295

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1295

Gly Ser Gly Phe Ser Ser Trp Gly

1

5

<210> 1296

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1296

Asp Pro Ala Phe Ser Ser Trp Gly

1

5

<210> 1297

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1297

Gly Ala Ser Phe Tyr Ser Trp Gly

1

5

<210> 1298

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1298

Ile Ile Gly Gly Arg Glu Ser Arg Pro His  
1 5 10

<210> 1299

<211> 38

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1299

His Ser Asp Gly Ile Phe Thr Asp Ser Tyr Ser Arg Tyr Arg Lys Gln  
1 5 10 15

Met Ala Val Lys Lys Tyr Leu Ala Ala Val Leu Gly Lys Arg Tyr Lys  
20 25 30

Gln Arg Val Lys Asn Lys  
35

<210> 1300

<211> 30

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1300

His Ser Asp Gly Ile Phe Thr Asp Ser Tyr Ser Arg Tyr Arg Arg Gln  
1 5 10 15

Leu Ala Val Arg Arg Tyr Leu Ala Ala Val Leu Gly Lys Arg  
20 25 30



<210> 1301  
<211> 21  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1301  
Phe Thr Asp Ser Tyr Ser Arg Tyr Arg Lys Met Ala Val Lys Lys Tyr  
1 5 10 15  
Leu Ala Ala Val Leu  
20

<210> 1302  
<211> 38  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1302  
His Ser Asp Gly Ile Phe Thr Asp Ser Tyr Ser Arg Tyr Arg Lys Gln  
1 5 10 15  
Met Ala Val Lys Lys Tyr Leu Ala Ala Val Leu Gly Lys Arg Tyr Lys  
20 25 30  
Gln Arg Ile Lys Asn Lys  
35

<210> 1303  
<211> 27  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1303  
His Ser Asp Gly Ile Phe Thr Asp Ser Tyr Ser Arg Tyr Arg Lys Gln

UNIVERSITY OF CALIFORNIA

<210> 1304

<212> PRT

<220>

<400> 1304

Tyr Leu Ala Ala Val Leu  
20

<210> 1305

&lt;211&gt; 38

&lt;212&gt; PRT

<213> Artificial Sequence

 $\langle 220 \rangle$ 

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 1305

His Ser Asp Gly Ile Phe Thr Asp Ser Tyr Ser Arg Tyr Arg Lys Gln  
1 5 10 15

Met Ala Val Lys Lys Tyr Leu Ala Ala Val Leu Gly Lys Arg Tyr Lys  
20 25 30

Gln Arg Val Lys Asn Lys  
35

<210> 1306

&lt;211&gt; 33

<212> PRT

&lt;213&gt; Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1306

Phe Thr Asp Ser Tyr Ser Arg Tyr Arg Lys Gln Met Ala Val Lys Lys  
1 5 10 15

Tyr Leu Ala Ala Val Leu Gly Lys Arg Tyr Lys Gln Arg Val Lys Asn  
20 25 30

Lys

<210> 1307

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1307

Gln Met Ala Val Lys Lys Tyr Leu Ala Ala Val Leu Gly Lys Arg Tyr  
1 5 10 15

Lys Gln Arg Val Lys Asn Lys  
20

<210> 1308

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1308

Gly Lys Arg Tyr Lys Gln Arg Val Lys Asn Lys  
1 5 10

<210> 1309

<211> 8

<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1309  
Tyr Lys Gln Arg Val Lys Asn Lys  
1 5

<210> 1310  
<211> 29  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1310  
Asp Val Ala His Gly Ile Leu Asn Glu Ala Tyr Arg Lys Val Leu Asp  
1 5 10 15  
Gln Leu Ser Ala Gly Lys His Leu Gln Ser Leu Val Ala  
20 25

<210> 1311  
<211> 29  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1311  
Asp Val Ala His Glu Ile Leu Asn Glu Ala Tyr Arg Lys Val Leu Asp  
1 5 10 15  
Gln Leu Ser Ala Arg Lys Tyr Leu Gln Ser Met Val Ala  
20 25

<210> 1312  
<211> 20

<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1312  
Ser Asp Glu Asp Ser Asp Gly Asp Arg Pro Gln Ala Ser Pro Gly Leu  
1 5 10 15

Gly Pro Gly Pro  
20

<210> 1313  
<211> 52  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1313  
Gly Glu Ser Arg Ser Glu Ala Leu Ala Val Asp Gly Ala Gly Lys Pro  
1 5 10 15

Gly Ala Glu Glu Ala Gln Asp Pro Glu Gly Lys Gly Glu Gln Glu His  
20 25 30

Ser Gln Gln Lys Glu Glu Glu Glu Glu Met Ala Val Val Pro Gln Gly  
35 40 45

Leu Phe Arg Gly  
50

<210> 1314  
<211> 29  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1314



<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1317

Gly Trp Pro Gln Ala Pro Ala Asp Gly Ala Gly Lys Thr Gly Ala Glu  
1 5 10 15

Glu Ala Gln Pro Pro Glu Gly Lys Gly Ala Arg Glu His Ser Arg Gln  
20 25 30

Glu Glu Glu Glu Glu Thr Ala Gly Ala Pro Gln Gly Leu Phe Arg Gly  
35 40 45

<210> 1318

<211> 49

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1318

Tyr Gly Trp Pro Gln Ala Pro Ala Asp Gly Ala Gly Lys Thr Gly Ala  
1 5 10 15

Glu Glu Ala Gln Pro Pro Glu Gly Lys Gly Ala Arg Glu His Ser Arg  
20 25 30

Gln Glu Glu Glu Glu Glu Thr Ala Gly Ala Pro Gln Gly Leu Phe Arg  
35 40 45

Gly

<210> 1319

<211> 50

<212> PRT

<213> Artificial Sequence

<220>





20

25

30

Gln Glu Glu Asp Gly Glu Glu Ala Met Ala Gly Pro Pro Gln Gly Leu  
 35 40 45

Phe Pro Gly  
 50

&lt;210&gt; 1322

&lt;211&gt; 52

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Synthetic  
 Peptide

&lt;400&gt; 1322

Tyr Asp Asp Gly Gln Ser Glu Ser Gln Ala Val Asn Gly Lys Thr Gly  
 1 5 10 15

Ala Ser Glu Ala Val Pro Ser Glu Gly Lys Gly Glu Leu Glu His Ser  
 20 25 30

Gln Gln Glu Glu Asp Gly Glu Glu Ala Met Ala Gly Pro Pro Gln Gly  
 35 40 45

Leu Phe Pro Gly  
 50

&lt;210&gt; 1323

&lt;211&gt; 26

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Synthetic  
 Peptide

&lt;400&gt; 1323

Gly Glu Leu Glu His Ser Gln Gln Glu Glu Asp Gly Glu Glu Ala Met  
 1 5 10 15

Ala Gly Pro Pro Gln Gly Leu Phe Pro Gly  
 20 25

<210> 1324

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1324

Gln Glu Glu Glu Glu Thr Ala Gly Ala Pro Gln Gly Leu Phe Arg  
1 5 10 15

Gly

<210> 1325

<211> 2

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1325

Pro Gly  
1

<210> 1326

<211> 1

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1326

Lys  
1

<210> 1327

<211> 4

<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1327  
Gly Phe Ala Asp  
1

<210> 1328  
<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1328  
Asp Tyr Val Pro Met Leu  
1 5

<210> 1329  
<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1329  
Asp Tyr Val Pro Met Leu  
1 5

<210> 1330  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1330

Gln Lys Arg Pro Ser Gln Arg Ser Lys Tyr Leu  
1 5 10

<210> 1331

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1331

Pro Leu Ser Arg Thr Leu Ser Val Ala Ala Lys Lys  
1 5 10

<210> 1332

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1332

Ala Arg Arg Pro Glu Gly Arg Thr Trp Ala Gln Pro Gly Tyr  
1 5 10

<210> 1333

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1333

Arg Gly Tyr Ser Leu Gly  
1 5

<210> 1334  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1334  
Lys Lys Ala Leu Arg Arg Gln Glu Ala Val Asp Ala Leu  
1 5 10

<210> 1335  
<211> 25  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1335  
Ile Thr Ser Phe Glu Glu Ala Lys Gly Leu Asp Arg Ile Asn Glu Arg  
1 5 10 15  
Met Pro Pro Arg Arg Asp Ala Met Pro  
20 25

<210> 1336  
<211> 20  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1336  
Leu Lys Lys Phe Asn Ala Arg Arg Lys Leu Lys Gly Ala Ile Leu Thr  
1 5 10 15  
Thr Met Leu Ala  
20

<210> 1337  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1337  
Pro Leu Ser Arg Thr Leu Ser Val Ser Ser  
1 5 10

<210> 1338  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1338  
Pro Leu Arg Arg Thr Leu Ser Val Ala Ala  
1 5 10

<210> 1339  
<211> 17  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1339  
Leu Gln Asn Arg Arg Gly Leu Asp Leu Leu Phe Leu Lys Glu Gly Gly  
1 5 10 15

Leu

<210> 1340  
<211> 8  
<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1340

Cys Leu Arg Arg Ala Ser Leu Gly  
1 5

<210> 1341

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1341

Phe Lys Lys Ser Phe Lys Leu  
1 5

<210> 1342

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1342

Lys Lys Ala Leu His Arg Gln Glu Thr Val Asp Ala Leu  
1 5 10

<210> 1343

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1343

Lys Arg Thr Leu Arg Arg

1

5

<210> 1344

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1344

Arg Thr Lys Arg Ser Gly Ser Val Tyr Glu Pro Leu Lys Ile

1

5

10

<210> 1345

<211> 26

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1345

Gly Ile Gly Ala Val Leu Lys Val Leu Thr Thr Gly Leu Pro Ala Leu

1

5

10

15

Ile Ser Trp Ile Lys Arg Lys Arg Gln Gln

20

25

<210> 1346

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1346

Arg Arg Lys Ala Ser Gly Pro Pro Val

1

5



<210> 1347  
<211> 17  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1347  
Arg Phe Ala Arg Lys Gly Ala Leu Arg Gln Lys Asn Val His Glu Val  
1 5 10 15

Lys

<210> 1348  
<211> 18  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1348  
Arg Phe Ala Arg Lys Gly Ala Leu Glu Gln Lys Asn Val His Glu Val  
1 5 10 15

Lys Asn

<210> 1349  
<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1349  
Ser Phe Val Asn Ser Glu Phe Leu Lys Pro Glu Val Lys Ser  
1 5 10

<210> 1350  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1350  
Ser Tyr Thr Asn Pro Glu Phe Val Ile Asn Val  
1 5 10

<210> 1351  
<211> 15  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1351  
Ala Gly Asn Lys Val Ile Ser Pro Ser Glu Asp Arg Arg Gln Cys  
1 5 10 15

<210> 1352  
<211> 18  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1352  
Gly Pro Lys Thr Pro Glu Glu Lys Thr Ala Asn Thr Ile Ser Lys Phe  
1 5 10 15

Asp Cys

<210> 1353

<211> 29  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1353  
Leu Leu Tyr Glu Met Leu Ala Gly Gln Ala Pro Phe Glu Gly Glu Asp  
1 5 10 15  
Glu Asp Glu Leu Phe Gln Ser Ile Met Glu His Asn Val  
20 25

<210> 1354  
<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1354  
Asn Tyr Pro Leu Glu Leu Tyr Glu Arg Val Arg Thr Gly Cys  
1 5 10

<210> 1355  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1355  
Val Arg Lys Arg Thr Leu Arg Arg Leu  
1 5

<210> 1356  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1356  
Cys Asp Asn Gln Ile Lys Lys Met  
1 5

<210> 1357  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1357  
Ile Tyr Gly Glu Phe  
1 5

<210> 1358  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1358  
Ile Tyr Gly Glu Phe  
1 5

<210> 1359  
<211> 17  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1359

Thr Tyr Ala Asp Phe Ile Ala Ser Gly Arg Thr Gly Arg Arg Asn Ala  
1 5 10 15  
Ile

<210> 1360

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1360

Gln Lys Arg Pro Ser Gln Arg Ser Lys Tyr Leu  
1 5 10

<210> 1361

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1361

Arg Arg Glu Glu Glu Thr Glu Glu Glu  
1 5

<210> 1362

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1362

Arg Arg Lys Ala Ser Gly Pro  
1 5

<210> 1363  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1363  
Arg Arg Leu Ile Glu Asp Asn Glu Tyr Thr Ala Arg Gly  
1 5 10

<210> 1364  
<211> 15  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1364  
Pro Leu Ala Arg Thr Leu Ser Val Ala Gly Leu Pro Gly Lys Lys  
1 5 10 15

<210> 1365  
<211> 32  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1365  
Lys Glu Ala Lys Glu Lys Arg Gln Glu Gln Ile Ala Lys Arg Arg Arg  
1 5 10 15  
Leu Ser Ser Leu Arg Ala Ser Thr Ser Lys Ser Gly Gly Ser Gln Lys  
20 25 30

<210> 1366  
<211> 20  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1366  
Tyr Ser Phe Val His His Gly Phe Phe Asn Phe Arg Val Ser Trp Arg  
1 5 10 15

Glu Met Leu Ala  
20

<210> 1367  
<211> 21  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1367  
Val Ala Pro Ser Asp Ser Ile Gln Ala Glu Glu Trp Tyr Phe Gly Lys  
1 5 10 15

Ile Thr Arg Arg Glu  
20

<210> 1368  
<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1368  
His Arg His Phe Leu Arg  
1 5

<210> 1369  
<211> 25  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1369  
Arg Cys Leu Gly Thr Val Gln Gly Gln Phe Pro Leu Cys Tyr His Phe  
1 5 10 15  
  
Leu Ser Ala Pro Gly Arg Phe Gln Glu  
20 25

<210> 1370  
<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1370  
Met Tyr Ser Asn Val Ile Gly Thr Val Thr Ser Gly Lys Arg  
1 5 10

<210> 1371  
<211> 25  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1371  
Phe Tyr Lys Ala Asp Gly Val Val Phe Ser Ile Tyr Asp Val Pro Gly  
1 5 10 15  
  
Arg Gln Val Pro Leu Ser Ala Arg Gly  
20 25



<210> 1372  
<211> 20  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1372  
Trp Ser Pro Gln Glu Glu Asp Arg Ile Ile Glu Gly Gly Ile Tyr Asp  
1 5 10 15

Ala Asp Leu Asn  
20

<210> 1373  
<211> 20  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1373  
Val Ser Ser Ala Glu Gly Trp His Gly Asn Val Thr Leu Asn Ile Arg  
1 5 10 15

Pro Ser Thr Gly  
20

<210> 1374  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1374  
Cys Ser Pro Cys His Ala Met Lys Met Asn Ile  
1 5 10

<210> 1375

<211> 27

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1375

Glu Val Ser Phe Leu Asn Cys Ser Leu Asp Asn Gly Gly Cys Thr Pro  
1 5 10 15

Leu Leu Pro Arg Gly Gly Gly Leu Ala Ala Leu  
20 25

<210> 1376

<211> 33

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1376

Met Ala Pro Glu Glu Ile Ile Met Asp Arg Pro Phe Leu Phe Val Val  
1 5 10 15

Arg His Asn Pro Thr Gly Thr Val Leu Phe Met Gly Gln Val Met Glu  
20 25 30

Pro

<210> 1377

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1377

Cys Glu Asn Gly Gly Phe Cys Ser Gly Val Cys His Asn Leu Pro Gly  
 1 5 10 15

Thr Phe Glu Cys Ile Cys Gly Pro Asp Ser Ala Leu Val Arg His Ile  
 20 25 30

Gly Thr Asp Cys  
 35

<210> 1378

<211> 24

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 1378

His Pro Pro Cys Cys Leu Tyr Gly Lys Cys Arg Arg Tyr Pro Gly Cys  
 1 5 10 15

Ser Ser Ala Ser Cys Cys Gln Leu  
 20

<210> 1379

<211> 48

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 1379

Glu Asp Asn Cys Ile Ala Glu Asp Tyr Gly Lys Cys Thr Trp Gly Gly  
 1 5 10 15

Thr Lys Cys Cys Arg Gly Arg Pro Cys Arg Cys Ser Met Ile Gly Thr  
 20 25 30

Asn Cys Glu Cys Thr Pro Arg Leu Ile Met Glu Gly Leu Ser Phe Ala  
 35 40 45

<210> 1380

<211> 35

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1380

Gly Gly Cys Leu Pro His Asn Arg Phe Cys Asn Ala Leu Ser Gly Pro  
1 5 10 15

Arg Cys Cys Ser Gly Leu Lys Cys Lys Glu Leu Ser Ile Trp Asp Ser  
20 25 30

Arg Cys Leu  
35

<210> 1381

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1381

Cys Asn Cys Lys Ala Pro Glu Thr Ala Leu Cys Ala Arg Arg Cys Gln  
1 5 10 15

Gln His

<210> 1382

<211> 60

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1382

Trp Gln Pro Pro Trp Tyr Cys Lys Glu Pro Val Arg Ile Gly Ser Cys  
1 5 10 15

Lys Lys Gln Phe Ser Ser Phe Tyr Phe Lys Trp Thr Ala Lys Lys Cys  
20 25 30

Leu Pro Phe Leu Phe Ser Gly Cys Gly Gly Asn Ala Asn Arg Phe Gln  
35 40 45

Thr Ile Gly Glu Cys Arg Lys Lys Cys Leu Gly Lys  
50 55 60

<210> 1383

<211> 60

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1383

Arg Ile Cys Tyr Ile His Lys Ala Ser Leu Pro Arg Ala Thr Lys Thr  
1 5 10 15

Cys Val Glu Asn Thr Cys Tyr Lys Met Phe Ile Arg Thr Gln Arg Glu  
20 25 30

Tyr Ile Ser Glu Arg Gly Cys Gly Cys Pro Thr Ala Met Trp Pro Tyr  
35 40 45

Gln Thr Glu Cys Cys Lys Gly Asp Arg Cys Asn Lys  
50 55 60

<210> 1384

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1384

Phe Thr Asn Val Ser Cys Thr Thr Ser Lys Glu Cys Trp Ser Val Cys

1

5

10

15

Gln Arg Leu His Asn Thr Ser Arg Gly Lys Cys Met Asn Lys Lys Cys  
 20 25 30

Arg Cys Tyr Ser  
 35

<210> 1385

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 1385

Met Cys Met Pro Cys Phe Thr Thr Asp His Gln Met Ala Arg Lys Cys  
 1 5 10 15

Asp Asp Cys Cys Gly Gly Lys Gly Arg Gly Lys Cys Tyr Gly Pro Gln  
 20 25 30

Cys Leu Cys Arg  
 35

<210> 1386

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 1386

Glu Cys Cys Asn Pro Ala Cys Gly Arg His Tyr Ser Cys  
 1 5 10

<210> 1387

<211> 31

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1387

Ala Cys Ser Gly Arg Gly Ser Arg Cys Gln Cys Cys Met Gly Leu Arg  
1 5 10 15

Cys Gly Arg Gly Asn Pro Gln Lys Cys Ile Gly Ala His Asp Val  
20 25 30

<210> 1388

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1388

Gly Arg Cys Cys His Pro Ala Cys Gly Lys Asn Tyr Ser Cys  
1 5 10

<210> 1389

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1389

Arg Asp Cys Cys Tyr His Pro Thr Cys Asn Met Ser Asn Pro Gln Ile  
1 5 10 15

Cys

<210> 1390

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1390

Tyr Cys Cys His Pro Ala Cys Gly Lys Asn Phe Asp Cys  
1 5 10

<210> 1391

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1391

Gly Cys Cys Ser Asp Pro Arg Cys Ala Trp Arg Cys  
1 5 10

<210> 1392

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1392

Ile Cys Cys Asn Pro Ala Cys Gly Pro Lys Tyr Ser Cys  
1 5 10

<210> 1393

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1393

Arg Asp Cys Cys Thr Arg Lys Cys Lys Asp Arg Arg Cys Lys Met Lys



Cys Cys Ala

<210> 1394

<211> 24

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1394

Cys Lys Ser Gly Ser Ser Cys Ser Thr Ser Tyr Asn Cys Cys Arg Ser  
1 5 10 15

Cys Asn Tyr Thr Lys Arg Cys Tyr  
20

<210> 1395

<211> 25

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1395

Cys Lys Gly Lys Gly Ala Lys Cys Ser Arg Leu Met Tyr Asp Cys Cys  
1 5 10 15

Thr Gly Ser Cys Arg Ser Gly Lys Cys  
20 25

<210> 1396

<211> 26

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1396

Cys Lys Gly Lys Gly Ala Pro Cys Arg Lys Thr Met Tyr Asp Cys Cys  
1 5 10 15

Ser Gly Ser Cys Gly Arg Arg Gly Lys Cys  
20 25

<210> 1397

<211> 26

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1397

Cys Lys Leu Lys Gly Gln Ser Cys Arg Lys Thr Ser Tyr Asp Cys Cys  
1 5 10 15

Ser Gly Ser Cys Gly Arg Ser Gly Lys Cys  
20 25

<210> 1398

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1398

Lys Thr Lys Cys Lys Phe Leu Lys Lys Cys  
1 5 10

<210> 1399

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1399

Arg Asp Cys Cys Thr Lys Lys Cys Lys Asp Arg Gln Cys Lys Gln Arg  
1 5 10 15

Cys Cys Ala

<210> 1400

<211> 37

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1400

Glu Phe Thr Asp Val Asp Cys Ser Val Ser Lys Glu Cys Trp Ser Val  
1 5 10 15

Cys Lys Asp Leu Phe Gly Val Asp Arg Gly Lys Cys Met Gly Lys Lys  
20 25 30

Cys Arg Cys Tyr Gln  
35

<210> 1401

<211> 37

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1401

Gly Val Glu Ile Asn Val Lys Cys Ser Gly Ser Pro Gln Cys Leu Lys  
1 5 10 15

Pro Cys Lys Asp Ala Gly Met Arg Phe Gly Lys Cys Met Asn Arg Lys  
20 25 30

Cys His Cys Thr Pro  
35

<210> 1402  
<211> 37  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1402  
Gly Val Glu Ile Asn Val Lys Cys Ser Gly Ser Pro Gln Cys Leu Lys  
1 5 10 15  
Pro Cys Lys Asp Ala Gly Met Arg Phe Gly Lys Cys Met Asn Arg Lys  
20 25 30

Cys His Cys Thr Pro  
35

<210> 1403  
<211> 22  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1403  
Ile Lys Cys Asn Cys Lys Arg His Val Ile Lys Pro His Ile Cys Arg  
1 5 10 15  
Lys Ile Cys Gly Lys Asn  
20

<210> 1404  
<211> 39  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1404

Thr Ile Ile Asn Val Lys Cys Thr Ser Pro Lys Gln Cys Leu Pro Pro  
 1 5 10 15

Cys Lys Ala Gln Phe Gly Gln Ser Ala Gly Ala Lys Cys Met Asn Gly  
 20 25 30

Lys Cys Lys Cys Tyr Pro His  
 35

<210> 1405

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 1405

Phe Asp Arg Ala  
 1

<210> 1406

<211> 44

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 1406

Ala Asp Cys Ser Ala Thr Gly Asp Thr Cys Asp His Thr Lys Lys Cys  
 1 5 10 15

Cys Asp Asp Cys Tyr Thr Cys Arg Cys Gly Thr Pro Trp Gly Ala Asn  
 20 25 30

Cys Arg Cys Asp Tyr Tyr Lys Ala Arg Cys Asp Thr  
 35 40

<210> 1407

<211> 31

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1407

Ala Phe Cys Asn Leu Arg Met Cys Gln Leu Ser Cys Arg Ser Leu Gly  
1 5 10 15

Leu Leu Gly Lys Cys Ile Gly Asp Lys Cys Glu Cys Val Lys His  
20 25 30

<210> 1408

<211> 35

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1408

Arg Ser Cys Ile Asp Thr Ile Pro Lys Ser Arg Cys Thr Ala Phe Gln  
1 5 10 15

Cys Lys His Ser Met Lys Tyr Arg Leu Ser Phe Cys Arg Lys Thr Cys  
20 25 30

Gly Thr Cys  
35

<210> 1409

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1409

Phe Leu Pro Leu Ile Leu Gly Lys Leu Val Lys Gly Leu Leu  
1 5 10

<210> 1410

<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1410  
Ile Asn Leu Lys Ala Ile Ala Ala Leu Val Lys Lys Val Leu  
1 5 10

<210> 1411  
<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1411  
Ile Asn Leu Lys Ala Leu Ala Ala Leu Ala Lys Lys Ile Leu  
1 5 10

<210> 1412  
<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1412  
Ile Asn Leu Lys Ala Leu Ala Ala Leu Ala Lys Ala Leu Leu  
1 5 10

<210> 1413  
<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic

Peptide

<400> 1413

Ile Asn Leu Lys Ala Leu Ala Ala Leu Ala Lys Arg Leu Leu  
1 5 10

<210> 1414

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1414

Ile Asn Leu Lys Ala Lys Ala Ala Leu Ala Lys Lys Leu Leu  
1 5 10

<210> 1415

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1415

Ile Asn Trp Lys Gly Ile Ala Ala Met Ala Lys Lys Leu Leu  
1 5 10

<210> 1416

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1416

Phe Met Ser Ser His Gln Ser Gln Ala Ser Leu Glu Leu Ala Ile Lys  
1 5 10 15



Gln Trp Gly Ser Gln  
20

<210> 1417  
<211> 20  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1417  
Phe Asn Lys Ile Thr Pro Asn Leu Ala Glu Phe Ala Phe Ser Leu Tyr  
1 5 10 15

Arg Gln Leu Ala  
20

<210> 1418  
<211> 34  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1418  
Trp Ser Pro Lys Glu Glu Asp Arg Ile Ile Pro Gly Gly Ile Tyr Asn  
1 5 10 15

Ala Asp Leu Asn Asp Glu Trp Val Gln Arg Ala Leu His Phe Ala Ile  
20 25 30

Ser Glu

<210> 1419  
<211> 36  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic

# Peptide

<400> 1419

Tyr Thr Ser Leu Ile His Ser Leu Ile Glu Glu Ser Gln Asn Gln Gln  
1 5 10 15

Glu Lys Asn Glu Gln Glu Leu Leu Glu Leu Asp Lys Trp Ala Ser Leu  
20 25 30

Trp Asn Trp Phe  
35

<210> 1420

<211> 38

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1420

Asn Asn Leu Leu Arg Ala Ile Glu Ala Gln Gln His Leu Leu Gln Leu  
1 5 10 15

Thr Val Trp Gln Ile Lys Gln Leu Gln Ala Arg Ile Leu Ala Val Glu  
20 25 30

Arg Tyr Leu Lys Asp Gln  
35

<210> 1421

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1421

Tyr Thr Asn Thr Ile Tyr Thr Leu Leu Glu Glu Ser Gln Asn Gln Gln  
1 5 10 15

Glu Lys Asn Glu Gln Glu Leu Leu Glu Leu Asp Lys Trp Ala Ser Leu  
20 25 30

Trp Asn Trp Phe  
35

<210> 1422  
<211> 36  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1422  
Tyr Thr Gly Ile Ile Tyr Asn Leu Leu Glu Glu Ser Gln Asn Gln Gln  
1 5 10 15

Glu Lys Asn Glu Gln Glu Leu Leu Glu Leu Asp Lys Trp Ala Asn Leu  
20 25 30

Trp Asn Trp Phe  
35

<210> 1423  
<211> 36  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1423  
Tyr Thr Ser Leu Ile Tyr Ser Leu Leu Glu Lys Ser Gln Thr Gln Gln  
1 5 10 15

Glu Lys Asn Glu Gln Glu Leu Leu Glu Leu Asp Lys Trp Ala Ser Leu  
20 25 30

Trp Asn Trp Phe  
35

<210> 1424  
<211> 36  
<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1424

Leu Glu Ala Asn Ile Ser Lys Ser Leu Glu Gln Ala Gln Ile Gln Gln  
1 5 10 15

Glu Lys Asn Met Tyr Glu Leu Gln Lys Leu Asn Ser Trp Asp Ile Phe  
20 25 30

Gly Asn Trp Phe  
35

<210> 1425

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1425

Leu Glu Ala Asn Ile Ser Gln Ser Leu Glu Gln Ala Gln Ile Gln Gln  
1 5 10 15

Glu Lys Asn Met Tyr Glu Leu Gln Lys Leu Asn Ser Trp Asp Val Phe  
20 25 30

Thr Asn Trp Leu  
35

<210> 1426

<211> 41

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1426

Cys Gly Gly Asn Asn Leu Leu Arg Ala Ile Glu Ala Gln Gln His Leu

1

5

10

15

Leu Gln Leu Thr Val Trp Gly Ile Lys Gln Leu Gln Ala Arg Ile Leu  
 20 25 30

Ala Val Glu Arg Tyr Leu Lys Asp Gln  
 35 40

&lt;210&gt; 1427

&lt;211&gt; 38

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Synthetic  
 Peptide

&lt;400&gt; 1427

Gln Gln Leu Leu Asp Val Val Lys Arg Gln Gln Glu Met Leu Arg Leu  
 1 5 10 15

Thr Val Trp Gly Thr Lys Asn Leu Gln Ala Arg Val Thr Ala Ile Glu  
 20 25 30

Lys Tyr Leu Lys Asp Gln  
 35

&lt;210&gt; 1428

&lt;211&gt; 46

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Synthetic  
 Peptide

&lt;400&gt; 1428

Tyr Thr Ser Val Ile Thr Ile Glu Leu Ser Asn Ile Lys Glu Asn Lys  
 1 5 10 15

Cys Asn Gly Ala Lys Val Lys Leu Ile Lys Gln Glu Leu Asp Lys Tyr  
 20 25 30

Lys Asn Ala Val Thr Glu Leu Gln Leu Leu Met Gln Ser Thr  
 35 40 45

<210> 1429  
<211> 54  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1429  
Ala Ser Gly Val Ala Val Ser Lys Val Leu His Leu Glu Gly Glu Val  
1 5 10 15  
Asn Lys Ile Ala Leu Leu Ser Thr Asn Lys Ala Val Val Ser Leu Ser  
20 25 30  
Asn Gly Val Ser Val Leu Thr Ser Lys Val Leu Asp Leu Lys Asn Tyr  
35 40 45  
Ile Asp Lys Gln Leu Leu  
50

<210> 1430  
<211> 53  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1430  
Gly Glu Pro Ile Ile Asn Phe Tyr Asp Pro Leu Val Phe Pro Ser Asp  
1 5 10 15  
Glu Phe Asp Ala Ser Ile Ser Gln Val Asn Glu Lys Ile Asn Gln Ser  
20 25 30  
Leu Ala Phe Ile Arg Lys Ser Asp Glu Leu Leu His Asn Val Asn Ala  
35 40 45  
Gly Lys Ser Thr Thr  
50

<210> 1431

<211> 48  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1431  
Tyr Thr Ser Val Ile Thr Ile Glu Leu Ser Asn Ile Lys Glu Asn Lys  
1 5 10 15  
Cys Asn Gly Thr Asp Ala Lys Val Lys Leu Ile Lys Gln Glu Leu Asp  
20 25 30  
Lys Tyr Lys Asn Ala Val Thr Glu Leu Gln Leu Leu Met Gln Ser Thr  
35 40 45

<210> 1432  
<211> 34  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1432  
Tyr Thr Ser Val Ile Thr Ile Glu Leu Ser Asn Ile Lys Glu Asn Lys  
1 5 10 15  
Cys Asn Gly Asp Ala Lys Val Lys Leu Ile Lys Gln Glu Leu Asp Lys  
20 25 30

Tyr Lys

<210> 1433  
<211> 34  
<212> PRT  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1433

Thr	Ser	Val	Ile	Thr	Ile	Glu	Leu	Ser	Asn	Ile	Lys	Glu	Asn	Lys	Cys
1				5				10					15		

Asn	Gly	Asp	Ala	Lys	Val	Lys	Leu	Ile	Lys	Gln	Glu	Leu	Asp	Lys	Tyr
			20					25					30		

Lys Asn

<210> 1434

<211> 34

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1434

Val	Ile	Thr	Ile	Glu	Leu	Ser	Asn	Ile	Lys	Glu	Asn	Lys	Cys	Asn	Gly
1				5				10					15		

Asp	Ala	Lys	Val	Lys	Leu	Ile	Lys	Gln	Glu	Leu	Asp	Lys	Tyr	Lys	Asn
			20					25					30		

Ala Val

<210> 1435

<211> 34

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1435

Val	Ile	Thr	Ile	Glu	Leu	Ser	Asn	Ile	Lys	Glu	Asn	Lys	Met	Asn	Gly
1				5				10					15		

Asp Ala Lys Val Lys Leu Ile Lys Gln Glu Leu Asp Lys Tyr Lys Asn



Ala Val

<210> 1436

<211> 33

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1436

Val	Ala	Val	Ser	Lys	Val	Leu	His	Leu	Glu	Gly	Glu	Val	Asn	Lys	Ile
1				5					10					15	

Ala	Leu	Leu	Ser	Thr	Asn	Lys	Ala	Val	Val	Ser	Leu	Ser	Asn	Gly	Val
				20				25					30		

Ser

<210> 1437

<211> 33

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1437

Ala	Val	Ser	Lys	Val	Leu	His	Leu	Glu	Gly	Glu	Val	Asn	Lys	Ile	Ala
1					5				10				15		

Leu	Leu	Ser	Thr	Asn	Lys	Ala	Val	Val	Ser	Leu	Ser	Asn	Gly	Val	Ser
				20				25					30		

Val

<210> 1438

<211> 33

<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1438  
Val Ser Lys Val Leu His Leu Glu Gly Glu Val Asn Lys Ile Ala Leu  
1 5 10 15  
Leu Ser Thr Asn Lys Ala Val Val Ser Leu Ser Asn Gly Val Ser Val  
20 25 30

Leu

<210> 1439  
<211> 33  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1439  
Ser Lys Val Leu His Leu Glu Gly Glu Val Asn Lys Ile Ala Leu Leu  
1 5 10 15  
Ser Thr Asn Lys Ala Val Val Ser Leu Ser Asn Gly Val Ser Val Leu  
20 25 30

Thr

<210> 1440  
<211> 33  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1440

Lys Val Leu His Leu Glu Gly Glu Val Asn Lys Ile Ala Leu Leu Ser  
 1 5 10 15

Thr Asn Lys Ala Val Val Ser Leu Ser Asn Gly Val Ser Val Leu Thr  
 20 25 30

Ser

<210> 1441

<211> 33

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 1441

Leu Glu Gly Glu Val Asn Lys Ile Ala Leu Leu Ser Thr Asn Lys Ala  
 1 5 10 15

Val Val Ser Leu Ser Asn Gly Val Ser Val Leu Thr Ser Lys Val Leu  
 20 25 30

Asp

<210> 1442

<211> 33

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 1442

Gly Glu Val Asn Lys Ile Ala Leu Leu Ser Thr Asn Lys Ala Val Val  
 1 5 10 15

Ser Leu Ser Asn Gly Val Ser Val Leu Thr Ser Lys Val Leu Asp Leu  
 20 25 30

Lys

<210> 1443  
<211> 33  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1443  
Glu Val Asn Lys Ile Ala Leu Leu Ser Thr Asn Lys Ala Val Val Ser  
1 5 10 15  
Leu Ser Asn Gly Val Ser Val Leu Thr Ser Lys Val Leu Asp Leu Lys  
20 25 30

Asn

<210> 1444  
<211> 33  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1444  
Val Asn Lys Ile Ala Leu Leu Ser Thr Asn Lys Ala Val Val Ser Leu  
1 5 10 15  
Ser Asn Gly Val Ser Val Leu Thr Ser Lys Val Leu Asp Leu Lys Asn  
20 25 30

Tyr

<210> 1445  
<211> 33  
<212> PRT  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1445

Asn Lys Ile Ala Leu Leu Ser Thr Asn Lys Ala Val Val Ser Leu Ser  
1 5 10 15

Asn Gly Val Ser Val Leu Thr Ser Lys Val Leu Asp Leu Lys Asn Tyr  
20 25 30

Ile

<210> 1446

<211> 33

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1446

Lys Ile Ala Leu Leu Ser Thr Asn Lys Ala Val Val Ser Leu Ser Asn  
1 5 10 15

Gly Val Ser Val Leu Thr Ser Lys Val Leu Asp Leu Lys Asn Tyr Ile  
20 25 30

Asp

<210> 1447

<211> 33

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1447

Ile Ala Leu Leu Ser Thr Asn Lys Ala Val Val Ser Leu Ser Asn Gly  
1 5 10 15

Val Ser Val Leu Thr Ser Lys Val Leu Asp Leu Lys Asn Tyr Ile Asp

Lys

&lt;210&gt; 1448

&lt;211&gt; 33

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Synthetic  
Peptide

&lt;400&gt; 1448

Ala Leu Leu Ser Thr Asn Lys Ala Val Val Ser Leu Ser Asn Gly Val  
1 5 10 15Ser Val Leu Thr Ser Lys Val Leu Asp Leu Lys Asn Tyr Ile Asp Lys  
20 25 30

Gln

&lt;210&gt; 1449

&lt;211&gt; 70

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Synthetic  
Peptide

&lt;400&gt; 1449

Gly Thr Ile Ala Leu Gly Val Ala Thr Ser Ala Gln Ile Thr Ala Ala  
1 5 10 15Val Ala Leu Val Glu Ala Lys Gln Ala Arg Ser Asp Ile Glu Lys Leu  
20 25 30Lys Glu Ala Ile Arg Asp Thr Asn Lys Ala Val Gln Ser Val Gln Ser  
35 40 45Ser Ile Gly Asn Leu Ile Val Ala Ile Lys Ser Val Gln Asp Tyr Val  
50 55 60

Asn Lys Glu Ile Val Pro  
65 70

<210> 1450  
<211> 56  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1450  
Tyr Thr Pro Asn Asp Ile Thr Leu Asn Asn Ser Val Ala Leu Asp Pro  
1 5 10 15

Ile Asp Ile Ser Ile Glu Leu Asn Lys Ala Lys Ser Asp Leu Glu Glu  
20 25 30

Ser Lys Glu Trp Ile Arg Arg Ser Asn Gln Lys Leu Asp Ser Ile Gly  
35 40 45

Asn Trp His Gln Ser Ser Thr Thr  
50 55

<210> 1451  
<211> 35  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1451  
Thr Leu Asn Asn Ser Val Ala Leu Asp Pro Ile Asp Ile Ser Ile Glu  
1 5 10 15

Leu Asn Lys Ala Lys Ser Asp Leu Glu Ser Lys Glu Trp Ile Arg  
20 25 30

Arg Ser Asn  
35

<210> 1452

<211> 35  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1452  
Leu Asn Asn Ser Val Ala Leu Asp Pro Ile Asp Ile Ser Ile Glu Leu  
1 5 10 15  
Asn Lys Ala Lys Ser Asp Leu Glu Glu Ser Lys Glu Trp Ile Arg Arg  
20 25 30  
Ser Asn Gln  
35

<210> 1453  
<211> 35  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1453  
Asn Asn Ser Val Ala Leu Asp Pro Ile Asp Ile Ser Ile Glu Leu Asn  
1 5 10 15  
Lys Ala Lys Ser Asp Leu Glu Glu Ser Lys Glu Trp Ile Arg Arg Ser  
20 25 30  
Asn Gln Lys  
35

<210> 1454  
<211> 35  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide



<400> 1454

Asn Ser Val Ala Leu Asp Pro Ile Asp Ile Ser Ile Glu Leu Asn Lys  
1 5 10 15

Ala Lys Ser Asp Leu Glu Glu Ser Lys Glu Trp Ile Arg Arg Ser Asn  
20 25 30

Gln Lys Leu  
35

<210> 1455

<211> 35

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1455

Ser Val Ala Leu Asp Pro Ile Asp Ile Ser Ile Glu Leu Asn Lys Ala  
1 5 10 15

Lys Ser Asp Leu Glu Glu Ser Lys Glu Trp Ile Arg Arg Ser Asn Gln  
20 25 30

Lys Leu Asp  
35

<210> 1456

<211> 35

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1456

Val Ala Leu Asp Pro Ile Asp Ile Ser Ile Glu Leu Asn Lys Ala Lys  
1 5 10 15

Ser Asp Leu Glu Glu Ser Lys Glu Trp Ile Arg Arg Ser Asn Gln Lys  
20 25 30

Leu Asp Ser

&lt;210&gt; 1457

&lt;211&gt; 35

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Synthetic  
Peptide

&lt;400&gt; 1457

Ala Leu Asp Pro Ile Asp Ile Ser Ile Glu Leu Asn Lys Ala Lys Ser

1

5

10

15

Asp Leu Glu Glu Ser Lys Glu Trp Ile Arg Arg Ser Asn Gln Lys Leu

20

25

30

Asp Ser Ile

35

&lt;210&gt; 1458

&lt;211&gt; 35

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Synthetic  
Peptide

&lt;400&gt; 1458

Leu Asp Pro Ile Asp Ile Ser Ile Glu Leu Asn Lys Ala Lys Ser Asp

1

5

10

15

Leu Glu Glu Ser Lys Glu Trp Ile Arg Arg Ser Asn Gln Lys Leu Asp

20

25

30

Ser Ile Gly

35

&lt;210&gt; 1459

&lt;211&gt; 35

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1459  
Asp Pro Ile Asp Ile Ser Ile Glu Leu Asn Lys Ala Lys Ser Asp Leu  
1 5 10 15  
Glu Glu Ser Lys Glu Trp Ile Arg Arg Ser Asn Gln Lys Leu Asp Ser  
20 25 30  
Ile Gly Asn  
35

<210> 1460  
<211> 35  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide  
<400> 1460  
Pro Ile Asp Ile Ser Ile Glu Leu Asn Lys Ala Lys Ser Asp Leu Glu  
1 5 10 15  
Glu Ser Lys Glu Trp Ile Arg Arg Ser Asn Gln Lys Leu Asp Ser Ile  
20 25 30  
Gly Asn Trp  
35

<210> 1461  
<211> 35  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide  
<400> 1461  
Ile Asp Ile Ser Ile Glu Leu Asn Lys Ala Lys Ser Asp Leu Glu Glu  
1 5 10 15

Ser Lys Glu Trp Ile Arg Arg Ser Asn Gln Lys Leu Asp Ser Ile Gly  
 20 25 30

Asn Trp His  
 35

<210> 1462  
 <211> 35  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 1462  
 Asp Ile Ser Ile Glu Leu Asn Lys Ala Lys Ser Asp Leu Glu Glu Ser  
 1 5 10 15

Lys Glu Trp Ile Arg Arg Ser Asn Gln Lys Leu Asp Ser Ile Gly Asn  
 20 25 30

Trp His Gln  
 35

<210> 1463  
 <211> 35  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 1463  
 Ile Ser Ile Glu Leu Asn Lys Ala Lys Ser Asp Leu Glu Glu Ser Lys  
 1 5 10 15

Glu Trp Ile Arg Arg Ser Asn Gln Lys Leu Asp Ser Ile Gly Asn Trp  
 20 25 30

His Gln Ser  
 35

<210> 1464

<211> 35  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1464  
Ser Ile Glu Leu Asn Lys Ala Lys Ser Asp Leu Glu Glu Ser Lys Glu  
1 5 10 15

Trp Ile Arg Arg Ser Asn Gln Lys Leu Asp Ser Ile Gly Asn Trp His  
20 25 30

Gln Ser Ser  
35

<210> 1465  
<211> 35  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1465  
Ile Glu Leu Asn Lys Ala Lys Ser Asp Leu Glu Glu Ser Lys Glu Trp  
1 5 10 15

Ile Arg Arg Ser Asn Gln Lys Leu Asp Ser Ile Gly Asn Trp His Gln  
20 25 30

Ser Ser Thr  
35

<210> 1466  
<211> 35  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1466

Glu Leu Asn Lys Ala Lys Ser Asp Leu Glu Glu Ser Lys Glu Trp Ile  
1 5 10 15

Arg Arg Ser Asn Gln Lys Leu Asp Ser Ile Gly Asn Trp His Gln Ser  
20 25 30

Ser Thr Thr  
35

<210> 1467

<211> 35

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1467

Thr Ala Ala Val Ala Leu Val Glu Ala Lys Gln Ala Arg Ser Asp Ile  
1 5 10 15

Glu Lys Leu Lys Glu Ala Ile Arg Asp Thr Asn Lys Ala Val Gln Ser  
20 25 30

Val Gln Ser  
35

<210> 1468

<211> 35

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1468

Ala Val Ala Leu Val Glu Ala Lys Gln Ala Arg Ser Asp Ile Glu Lys  
1 5 10 15

Leu Lys Glu Ala Ile Arg Asp Thr Asn Lys Ala Val Gln Ser Val Gln  
20 25 30

Ser Ser Ile

<210> 1469  
 <211> 35  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 1469  
 Leu Val Glu Ala Lys Gln Ala Arg Ser Asp Ile Glu Lys Leu Lys Glu  
 1 5 10 15  
 Ala Ile Arg Asp Thr Asn Lys Ala Val Gln Ser Val Gln Ser Ser Ile  
 20 25 30

Gly Asn Leu  
 35

<210> 1470  
 <211> 35  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 1470  
 Val Glu Ala Lys Gln Ala Arg Ser Asp Ile Glu Lys Leu Lys Glu Ala  
 1 5 10 15  
 Ile Arg Asp Thr Asn Lys Ala Val Gln Ser Val Gln Ser Ser Ile Gly  
 20 25 30

Asn Leu Ile  
 35

<210> 1471  
 <211> 35  
 <212> PRT  
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1471

Glu Ala Lys Gln Ala Arg Ser Asp Ile Glu Lys Leu Lys Glu Ala Ile  
1 5 10 15

Arg Asp Thr Asn Lys Ala Val Gln Ser Val Gln Ser Ser Ile Gly Asn  
20 25 30

Leu Ile Val  
35

<210> 1472

<211> 35

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1472

Ala Lys Gln Ala Arg Ser Asp Ile Glu Lys Leu Lys Glu Ala Ile Arg  
1 5 10 15

Asp Thr Asn Lys Ala Val Gln Ser Val Gln Ser Ser Ile Gly Asn Leu  
20 25 30

Ile Val Ala  
35

<210> 1473

<211> 35

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1473

Lys Gln Ala Arg Ser Asp Ile Glu Lys Leu Lys Glu Ala Ile Arg Asp  
1 5 10 15



Thr Asn Lys Ala Val Gln Ser Val Gln Ser Ser Ile Gly Asn Leu Ile  
 20 25 30

Val Ala Ile  
 35

<210> 1474  
 <211> 35  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 1474  
 Gln Ala Arg Ser Asp Ile Glu Lys Leu Lys Glu Ala Ile Arg Asp Thr  
 1 5 10 15

Asn Lys Ala Val Gln Ser Val Gln Ser Ser Ile Gly Asn Leu Ile Val  
 20 25 30

Ala Ile Lys  
 35

<210> 1475  
 <211> 35  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 1475  
 Ala Arg Ser Asp Ile Glu Lys Leu Lys Glu Ala Ile Arg Asp Thr Asn  
 1 5 10 15

Lys Ala Val Gln Ser Val Gln Ser Ser Ile Gly Asn Leu Ile Val Ala  
 20 25 30

Ile Lys Ser  
 35

<210> 1476

<211> 35  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1476  
Arg Ser Asp Ile Glu Lys Leu Lys Glu Ala Ile Arg Asp Thr Asn Lys  
1 5 10 15  
Ala Val Gln Ser Val Gln Ser Ser Ile Gly Asn Leu Ile Val Ala Ile  
20 25 30  
Lys Ser Val  
35

<210> 1477  
<211> 35  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1477  
Ser Asp Ile Glu Lys Leu Lys Glu Ala Ile Arg Asp Thr Asn Lys Ala  
1 5 10 15  
Val Gln Ser Val Gln Ser Ser Ile Gly Asn Leu Ile Val Ala Ile Lys  
20 25 30  
Ser Val Gln  
35

<210> 1478  
<211> 35  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1478

Lys Leu Lys Glu Ala Ile Arg Asp Thr Asn Lys Ala Val Gln Ser Val  
1 5 10 15

Gln Ser Ser Ile Gly Asn Leu Ile Val Ala Ile Lys Ser Val Gln Asp  
20 25 30

Tyr Val Asn  
35

<210> 1479

<211> 35

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1479

Leu Lys Glu Ala Ile Arg Asp Thr Asn Lys Ala Val Gln Ser Val Gln  
1 5 10 15

Ser Ser Ile Gly Asn Leu Ile Val Ala Ile Lys Ser Val Gln Asp Tyr  
20 25 30

Val Asn Lys  
35

<210> 1480

<211> 35

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1480

Ala Ile Arg Asp Thr Asn Lys Ala Val Gln Ser Val Gln Ser Ser Ile  
1 5 10 15

Gly Asn Leu Ile Val Ala Ile Lys Ser Val Gln Asp Tyr Val Asn Lys  
20 25 30

Glu Ile Val

<210> 1481  
 <211> 47  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 1481  
 Thr Trp Gln Glu Trp Glu Arg Lys Val Asp Phe Leu Glu Glu Asn Ile  
           1                  5                  10                  15  
 Thr Ala Leu Leu Glu Glu Ala Gln Ile Gln Gln Glu Lys Asn Met Tyr  
                   20                  25                  30  
 Glu Leu Gln Lys Leu Asn Ser Trp Asp Val Phe Gly Asn Trp Phe  
                   35                  40                  45

<210> 1482  
 <211> 35  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 1482  
 Trp Gln Glu Trp Glu Arg Lys Val Asp Phe Leu Glu Glu Asn Ile Thr  
           1                  5                  10                  15  
 Ala Leu Leu Glu Glu Ala Gln Ile Gln Gln Glu Lys Asn Met Tyr Glu  
                   20                  25                  30  
 Leu Gln Lys  
           35

<210> 1483  
 <211> 35  
 <212> PRT  
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1483

Gln Glu Trp Glu Arg Lys Val Asp Phe Leu Glu Glu Asn Ile Thr Ala  
1 5 10 15

Leu Leu Glu Glu Ala Gln Ile Gln Gln Glu Lys Asn Met Tyr Glu Leu  
20 25 30

Gln Lys Leu  
35

<210> 1484

<211> 35

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1484

Glu Trp Glu Arg Lys Val Asp Phe Leu Glu Glu Asn Ile Thr Ala Leu  
1 5 10 15

Leu Glu Glu Ala Gln Ile Gln Gln Glu Lys Asn Met Tyr Glu Leu Gln  
20 25 30

Lys Leu Asn  
35

<210> 1485

<211> 35

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1485

Trp Glu Arg Lys Val Asp Phe Leu Glu Glu Asn Ile Thr Ala Leu Leu  
1 5 10 15

Glu Glu Ala Gln Ile Gln Gln Glu Lys Asn Met Tyr Glu Leu Gln Lys  
 20 25 30

Leu Asn Ser  
 35

<210> 1486

<211> 35

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 1486

Glu Arg Lys Val Asp Phe Leu Glu Glu Asn Ile Thr Ala Leu Leu Glu  
 1 5 10 15

Glu Ala Gln Ile Gln Gln Glu Lys Asn Met Tyr Glu Leu Gln Lys Leu  
 20 25 30

Asn Ser Trp  
 35

<210> 1487

<211> 35

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 1487

Arg Lys Val Asp Phe Leu Glu Glu Asn Ile Thr Ala Leu Leu Glu Glu  
 1 5 10 15

Ala Gln Ile Gln Gln Glu Lys Asn Met Tyr Glu Leu Gln Lys Leu Asn  
 20 25 30

Ser Trp Asp  
 35

<210> 1488

<211> 35  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1488  
Lys Val Asp Phe Leu Glu Glu Asn Ile Thr Ala Leu Leu Glu Glu Ala  
1 5 10 15  
Gln Ile Gln Gln Glu Lys Asn Met Tyr Glu Leu Gln Lys Leu Asn Ser  
20 25 30  
Trp Asp Val  
35

<210> 1489  
<211> 35  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1489  
Val Asp Phe Leu Glu Glu Asn Ile Thr Ala Leu Leu Glu Glu Ala Gln  
1 5 10 15  
Ile Gln Gln Glu Lys Asn Met Tyr Glu Leu Gln Lys Leu Asn Ser Trp  
20 25 30  
Asp Val Phe  
35

<210> 1490  
<211> 35  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1490

Asp Phe Leu Glu Glu Asn Ile Thr Ala Leu Leu Glu Glu Ala Gln Ile  
1 5 10 15

Gln Gln Glu Lys Asn Met Tyr Glu Leu Gln Lys Leu Asn Ser Trp Asp  
20 25 30

Val Phe Gly  
35

<210> 1491

<211> 35

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1491

Phe Leu Glu Glu Asn Ile Thr Ala Leu Leu Glu Glu Ala Gln Ile Gln  
1 5 10 15

Gln Glu Lys Asn Met Tyr Glu Leu Gln Lys Leu Asn Ser Trp Asp Val  
20 25 30

Phe Gly Asn  
35

<210> 1492

<211> 35

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1492

Pro Asp Ala Val Tyr Leu His Arg Ile Asp Leu Gly Pro Pro Ile Ser  
1 5 10 15

Leu Glu Arg Leu Asp Val Gly Thr Asn Leu Gly Asn Ala Ile Ala Lys  
20 25 30

Leu Glu Asp



<210> 1493  
 <211> 34  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 1493  
 Leu Glu Arg Leu Asp Val Gly Thr Asn Leu Gly Asn Ala Ile Ala Lys  
 1 5 10 15  
 Leu Glu Ala Lys Glu Leu Leu Glu Ser Ser Asp Gln Ile Leu Arg Ser  
 20 25 30

Met Lys

<210> 1494  
 <211> 34  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 1494  
 Leu His Arg Ile Asp Leu Gly Pro Pro Ile Ser Leu Glu Arg Leu Asp  
 1 5 10 15  
 Val Gly Thr Asn Leu Gly Asn Ala Ile Ala Lys Leu Glu Ala Lys Glu  
 20 25 30

Leu Leu

<210> 1495  
 <211> 34  
 <212> PRT  
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1495

His Arg Ile Asp Leu Gly Pro Pro Ile Ser Leu Glu Arg Leu Asp Val  
1 5 10 15

Gly Thr Asn Leu Gly Asn Ala Ile Ala Lys Leu Glu Ala Lys Glu Leu  
20 25 30

Leu Glu

<210> 1496

<211> 34

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1496

Arg Ile Asp Leu Gly Pro Pro Ile Ser Leu Glu Arg Leu Asp Val Gly  
1 5 10 15

Thr Asn Leu Gly Asn Ala Ile Ala Lys Leu Glu Ala Lys Glu Leu Leu  
20 25 30

Glu Ser

<210> 1497

<211> 34

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1497

Ile Asp Leu Gly Pro Pro Ile Ser Leu Glu Arg Leu Asp Val Gly Thr  
1 5 10 15

Asn Leu Gly Asn Ala Ile Ala Lys Leu Glu Ala Lys Glu Leu Leu Glu  
 20 25 30

Ser Ser

<210> 1498  
 <211> 34  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 1498  
 Asp Leu Gly Pro Pro Ile Ser Leu Glu Arg Leu Asp Val Gly Thr Asn  
 1 5 10 15

Leu Gly Asn Ala Ile Ala Lys Leu Glu Ala Lys Glu Leu Leu Glu Ser  
 20 25 30

Ser Asp

<210> 1499  
 <211> 34  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 1499  
 Leu Gly Pro Pro Ile Ser Leu Glu Arg Leu Asp Val Gly Thr Asn Leu  
 1 5 10 15

Gly Asn Ala Ile Ala Lys Leu Glu Ala Lys Glu Leu Leu Glu Ser Ser  
 20 25 30

Asp Gln

<210> 1500

<211> 34  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1500  
Gly Pro Pro Ile Ser Leu Glu Arg Leu Asp Val Gly Thr Asn Leu Gly  
1 5 10 15  
Asn Ala Ile Ala Lys Leu Glu Ala Lys Glu Leu Leu Glu Ser Ser Asp  
20 25 30  
Gln Ile

<210> 1501  
<211> 34  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1501  
Pro Pro Ile Ser Leu Glu Arg Leu Asp Val Gly Thr Asn Leu Gly Asn  
1 5 10 15  
Ala Ile Ala Lys Leu Glu Ala Lys Glu Leu Leu Glu Ser Ser Asp Gln  
20 25 30  
Ile Leu

<210> 1502  
<211> 34  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1502

Pro Ile Ser Leu Glu Arg Leu Asp Val Gly Thr Asn Leu Gly Asn Ala  
1 5 10 15

Ile Ala Lys Leu Glu Ala Lys Glu Leu Leu Glu Ser Ser Asp Gln Ile  
20 25 30

Leu Arg

<210> 1503

<211> 34

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1503

Ser Leu Glu Arg Leu Asp Val Gly Thr Asn Leu Gly Asn Ala Ile Ala  
1 5 10 15

Lys Leu Glu Ala Lys Glu Leu Leu Glu Ser Ser Asp Gln Ile Leu Arg  
20 25 30

Ser Met

<210> 1504

<211> 34

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1504

Leu Glu Arg Leu Asp Val Gly Thr Asn Leu Gly Asn Ala Ile Ala Lys  
1 5 10 15

Leu Glu Ala Lys Glu Leu Leu Glu Ser Ser Asp Gln Ile Leu Arg Ser  
20 25 30

Met Lys

<210> 1505  
<211> 22  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1505  
Tyr Leu Cys Glu Phe Cys Leu Lys Tyr Gly Arg Ser Leu Lys Cys Leu  
1 5 10 15

Gln Arg His Leu Thr Lys  
20

<210> 1506  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1506  
Ala Ser Thr Thr Thr Asn Tyr Thr  
1 5

<210> 1507  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1507  
Ala Ser Thr Thr Thr Asn Tyr Thr  
1 5

<210> 1508  
<211> 8  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1508  
Ser Gln Asn Tyr Pro Ile Val Gln  
1 5

<210> 1509  
<211> 6  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1509  
Glu Leu Asp Lys Trp Ala  
1 5

<210> 1510  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1510  
Arg Gly Val Val Asn Ala Ser Ser Arg Leu Ala  
1 5 10

<210> 1511  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1511

Arg Gly Arg Arg Gln Pro Ile Pro Lys Ala  
1 5 10

<210> 1512

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1512

Leu Thr Thr Gly Ser Val Val Ile Val Gly Arg Ile Ile Leu Ser Gly  
1 5 10 15

Arg Pro Ala Val Val Pro Asp  
20

<210> 1513

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1513

Gly Ser Val Val Ile Val Gly Arg Ile Ile Leu Ser Gly Arg  
1 5 10

<210> 1514

<211> 27

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide



<400> 1514  
Pro Leu Gly Phe Phe Pro Asp His Gln Leu Asp Pro Ala Phe Gly Ala  
1 5 10 15

Asn Ser Asn Asn Pro Asp Trp Asp Phe Asn Pro  
20 25

<210> 1515

<211> 26

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1515

Met Gln Trp Asn Ser Thr Thr Phe His Gln Thr Leu Gln Asp Pro Arg  
1 5 10 15

Val Arg Gly Leu Tyr Phe Pro Ala Gly Gly  
20 25

<210> 1516

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1516

Met Gln Trp Asn Ser Thr Ala Phe His Gln Thr  
1 5 10

<210> 1517

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1517  
Tyr Gly Ala Val Val Asn Asp Leu  
1 5

<210> 1518  
<211> 21  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1518  
Cys Thr His Gly Ile Arg Pro Val Val Ser Thr Gln Leu Leu Leu Asn  
1 5 10 15

Gly Ser Leu Ala Glu  
20

<210> 1519  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1519  
Ser Glu Asn Tyr Pro Ile Val  
1 5

<210> 1520  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1520  
Lys Ala Arg Val Phe Glu Ala  
1 5

<210> 1521  
<211> 15  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1521  
Arg Ile Gln Arg Gly Pro Gly Arg Ala Phe Val Thr Ile Gly Lys  
1 5 10 15

<210> 1522  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1522  
Ala Ser Thr Thr Thr Asn Tyr Thr  
1 5

<210> 1523  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1523  
Ala Ser Thr Thr Thr Asn Tyr Thr  
1 5

<210> 1524  
<211> 15  
<212> PRT  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1524

Arg Ile Gln Arg Gly Pro Gly Arg Ala Phe Val Thr Ile Gly Lys  
1 5 10 15

<210> 1525

<211> 38

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1525

Asn Asn Leu Leu Arg Ala Ile Glu Ala Gln Gln His Leu Leu Gln Leu  
1 5 10 15

Thr Val Trp Gly Ile Lys Gln Leu Gln Ala Arg Ile Leu Ala Val Glu  
20 25 30

Arg Tyr Leu Lys Asp Gln  
35

<210> 1526

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1526

Arg Gly Pro Gly Arg Ala Phe Val Thr Ile  
1 5 10

<210> 1527

<211> 3

<212> PRT

<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1527  
Phe Phe Gly  
1

<210> 1528  
<211> 36  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1528  
Tyr Thr Ser Leu Ile His Ser Leu Ile Glu Glu Ser Gln Asn Gln Gln  
1 5 10 15  
Glu Lys Asn Glu Gln Glu Leu Leu Glu Leu Asp Lys Trp Ala Ser Leu  
20 25 30  
Trp Asn Trp Phe  
35

<210> 1529  
<211> 2  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1529  
Thr Gln  
1

<210> 1530  
<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1530  
Trp His Trp Leu Gln Leu  
1 5

<210> 1531  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1531  
Gly Pro Gly Ala Gly  
1 5

<210> 1532  
<211> 2  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1532  
His Gly  
1

<210> 1533  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1533

Phe Val Phe Leu Met  
1 5

<210> 1534  
<211> 3  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1534  
Thr Ser Lys  
1

<210> 1535  
<211> 3  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1535  
Lys His Gly  
1

<210> 1536  
<211> 16  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1536  
Lys Asn Arg Trp Glu Asp Pro Gly Lys Gln Leu Tyr Asn Val Glu Ala  
1 5 10 15

<210> 1537  
<211> 10

<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1537  
Leu Arg Ala His Ala Val Asp Val Asn Gly  
1 5 10

<210> 1538  
<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1538  
Trp Ser Lys Met Asp Gln Leu Ala Lys Glu Leu Thr Ala Glu  
1 5 10

<210> 1539  
<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1539  
Thr Pro Arg Lys  
1

<210> 1540  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide



<400> 1540

Gly Glu Leu Gln Asn Gln Leu Ile Arg Lys Ser Asn  
1 5 10

<210> 1541

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1541

Gly Glu Tyr Gln Lys Met Leu Asn Leu Arg Ala Glu Val Lys Lys Asn  
1 5 10 15

Ala

<210> 1542

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1542

Pro Phe Cys Asn Ala Phe Thr Gly Cys  
1 5

<210> 1543

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1543

Glu Lys Ala His Asp Gly Gly Arg

<210> 1544  
<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1544  
Pro Phe Thr Arg Asn Tyr Tyr Val Arg Ala Val Leu His Leu  
1 5 10

<210> 1545  
<211> 39  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1545  
Ala Pro Arg Leu Pro Gln Cys Gln Gly Asp Asp Gln Glu Lys Cys Leu  
1 5 10 15

Cys Asn Lys Asp Glu Cys Pro Pro Gly Gln Cys Arg Phe Pro Arg Gly  
20 25 30

Asp Ala Asp Pro Tyr Cys Glu  
35

<210> 1546  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1546  
Lys Gly Asp Glu Glu Ser Leu Ala

1

5

<210> 1547  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1547  
Trp Ala Gly Gly Asp Ala Ser Gly Glu  
1 5

<210> 1548  
<211> 20  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1548  
Gln Ala Thr Val Gly Asp Val Asn Thr Asp Arg Pro Gly Leu Leu Asp  
1 5 10 15  
Leu Lys Tyr Tyr  
20

<210> 1549  
<211> 17  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1549  
Thr Lys Arg Arg Ala Ile Gly Phe Lys Lys Leu Ala Glu Ala Val Lys  
1 5 10 15  
Cys

<210> 1550  
<211> 8  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1550  
Ser Ile Ile Asn Phe Glu Lys Leu  
1 5

<210> 1551  
<211> 6  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1551  
Phe Gln Val Val Cys Gly  
1 5

<210> 1552  
<211> 6  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1552  
Ala Arg Met Ala Pro Glu  
1 5

<210> 1553  
<211> 4  
<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1553

Gly Gln Pro Arg

1

<210> 1554

<211> 3

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1554

Thr Val Leu

1

<210> 1555

<211> 49

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1555

Leu Leu Ser Lys Arg Gly His Cys Pro Arg Ile Leu Phe Arg Cys Pro

1

5

10

15

Leu Ser Asn Pro Ser Asn Lys Cys Trp Arg Asp Tyr Asp Cys Pro Gly

20

25

30

Val Lys Lys Cys Cys Glu Gly Phe Cys Gly Lys Asp Cys Leu Tyr Pro

35

40

45

Lys

<210> 1556  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1556  
Gly Phe Asp Leu Asn Gly Gly Gly Val Gly  
1 5 10

<210> 1557  
<211> 18  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1557  
Ala Val Gln Ser Lys Pro Pro Ser Lys Arg Asp Pro Pro Lys Met Gln  
1 5 10 15

Thr Asp

<210> 1558  
<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1558  
Thr Lys Pro Arg  
1

<210> 1559  
<211> 11  
<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 1559

Tyr Leu Asn Phe Thr Pro Asn Trp Gly Thr Tyr  
1 5 10

<210> 1560

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 1560

Asp Leu Trp Gln Lys  
1 5

<210> 1561

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 1561

Trp Tyr Glu Pro Ile Tyr Leu Gly Gly Val Phe Gln Leu Glu Lys Gly  
1 5 10 15

Asp

<210> 1562

<211> 39

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1562

Ala Pro Arg Leu Pro Gln Cys Gln Gly Asp Gln Glu Lys Cys Leu Cys  
1 5 10 15

Asn Lys Asp Glu Cys Pro Pro Gly Gln Cys Arg Phe Pro Arg Gly Asp  
20 25 30

Ala Asp Pro Tyr Cys Glu Asp  
35

<210> 1563

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1563

Thr Lys Pro Arg  
1

<210> 1564

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1564

Glu Glu Val Val Ala Cys  
1 5

<210> 1565

<211> 4

<212> PRT

<213> Artificial Sequence

<220>



<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1565  
Ser Asp Lys Pro  
1

<210> 1566  
<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1566  
Arg Phe Trp Ile Asn Lys  
1 5

<210> 1567  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1567  
Cys Gly Tyr Gly Pro Lys Lys Lys Arg Lys Val Gly Gly  
1 5 10

<210> 1568  
<211> 1  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1568  
Leu  
1

<210> 1569  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1569  
Asp Asp Asp Asp Asp  
1 5

<210> 1570  
<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1570  
Asp Asp Asp Asp Asp Asp  
1 5

<210> 1571  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1571  
Asn Pro Asn Ala Asn Pro Asn Ala  
1 5

<210> 1572  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1572  
Val Ala Ile Thr Val Leu Val Lys  
1 5

<210> 1573  
<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1573  
Val Gly Val Arg Val Arg  
1 5

<210> 1574  
<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1574  
Val Ile His Ser  
1

<210> 1575  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1575

Val Pro Asp Pro Arg  
1 5

<210> 1576  
<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1576  
Val Thr Cys Gly  
1

<210> 1577  
<211> 3  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1577  
Arg Ser Arg  
1

<210> 1578  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1578  
Ser Ala Lys Leu Cys Pro Gly Gly Asn Cys Val  
1 5 10

<210> 1579  
<211> 6

<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1579  
Asp His Ala Arg Trp Lys  
1 5

<210> 1580  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1580  
Pro Gln Asp Pro Gln Asp Leu  
1 5

<210> 1581  
<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1581  
Gln His Phe Arg Trp Gly  
1 5

<210> 1582  
<211> 19  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1582  
 Asn Gln Glu Gln Val Ser Pro Leu Thr Leu Leu Lys Leu Gly Asn Gln  
 1 5 10 15

Glu Pro Gly

<210> 1583  
 <211> 20  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 1583  
 Leu Ser Ala Leu Ser Leu Asp Glu Pro Phe Ile Gln Lys Asp Val Glu  
 1 5 10 15

Leu Arg Ile Met  
 20

<210> 1584  
 <211> 15  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 1584  
 Ala Pro Glu Ala Gln Val Ser Val Gln Pro Asn Phe Gln Gln Asp  
 1 5 10 15

<210> 1585  
 <211> 27  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 1585

Glu Tyr Gly Gly Thr Lys Val Leu Asp Asp Lys Asp Tyr Phe Leu Phe  
1 5 10 15

Arg Asp Gly Asp Ile Leu Gly Lys Tyr Val Asp  
20 25

<210> 1586

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1586

Lys Ala Tyr Ile Asn Lys Val Glu Glu Leu Lys Lys Lys Tyr Gly Ile  
1 5 10 15

<210> 1587

<211> 24

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1587

Ser Gln Gln Ser Ser Ser Tyr Gly Gln Gln Ser Glu Lys Pro Tyr Gln  
1 5 10 15

Cys Asp Phe Lys Asp Cys Glu Arg  
20

<210> 1588

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1588

Ala Thr Glu Ser Ile Ala Tyr Leu Ala Pro Pro Tyr Ala Phe Arg  
1 5 10 15

<210> 1589

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1589

Lys Arg Lys Arg Ser Glu Met Leu Phe Arg Gly Arg Arg Ala Ser Gln  
1 5 10 15

<210> 1590

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1590

Val Ser His Pro Tyr Ser Gln His Leu Glu Gly Lys Gly  
1 5 10

<210> 1591

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1591

Ala Leu Thr Asp Phe Phe Arg  
1 5



<210> 1592  
<211> 20  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1592  
Gln Ala Ile Gly Leu Met Gly Tyr Arg Leu Ser Pro Gln Thr Leu Thr  
1 5 10 15  
Thr Ile Val Lys  
20

<210> 1593  
<211> 17  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1593  
Met Gly Phe Asn Ala Phe Lys Glu Leu Trp Ala Ala Leu Asn Ala Trp  
1 5 10 15  
Lys

<210> 1594  
<211> 16  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1594  
Glu Val Gln Leu Val Glu Ser Gly Val Gly Leu Val Gln Pro Gly Asp  
1 5 10 15

<210> 1595  
<211> 17  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1595  
Glu Leu Asp Ala Lys Ile Pro Ser Thr Gly Asp Ala Thr Glu Trp Arg  
1 5 10 15

Asn

<210> 1596  
<211> 20  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1596  
Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala His Gly  
1 5 10 15

Val Thr Ser Ala  
20

<210> 1597  
<211> 20  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1597  
Gly Lys Glu Ile Leu Val Gly Asp Val Gly Gln Thr Val Asp Asp Pro  
1 5 10 15

Tyr Ala Thr Phe

<210> 1598  
 <211> 15  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 1598  
 Glu Leu Ser Leu Ala Gly Asn Glu Leu Gly Asp Glu Gly Ala Arg  
 1 5 10 15

<210> 1599  
 <211> 22  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 1599  
 Met Phe Ile Val Asn Thr Asn Val Pro Arg Ala Ser Val Pro Asp Gly  
 1 5 10 15

Phe Leu Ser Glu Leu Thr  
 20

<210> 1600  
 <211> 35  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 1600  
 Phe Gly Ser Phe Phe Thr Leu Asn Leu Phe Ile Gly Ile Ile Ile Asp  
 1 5 10 15

Asn Phe Trp Gln Gln Lys Lys Lys Leu Gly Gly Lys Asp Ile Phe Met

Thr Glu Glu

35

<210> 1601

<211> 27

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1601

Gly Leu Pro Gly Arg Asp Gly Arg Asp Gly Arg Glu Gly Phe Arg Gly  
1 5 10 15

Glu Glu Gly Asp Pro Gly Leu Pro Gly Ala Ala  
20 25

<210> 1602

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1602

Cys Lys Thr Cys Gln Arg Lys Phe Ser Arg Ser Gly His Leu Lys Thr  
1 5 10 15

His Thr Arg Thr His

20

<210> 1603

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1603  
His Val Ser Ser Glu Ala Phe Arg Met Cys Asp Val Cys Leu Glu  
1 5 10 15

<210> 1604  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1604  
Pro His Ser Arg Asn  
1 5

<210> 1605  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1605  
Pro His Ser Cys Asn  
1 5

<210> 1606  
<211> 28  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1606  
Met Gly Pro Gly Ala Pro Phe Ala Arg Val Gly Trp Pro Leu Pro Leu  
1 5 10 15

Leu Val Val Met Ala Gly Val Ala Pro Val Trp Ala

<210> 1607  
 <211> 15  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 1607  
 Met Val Lys Ser His Ile Gly Ser Trp Ile Leu Val Leu Phe Val  
 1 5 10 15

<210> 1608  
 <211> 9  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 1608  
 Cys Ser Leu Pro Gly Ser Ala Ala Ala  
 1 5

<210> 1609  
 <211> 15  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 Peptide

<400> 1609  
 Arg Gly Leu Lys Arg Gln Ser Asp Glu Arg Lys Arg Asp Arg Glu  
 1 5 10 15

<210> 1610  
 <211> 57  
 <212> PRT

[illegible]

<223> Description of Artificial Sequence: Synthetic Peptide

Gly Arg Ser His Met Val Leu Asn Ser Ala Leu Glu Gly Ala Arg Gly  
1 5 10 15

Gly Pro Gly Gly Glu Glu Ile Pro Glu Arg Phe Ser Ile Pro Glu Leu  
20 25 30

Gln Trp Met Leu Ser Asn Ala Glu Leu Ala Pro Val Gln Ala Asp Glu  
35 40 45

Pro Pro Gln Ser Arg Met Asp Leu Val  
50 55

<211> 35

&lt;212&gt; PRT

<213> Artificial Sequence

<223> Description of Artificial Sequence: Synthetic Peptide

Gln Ala Arg Ala Val Gly Leu Ala Gly Thr Ser Arg Ala Phe Leu Ser  
1 5 10 15

Ser Arg Leu Gln Asp Leu Tyr Ser Ile Val Arg Arg Ala Asp Arg Ala  
20 25 30

Ala Val Met  
35

<211> 15

<212> PRT

<213> Artificial Sequence

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 1612  
Met Val Lys Ser His Ile Gly Ser Trp Ile Leu Val Leu Phe Val  
1 5 10 15

<210> 1613  
<211> 29  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1613  
Leu Arg Asp Leu Val Ser Tyr Cys Arg Ala Arg Gly Lys Gly Arg Glu  
1 5 10 15

Arg Met Asn Gly Thr Arg Lys Gly His Leu Leu Tyr Met  
20 25

<210> 1614  
<211> 33  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1614  
Gly Lys Arg Ser Ser Pro Glu Thr Leu Ile Ser Asp Leu Leu Met Arg  
1 5 10 15

Glu Ser Thr Glu Asn Val Pro Arg Thr Arg Leu Glu Asp Pro Ala Met  
20 25 30

Trp

<210> 1615  
<211> 30  
<212> PRT  
<213> Artificial Sequence



<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1615

Asp Val Glu Pro Leu Leu Gly Phe Leu Ser Pro Lys Ser Gly Gln Glu  
1 5 10 15

Asn Glu Val Asp Asp Phe Pro Tyr Lys Gly Gln Gly Glu Leu  
20 25 30

<210> 1616

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1616

Phe Cys Lys Cys Arg Leu Glu Pro Met Lys Ala Thr Cys Asp Ile Ser  
1 5 10 15

Glu Cys Pro Glu  
20

<210> 1617

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Peptide

<400> 1617

Lys Ser His Gly Arg Thr Gln Asn Pro Val Val His Phe Phe Lys Asn  
1 5 10 15

Ile Val Thr Pro  
20

Atty Docket No. REDC-2110 USA II**COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

**PROTECTION OF ENDOGENOUS THERAPEUTIC PEPTIDES FROM PEPTIDASE ACTIVITY THROUGH CONJUGATION TO BLOOD COMPONENTS**

the specification of which (check one)    is attached hereto or   X   was filed on 17 May 2000 as Application No. PCT/US00/13576 and was amended on 06 July 2000 (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose all information which is material to patentability as defined in 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)

Priority Claimed	
Yes No	

Number	Country	Day/Month/Year Filed

Number	Country	Day/Month/Year Filed

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) below.

60/134,406	17 May 1999
Application Number	Filing Date

60/153,406	10 September 1999
Application Number	Filing Date

60/159,783	15 October 1999
Application Number	Filing Date

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or § 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose all information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

Application Number	Filing Date	Status: Patented, Pending, Abandoned

Application Number	Filing Date	Status: Patented, Pending, Abandoned

I HEREBY APPOINT THE FOLLOWING AS MY ATTORNEYS WITH FULL POWER OF SUBSTITUTION TO PROSECUTE THIS APPLICATION AND TRANSACT ALL BUSINESS IN THE PATENT OFFICE CONNECTED THEREWITH:

Karl A. Limbach	18,689	Alfred A. Equitz	30,922	Mayumi Maeda	40,075
George C. Limbach	19,305	Charles P. Sammut	28,901	Michael R. Ward	38,651
John K. Uilkema	20,282	Mark C. Pickering	36,239	Roger S. Sampson	44,314
Neil A. Smith	25,441	Patricia Coleman James	37,155	Charles L. Hamilton	42,624
Veronica C. Devitt	29,375	Kathleen A. Frost	37,326	Andrew V. Smith	43,132
Ronald L. Yin	27,607	Alan A. Limbach	39,749	Eric N. Hoover	37,355
Gerald T. Sekimura	30,103	Douglas C. Limbach	35,249	Frank J. Mycroft	P-46,946
Michael A. Stallman	29,444	Seong-Kun Oh*		Parisa Jorjani	P-46,813
Philip A. Girard	28,848	Cameron A. King	41,897	J. Thomas McCarthy	22,420
Michael J. Pollock	29,098	Kyla L. Harriel	41,816	Joel G. Ackerman	24,307
Stephen M. Everett	30,050				

\* Recognition under 37 CFR 10.9(b)

Send correspondence to Limbach & Limbach L.L.P.  
Attn: Michael R. Ward, Esq.  
2001 Ferry Building  
San Francisco, CA 94111  
Telephone: 415/433-4150

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both, under 18 U.S.C. § 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor DOMINIQUE P. BRIDON

Inventor's signature \_\_\_\_\_

Date \_\_\_\_\_

Residence 243 Chemin Cote Ste-Catherine, Outremont, Quebec H2V 2B2, Canada

Citizenship France

Post Office Address 243 Chemin Cote Ste-Catherine, Outremont, Quebec H2V 2B2, Canada

Full name of second joint inventor, if any, ALAN M. EZRIN

Inventor's signature \_\_\_\_\_

Date \_\_\_\_\_

Residence 110 Quintas Lane, Moraga, California 94556

Citizenship United States of America

Post Office Address 110 Quintas Lane, Moraga, California 94556

Full name of third joint inventor, if any, PETER G. MILNER

Inventor's signature Peter G. Milner

Date 7/12/2000

Residence 14690 Manuella Road, Los Altos Hills, California 94022

Citizenship United Kingdom

Post Office Address 14690 Manuella Road, Los Altos Hills, California 94022

Post Office Address 3450 Drummond Street, Montreal, Quebec H3G 1T3, Canada

Post Office Address 4700 Bonavista Street, #407, Montreal, Quebec H3W 2L5, Canada

Atty Docket No. REDC-2110 USA II

**COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

**PROTECTION OF ENDOGENOUS THERAPEUTIC PEPTIDES FROM PEPTIDASE ACTIVITY THROUGH CONJUGATION TO BLOOD COMPONENTS**

the specification of which (check one) ☐ is attached hereto or ☒ was filed on 17 May 2000 as Application No. PCT/US00/13576 and was amended on 06 July 2000 (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose all information which is material to patentability as defined in 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)

Priority Claimed	
Yes	No
<input type="checkbox"/>	<input type="checkbox"/>

Number	Country	Day/Month/Year Filed
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Number	Country	Day/Month/Year Filed
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) below.

<u>60/134,406</u>	<u>17 May 1999</u>
Application Number	Filing Date

<u>60/153,406</u>	<u>10 September 1999</u>
Application Number	Filing Date

<u>60/159,783</u>	<u>15 October 1999</u>
Application Number	Filing Date

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or § 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose all information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

Application Number	Filing Date	Status: Patented, Pending, Abandoned
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Application Number	Filing Date	Status: Patented, Pending, Abandoned
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

I HEREBY APPOINT THE FOLLOWING AS MY ATTORNEYS WITH FULL POWER OF SUBSTITUTION TO PROSECUTE THIS APPLICATION AND TRANSACT ALL BUSINESS IN THE PATENT OFFICE CONNECTED THEREWITH:


Karl A. Limbach	18,689	Alfred A. Equitz	30,922	Mayumi Maeda	40,075
George C. Limbach	19,305	Charles P. Sammut	28,901	Michael R. Ward	38,651
John K. Uilkema	20,282	Mark C. Pickering	36,239	Roger S. Sampson	44,314
Neil A. Smith	25,441	Patricia Coleman James	37,155	Charles L. Hamilton	42,624
Veronica C. Devitt	29,375	Kathleen A. Frost	37,326	Andrew V. Smith	43,132
Ronald L. Yin	27,607	Alan A. Limbach	39,749	Eric N. Hoover	37,355
Gerald T. Sekimura	30,103	Douglas C. Limbach	35,249	Frank J. Mycroft	P-46,946
Michael A. Stallman	29,444	Seong-Kun Oh*		Parisa Jorjani	P-46,813
Philip A. Girard	28,848	Cameron A. King	41,897	J. Thomas McCarthy	22,420
Michael J. Pollock	29,098	Kyla L. Harriel	41,816	Joel G. Ackerman	24,307
Stephen M. Everett	30,050				

\* Recognition under 37 CFR 10.9(b)

Send correspondence to Limbach & Limbach L.L.P.  
Attn: Michael R. Ward, Esq.  
2001 Ferry Building  
San Francisco, CA 94111  
Telephone: 415/433-4150

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both, under 18 U.S.C. § 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor DOMINIQUE P. BRIDON

Inventor's signature 

Date


July 12, 2000

Residence 243 Chemin Cote Ste-Catherine, Outremont, Quebec H2V 2B2, Canada CAN

Citizenship France

Post Office Address 243 Chemin Cote Ste-Catherine, Outremont, Quebec H2V 2B2, Canada

Full name of second joint inventor, if any, ALAN M. EZRIN

Inventor's signature 

Date

August 25, 2000

Residence 110 Quintas Lane, Moraga, California 94556 CAN

Citizenship United States of America

Post Office Address 110 Quintas Lane, Moraga, California 94556

Full name of third joint inventor, if any, PETER G. MILNER

Inventor's signature \_\_\_\_\_

Date

Residence 14690 Manuella Road, Los Altos Hills, California 94022

Citizenship United Kingdom

Post Office Address 14690 Manuella Road, Los Altos Hills, California 94022

Full name of fourth joint inventor, if any, DARREN L. HOLMES

Inventor's signature \_\_\_\_\_ Date \_\_\_\_\_

Residence 3450 Drummond Street, Montreal, Quebec H3G 1T3, Canada

Citizenship United States of America

Post Office Address 3450 Drummond Street, Montreal, Quebec H3G 1T3, Canada

Full name of fifth joint inventor, if any, KAREN THIBAUDEAU

Inventor's signature \_\_\_\_\_ Date \_\_\_\_\_

Residence 4700 Bonavista Street, #407, Montreal, Quebec H3W 2L5, Canada

Citizenship France

Post Office Address 4700 Bonavista Street, #407, Montreal, Quebec H3W 2L5, Canada